primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
1524040412,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Hypotension,,2021,Q1,12,F,20180723.0,20201127.0,20180804,20210122,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,73.0,KG,20210122.0,,MD,CA,CA,2021,Q1,Elderly
1524040412,15240404,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Subdural haematoma,,2021,Q1,12,F,20180723.0,20201127.0,20180804,20210122,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-038855",BOEHRINGER INGELHEIM,,88.0,YR,E,M,Y,73.0,KG,20210122.0,,MD,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Aspiration,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Asthma,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Bilevel positive airway pressure,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Blood count abnormal,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Bronchial hyperreactivity,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Condition aggravated,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Cough,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Drug ineffective,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Dyspnoea,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Hospitalisation,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Left ventricular dysfunction,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Obstructive airways disorder,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Pneumonia,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Pneumonitis,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Productive cough,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Pulmonary function test abnormal,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Rales,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Respiratory symptom,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Sleep disorder due to a general medical condition,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Sputum discoloured,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Therapeutic product effect incomplete,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Therapy cessation,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Wheezing,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
153959726,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Wrong technique in product usage process,,2021,Q1,6,F,201704.0,20210217.0,20180918,20210224,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210224.0,,CN,CA,CA,2021,Q1,Elderly
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Abdominal mass,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Back pain,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Fall,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Metastases to spine,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Nail discolouration,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Needle issue,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Pain in extremity,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Sinusitis,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Vertigo,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Vitamin D decreased,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Abdominal mass,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Back pain,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Fall,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Metastases to spine,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Nail discolouration,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Needle issue,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Pain in extremity,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Sinusitis,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Vertigo,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
157777056,15777705,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,25.0,MG,,,2021,Q1,Vitamin D decreased,,2021,Q1,6,F,,20210216.0,20181231,20210226,EXP,,PHHY2018GB197608,NOVARTIS,,59.0,YR,,M,Y,,,20210226.0,,CN,COUNTRY NOT SPECIFIED,GB,2021,Q1,Adult
162879192,16287919,69,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,69,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q1,Chronic kidney disease,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,69,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q1,Nephrogenic anaemia,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,69,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q1,Renal failure,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
170195616,17019561,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Colitis,,2021,Q1,6,F,20191102.0,20201012.0,20191112,20210126,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-112197",BOEHRINGER INGELHEIM,,15.0,YR,T,F,Y,96.0,KG,20210126.0,,MD,US,US,2021,Q1,Youth
170195616,17019561,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Tubulointerstitial nephritis,,2021,Q1,6,F,20191102.0,20201012.0,20191112,20210126,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-112197",BOEHRINGER INGELHEIM,,15.0,YR,T,F,Y,96.0,KG,20210126.0,,MD,US,US,2021,Q1,Youth
170475988,17047598,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,8,F,20191112.0,20210319.0,20191119,20210326,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-114461",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,52.2,KG,20210326.0,,MD,BR,BR,2021,Q1,Elderly
170881362,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,2,F,,20210315.0,20191128,20210324,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20210324.0,,CN,CA,CA,2021,Q1,Adult
170881362,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Metabolic acidosis,,2021,Q1,2,F,,20210315.0,20191128,20210324,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20210324.0,,CN,CA,CA,2021,Q1,Adult
170881362,17088136,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Respiratory acidosis,,2021,Q1,2,F,,20210315.0,20191128,20210324,EXP,,CA-APOTEX-2019AP025420,APOTEX,,54.0,YR,,M,Y,70.0,KG,20210324.0,,CN,CA,CA,2021,Q1,Adult
172259944,17225994,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,131597.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Cardiac failure,,2021,Q1,4,F,20191219.0,20210113.0,20200102,20210120,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-122749",BOEHRINGER INGELHEIM,,81.0,YR,E,F,Y,81.0,KG,20210120.0,,MD,NL,NL,2021,Q1,Elderly
178096285,17809628,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q1,Atrial fibrillation,,2021,Q1,5,F,20180204.0,20210301.0,20200520,20210303,EXP,,US-ABBVIE-18K-163-3095220-00,ABBVIE,,62.0,YR,,F,Y,61.7,KG,20210303.0,,CN,US,US,2021,Q1,Adult
178096285,17809628,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q1,Coronary artery disease,,2021,Q1,5,F,20180204.0,20210301.0,20200520,20210303,EXP,,US-ABBVIE-18K-163-3095220-00,ABBVIE,,62.0,YR,,F,Y,61.7,KG,20210303.0,,CN,US,US,2021,Q1,Adult
178096285,17809628,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q1,Hyperkalaemia,,2021,Q1,5,F,20180204.0,20210301.0,20200520,20210303,EXP,,US-ABBVIE-18K-163-3095220-00,ABBVIE,,62.0,YR,,F,Y,61.7,KG,20210303.0,,CN,US,US,2021,Q1,Adult
178096285,17809628,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q1,Mitral valve incompetence,,2021,Q1,5,F,20180204.0,20210301.0,20200520,20210303,EXP,,US-ABBVIE-18K-163-3095220-00,ABBVIE,,62.0,YR,,F,Y,61.7,KG,20210303.0,,CN,US,US,2021,Q1,Adult
178096285,17809628,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q1,Myocardial infarction,,2021,Q1,5,F,20180204.0,20210301.0,20200520,20210303,EXP,,US-ABBVIE-18K-163-3095220-00,ABBVIE,,62.0,YR,,F,Y,61.7,KG,20210303.0,,CN,US,US,2021,Q1,Adult
179120937,17912093,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, BID",,,,,,,,25.0,MG,,BID,2021,Q1,Haematuria,,2021,Q1,7,F,20200601.0,20210129.0,20200618,20210205,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-047354,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,115.0,KG,20210205.0,,MD,SK,SK,2021,Q1,Elderly
179120937,17912093,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, BID",,,,,,,,25.0,MG,,BID,2021,Q1,Renal impairment,,2021,Q1,7,F,20200601.0,20210129.0,20200618,20210205,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-047354,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,115.0,KG,20210205.0,,MD,SK,SK,2021,Q1,Elderly
179120937,17912093,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, BID",,,,,,,,25.0,MG,,BID,2021,Q1,Urinary retention,,2021,Q1,7,F,20200601.0,20210129.0,20200618,20210205,EXP,,SK-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-047354,BRISTOL MYERS SQUIBB,,68.0,YR,,M,Y,115.0,KG,20210205.0,,MD,SK,SK,2021,Q1,Elderly
179959236,17995923,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Cerebral haematoma,,2021,Q1,6,F,20200124.0,20210310.0,20200708,20210317,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-033561",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,52.0,KG,20210317.0,,MD,HU,HU,2021,Q1,Elderly
179959236,17995923,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Paraneoplastic syndrome,,2021,Q1,6,F,20200124.0,20210310.0,20200708,20210317,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-033561",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,52.0,KG,20210317.0,,MD,HU,HU,2021,Q1,Elderly
179959236,17995923,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Vulval cancer,,2021,Q1,6,F,20200124.0,20210310.0,20200708,20210317,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-033561",BOEHRINGER INGELHEIM,,80.0,YR,E,F,Y,52.0,KG,20210317.0,,MD,HU,HU,2021,Q1,Elderly
180929886,18092988,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Septic shock,,2021,Q1,6,F,20200720.0,20210212.0,20200730,20210217,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-037161",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,61.6,KG,20210217.0,,MD,KR,KR,2021,Q1,Elderly
180929886,18092988,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Urinary tract infection,,2021,Q1,6,F,20200720.0,20210212.0,20200730,20210217,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-037161",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,61.6,KG,20210217.0,,MD,KR,KR,2021,Q1,Elderly
181260012,18126001,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Staphylococcal bacteraemia,,2021,Q1,2,F,20200130.0,20210310.0,20200807,20210311,EXP,,"PL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-027352",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,86.0,KG,20210311.0,,MD,PL,PL,2021,Q1,Elderly
181436194,18143619,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q1,Monoparesis,,2021,Q1,4,F,20200805.0,20210309.0,20200813,20210319,EXP,,DE-ROCHE-2655728,ROCHE,,72.0,YR,,F,Y,63.0,KG,20210319.0,,MD,DE,DE,2021,Q1,Elderly
181905592,18190559,5,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Abdominal pain,,2021,Q1,2,F,,20210215.0,20200825,20210223,EXP,,CA-TEVA-2020-CA-1817791,TEVA,,61.0,YR,A,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Adult
181905592,18190559,5,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Dehydration,,2021,Q1,2,F,,20210215.0,20200825,20210223,EXP,,CA-TEVA-2020-CA-1817791,TEVA,,61.0,YR,A,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Adult
181905592,18190559,5,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Nausea,,2021,Q1,2,F,,20210215.0,20200825,20210223,EXP,,CA-TEVA-2020-CA-1817791,TEVA,,61.0,YR,A,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Adult
181905592,18190559,5,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Vomiting,,2021,Q1,2,F,,20210215.0,20200825,20210223,EXP,,CA-TEVA-2020-CA-1817791,TEVA,,61.0,YR,A,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Blood bicarbonate abnormal,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Blood insulin decreased,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Disorientation,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Dysmenorrhoea,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Electrolyte imbalance,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Fasting,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,General physical health deterioration,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Hysterectomy,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Insulin C-peptide decreased,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Ketoacidosis,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Leukocytosis,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Metabolic acidosis,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Nervous system disorder,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Neurological decompensation,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,PCO2 abnormal,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,PO2 abnormal,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Systemic inflammatory response syndrome,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Tachycardia,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,Uterine haemorrhage,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182011842,18201184,2,SS,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U, UNKNOWN,,,850.0,MG,,,2021,Q1,pH body fluid abnormal,,2021,Q1,2,F,201610.0,20210113.0,20200827,20210119,EXP,,"MX-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-044111",BOEHRINGER INGELHEIM,"ZERON H, UBIERNA J, POST HYSTERECTOMY KETOACIDOSIS DUE TO EMPAGLIFLOZIN. REVISTA PERUANA DE GINECOLOGIA Y OBSTETRICIA. 2020 FEB 05? 66?1: 73?77.",42.0,YR,A,F,Y,,,20210119.0,,MD,MX,MX,2021,Q1,Adult
182423117,18242311,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Cardiac failure,,2021,Q1,7,F,20200313.0,20201212.0,20200908,20210112,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015662",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,72.2,KG,20210112.0,,MD,BR,BR,2021,Q1,Elderly
182423117,18242311,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Metabolic acidosis,,2021,Q1,7,F,20200313.0,20201212.0,20200908,20210112,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015662",BOEHRINGER INGELHEIM,,79.0,YR,E,F,Y,72.2,KG,20210112.0,,MD,BR,BR,2021,Q1,Elderly
182854358,18285435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Bacteraemia,,2021,Q1,8,F,20200906.0,20210223.0,20200918,20210301,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-047126",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,121.6,KG,20210301.0,,MD,US,US,2021,Q1,Adult
182854358,18285435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Sepsis,,2021,Q1,8,F,20200906.0,20210223.0,20200918,20210301,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-047126",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,121.6,KG,20210301.0,,MD,US,US,2021,Q1,Adult
182854358,18285435,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Urinary tract infection,,2021,Q1,8,F,20200906.0,20210223.0,20200918,20210301,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-047126",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,121.6,KG,20210301.0,,MD,US,US,2021,Q1,Adult
183614854,18361485,16,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Dementia,,2021,Q1,4,F,20200708.0,20210324.0,20201008,20210330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-034633",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,63.3,KG,20210330.0,,MD,JP,JP,2021,Q1,Elderly
183614854,18361485,17,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Dementia,,2021,Q1,4,F,20200708.0,20210324.0,20201008,20210330,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-034633",BOEHRINGER INGELHEIM,,83.0,YR,E,F,Y,63.3,KG,20210330.0,,MD,JP,JP,2021,Q1,Elderly
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Acetonaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Altered state of consciousness,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Hyperlactacidaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Hypoglycaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Lactic acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Metabolic acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Toxicity to various agents,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Acetonaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Altered state of consciousness,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Hyperlactacidaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Hypoglycaemia,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Lactic acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Metabolic acidosis,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183846677,18384667,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Toxicity to various agents,,2021,Q1,7,F,,20210305.0,20201015,20210308,EXP,,NVSC2020PT275038,NOVARTIS,"SOFIA C, SUSANA E, INES S, FRANCISCO R, DIANA C, DIOGO C. METFORMIN POISONING?MULTIFACTORIAL METABOLIC ACIDOSIS. BOOK OF ABSTRACTS OF THE CONGRESS OF INTERNAL MEDICINE. 2020?535?6",54.0,YR,,M,Y,,,20210308.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Acetonaemia,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Acidosis,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Altered state of consciousness,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Hyperlactacidaemia,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Hypoglycaemia,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Lactic acidosis,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Metabolic acidosis,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
183853596,18385359,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Toxicity to various agents,,2021,Q1,6,F,,20210304.0,20201014,20210312,EXP,,PT-AUROBINDO-AUR-APL-2020-051831,AUROBINDO,,54.0,YR,,M,Y,,,20210312.0,,HP,PT,PT,2021,Q1,Adult
184821753,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q1,Cataract,,2021,Q1,3,F,20201019.0,20210310.0,20201110,20210312,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210312.0,,MD,JP,JP,2021,Q1,Adult
184821753,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q1,Eczema asteatotic,,2021,Q1,3,F,20201019.0,20210310.0,20201110,20210312,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210312.0,,MD,JP,JP,2021,Q1,Adult
184821753,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q1,Rash pruritic,,2021,Q1,3,F,20201019.0,20210310.0,20201110,20210312,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210312.0,,MD,JP,JP,2021,Q1,Adult
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Anxiety,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Arthralgia,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Back pain,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Bacterial test positive,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Balanoposthitis,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Blood glucose abnormal,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Disturbance in attention,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Dysuria,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Emotional distress,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Erectile dysfunction,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Fall,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Fatigue,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Feeling hot,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Flank pain,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Gastrointestinal disorder,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Glycosylated haemoglobin abnormal,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Groin pain,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Haematoma,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Headache,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Herpes zoster,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Hyperhidrosis,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Hypoaesthesia,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Incontinence,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Leukocyturia,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Loss of libido,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Malaise,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Muscle tightness,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Nausea,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Osteoarthritis,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pain in extremity,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Peripheral coldness,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Phimosis,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Plantar fasciitis,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pollakiuria,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pruritus,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Quality of life decreased,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Renal cyst,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Restlessness,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sacroiliac joint dysfunction,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sense of oppression,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sleep disorder,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Stress urinary incontinence,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Urinary tract infection bacterial,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
184922264,18492226,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Urine flow decreased,,2021,Q1,4,F,20140414.0,20210210.0,20201111,20210302,EXP,,NVSC2020DE140272,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Anxiety,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Arrhythmia,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Arthralgia,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Back pain,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Bacterial test positive,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Balanoposthitis,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Blood glucose abnormal,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Diabetes mellitus,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Disturbance in attention,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Dysuria,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Emotional distress,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Erectile dysfunction,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Fall,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Fatigue,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Feeling hot,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Flank pain,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Gastrointestinal disorder,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Glycosylated haemoglobin abnormal,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Glycosylated haemoglobin increased,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Groin pain,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Haematoma,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Headache,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Herpes zoster,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Hyperhidrosis,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Hypoaesthesia,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Incontinence,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Leukocyturia,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Loss of libido,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Malaise,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Muscle tightness,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Nausea,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Osteoarthritis,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Pain in extremity,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Peripheral coldness,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Phimosis,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Plantar fasciitis,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Pollakiuria,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Pruritus,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Quality of life decreased,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Renal cyst,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Restlessness,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Sacroiliac joint dysfunction,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Sense of oppression,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Sleep disorder,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Stress urinary incontinence,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Urinary tract infection bacterial,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
185387166,18538716,20,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, ONCE A DAY (1?0?0?0), IN MORNING )",,,U,,,,,,,TABLET,QD,2021,Q1,Urine flow decreased,,2021,Q1,6,F,20140414.0,20210304.0,20201124,20210317,EXP,,DE-AUROBINDO-AUR-APL-2020-026873,AUROBINDO,,65.0,YR,,M,Y,134.0,KG,20210317.0,,CN,DE,DE,2021,Q1,Elderly
186044462,18604446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Diabetic nephropathy,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Fall,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Humerus fracture,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Peripheral arterial occlusive disease,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Peripheral artery occlusion,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2021,Q1,Diabetic nephropathy,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2021,Q1,Fall,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2021,Q1,Humerus fracture,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2021,Q1,Peripheral arterial occlusive disease,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186044462,18604446,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,5 MG,,,U,,,,,5.0,MG,,,2021,Q1,Peripheral artery occlusion,,2021,Q1,2,F,,20201223.0,20201211,20210104,EXP,,NVSJ2020JP013075,NOVARTIS,,74.0,YR,,F,Y,48.2,KG,20210104.0,,CN,COUNTRY NOT SPECIFIED,JP,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Arrhythmia,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Arthralgia,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Back pain,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Bacterial test positive,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Balanoposthitis,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Blood glucose abnormal,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Diabetes mellitus,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Dysuria,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Emotional distress,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Erectile dysfunction,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Fall,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Fatigue,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Flank pain,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Gastrointestinal disorder,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Glycosylated haemoglobin abnormal,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Groin pain,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Haematoma,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Headache,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Herpes zoster,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Hypoaesthesia,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Incontinence,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Leukocyturia,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Loss of libido,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Malaise,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Nausea,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Osteoarthritis,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Pain in extremity,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Peripheral coldness,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Phimosis,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Plantar fasciitis,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Pollakiuria,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Pruritus,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Quality of life decreased,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Renal cyst,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Restlessness,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Sacroiliac joint dysfunction,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Stress urinary incontinence,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Urinary tract infection bacterial,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186179862,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q1,Urine flow decreased,,2021,Q1,2,F,20140414.0,20210218.0,20201215,20210301,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210301.0,,MD,DE,DE,2021,Q1,Elderly
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Altered state of consciousness,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Cellulitis,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Chills,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Hidradenitis,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186193443,18619344,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Vomiting,,2021,Q1,3,F,202011.0,20210302.0,20201215,20210304,EXP,,JP-ABBVIE-20K-087-3693211-00,ABBVIE,,50.0,YR,,M,Y,,,20210304.0,,MD,JP,JP,2021,Q1,Adult
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Anxiety,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Arthralgia,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Back pain,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Bacterial test positive,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Balanoposthitis,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Blood glucose abnormal,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Disturbance in attention,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Dysuria,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Emotional distress,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Erectile dysfunction,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Fall,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Fatigue,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Feeling hot,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Flank pain,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Gastrointestinal disorder,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Glycosylated haemoglobin increased,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Groin pain,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Haematoma,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Headache,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Herpes zoster,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Hyperhidrosis,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Hypoaesthesia,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Incontinence,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Leukocyturia,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Loss of libido,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Malaise,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Muscle tightness,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Nausea,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Osteoarthritis,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pain in extremity,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Peripheral coldness,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Phimosis,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Plantar fasciitis,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pollakiuria,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Pruritus,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Quality of life decreased,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Renal cyst,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Restlessness,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sacroiliac joint dysfunction,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sense of oppression,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Sleep disorder,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Stress urinary incontinence,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Urinary tract infection bacterial,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186551343,18655134,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, QD (1?0?0?0), IN MORNING",,,U,,,,,,,TABLET,QD,2021,Q1,Urine flow decreased,,2021,Q1,3,F,20140414.0,20210210.0,20201223,20210302,EXP,,NVSC2020DE337118,NOVARTIS,,65.0,YR,,M,Y,134.0,KG,20210302.0,,MD,DE,DE,2021,Q1,Elderly
186646864,18664686,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Arrhythmia,,2021,Q1,4,F,20201216.0,20210225.0,20201225,20210306,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210306.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q1,Adult
186646864,18664686,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Intracardiac thrombus,,2021,Q1,4,F,20201216.0,20210225.0,20201225,20210306,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210306.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q1,Adult
186646864,18664686,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Supraventricular extrasystoles,,2021,Q1,4,F,20201216.0,20210225.0,20201225,20210306,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210306.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q1,Adult
186646864,18664686,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Tachycardia,,2021,Q1,4,F,20201216.0,20210225.0,20201225,20210306,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210306.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q1,Adult
186646864,18664686,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Ventricular extrasystoles,,2021,Q1,4,F,20201216.0,20210225.0,20201225,20210306,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210306.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q1,Adult
186758492,18675849,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,131597.0,,,FILM-COATED TABLET,,2021,Q1,Ventricular extrasystoles,,2021,Q1,2,F,20201221.0,20210106.0,20201229,20210111,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-072222",BOEHRINGER INGELHEIM,,81.0,YR,E,F,Y,,,20210111.0,,MD,BR,BR,2021,Q1,Elderly
186816944,18681694,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,Y,,,,,10.0,MG,,,2021,Q1,Atrial fibrillation,,2021,Q1,4,F,202012.0,20210304.0,20201230,20210317,EXP,,NVSJ2020JP013977,NOVARTIS,,49.0,YR,,M,Y,,,20210317.0,,PH,JP,JP,2021,Q1,Adult
186816944,18681694,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,Y,,,,,10.0,MG,,,2021,Q1,Cardiac failure,,2021,Q1,4,F,202012.0,20210304.0,20201230,20210317,EXP,,NVSJ2020JP013977,NOVARTIS,,49.0,YR,,M,Y,,,20210317.0,,PH,JP,JP,2021,Q1,Adult
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Aggression,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Anger,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Depression,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Mood altered,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Personality change,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186958341,18695834,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Tachyphrenia,,2021,Q1,1,I,20200710.0,20201223.0,20210104,20210104,EXP,GB-MHRA-EYC 00234802,GB-MYLANLABS-2020M1105750,MYLAN,,65.0,YR,,M,Y,90.0,KG,20210104.0,,CN,GB,GB,2021,Q1,Elderly
186973571,18697357,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q1,Hypokalaemia,,2021,Q1,1,I,20201109.0,20201224.0,20210104,20210104,EXP,DK-DKMA-WBS-0027902,DK-NOVOPROD-777437,NOVO NORDISK,,67.0,YR,,M,Y,,,20210104.0,,MD,DK,DK,2021,Q1,Elderly
187056651,18705665,6,C,Empagliflozin 10 mg tab,,2,,,,,,,,,,,,,,2021,Q1,Cough,,2021,Q1,1,I,20201216.0,,20210105,20210105,DIR,,,FDA-CTU,,72.0,YR,,M,N,104.6,KG,20210105.0,N,PH,US,US,2021,Q1,Elderly
187056651,18705665,6,C,Empagliflozin 10 mg tab,,2,,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,20201216.0,,20210105,20210105,DIR,,,FDA-CTU,,72.0,YR,,M,N,104.6,KG,20210105.0,N,PH,US,US,2021,Q1,Elderly
187066881,18706688,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Penile discomfort,,2021,Q1,1,I,20200914.0,,20210105,20210105,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187066881,18706688,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Pollakiuria,,2021,Q1,1,I,20200914.0,,20210105,20210105,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187066881,18706688,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Thirst,,2021,Q1,1,I,20200914.0,,20210105,20210105,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187089301,18708930,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Acute myocardial infarction,,2021,Q1,1,I,,20210101.0,20210107,20210107,EXP,,HR-JNJFOC-20210106835,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,,,20210107.0,,MD,HR,HR,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Abdominal pain upper,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Nausea,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Treatment noncompliance,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Vomiting,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187178291,18717829,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Weight decreased,,2021,Q1,1,I,20200728.0,,20210107,20210107,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,,US,US,2021,Q1,Adult
187182721,18718272,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Diverticulitis,,2021,Q1,1,I,20200525.0,20210106.0,20210108,20210108,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210108.0,,HP,GB,GB,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Abdominal pain upper,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Chills,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Decreased appetite,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Fatigue,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Hypophagia,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Lactic acidosis,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Nausea,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Pyrexia,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187238301,18723830,2,SS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q1,Vomiting,,2021,Q1,1,I,20201022.0,,20210107,20210107,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20201218.0,N,PH,US,US,2021,Q1,Adult
187240161,18724016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,TABLET,QD,2021,Q1,Cardiac failure,,2021,Q1,1,I,20201224.0,,20210108,20210108,DIR,,,FDA-CTU,,72.0,YR,,M,N,69.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
187240161,18724016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,1,I,20201224.0,,20210108,20210108,DIR,,,FDA-CTU,,72.0,YR,,M,N,69.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
187244801,18724480,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,1.0,DF,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20200616.0,,20210111,20210111,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20200819.0,N,PH,US,US,2021,Q1,Adult
187244801,18724480,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,1.0,DF,TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,20200616.0,,20210111,20210111,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20200819.0,N,PH,US,US,2021,Q1,Adult
187245331,18724533,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,1,I,20201026.0,,20210107,20210107,DIR,,,FDA-CTU,,84.0,YR,,M,N,87.0,KG,20201231.0,N,PH,US,US,2021,Q1,Elderly
187245331,18724533,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20201026.0,,20210107,20210107,DIR,,,FDA-CTU,,84.0,YR,,M,N,87.0,KG,20201231.0,N,PH,US,US,2021,Q1,Elderly
187245331,18724533,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Hypovolaemia,,2021,Q1,1,I,20201026.0,,20210107,20210107,DIR,,,FDA-CTU,,84.0,YR,,M,N,87.0,KG,20201231.0,N,PH,US,US,2021,Q1,Elderly
187245331,18724533,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Orthostatic hypotension,,2021,Q1,1,I,20201026.0,,20210107,20210107,DIR,,,FDA-CTU,,84.0,YR,,M,N,87.0,KG,20201231.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Adverse drug reaction,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Blood glucose increased,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Culture urine positive,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Escherichia infection,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Glycosylated haemoglobin increased,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Hypotension,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Infection,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Micturition urgency,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Pollakiuria,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Prostatic specific antigen increased,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Prostatomegaly,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Pyrexia,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Treatment noncompliance,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Urosepsis,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187247661,18724766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB ;?,,,N,D,,,,,,COATED TABLET,QD,2021,Q1,Vomiting,,2021,Q1,1,I,20200808.0,,20210111,20210111,DIR,,,FDA-CTU,,71.0,YR,,M,N,89.0,KG,20201018.0,N,PH,US,US,2021,Q1,Elderly
187357531,18735753,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,20200728.0,,20210108,20210108,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,PH,US,US,2021,Q1,Adult
187357531,18735753,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Treatment noncompliance,,2021,Q1,1,I,20200728.0,,20210108,20210108,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,PH,US,US,2021,Q1,Adult
187357531,18735753,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Weight decreased,,2021,Q1,1,I,20200728.0,,20210108,20210108,DIR,,,FDA-CTU,,45.0,YR,,M,N,72.0,KG,20200919.0,N,PH,US,US,2021,Q1,Adult
187363821,18736382,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,20200908.0,,20210108,20210108,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Adult
187390241,18739024,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20200714.0,,20210108,20210108,DIR,,,FDA-CTU,,72.0,YR,,M,N,136.0,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
187403111,18740311,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,U,U,,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210106.0,20210114,20210114,EXP,,US-MYLANLABS-2021M1001691,MYLAN,"YANG M?JJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J?AM?SOC?NEPHROL 2019?30:863 (PLUS POSTER) ABSTR. SA?PO388.",69.0,YR,,F,Y,,,20210114.0,,HP,US,US,2021,Q1,Elderly
187403111,18740311,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,U,U,,,,25.0,MG,,QD,2021,Q1,Hyperkalaemia,,2021,Q1,1,I,,20210106.0,20210114,20210114,EXP,,US-MYLANLABS-2021M1001691,MYLAN,"YANG M?JJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J?AM?SOC?NEPHROL 2019?30:863 (PLUS POSTER) ABSTR. SA?PO388.",69.0,YR,,F,Y,,,20210114.0,,HP,US,US,2021,Q1,Elderly
187403791,18740379,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20200113.0,,20210113,20210113,DIR,,,FDA-CTU,,57.0,YR,,F,N,,,20201217.0,N,PH,US,US,2021,Q1,Adult
187403791,18740379,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Nausea,,2021,Q1,1,I,20200113.0,,20210113,20210113,DIR,,,FDA-CTU,,57.0,YR,,F,N,,,20201217.0,N,PH,US,US,2021,Q1,Adult
187403791,18740379,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Vomiting,,2021,Q1,1,I,20200113.0,,20210113,20210113,DIR,,,FDA-CTU,,57.0,YR,,F,N,,,20201217.0,N,PH,US,US,2021,Q1,Adult
187444252,18744425,2,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,2,F,,20210119.0,20210115,20210129,EXP,,US-AUROBINDO-AUR-APL-2021-001473,AUROBINDO,,69.0,YR,,F,Y,,,20210129.0,,HP,US,US,2021,Q1,Elderly
187444252,18744425,2,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,2,F,,20210119.0,20210115,20210129,EXP,,US-AUROBINDO-AUR-APL-2021-001473,AUROBINDO,,69.0,YR,,F,Y,,,20210129.0,,HP,US,US,2021,Q1,Elderly
187444252,18744425,2,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, ONCE A DAY",,,U,,,,,25.0,MG,,QD,2021,Q1,Metabolic acidosis,,2021,Q1,2,F,,20210119.0,20210115,20210129,EXP,,US-AUROBINDO-AUR-APL-2021-001473,AUROBINDO,,69.0,YR,,F,Y,,,20210129.0,,HP,US,US,2021,Q1,Elderly
187500811,18750081,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Sudden cardiac death,,2021,Q1,1,I,20210111.0,20210114.0,20210118,20210118,EXP,GB-MHRA-WEBCOVID-20210113134901,GB-ROCHE-2750159,ROCHE,,70.0,YR,,M,Y,72.0,KG,20210118.0,,PH,GB,GB,2021,Q1,Elderly
187551021,18755102,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1/2 TAB;?,,,N,D,,,,,,TABLET,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200914.0,,20210114,20210114,DIR,,,FDA-CTU,,71.0,YR,,M,N,93.0,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187573531,18757353,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,U,, UNKNOWN,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210106.0,20210119,20210119,EXP,,US-LUPIN PHARMACEUTICALS INC.-2021-00253,LUPIN,,69.0,YR,,F,Y,,,20210119.0,,HP,US,US,2021,Q1,Elderly
187573531,18757353,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,U,, UNKNOWN,,,25.0,MG,,QD,2021,Q1,Hyperkalaemia,,2021,Q1,1,I,,20210106.0,20210119,20210119,EXP,,US-LUPIN PHARMACEUTICALS INC.-2021-00253,LUPIN,,69.0,YR,,F,Y,,,20210119.0,,HP,US,US,2021,Q1,Elderly
187577861,18757786,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Blood creatinine increased,,2021,Q1,1,I,,20210105.0,20210119,20210119,PER,,AU-LUPIN PHARMACEUTICALS INC.-2021-00175,LUPIN,DAVIS TME. FENOFIBRATE AND IMPAIRED TASTE PERCEPTION IN TYPE 2 DIABETES. AMERICAN JOURNAL OF CASE REPORTS. 2020?21:E927647?1?E927647?4,65.0,YR,,F,Y,80.0,KG,20210119.0,,HP,AU,AU,2021,Q1,Elderly
187577861,18757786,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Decreased appetite,,2021,Q1,1,I,,20210105.0,20210119,20210119,PER,,AU-LUPIN PHARMACEUTICALS INC.-2021-00175,LUPIN,DAVIS TME. FENOFIBRATE AND IMPAIRED TASTE PERCEPTION IN TYPE 2 DIABETES. AMERICAN JOURNAL OF CASE REPORTS. 2020?21:E927647?1?E927647?4,65.0,YR,,F,Y,80.0,KG,20210119.0,,HP,AU,AU,2021,Q1,Elderly
187577861,18757786,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Taste disorder,,2021,Q1,1,I,,20210105.0,20210119,20210119,PER,,AU-LUPIN PHARMACEUTICALS INC.-2021-00175,LUPIN,DAVIS TME. FENOFIBRATE AND IMPAIRED TASTE PERCEPTION IN TYPE 2 DIABETES. AMERICAN JOURNAL OF CASE REPORTS. 2020?21:E927647?1?E927647?4,65.0,YR,,F,Y,80.0,KG,20210119.0,,HP,AU,AU,2021,Q1,Elderly
187582231,18758223,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,112.042,DF,U,,,,,1.0,DF,,QD,2021,Q1,Bronchospasm,,2021,Q1,1,I,20210105.0,20210111.0,20210119,20210119,EXP,GB-MHRA-TPP32011192C4480557YC1609839981490,GB-PERRIGO-21GB000197,PERRIGO,,52.0,YR,,M,Y,95.0,KG,20210119.0,,MD,GB,GB,2021,Q1,Adult
187585881,18758588,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, DAILY",,,,,,,,10.0,MG,,,2021,Q1,Taste disorder,,2021,Q1,1,I,,20210105.0,20210120,20210120,EXP,,AU-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-275894,RANBAXY,DAVIS TME. FENOFIBRATE AND IMPAIRED TASTE PERCEPTION IN TYPE 2 DIABETES. AM J CASE REP. 2020?21:E927647?1?4,65.0,YR,,F,Y,80.0,KG,20210120.0,,HP,AU,AU,2021,Q1,Elderly
187600071,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210108.0,20210120,20210120,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2019?30:863.",69.0,YR,E,F,Y,,,20210120.0,,HP,US,US,2021,Q1,Elderly
187600071,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210108.0,20210120,20210120,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2019?30:863.",69.0,YR,E,F,Y,,,20210120.0,,HP,US,US,2021,Q1,Elderly
187600071,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,,20210108.0,20210120,20210120,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2019?30:863.",69.0,YR,E,F,Y,,,20210120.0,,HP,US,US,2021,Q1,Elderly
187631303,18763130,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Acute kidney injury,,2021,Q1,3,F,20201027.0,20210212.0,20210120,20210218,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-075974",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,71.1,KG,20210218.0,,MD,GB,GB,2021,Q1,Elderly
187632011,18763201,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D, UNKNOWN,,,,,,QD,2021,Q1,Fournier's gangrene,,2021,Q1,1,I,20201102.0,,20210120,20210120,DIR,,,FDA-CTU,,65.0,YR,,M,N,80.0,KG,20210120.0,N,CN,US,US,2021,Q1,Elderly
187648381,18764838,9,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,1 DOSAGE FORM,112.042,DF,U,,,,,1.0,DF,,,2021,Q1,Bronchospasm,,2021,Q1,1,I,20210105.0,20210111.0,20210121,20210121,EXP,,GB-AUROBINDO-AUR-APL-2021-001814,AUROBINDO,,52.0,YR,,M,Y,95.0,KG,20210121.0,,MD,GB,GB,2021,Q1,Adult
187649431,18764943,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK (TAKE ONE DAILY),,,,,,,,,,,,2021,Q1,Hypersensitivity,,2021,Q1,1,I,20210113.0,20210115.0,20210121,20210121,EXP,,GB-AUROBINDO-AUR-APL-2021-002353,AUROBINDO,,65.0,YR,,F,Y,77.0,KG,20210121.0,,MD,GB,GB,2021,Q1,Elderly
187649431,18764943,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK (TAKE ONE DAILY),,,,,,,,,,,,2021,Q1,Peripheral swelling,,2021,Q1,1,I,20210113.0,20210115.0,20210121,20210121,EXP,,GB-AUROBINDO-AUR-APL-2021-002353,AUROBINDO,,65.0,YR,,F,Y,77.0,KG,20210121.0,,MD,GB,GB,2021,Q1,Elderly
187649431,18764943,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK (TAKE ONE DAILY),,,,,,,,,,,,2021,Q1,Pruritus,,2021,Q1,1,I,20210113.0,20210115.0,20210121,20210121,EXP,,GB-AUROBINDO-AUR-APL-2021-002353,AUROBINDO,,65.0,YR,,F,Y,77.0,KG,20210121.0,,MD,GB,GB,2021,Q1,Elderly
187649431,18764943,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK (TAKE ONE DAILY),,,,,,,,,,,,2021,Q1,Swelling face,,2021,Q1,1,I,20210113.0,20210115.0,20210121,20210121,EXP,,GB-AUROBINDO-AUR-APL-2021-002353,AUROBINDO,,65.0,YR,,F,Y,77.0,KG,20210121.0,,MD,GB,GB,2021,Q1,Elderly
187658501,18765850,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276512,RANBAXY,"YANG M?J J, JESUS EJD, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187658501,18765850,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276512,RANBAXY,"YANG M?J J, JESUS EJD, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187666251,18766625,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276253,RANBAXY,"YANG MJJ, JESUS EJD, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863/SA?PO388",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187666251,18766625,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276253,RANBAXY,"YANG MJJ, JESUS EJD, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863/SA?PO388",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187667741,18766774,2,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Anaphylactic reaction,,2021,Q1,1,I,20210115.0,,20210120,20210120,DIR,,,FDA-CTU,,56.0,YR,,M,N,146.2,KG,20210120.0,N,HP,US,US,2021,Q1,Adult
187667741,18766774,2,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,20210115.0,,20210120,20210120,DIR,,,FDA-CTU,,56.0,YR,,M,N,146.2,KG,20210120.0,N,HP,US,US,2021,Q1,Adult
187667741,18766774,2,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Dyspepsia,,2021,Q1,1,I,20210115.0,,20210120,20210120,DIR,,,FDA-CTU,,56.0,YR,,M,N,146.2,KG,20210120.0,N,HP,US,US,2021,Q1,Adult
187667741,18766774,2,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Movement disorder,,2021,Q1,1,I,20210115.0,,20210120,20210120,DIR,,,FDA-CTU,,56.0,YR,,M,N,146.2,KG,20210120.0,N,HP,US,US,2021,Q1,Adult
187669481,18766948,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Abdominal pain,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276307,RANBAXY,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187669481,18766948,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276307,RANBAXY,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187669481,18766948,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Nausea,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276307,RANBAXY,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187669481,18766948,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, DAILY",,,U,,,,,25.0,MG,,,2021,Q1,Vomiting,,2021,Q1,1,I,,20210106.0,20210121,20210121,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-276307,RANBAXY,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863(SA?PO388)",69.0,YR,,F,Y,,,20210121.0,,HP,US,US,2021,Q1,Elderly
187698491,18769849,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20201009.0,20210118.0,20210121,20210121,EXP,GB-MHRA-EYC 00236997,GB-SA-2021SA015132,SANOFI AVENTIS,,56.0,YR,A,F,Y,61.7,KG,20210121.0,,MD,GB,GB,2021,Q1,Adult
187729341,18772934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210108.0,20210121,20210121,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK051626,GLENMARK,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A.. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY.. 2019?30:863",69.0,YR,,F,Y,,,20210122.0,,HP,US,US,2021,Q1,Elderly
187729341,18772934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210108.0,20210121,20210121,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK051626,GLENMARK,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A.. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY.. 2019?30:863",69.0,YR,,F,Y,,,20210122.0,,HP,US,US,2021,Q1,Elderly
187729341,18772934,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,,20210108.0,20210121,20210121,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK051626,GLENMARK,"YANG MJJ, DE JESUS EJ, BELAL AA, KORATALA A.. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION.. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY.. 2019?30:863",69.0,YR,,F,Y,,,20210122.0,,HP,US,US,2021,Q1,Elderly
187731771,18773177,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q1,Rash,,2021,Q1,1,I,20201221.0,,20210121,20210121,DIR,,,FDA-CTU,,61.0,YR,,M,N,,,20201222.0,N,MD,US,US,2021,Q1,Adult
187732991,18773299,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q1,Epididymitis,,2021,Q1,1,I,20201102.0,,20210121,20210121,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20201120.0,N,MD,US,US,2021,Q1,Elderly
187738071,18773807,7,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,20210121.0,,20210122,20210122,DIR,,,FDA-CTU,,51.0,YR,,M,N,136.0,KG,20210122.0,N,PH,US,US,2021,Q1,Adult
187738071,18773807,7,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,20210121.0,,20210122,20210122,DIR,,,FDA-CTU,,51.0,YR,,M,N,136.0,KG,20210122.0,N,PH,US,US,2021,Q1,Adult
187738071,18773807,7,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,20210121.0,,20210122,20210122,DIR,,,FDA-CTU,,51.0,YR,,M,N,136.0,KG,20210122.0,N,PH,US,US,2021,Q1,Adult
187738071,18773807,7,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Vomiting,,2021,Q1,1,I,20210121.0,,20210122,20210122,DIR,,,FDA-CTU,,51.0,YR,,M,N,136.0,KG,20210122.0,N,PH,US,US,2021,Q1,Adult
187756401,18775640,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,D,,,,,25.0,MG,,,2021,Q1,Cerebrovascular accident,,2021,Q1,1,I,,20210114.0,20210122,20210122,EXP,,CA-APOTEX-2021AP001405,APOTEX,"YEUNG RO, AL JUNDI M, GUBBI S, BOMPU ME, SIRRS S, TARNOPOLSKY M ET AL. MANAGEMENT OF MITOCHONDRIAL DIABETES IN THE ERA OF NOVEL THERAPIES. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2021?35(1):1?6",51.0,YR,,M,Y,,,20210122.0,,HP,CA,CA,2021,Q1,Adult
187756401,18775640,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,D,,,,,25.0,MG,,,2021,Q1,Lactic acidosis,,2021,Q1,1,I,,20210114.0,20210122,20210122,EXP,,CA-APOTEX-2021AP001405,APOTEX,"YEUNG RO, AL JUNDI M, GUBBI S, BOMPU ME, SIRRS S, TARNOPOLSKY M ET AL. MANAGEMENT OF MITOCHONDRIAL DIABETES IN THE ERA OF NOVEL THERAPIES. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2021?35(1):1?6",51.0,YR,,M,Y,,,20210122.0,,HP,CA,CA,2021,Q1,Adult
187756401,18775640,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,D,,,,,25.0,MG,,,2021,Q1,Therapeutic product effect incomplete,,2021,Q1,1,I,,20210114.0,20210122,20210122,EXP,,CA-APOTEX-2021AP001405,APOTEX,"YEUNG RO, AL JUNDI M, GUBBI S, BOMPU ME, SIRRS S, TARNOPOLSKY M ET AL. MANAGEMENT OF MITOCHONDRIAL DIABETES IN THE ERA OF NOVEL THERAPIES. JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2021?35(1):1?6",51.0,YR,,M,Y,,,20210122.0,,HP,CA,CA,2021,Q1,Adult
187757101,18775710,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM (10 MG, 1?0?0?0)",,,,,,,,10.0,MG,,,2021,Q1,Anaemia,,2021,Q1,1,I,,20210118.0,20210122,20210122,EXP,,DE-MYLANLABS-2021M1003491,MYLAN,,80.0,YR,,F,Y,,,20210122.0,,MD,DE,DE,2021,Q1,Elderly
187757101,18775710,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM (10 MG, 1?0?0?0)",,,,,,,,10.0,MG,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210118.0,20210122,20210122,EXP,,DE-MYLANLABS-2021M1003491,MYLAN,,80.0,YR,,F,Y,,,20210122.0,,MD,DE,DE,2021,Q1,Elderly
187757101,18775710,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM (10 MG, 1?0?0?0)",,,,,,,,10.0,MG,,,2021,Q1,General physical health deterioration,,2021,Q1,1,I,,20210118.0,20210122,20210122,EXP,,DE-MYLANLABS-2021M1003491,MYLAN,,80.0,YR,,F,Y,,,20210122.0,,MD,DE,DE,2021,Q1,Elderly
187757101,18775710,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM (10 MG, 1?0?0?0)",,,,,,,,10.0,MG,,,2021,Q1,Haematochezia,,2021,Q1,1,I,,20210118.0,20210122,20210122,EXP,,DE-MYLANLABS-2021M1003491,MYLAN,,80.0,YR,,F,Y,,,20210122.0,,MD,DE,DE,2021,Q1,Elderly
187757101,18775710,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM (10 MG, 1?0?0?0)",,,,,,,,10.0,MG,,,2021,Q1,Pallor,,2021,Q1,1,I,,20210118.0,20210122,20210122,EXP,,DE-MYLANLABS-2021M1003491,MYLAN,,80.0,YR,,F,Y,,,20210122.0,,MD,DE,DE,2021,Q1,Elderly
187761951,18776195,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM DAILY;,,,U,,,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210111.0,20210122,20210122,EXP,,US-TEVA-2021-US-1870060,TEVA,"YANG M?JJ, DE JESUS EJ, BELAL AA, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J?AM?SOC?NEPHROL 2019?30:863 (PLUS POSTER) ABSTR. SA?PO388.",69.0,YR,E,F,Y,,,20210122.0,,HP,US,US,2021,Q1,Elderly
187809671,18780967,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,PC,2021,Q1,Nephropathy,,2021,Q1,1,I,20200708.0,,20210122,20210122,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20200919.0,N,PH,US,US,2021,Q1,Elderly
187941292,18794129,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Acute kidney injury,,2021,Q1,2,F,20210113.0,20210216.0,20210127,20210219,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-078050",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,104.0,KG,20210219.0,,MD,IT,IT,2021,Q1,Adult
187941292,18794129,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q1,Metabolic acidosis,,2021,Q1,2,F,20210113.0,20210216.0,20210127,20210219,EXP,,"IT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-078050",BOEHRINGER INGELHEIM,,64.0,YR,A,M,Y,104.0,KG,20210219.0,,MD,IT,IT,2021,Q1,Adult
188004781,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210127.0,20210128,20210128,EXP,DE-BFARM-21000617,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210128.0,,HP,DE,DE,2021,Q1,Elderly
188004781,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210127.0,20210128,20210128,EXP,DE-BFARM-21000617,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210128.0,,HP,DE,DE,2021,Q1,Elderly
188004781,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210127.0,20210128,20210128,EXP,DE-BFARM-21000617,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210128.0,,HP,DE,DE,2021,Q1,Elderly
188004781,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210127.0,20210128,20210128,EXP,DE-BFARM-21000617,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210128.0,,HP,DE,DE,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Fall,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Haemorrhage,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Head injury,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Hypotonia,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Penile haemorrhage,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Penis injury,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Pruritus,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Pruritus genital,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Sedation,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188028184,18802818,24,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Somnolence,,2021,Q1,4,F,,20210210.0,20210129,20210220,EXP,,PL-AUROBINDO-AUR-APL-2020-039462,AUROBINDO,WORO? J. PENIS PRURITUS AS AN ADVERSE EFFECT OF QUETIAPINE INTERACTION WITH OTHER DRUGS USED BY THE PATIENT. PRACTICAL MEDICINE ? PSYCHIATRY. 2020?77(6):78?79,68.0,YR,,M,Y,,,20210220.0,,HP,PL,PL,2021,Q1,Elderly
188080651,18808065,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Genital rash,,2021,Q1,1,I,20210113.0,,20210128,20210128,DIR,,,FDA-CTU,,62.0,YR,,M,N,,,20210127.0,N,PH,US,US,2021,Q1,Adult
188080651,18808065,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Pollakiuria,,2021,Q1,1,I,20210113.0,,20210128,20210128,DIR,,,FDA-CTU,,62.0,YR,,M,N,,,20210127.0,N,PH,US,US,2021,Q1,Adult
188080651,18808065,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20210113.0,,20210128,20210128,DIR,,,FDA-CTU,,62.0,YR,,M,N,,,20210127.0,N,PH,US,US,2021,Q1,Adult
188088171,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210125.0,20210129,20210129,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210129.0,,MD,DE,DE,2021,Q1,Elderly
188088171,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210125.0,20210129,20210129,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210129.0,,MD,DE,DE,2021,Q1,Elderly
188088171,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210125.0,20210129,20210129,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210129.0,,MD,DE,DE,2021,Q1,Elderly
188088171,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210125.0,20210129,20210129,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210129.0,,MD,DE,DE,2021,Q1,Elderly
188122781,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210129,20210129,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210130.0,,MD,DE,DE,2021,Q1,Elderly
188122781,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210121.0,20210129,20210129,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210130.0,,MD,DE,DE,2021,Q1,Elderly
188122781,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210121.0,20210129,20210129,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210130.0,,MD,DE,DE,2021,Q1,Elderly
188122781,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210129,20210129,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210130.0,,MD,DE,DE,2021,Q1,Elderly
188160451,18816045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,N,,,,,,,,2021,Q1,Angioedema,,2021,Q1,1,I,20201123.0,,20210130,20210130,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188160451,18816045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,N,,,,,,,,2021,Q1,Expired product administered,,2021,Q1,1,I,20201123.0,,20210130,20210130,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188160451,18816045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,N,,,,,,,,2021,Q1,Pharyngeal swelling,,2021,Q1,1,I,20201123.0,,20210130,20210130,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188160451,18816045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,N,,,,,,,,2021,Q1,Swelling face,,2021,Q1,1,I,20201123.0,,20210130,20210130,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188160451,18816045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,N,,,,,,,,2021,Q1,Swollen tongue,,2021,Q1,1,I,20201123.0,,20210130,20210130,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188185511,18818551,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210127.0,20210202,20210202,EXP,,DE-009507513-2101DEU012565,MERCK,,75.0,YR,,F,Y,,,20210202.0,,MD,DE,DE,2021,Q1,Elderly
188185511,18818551,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210127.0,20210202,20210202,EXP,,DE-009507513-2101DEU012565,MERCK,,75.0,YR,,F,Y,,,20210202.0,,MD,DE,DE,2021,Q1,Elderly
188185511,18818551,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210127.0,20210202,20210202,EXP,,DE-009507513-2101DEU012565,MERCK,,75.0,YR,,F,Y,,,20210202.0,,MD,DE,DE,2021,Q1,Elderly
188185511,18818551,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210127.0,20210202,20210202,EXP,,DE-009507513-2101DEU012565,MERCK,,75.0,YR,,F,Y,,,20210202.0,,MD,DE,DE,2021,Q1,Elderly
188213601,18821360,1,PS,"EMPAGLIFLOZIN/METFORMIN (EMPAGLIFLOZIN 5MG/METFORMIN 1000MG 24 HR TAB,",EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,2.0,DF,COATED TABLET,QD,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20201006.0,,20210201,20210201,DIR,,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
188213601,18821360,1,PS,"EMPAGLIFLOZIN/METFORMIN (EMPAGLIFLOZIN 5MG/METFORMIN 1000MG 24 HR TAB,",EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,2.0,DF,COATED TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,20201006.0,,20210201,20210201,DIR,,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
188213601,18821360,1,PS,"EMPAGLIFLOZIN/METFORMIN (EMPAGLIFLOZIN 5MG/METFORMIN 1000MG 24 HR TAB,",EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,2.0,DF,COATED TABLET,QD,2021,Q1,Vomiting,,2021,Q1,1,I,20201006.0,,20210201,20210201,DIR,,,FDA-CTU,,74.0,YR,,M,N,110.0,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
188222031,18822203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q1,Dizziness,,2021,Q1,1,I,20200908.0,,20210201,20210201,DIR,,,FDA-CTU,,86.0,YR,,M,N,98.0,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
188222031,18822203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q1,Syncope,,2021,Q1,1,I,20200908.0,,20210201,20210201,DIR,,,FDA-CTU,,86.0,YR,,M,N,98.0,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
188410681,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210126.0,20210204,20210204,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210204.0,,MD,DE,DE,2021,Q1,Elderly
188410681,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210126.0,20210204,20210204,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210204.0,,MD,DE,DE,2021,Q1,Elderly
188410681,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210126.0,20210204,20210204,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210204.0,,MD,DE,DE,2021,Q1,Elderly
188410681,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210126.0,20210204,20210204,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210204.0,,MD,DE,DE,2021,Q1,Elderly
188461892,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,2,F,20201203.0,20210212.0,20210204,20210222,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210222.0,,MD,DE,DE,2021,Q1,Elderly
188461892,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,2,F,20201203.0,20210212.0,20210204,20210222,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210222.0,,MD,DE,DE,2021,Q1,Elderly
188461892,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,2,F,20201203.0,20210212.0,20210204,20210222,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210222.0,,MD,DE,DE,2021,Q1,Elderly
188461892,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,2,F,20201203.0,20210212.0,20210204,20210222,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210222.0,,MD,DE,DE,2021,Q1,Elderly
188483581,18848358,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG (25 MG,1 IN 1 D)",,,,,,,,,,,,2021,Q1,Abdominal pain upper,,2021,Q1,1,I,20201222.0,20210125.0,20210204,20210204,EXP,,GB-ASTRAZENECA-2021A027050,ASTRAZENECA,,55.0,YR,,M,Y,,,20210204.0,,,DE,GB,2021,Q1,Adult
188483581,18848358,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG (25 MG,1 IN 1 D)",,,,,,,,,,,,2021,Q1,Hypertriglyceridaemia,,2021,Q1,1,I,20201222.0,20210125.0,20210204,20210204,EXP,,GB-ASTRAZENECA-2021A027050,ASTRAZENECA,,55.0,YR,,M,Y,,,20210204.0,,,DE,GB,2021,Q1,Adult
188483581,18848358,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG (25 MG,1 IN 1 D)",,,,,,,,,,,,2021,Q1,Pancreatitis acute,,2021,Q1,1,I,20201222.0,20210125.0,20210204,20210204,EXP,,GB-ASTRAZENECA-2021A027050,ASTRAZENECA,,55.0,YR,,M,Y,,,20210204.0,,,DE,GB,2021,Q1,Adult
188494021,18849402,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210205.0,,HP,NL,DE,2021,Q1,Elderly
188494021,18849402,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210205.0,,HP,NL,DE,2021,Q1,Elderly
188494021,18849402,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210205.0,,HP,NL,DE,2021,Q1,Elderly
188494021,18849402,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210205.0,,HP,NL,DE,2021,Q1,Elderly
188504971,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210205.0,,HP,DE,DE,2021,Q1,Elderly
188504971,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210205.0,,HP,DE,DE,2021,Q1,Elderly
188504971,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210205.0,,HP,DE,DE,2021,Q1,Elderly
188504971,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210121.0,20210205,20210205,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210205.0,,HP,DE,DE,2021,Q1,Elderly
188560201,18856020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Abdominal pain upper,,2021,Q1,1,I,20201222.0,20210125.0,20210206,20210206,EXP,GB-MHRA-ADR 24627360,GB-ACCORD-216426,ACCORD,,55.0,YR,,M,Y,,,20210206.0,,PH,GB,GB,2021,Q1,Adult
188560201,18856020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Hypertriglyceridaemia,,2021,Q1,1,I,20201222.0,20210125.0,20210206,20210206,EXP,GB-MHRA-ADR 24627360,GB-ACCORD-216426,ACCORD,,55.0,YR,,M,Y,,,20210206.0,,PH,GB,GB,2021,Q1,Adult
188560201,18856020,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Pancreatitis acute,,2021,Q1,1,I,20201222.0,20210125.0,20210206,20210206,EXP,GB-MHRA-ADR 24627360,GB-ACCORD-216426,ACCORD,,55.0,YR,,M,Y,,,20210206.0,,PH,GB,GB,2021,Q1,Adult
188578111,18857811,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, EVERYDAY",,,,,,,,10.0,MG,,QD,2021,Q1,Bradycardia,,2021,Q1,1,I,2021.0,20210130.0,20210208,20210208,PER,,JP-AMGEN-JPNSP2021019946,AMGEN,,39.0,YR,A,F,Y,110.0,KG,20210208.0,,MD,JP,JP,2021,Q1,Adult
188578111,18857811,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, EVERYDAY",,,,,,,,10.0,MG,,QD,2021,Q1,Product use issue,,2021,Q1,1,I,2021.0,20210130.0,20210208,20210208,PER,,JP-AMGEN-JPNSP2021019946,AMGEN,,39.0,YR,A,F,Y,110.0,KG,20210208.0,,MD,JP,JP,2021,Q1,Adult
188625991,18862599,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Cytomegalovirus oesophagitis,,2021,Q1,1,I,,20210129.0,20210208,20210208,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-277831,RANBAXY,"YAMAMOTO S, IWAMURO M, MIYAKE M, NISHIMURA N, MIZUNO M, OKADA H. SEVERE BLEEDING DUE TO CYTOMEGALOVIRUS ESOPHAGITIS IN A PATIENT WITH DIABETES AFTER INTERBODY FUSION SURGERY. INTERN MED. 2019?58:2949?2955",49.0,YR,,M,Y,,,20210208.0,,MD,JP,JP,2021,Q1,Adult
188667721,18866772,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Arthralgia,,2021,Q1,1,I,20210108.0,,20210208,20210208,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188667721,18866772,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Chromaturia,,2021,Q1,1,I,20210108.0,,20210208,20210208,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q1,Elderly
188681741,18868174,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Abdominal pain upper,,2021,Q1,1,I,20201222.0,20210125.0,20210209,20210209,EXP,GB-MHRA-MIDB-8089E527-A0D1-4FFF-92A7-7467480D4ABD,GB-TEVA-2021-GB-1875002,TEVA,,55.0,YR,A,M,Y,,,20210209.0,,PH,GB,GB,2021,Q1,Adult
188681741,18868174,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Hypertriglyceridaemia,,2021,Q1,1,I,20201222.0,20210125.0,20210209,20210209,EXP,GB-MHRA-MIDB-8089E527-A0D1-4FFF-92A7-7467480D4ABD,GB-TEVA-2021-GB-1875002,TEVA,,55.0,YR,A,M,Y,,,20210209.0,,PH,GB,GB,2021,Q1,Adult
188681741,18868174,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,,,,,,25.0,MG,TABLET,QD,2021,Q1,Pancreatitis acute,,2021,Q1,1,I,20201222.0,20210125.0,20210209,20210209,EXP,GB-MHRA-MIDB-8089E527-A0D1-4FFF-92A7-7467480D4ABD,GB-TEVA-2021-GB-1875002,TEVA,,55.0,YR,A,M,Y,,,20210209.0,,PH,GB,GB,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Asthenia,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Blood glucose increased,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Blood urine,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Dysuria,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Fatigue,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Glycosuria,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Glycosylated haemoglobin increased,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Infection,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Klebsiella infection,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Leukocytosis,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Penile discomfort,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Pollakiuria,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Self-medication,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Tachycardia,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,Urine ketone body present,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188773121,18877312,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,, 956953,20220131.0,,25.0,MG,,QD,2021,Q1,White blood cells urine,,2021,Q1,1,I,20200102.0,,20210210,20210210,DIR,,,FDA-CTU,,64.0,YR,,M,N,96.0,KG,20200218.0,N,PH,US,US,2021,Q1,Adult
188780161,18878016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,20210127.0,,20210210,20210210,DIR,,,FDA-CTU,,54.0,YR,,M,N,77.0,KG,20210209.0,N,PH,US,US,2021,Q1,Adult
188861431,18886143,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20201102.0,,20210211,20210211,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20201222.0,N,PH,US,US,2021,Q1,Elderly
188916511,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Language disorder,,2021,Q1,1,I,20201203.0,20210204.0,20210215,20210215,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210215.0,,MD,DE,DE,2021,Q1,Elderly
188916511,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Myalgia,,2021,Q1,1,I,20201203.0,20210204.0,20210215,20210215,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210215.0,,MD,DE,DE,2021,Q1,Elderly
188916511,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,20201203.0,20210204.0,20210215,20210215,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210215.0,,MD,DE,DE,2021,Q1,Elderly
188916511,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q1,Sensorimotor disorder,,2021,Q1,1,I,20201203.0,20210204.0,20210215,20210215,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210215.0,,MD,DE,DE,2021,Q1,Elderly
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Akinesia,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Cardiac failure,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Decreased appetite,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Hepatic steatosis,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Iron deficiency anaemia,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Mitral valve incompetence,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Oedema peripheral,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Peripheral swelling,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Polyarthritis,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Ventricular hypokinesia,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Weight decreased,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188949541,18894954,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"20 MILLIGRAM, QD (10 MG, BID)",,,Y,U,,,,20.0,MG,,QD,2021,Q1,Weight increased,,2021,Q1,1,I,2016.0,20210209.0,20210215,20210215,EXP,,PL-MYLANLABS-2021M1008710,MYLAN,,55.0,YR,,M,Y,,,20210215.0,,MD,PL,PL,2021,Q1,Adult
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Acute coronary syndrome,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Atrial fibrillation,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Coronary arterial stent insertion,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Epistaxis,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Haemorrhage,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Off label use,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188973722,18897372,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,,,,,10.0,MG,,,2021,Q1,Product use in unapproved indication,,2021,Q1,2,F,,20210317.0,20210215,20210326,EXP,,SI-JNJFOC-20210226242,JOHNSON AND JOHNSON,,78.0,YR,E,M,Y,75.0,KG,20210326.0,,HP,SI,SI,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Acute myocardial infarction,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Angina pectoris,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Blood glucose abnormal,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Blood glucose increased,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Coronary artery stenosis,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Glycosylated haemoglobin increased,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
188997031,18899703,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Therapeutic response decreased,,2021,Q1,1,I,2016.0,20210208.0,20210216,20210216,EXP,,NVSC2021HU032975,NOVARTIS,,68.0,YR,,M,Y,,,20210216.0,,MD,HU,HU,2021,Q1,Elderly
189041281,18904128,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Chills,,2021,Q1,1,I,,20210210.0,20210217,20210217,EXP,,CA-CELGENEUS-CAN-20210203228,CELGENE,,66.0,YR,,M,Y,,,20210217.0,,HP,CA,CA,2021,Q1,Elderly
189041281,18904128,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Sepsis,,2021,Q1,1,I,,20210210.0,20210217,20210217,EXP,,CA-CELGENEUS-CAN-20210203228,CELGENE,,66.0,YR,,M,Y,,,20210217.0,,HP,CA,CA,2021,Q1,Elderly
189041281,18904128,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Vomiting,,2021,Q1,1,I,,20210210.0,20210217,20210217,EXP,,CA-CELGENEUS-CAN-20210203228,CELGENE,,66.0,YR,,M,Y,,,20210217.0,,HP,CA,CA,2021,Q1,Elderly
189041711,18904171,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20200423.0,,20210217,20210217,DIR,,,FDA-CTU,,67.0,YR,,M,N,81.0,KG,20210208.0,N,PH,US,US,2021,Q1,Elderly
189041711,18904171,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Nausea,,2021,Q1,1,I,20200423.0,,20210217,20210217,DIR,,,FDA-CTU,,67.0,YR,,M,N,81.0,KG,20210208.0,N,PH,US,US,2021,Q1,Elderly
189041711,18904171,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q1,Vomiting,,2021,Q1,1,I,20200423.0,,20210217,20210217,DIR,,,FDA-CTU,,67.0,YR,,M,N,81.0,KG,20210208.0,N,PH,US,US,2021,Q1,Elderly
189044841,18904484,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Balanoposthitis,,2021,Q1,1,I,20210209.0,,20210217,20210217,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210210.0,N,PH,US,US,2021,Q1,Elderly
189044841,18904484,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Rash,,2021,Q1,1,I,20210209.0,,20210217,20210217,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210210.0,N,PH,US,US,2021,Q1,Elderly
189111861,18911186,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNK,,,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210208.0,20210218,20210218,EXP,,DE-NOVOPROD-787161,NOVO NORDISK,,55.0,YR,,M,Y,,,20210218.0,,MD,DE,DE,2021,Q1,Adult
189137611,18913761,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Cough,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Dizziness,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Headache,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Respiratory tract congestion,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Cough,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Dizziness,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Headache,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189137611,18913761,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,D,,,,,,,,,2021,Q1,Respiratory tract congestion,,2021,Q1,1,I,2017.0,20200121.0,20210218,20210218,PER,,US-NOVOPROD-709116,NOVO NORDISK,,55.0,YR,,F,Y,122.0,KG,20210218.0,,CN,US,US,2021,Q1,Adult
189157511,18915751,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210205.0,20210219,20210219,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-281429,RANBAXY,"DASS B, BECK A, HOLMES C, MORTON G. EUGLYCEMIC DKA (EUDKA) AS A PRESENTATION OF COVID?19.. CLIN CASE REP. 2021?9(1):395?398",59.0,YR,,F,Y,,,20210219.0,,HP,US,US,2021,Q1,Adult
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Asthenia,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Dropped head syndrome,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Dysphagia,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Gait disturbance,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Gastrointestinal tube insertion,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189204081,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Muscular weakness,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Asthma,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Chest discomfort,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Drug intolerance,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Hospitalisation,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Therapeutic product effect incomplete,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189233951,18923395,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,,,,,10.0,MG,,,2021,Q1,Tremor,,2021,Q1,1,I,,20210210.0,20210222,20210222,EXP,,CA-APOTEX-2021AP002765,APOTEX,,50.0,YR,,M,Y,85.0,KG,20210222.0,,CN,CA,CA,2021,Q1,Adult
189275831,18927583,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,0.5,DF,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20200918.0,,20210222,20210222,DIR,,,FDA-CTU,,74.0,YR,,M,N,77.0,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
189279841,18927984,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,20200903.0,,20210223,20210223,DIR,,,FDA-CTU,,72.0,YR,,M,N,83.91,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
189279891,18927989,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200921.0,,20210223,20210223,DIR,,,FDA-CTU,,73.0,YR,,M,N,75.75,KG,20201119.0,N,PH,US,US,2021,Q1,Elderly
189375691,18937569,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210110.0,,20210224,20210224,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q1,Adult
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Blood creatinine increased,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Blood potassium decreased,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Blood urea increased,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Chronic kidney disease,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Concomitant disease aggravated,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Decreased appetite,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Dizziness,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189377611,18937761,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 DF,,,U,,,,,1.0,DF,,,2021,Q1,Hypotension,,2021,Q1,1,I,,20210216.0,20210225,20210225,EXP,,NVSJ2021JP002642,NOVARTIS,,69.0,YR,,M,Y,,,20210225.0,,MD,JP,JP,2021,Q1,Elderly
189384571,18938457,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,N,,,,,,,,,2021,Q1,Dysuria,,2021,Q1,1,I,20210105.0,,20210224,20210224,DIR,,,FDA-CTU,,78.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q1,Elderly
189384571,18938457,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,N,,,,,,,,,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20210105.0,,20210224,20210224,DIR,,,FDA-CTU,,78.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q1,Elderly
189386751,18938675,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q1,Pollakiuria,,2021,Q1,1,I,20201117.0,,20210224,20210224,DIR,,,FDA-CTU,,55.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q1,Adult
189398711,18939871,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2021,Q1,Fournier's gangrene,,2021,Q1,1,I,20210115.0,,20210224,20210224,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q1,Adult
189461761,18946176,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q1,Diarrhoea,,2021,Q1,1,I,20210218.0,20210218.0,20210226,20210226,EXP,GB-MHRA-TPP976878C579002YC1613663795594,NVSC2021GB041869,NOVARTIS,,38.0,YR,,F,Y,202.0,KG,20210226.0,,HP,GB,GB,2021,Q1,Adult
189476731,18947673,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,D,, UNKNOWN,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210227,20210227,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-02386,LUPIN,,60.0,YR,,M,Y,,,20210227.0,,HP,AU,AU,2021,Q1,Adult
189476731,18947673,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210227,20210227,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-02386,LUPIN,,60.0,YR,,M,Y,,,20210227.0,,HP,AU,AU,2021,Q1,Adult
189476771,18947677,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,D,, UNKNOWN,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210227,20210227,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-02388,LUPIN,,75.0,YR,,M,Y,,,20210227.0,,HP,AU,AU,2021,Q1,Elderly
189477071,18947707,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, BID",,,D,, UNKNOWN,,,5.0,MG,,BID,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210227,20210227,EXP,,AU-LUPIN PHARMACEUTICALS INC.-2021-02424,LUPIN,,60.0,YR,,M,Y,,,20210227.0,,HP,AU,AU,2021,Q1,Adult
189487971,18948797,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG,,,Y,U, UNKNOWN,,204629.0,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210221.0,20210227,20210227,EXP,GB-MHRA-EYC 00241377,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-085063",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,,,20210227.0,,HP,GB,GB,2021,Q1,Adult
189519191,18951919,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 MILLIGRAM, QD",,,D,, UNKNOWN,,,12.5,MG,,QD,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210301,20210301,EXP,,AU-GENERIC HEALTH PTY. LTD.-2021-02422,LUPIN,,55.0,YR,,M,Y,,,20210301.0,,HP,AU,AU,2021,Q1,Adult
189519971,18951997,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"12.5 MILLIGRAM, BID",,,D,, UNKNOWN,,,12.5,MG,,BID,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210301,20210301,EXP,,AU-GENERIC HEALTH PTY. LTD.-2021-02421,LUPIN,,79.0,YR,,F,Y,,,20210301.0,,HP,AU,AU,2021,Q1,Elderly
189519971,18951997,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,, UNKNOWN,,,,,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210216.0,20210301,20210301,EXP,,AU-GENERIC HEALTH PTY. LTD.-2021-02421,LUPIN,,79.0,YR,,F,Y,,,20210301.0,,HP,AU,AU,2021,Q1,Elderly
189550471,18955047,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Hypotension,,2021,Q1,1,I,20210223.0,20210226.0,20210301,20210301,EXP,GB-MHRA-EYC 00242125,NVSC2021GB047040,NOVARTIS,,74.0,YR,,M,Y,92.0,KG,20210301.0,,HP,GB,GB,2021,Q1,Elderly
189573351,18957335,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,, UNKNOWN,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210223.0,20210302,20210302,EXP,,US-EMCURE PHARMACEUTICALS LTD-2021-EPL-000611,EMCURE,"TEKARLI M, VAN WAGONER E.. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT.. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3:1666?7",77.0,YR,,M,Y,,,20210302.0,,HP,US,US,2021,Q1,Elderly
189573351,18957335,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,, UNKNOWN,,,,,,,2021,Q1,Hypovolaemia,,2021,Q1,1,I,,20210223.0,20210302,20210302,EXP,,US-EMCURE PHARMACEUTICALS LTD-2021-EPL-000611,EMCURE,"TEKARLI M, VAN WAGONER E.. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT.. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3:1666?7",77.0,YR,,M,Y,,,20210302.0,,HP,US,US,2021,Q1,Elderly
189573351,18957335,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,, UNKNOWN,,,,,,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210223.0,20210302,20210302,EXP,,US-EMCURE PHARMACEUTICALS LTD-2021-EPL-000611,EMCURE,"TEKARLI M, VAN WAGONER E.. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT.. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3:1666?7",77.0,YR,,M,Y,,,20210302.0,,HP,US,US,2021,Q1,Elderly
189600311,18960031,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,UNKNOWN,,,D,,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210216.0,20210303,20210303,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202102-000177,UNICHEM,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3(8):1666?7. DOI:10.1002/JAC5.1351",77.0,YR,E,M,Y,,,20210303.0,,,COUNTRY NOT SPECIFIED,US,2021,Q1,Elderly
189600311,18960031,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,UNKNOWN,,,D,,,,,,,,,2021,Q1,Renal disorder,,2021,Q1,1,I,,20210216.0,20210303,20210303,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202102-000177,UNICHEM,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3(8):1666?7. DOI:10.1002/JAC5.1351",77.0,YR,E,M,Y,,,20210303.0,,,COUNTRY NOT SPECIFIED,US,2021,Q1,Elderly
189621351,18962135,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN  25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,0.5,DF,TABLET,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200914.0,,20210302,20210302,DIR,,,FDA-CTU,,71.0,YR,,M,N,93.0,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Dehydration,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Malaise,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Product dose omission issue,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189630731,18963073,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,,20210218.0,20210303,20210303,EXP,,CA-ROCHE-2772934,ROCHE,,58.0,YR,,M,Y,98.0,KG,20210303.0,,HP,CA,CA,2021,Q1,Adult
189634721,18963472,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 003086,20230331.0,,10.0,MG,,QD,2021,Q1,Cardiac tamponade,,2021,Q1,1,I,20210108.0,,20210303,20210303,DIR,,,FDA-CTU,,80.0,YR,,F,N,40.1,KG,20210303.0,Y,PH,US,US,2021,Q1,Elderly
189634721,18963472,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 003086,20230331.0,,10.0,MG,,QD,2021,Q1,Cardiogenic shock,,2021,Q1,1,I,20210108.0,,20210303,20210303,DIR,,,FDA-CTU,,80.0,YR,,F,N,40.1,KG,20210303.0,Y,PH,US,US,2021,Q1,Elderly
189634721,18963472,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 003086,20230331.0,,10.0,MG,,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210108.0,,20210303,20210303,DIR,,,FDA-CTU,,80.0,YR,,F,N,40.1,KG,20210303.0,Y,PH,US,US,2021,Q1,Elderly
189634721,18963472,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,D, 003086,20230331.0,,10.0,MG,,QD,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,20210108.0,,20210303,20210303,DIR,,,FDA-CTU,,80.0,YR,,F,N,40.1,KG,20210303.0,Y,PH,US,US,2021,Q1,Elderly
189655091,18965509,2,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210223.0,20210304,20210304,EXP,,US-AUROBINDO-AUR-APL-2021-008162,AUROBINDO,,77.0,YR,,M,Y,,,20210304.0,,HP,US,US,2021,Q1,Elderly
189655091,18965509,2,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Hypovolaemia,,2021,Q1,1,I,,20210223.0,20210304,20210304,EXP,,US-AUROBINDO-AUR-APL-2021-008162,AUROBINDO,,77.0,YR,,M,Y,,,20210304.0,,HP,US,US,2021,Q1,Elderly
189655091,18965509,2,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210223.0,20210304,20210304,EXP,,US-AUROBINDO-AUR-APL-2021-008162,AUROBINDO,,77.0,YR,,M,Y,,,20210304.0,,HP,US,US,2021,Q1,Elderly
189689961,18968996,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210224.0,20210304,20210304,EXP,,US-MYLANLABS-2021M1013043,MYLAN,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. J?AM?COLL?CLIN?PHARM 2020?3(8):1666 ABSTR. 468.",77.0,YR,,M,Y,,,20210304.0,,HP,US,US,2021,Q1,Elderly
189689961,18968996,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210224.0,20210304,20210304,EXP,,US-MYLANLABS-2021M1013043,MYLAN,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. J?AM?COLL?CLIN?PHARM 2020?3(8):1666 ABSTR. 468.",77.0,YR,,M,Y,,,20210304.0,,HP,US,US,2021,Q1,Elderly
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Angioedema,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Cardiac failure,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Dysphagia,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Glossitis,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Sepsis,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Swollen tongue,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189818631,18981863,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Taste disorder,,2021,Q1,1,I,,20210216.0,20210308,20210308,EXP,,AU-ASTRAZENECA-2021A064537,ASTRAZENECA,,57.0,YR,,M,Y,102.0,KG,20210308.0,,,AU,AU,2021,Q1,Adult
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Asthenia,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Dropped head syndrome,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Dysphagia,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Gait disturbance,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Gastrointestinal tube insertion,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189844121,18984412,3,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Muscular weakness,,2021,Q1,1,I,,20210228.0,20210308,20210308,EXP,,CA-ASTRAZENECA-2021A099010,ASTRAZENECA,,79.0,YR,,M,Y,,,20210308.0,,HP,CA,CA,2021,Q1,Elderly
189860021,18986002,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210224.0,20210309,20210309,EXP,,US-LUPIN PHARMACEUTICALS INC.-2021-02891,LUPIN,,77.0,YR,,M,Y,,,20210309.0,,HP,US,US,2021,Q1,Elderly
189860021,18986002,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210224.0,20210309,20210309,EXP,,US-LUPIN PHARMACEUTICALS INC.-2021-02891,LUPIN,,77.0,YR,,M,Y,,,20210309.0,,HP,US,US,2021,Q1,Elderly
189861991,18986199,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,U,,,,,,,UNKNOWN,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210223.0,20210309,20210309,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-21-53783,HIKMA,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3(8):1666?7. DOI: 10.1002/JAC5.1351.",77.0,YR,,M,Y,,,20210309.0,,,COUNTRY NOT SPECIFIED,US,2021,Q1,Elderly
189861991,18986199,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,U,,,,,,,UNKNOWN,,2021,Q1,Hypovolaemia,,2021,Q1,1,I,,20210223.0,20210309,20210309,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-21-53783,HIKMA,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3(8):1666?7. DOI: 10.1002/JAC5.1351.",77.0,YR,,M,Y,,,20210309.0,,,COUNTRY NOT SPECIFIED,US,2021,Q1,Elderly
189861991,18986199,3,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,U,,,,,,,UNKNOWN,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210223.0,20210309,20210309,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-21-53783,HIKMA,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2020?3(8):1666?7. DOI: 10.1002/JAC5.1351.",77.0,YR,,M,Y,,,20210309.0,,,COUNTRY NOT SPECIFIED,US,2021,Q1,Elderly
189868121,18986812,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Chills,,2021,Q1,1,I,20201219.0,,20210308,20210308,DIR,,,FDA-CTU,,68.0,YR,,M,N,90.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
189868121,18986812,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Flank pain,,2021,Q1,1,I,20201219.0,,20210308,20210308,DIR,,,FDA-CTU,,68.0,YR,,M,N,90.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
189868121,18986812,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Hypophagia,,2021,Q1,1,I,20201219.0,,20210308,20210308,DIR,,,FDA-CTU,,68.0,YR,,M,N,90.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
189868121,18986812,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Nephritis,,2021,Q1,1,I,20201219.0,,20210308,20210308,DIR,,,FDA-CTU,,68.0,YR,,M,N,90.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
189868121,18986812,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20201219.0,,20210308,20210308,DIR,,,FDA-CTU,,68.0,YR,,M,N,90.0,KG,20210107.0,N,PH,US,US,2021,Q1,Elderly
189871611,18987161,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Hypotension,,2021,Q1,1,I,20210223.0,20210228.0,20210309,20210309,EXP,GB-MHRA-EYC 00242125,GB-PFIZER INC-2021217240,PFIZER,,74.0,YR,,M,Y,92.0,KG,20210309.0,,MD,GB,GB,2021,Q1,Elderly
189919231,18991923,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,131597.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,1,I,20210218.0,20210304.0,20210310,20210310,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-088552",BOEHRINGER INGELHEIM,,87.0,YR,E,F,Y,74.0,KG,20210310.0,,MD,DE,DE,2021,Q1,Elderly
189952562,18995256,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q1,Hypoglycaemia,,2021,Q1,2,F,,20210311.0,20210310,20210326,PER,,GB-35507-2021-02855,LUPIN,,58.0,YR,,M,Y,,,20210326.0,,CN,NL,GB,2021,Q1,Adult
189964031,18996403,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Adverse drug reaction,,2021,Q1,1,I,20210223.0,20210304.0,20210311,20210311,EXP,GB-MHRA-EYC 00242533,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-087873",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,102.51,KG,20210311.0,,CN,GB,GB,2021,Q1,Adult
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Acute respiratory distress syndrome,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Bacterial infection,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Cardiogenic shock,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Cardiomyopathy,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Ischaemic cardiomyopathy,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
189996201,18999620,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q1,Septic shock,,2021,Q1,1,I,,20210304.0,20210311,20210311,EXP,,DE-DSJP-DSE-2021-106733,DAIICHI,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL.. ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210311.0,,MD,DE,DE,2021,Q1,Elderly
190005211,19000521,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D, C42504,20230630.0,,12.5,MG,,QD,2021,Q1,Nephrolithiasis,,2021,Q1,1,I,20201126.0,,20210311,20210311,DIR,,,FDA-CTU,,68.0,YR,,M,N,99.0,KG,20210218.0,N,PH,US,US,2021,Q1,Elderly
190022441,19002244,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Dry mouth,,2021,Q1,1,I,20210114.0,,20210312,20210312,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190022441,19002244,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pollakiuria,,2021,Q1,1,I,20210114.0,,20210312,20210312,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190022441,19002244,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Thirst,,2021,Q1,1,I,20210114.0,,20210312,20210312,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190024361,19002436,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q1,Pollakiuria,,2021,Q1,1,I,20210209.0,,20210312,20210312,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190024361,19002436,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q1,Urinary incontinence,,2021,Q1,1,I,20210209.0,,20210312,20210312,DIR,,,FDA-CTU,,70.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190026091,19002609,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2021,Q1,Urinary incontinence,,2021,Q1,1,I,20210305.0,,20210312,20210312,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20210310.0,N,PH,US,US,2021,Q1,Elderly
190037261,19003726,9,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Infection,,2021,Q1,1,I,,20210304.0,20210312,20210312,EXP,,JP-SYNEX-T202101114,MALLINCKRODT,,1.0,YR,,M,Y,,,20210312.0,,MD,US,JP,2021,Q1,Child
190038971,19003897,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,U, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q1,Blood creatine phosphokinase increased,,2021,Q1,1,I,20201030.0,20210307.0,20210313,20210313,EXP,GB-MHRA-EYC 00242723,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-088675",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,85.0,KG,20210313.0,,CN,GB,GB,2021,Q1,Adult
190038971,19003897,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,Y,U, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q1,Urine ketone body present,,2021,Q1,1,I,20201030.0,20210307.0,20210313,20210313,EXP,GB-MHRA-EYC 00242723,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-088675",BOEHRINGER INGELHEIM,,48.0,YR,A,F,Y,85.0,KG,20210313.0,,CN,GB,GB,2021,Q1,Adult
190055362,19005536,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Bifascicular block,,2021,Q1,2,F,,20210318.0,20210313,20210331,EXP,,NVSJ2021JP003972,NOVARTIS,,43.0,YR,,M,Y,85.6,KG,20210331.0,,MD,JP,JP,2021,Q1,Adult
190055362,19005536,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Weight increased,,2021,Q1,2,F,,20210318.0,20210313,20210331,EXP,,NVSJ2021JP003972,NOVARTIS,,43.0,YR,,M,Y,85.6,KG,20210331.0,,MD,JP,JP,2021,Q1,Adult
190090071,19009007,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210306.0,20210316,20210316,EXP,,ES-AUROBINDO-AUR-APL-2021-010242,AUROBINDO,,63.0,YR,,F,Y,,,20210316.0,,MD,ES,ES,2021,Q1,Adult
190090071,19009007,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Renal failure,,2021,Q1,1,I,,20210306.0,20210316,20210316,EXP,,ES-AUROBINDO-AUR-APL-2021-010242,AUROBINDO,,63.0,YR,,F,Y,,,20210316.0,,MD,ES,ES,2021,Q1,Adult
190091541,19009154,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Cutaneous calcification,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190091541,19009154,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Hyperphosphataemia,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190091541,19009154,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Skin necrosis,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190097311,19009731,9,C,EMPAGLIFLOZIN W/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 U, DAILY (25/5)",,,,,,,,5.0,IU,,QD,2021,Q1,Chest pain,,2021,Q1,1,I,202010.0,20210301.0,20210315,20210315,EXP,,AU-DSJP-DSE-2021-107519,DAIICHI,,69.0,YR,,M,Y,,,20210315.0,,CN,AU,AU,2021,Q1,Elderly
190097311,19009731,9,C,EMPAGLIFLOZIN W/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 U, DAILY (25/5)",,,,,,,,5.0,IU,,QD,2021,Q1,Drug ineffective,,2021,Q1,1,I,202010.0,20210301.0,20210315,20210315,EXP,,AU-DSJP-DSE-2021-107519,DAIICHI,,69.0,YR,,M,Y,,,20210315.0,,CN,AU,AU,2021,Q1,Elderly
190097311,19009731,9,C,EMPAGLIFLOZIN W/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"5 U, DAILY (25/5)",,,,,,,,5.0,IU,,QD,2021,Q1,Dyspnoea,,2021,Q1,1,I,202010.0,20210301.0,20210315,20210315,EXP,,AU-DSJP-DSE-2021-107519,DAIICHI,,69.0,YR,,M,Y,,,20210315.0,,CN,AU,AU,2021,Q1,Elderly
190156971,19015697,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10MG DAILY,,,Y,U, UNKNOWN,,131597.0,10.0,MG,TABLETS,QD,2021,Q1,Fungal infection,,2021,Q1,1,I,202012.0,20210315.0,20210317,20210317,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-090781",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20210317.0,,CN,US,US,2021,Q1,Elderly
190200132,19020013,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q1,Chronic left ventricular failure,,2021,Q1,2,F,20210227.0,20210322.0,20210317,20210326,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-089492",BOEHRINGER INGELHEIM,,75.0,YR,E,M,Y,137.45,KG,20210326.0,,MD,US,US,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Blood potassium increased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Brain natriuretic peptide decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Cardiac failure acute,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Carotid artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Coronary artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Cystitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Dyspnoea paroxysmal nocturnal,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Electrocardiogram QRS complex prolonged,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Fluid retention,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Hypotension,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Iron deficiency,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Ischaemic stroke,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Left ventricular dysfunction,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Musculoskeletal discomfort,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Prostatitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Blood potassium increased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Brain natriuretic peptide decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Cardiac failure acute,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Carotid artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Coronary artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Cystitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Dyspnoea paroxysmal nocturnal,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Electrocardiogram QRS complex prolonged,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Fluid retention,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Hypotension,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Iron deficiency,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Ischaemic stroke,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Left ventricular dysfunction,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Musculoskeletal discomfort,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Prostatitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Blood potassium increased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Brain natriuretic peptide decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Cardiac failure acute,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Carotid artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Coronary artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Cystitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Dyspnoea paroxysmal nocturnal,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Electrocardiogram QRS complex prolonged,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Fluid retention,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Hypotension,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Iron deficiency,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Ischaemic stroke,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Left ventricular dysfunction,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Musculoskeletal discomfort,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Prostatitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Blood potassium increased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Brain natriuretic peptide decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Cardiac failure acute,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Carotid artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Coronary artery stenosis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Cystitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Dyspnoea paroxysmal nocturnal,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Electrocardiogram QRS complex prolonged,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Fluid retention,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Hypotension,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Iron deficiency,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Ischaemic stroke,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Left ventricular dysfunction,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Musculoskeletal discomfort,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Prostatitis,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190209711,19020971,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,,,,,25.0,MG,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2015.0,20210309.0,20210317,20210317,EXP,,NVSC2021HU058671,NOVARTIS,,69.0,YR,,M,Y,,,20210317.0,,MD,HU,HU,2021,Q1,Elderly
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Asthma,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Bronchial hyperreactivity,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Chest discomfort,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Cough,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Forced expiratory volume decreased,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Inspiratory capacity decreased,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Obstructive airways disorder,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Sinusitis,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Therapeutic product effect incomplete,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Total lung capacity decreased,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Weight decreased,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190220711,19022071,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM, QD",,,D,,,,,10.0,MG,,,2021,Q1,Wheezing,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-APOTEX-2021AP006084,APOTEX,,50.0,YR,,M,Y,93.0,KG,20210318.0,,CN,CA,CA,2021,Q1,Adult
190222201,19022220,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210311.0,20210318,20210318,EXP,,US-SCIEGEN-2021SCILIT00271,SCIEGEN,,77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190222201,19022220,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,UNKNOWN,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210311.0,20210318,20210318,EXP,,US-SCIEGEN-2021SCILIT00271,SCIEGEN,,77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190241991,19024199,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,UNKNOWN,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210309.0,20210318,20210318,EXP,,US-LEADINGPHARMA-US-2021LEALIT00094,LEADING PHARMA,,77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190241991,19024199,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,, UNKNOWN,,,,,UNKNOWN,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210309.0,20210318,20210318,EXP,,US-LEADINGPHARMA-US-2021LEALIT00094,LEADING PHARMA,,77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190262041,19026204,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210310.0,20210318,20210318,EXP,,NVSC2021ES055458,NOVARTIS,,63.0,YR,,F,Y,,,20210318.0,,HP,ES,ES,2021,Q1,Adult
190262041,19026204,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Renal failure,,2021,Q1,1,I,,20210310.0,20210318,20210318,EXP,,NVSC2021ES055458,NOVARTIS,,63.0,YR,,F,Y,,,20210318.0,,HP,ES,ES,2021,Q1,Adult
190267361,19026736,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,ES-BAUSCH-BL-2021-008136,BAUSCH AND LOMB,,63.0,YR,,F,Y,,,20210318.0,,MD,ES,ES,2021,Q1,Adult
190267361,19026736,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Renal failure,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,ES-BAUSCH-BL-2021-008136,BAUSCH AND LOMB,,63.0,YR,,F,Y,,,20210318.0,,MD,ES,ES,2021,Q1,Adult
190269692,19026969,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,131597.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Goitre,,2021,Q1,2,F,20210111.0,20210319.0,20210318,20210325,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-089828",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,40.0,KG,20210325.0,,MD,CA,CA,2021,Q1,Elderly
190290681,19029068,2,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,US-TEVA-2021-US-1890375,TEVA,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. J?AM?COLL?CLIN?PHARM 2020?3(8):1666 ABSTR. 468.",77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190290681,19029068,2,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Renal impairment,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,US-TEVA-2021-US-1890375,TEVA,"TEKARLI M, VAN WAGONER E. RENAL DYSFUNCTION WITH CONCOMITANT USE OF SGLT?2 INHIBITORS AND THIAZIDE DIURETICS: A CASE REPORT. J?AM?COLL?CLIN?PHARM 2020?3(8):1666 ABSTR. 468.",77.0,YR,E,M,Y,,,20210318.0,,HP,US,US,2021,Q1,Elderly
190292712,19029271,8,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,2,F,20210305.0,20210326.0,20210318,20210331,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-090745",BOEHRINGER INGELHEIM,,83.0,YR,E,M,Y,80.1,KG,20210331.0,,MD,NL,NL,2021,Q1,Elderly
190367661,19036766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB;OTHER FREQUENCY:AM;?,,,Y,D,,,,1.0,DF,COATED TABLET,,2021,Q1,Fungal infection,,2021,Q1,1,I,20200529.0,,20210322,20210322,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20200718.0,N,PH,US,US,2021,Q1,Elderly
190367661,19036766,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1 TAB;OTHER FREQUENCY:AM;?,,,Y,D,,,,1.0,DF,COATED TABLET,,2021,Q1,Groin infection,,2021,Q1,1,I,20200529.0,,20210322,20210322,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20200718.0,N,PH,US,US,2021,Q1,Elderly
190395851,19039585,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Dyslipidaemia,,2021,Q1,1,I,20210205.0,20210309.0,20210322,20210322,EXP,GB-MHRA-EYC 00241143,GB-PFIZER INC-2021256696,PFIZER,,54.0,YR,,F,Y,,,20210322.0,,PH,GB,GB,2021,Q1,Adult
190399171,19039917,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210315.0,20210322,20210322,EXP,,GB-ASTRAZENECA-2021A136610,ASTRAZENECA,,67.0,YR,,F,Y,,,20210322.0,,HP,GB,GB,2021,Q1,Elderly
190415531,19041553,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210323,20210323,EXP,,GB-AUROBINDO-AUR-APL-2021-011305,AUROBINDO,,67.0,YR,,F,Y,,,20210323.0,,HP,GB,GB,2021,Q1,Elderly
190416451,19041645,3,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,1,I,20210222.0,20210315.0,20210322,20210322,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-090388",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,102.0,KG,20210322.0,,MD,DE,DE,2021,Q1,Elderly
190424651,19042465,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,TABLET,,2021,Q1,Thrombotic cerebral infarction,,2021,Q1,1,I,20200718.0,20210316.0,20210322,20210322,EXP,,JP-DSJP-DSJ-2021-108093,DAIICHI,,9.0,DEC,,F,Y,,,20210322.0,,HP,JP,JP,2021,Q1,Child
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Acute respiratory distress syndrome,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Bacterial infection,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Cardiogenic shock,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Cardiomyopathy,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Ischaemic cardiomyopathy,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190507021,19050702,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY",,,D,,,,,10.0,MG,,QD,2021,Q1,Septic shock,,2021,Q1,1,I,,20210312.0,20210324,20210324,EXP,,DE-AUROBINDO-AUR-APL-2021-011541,AUROBINDO,,65.0,YR,,M,Y,,,20210324.0,,HP,DE,DE,2021,Q1,Elderly
190509651,19050965,9,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q1,COVID-19,,2021,Q1,1,I,20200320.0,20210312.0,20210324,20210324,EXP,,GB-SAMSUNG BIOEPIS-SB-2021-07155,SAMSUNG BIOEPIS,,57.0,YR,A,M,Y,129.5,KG,20210324.0,,HP,GB,GB,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Blood pressure increased,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Posterior reversible encephalopathy syndrome,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Tachycardia,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Unresponsive to stimuli,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190512761,19051276,8,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Urinary incontinence,,2021,Q1,1,I,20210315.0,,20210324,20210324,DIR,,,FDA-CTU,,63.0,YR,,M,N,113.04,KG,20210324.0,N,PH,US,US,2021,Q1,Adult
190520611,19052061,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210324,20210324,EXP,GB-MHRA-EYC 00243565,GB-PFIZER INC-2021276293,PFIZER,,67.0,YR,,F,Y,,,20210324.0,,HP,GB,GB,2021,Q1,Elderly
190560441,19056044,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210325,20210325,EXP,GB-MHRA-ADR 24927692,GB-ACCORD-220404,ACCORD,,67.0,YR,,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Elderly
190563201,19056320,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210325,20210325,EXP,GB-MHRA-EYC 00243565,GB-MYLANLABS-2021M1015627,MYLAN,,67.0,YR,,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Elderly
190571221,19057122,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNKNOWN, UNKNOWN",,,U,,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210315.0,20210325,20210325,EXP,,GB-ENDO PHARMACEUTICALS INC-2021-001833,ENDO,,67.0,YR,,F,Y,,,20210325.0,,CN,GB,GB,2021,Q1,Elderly
190577411,19057741,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Drug-induced liver injury,,2021,Q1,1,I,20210308.0,20210315.0,20210324,20210324,EXP,,AR-ASTRAZENECA-2021A146146,ASTRAZENECA,,24482.0,DY,,M,Y,,,20210324.0,,MD,AR,AR,2021,Q1,Elderly
190577411,19057741,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q1,Hepatitis,,2021,Q1,1,I,20210308.0,20210315.0,20210324,20210324,EXP,,AR-ASTRAZENECA-2021A146146,ASTRAZENECA,,24482.0,DY,,M,Y,,,20210324.0,,MD,AR,AR,2021,Q1,Elderly
190624151,19062415,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210326,20210326,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-288133,RANBAXY,,67.0,YR,,F,Y,,,20210326.0,,HP,GB,GB,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Coma,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Haemorrhagic stroke,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Hypomagnesaemia,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Metastases to lymph nodes,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Rash,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627181,19062718,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210326,20210326,EXP,GB-MHRA-EYC 00243565,GB-TEVA-2021-GB-1892610,TEVA,,67.0,YR,E,F,Y,,,20210326.0,,HP,GB,GB,2021,Q1,Elderly
190637091,19063709,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,70963.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,1,I,20210318.0,20210319.0,20210326,20210326,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-092400",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,53.0,KG,20210326.0,,MD,JP,JP,2021,Q1,Elderly
190653101,19065310,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,U, UNKNOWN,,,,,,,2021,Q1,Liver injury,,2021,Q1,1,I,,20210314.0,20210327,20210327,EXP,GB-MHRA-EYC 00243565,GB-DRREDDYS-GER/UKI/21/0133338,DR REDDYS,,67.0,YR,E,F,Y,,,20210327.0,,HP,GB,GB,2021,Q1,Elderly
190679071,19067907,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Anaphylactic reaction,,2021,Q1,1,I,20210303.0,20210317.0,20210329,20210329,EXP,GB-MHRA-EYC 00243822,GB-PFIZER INC-2021294860,PFIZER,,82.0,YR,,M,Y,67.8,KG,20210329.0,,HP,GB,GB,2021,Q1,Elderly
190679071,19067907,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Erythema,,2021,Q1,1,I,20210303.0,20210317.0,20210329,20210329,EXP,GB-MHRA-EYC 00243822,GB-PFIZER INC-2021294860,PFIZER,,82.0,YR,,M,Y,67.8,KG,20210329.0,,HP,GB,GB,2021,Q1,Elderly
190679071,19067907,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Hypotension,,2021,Q1,1,I,20210303.0,20210317.0,20210329,20210329,EXP,GB-MHRA-EYC 00243822,GB-PFIZER INC-2021294860,PFIZER,,82.0,YR,,M,Y,67.8,KG,20210329.0,,HP,GB,GB,2021,Q1,Elderly
190679071,19067907,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Syncope,,2021,Q1,1,I,20210303.0,20210317.0,20210329,20210329,EXP,GB-MHRA-EYC 00243822,GB-PFIZER INC-2021294860,PFIZER,,82.0,YR,,M,Y,67.8,KG,20210329.0,,HP,GB,GB,2021,Q1,Elderly
190679071,19067907,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Tachycardia,,2021,Q1,1,I,20210303.0,20210317.0,20210329,20210329,EXP,GB-MHRA-EYC 00243822,GB-PFIZER INC-2021294860,PFIZER,,82.0,YR,,M,Y,67.8,KG,20210329.0,,HP,GB,GB,2021,Q1,Elderly
190717401,19071740,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,PK-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-287904,RANBAXY,"RASHID O, FAROOQ S, KIRAN Z, ISLAM N. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES STARTED ON EMPAGLIFLOZIN. BMJ CASE REP. 2016?MAY 1",42.0,YR,,M,Y,,,20210330.0,,HP,PK,US,2021,Q1,Adult
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Angina pectoris,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Blood pressure decreased,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Cardiac failure chronic,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Diabetes mellitus,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Fluid retention,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Hypothyroidism,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Mitral valve incompetence,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Oedema peripheral,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Systolic dysfunction,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Tachycardia,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q1,Ventricular dyssynchrony,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Angina pectoris,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Blood pressure decreased,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Cardiac failure chronic,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Diabetes mellitus,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Fluid retention,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Hypothyroidism,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Mitral valve incompetence,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Oedema peripheral,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Systolic dysfunction,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Tachycardia,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190718661,19071866,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Ventricular dyssynchrony,,2021,Q1,1,I,,20210315.0,20210330,20210330,EXP,,NVSJ2021JP004575,NOVARTIS,,83.0,YR,,M,Y,,,20210330.0,,CN,JP,JP,2021,Q1,Elderly
190720611,19072061,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Escherichia infection,,2021,Q1,1,I,20210122.0,,20210326,20210326,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210305.0,N,PH,US,US,2021,Q1,Elderly
190720611,19072061,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20210122.0,,20210326,20210326,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210305.0,N,PH,US,US,2021,Q1,Elderly
190724561,19072456,1,PS,EMPAGLIFLOZIN (EMPAGLIFIOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,20210211.0,,20210326,20210326,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20210312.0,N,PH,US,US,2021,Q1,Elderly
190727341,19072734,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20210304.0,,20210326,20210326,DIR,,,FDA-CTU,,90.0,YR,,M,N,,,20210317.0,N,PH,US,US,2021,Q1,Elderly
190727341,19072734,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2021,Q1,Dizziness,,2021,Q1,1,I,20210304.0,,20210326,20210326,DIR,,,FDA-CTU,,90.0,YR,,M,N,,,20210317.0,N,PH,US,US,2021,Q1,Elderly
190727341,19072734,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,OTHER FREQUENCY:AM;?,,,Y,,,,,12.5,MG,,,2021,Q1,Hypotension,,2021,Q1,1,I,20210304.0,,20210326,20210326,DIR,,,FDA-CTU,,90.0,YR,,M,N,,,20210317.0,N,PH,US,US,2021,Q1,Elderly
190760671,19076067,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q1,Cardiac failure,,2021,Q1,1,I,20210308.0,20210323.0,20210331,20210331,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-092822",BOEHRINGER INGELHEIM,,89.0,YR,E,F,Y,39.8,KG,20210331.0,,MD,JP,JP,2021,Q1,Elderly
190799071,19079907,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210325.0,20210331,20210331,EXP,,NVSC2021US069938,NOVARTIS,"GOPARAJU N, MANFREDONIA J, ANNAMARAJU P. HEMORRHAGIC FUNGAL CYSTITIS AND OBSTRUCTIVE ACUTE KIDNEY INJURY ASSOCIATED WITH EMPAGLIFLOZIN AND SECUKINUMAB. AMERICAN JOURNAL OF KIDNEY DISEASES. 2021?77(4)",74.0,YR,,F,Y,,,20210331.0,,HP,US,US,2021,Q1,Elderly
190799071,19079907,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210325.0,20210331,20210331,EXP,,NVSC2021US069938,NOVARTIS,"GOPARAJU N, MANFREDONIA J, ANNAMARAJU P. HEMORRHAGIC FUNGAL CYSTITIS AND OBSTRUCTIVE ACUTE KIDNEY INJURY ASSOCIATED WITH EMPAGLIFLOZIN AND SECUKINUMAB. AMERICAN JOURNAL OF KIDNEY DISEASES. 2021?77(4)",74.0,YR,,F,Y,,,20210331.0,,HP,US,US,2021,Q1,Elderly
190799071,19079907,2,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q1,Fungal cystitis,,2021,Q1,1,I,,20210325.0,20210331,20210331,EXP,,NVSC2021US069938,NOVARTIS,"GOPARAJU N, MANFREDONIA J, ANNAMARAJU P. HEMORRHAGIC FUNGAL CYSTITIS AND OBSTRUCTIVE ACUTE KIDNEY INJURY ASSOCIATED WITH EMPAGLIFLOZIN AND SECUKINUMAB. AMERICAN JOURNAL OF KIDNEY DISEASES. 2021?77(4)",74.0,YR,,F,Y,,,20210331.0,,HP,US,US,2021,Q1,Elderly
190809871,19080987,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20181114.0,20210331,20210331,EXP,,IL-VALIDUS PHARMACEUTICALS LLC-IL-2021VAL001014,VALIDUS,"PERLMAN A., HEYMAN S.N., STOKAR J., DARMON D., MUSZKAT M., SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT?2 INHIBITORS. ISR. MED. ASSOC. J... 2018?20(8):513?516",61.0,YR,,M,Y,,,20210331.0,,HP,IL,IL,2021,Q1,Adult
190809871,19080987,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2021,Q1,Glomerular filtration rate abnormal,,2021,Q1,1,I,,20181114.0,20210331,20210331,EXP,,IL-VALIDUS PHARMACEUTICALS LLC-IL-2021VAL001014,VALIDUS,"PERLMAN A., HEYMAN S.N., STOKAR J., DARMON D., MUSZKAT M., SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT?2 INHIBITORS. ISR. MED. ASSOC. J... 2018?20(8):513?516",61.0,YR,,M,Y,,,20210331.0,,HP,IL,IL,2021,Q1,Adult
190809871,19080987,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, UNK",,,U,,,,,25.0,MG,,,2021,Q1,Renal ischaemia,,2021,Q1,1,I,,20181114.0,20210331,20210331,EXP,,IL-VALIDUS PHARMACEUTICALS LLC-IL-2021VAL001014,VALIDUS,"PERLMAN A., HEYMAN S.N., STOKAR J., DARMON D., MUSZKAT M., SZALAT A. CLINICAL SPECTRUM AND MECHANISM OF ACUTE KIDNEY INJURY IN PATIENTS WITH DIABETES MELLITUS ON SGLT?2 INHIBITORS. ISR. MED. ASSOC. J... 2018?20(8):513?516",61.0,YR,,M,Y,,,20210331.0,,HP,IL,IL,2021,Q1,Adult
190813911,19081391,3,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,,20210322.0,20210331,20210331,EXP,,IT-BAXTER-2021BAX006220,BAXTER,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, FORTINI G, TOGNELLI S, GHIARA C, LUCARELLI G, UNGAR A, FATTIROLLI F, BALDASSERONI S. ARNI AND SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUROPEAN GERIATRIC MEDICINE. 2020?11(SUPPL 1):S157?S157.",68.0,YR,,M,Y,,,20210331.0,,HP,IT,IT,2021,Q1,Elderly
190813911,19081391,3,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Hyperkalaemia,,2021,Q1,1,I,,20210322.0,20210331,20210331,EXP,,IT-BAXTER-2021BAX006220,BAXTER,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, FORTINI G, TOGNELLI S, GHIARA C, LUCARELLI G, UNGAR A, FATTIROLLI F, BALDASSERONI S. ARNI AND SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUROPEAN GERIATRIC MEDICINE. 2020?11(SUPPL 1):S157?S157.",68.0,YR,,M,Y,,,20210331.0,,HP,IT,IT,2021,Q1,Elderly
190813911,19081391,3,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Hypovolaemia,,2021,Q1,1,I,,20210322.0,20210331,20210331,EXP,,IT-BAXTER-2021BAX006220,BAXTER,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, FORTINI G, TOGNELLI S, GHIARA C, LUCARELLI G, UNGAR A, FATTIROLLI F, BALDASSERONI S. ARNI AND SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUROPEAN GERIATRIC MEDICINE. 2020?11(SUPPL 1):S157?S157.",68.0,YR,,M,Y,,,20210331.0,,HP,IT,IT,2021,Q1,Elderly
190813911,19081391,3,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,,20210322.0,20210331,20210331,EXP,,IT-BAXTER-2021BAX006220,BAXTER,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, FORTINI G, TOGNELLI S, GHIARA C, LUCARELLI G, UNGAR A, FATTIROLLI F, BALDASSERONI S. ARNI AND SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUROPEAN GERIATRIC MEDICINE. 2020?11(SUPPL 1):S157?S157.",68.0,YR,,M,Y,,,20210331.0,,HP,IT,IT,2021,Q1,Elderly
190813911,19081391,3,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,1,I,,20210322.0,20210331,20210331,EXP,,IT-BAXTER-2021BAX006220,BAXTER,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, FORTINI G, TOGNELLI S, GHIARA C, LUCARELLI G, UNGAR A, FATTIROLLI F, BALDASSERONI S. ARNI AND SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUROPEAN GERIATRIC MEDICINE. 2020?11(SUPPL 1):S157?S157.",68.0,YR,,M,Y,,,20210331.0,,HP,IT,IT,2021,Q1,Elderly
190829421,19082942,1,PS,EMPAGLIFLOZIN  (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q1,Pulmonary embolism,,2021,Q1,1,I,20210316.0,,20210331,20210331,DIR,,,FDA-CTU,,64.0,YR,,M,N,87.0,KG,20210331.0,N,PH,US,US,2021,Q1,Adult
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Anxiety,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Arthralgia,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Basal cell carcinoma,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Blood pressure diastolic decreased,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Blood pressure increased,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Cataract,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Cough,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Dyspepsia,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Malaise,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Nasal congestion,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Nasopharyngitis,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Pancreatic carcinoma,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Pyrexia,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Second primary malignancy,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Skin mass,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
946404949,9464049,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q1,Vision blurred,,2021,Q1,49,F,20141127.0,20210310.0,20130819,20210319,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210319.0,,MD,CA,CA,2021,Q1,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Aspiration,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Asthma,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Bilevel positive airway pressure,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Blood count abnormal,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Bronchial hyperreactivity,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Condition aggravated,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Cough,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Drug ineffective,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Dyspnoea,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Hospitalisation,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Left ventricular dysfunction,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Loss of personal independence in daily activities,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Lung disorder,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Obstructive airways disorder,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Pneumonia,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Pneumonitis,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Productive cough,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Rales,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Respiratory symptom,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Sleep disorder due to a general medical condition,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Sputum discoloured,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Therapy cessation,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Wheezing,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
153959727,15395972,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Wrong technique in product usage process,,2021,Q2,7,F,201704.0,20210420.0,20180918,20210427,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK168066,GLAXOSMITHKLINE,,78.0,YR,,M,Y,,,20210427.0,,CN,CA,CA,2021,Q2,Elderly
1687739314,16877393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Ascites,,2021,Q2,14,F,20190301.0,20210505.0,20191002,20210507,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104458",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.4,KG,20210507.0,,MD,AR,AR,2021,Q2,Elderly
1687739314,16877393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Jaundice,,2021,Q2,14,F,20190301.0,20210505.0,20191002,20210507,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104458",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.4,KG,20210507.0,,MD,AR,AR,2021,Q2,Elderly
1687739314,16877393,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Liver disorder,,2021,Q2,14,F,20190301.0,20210505.0,20191002,20210507,EXP,,"AR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-104458",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,62.4,KG,20210507.0,,MD,AR,AR,2021,Q2,Elderly
169576847,16957684,4,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5?1000,MG,DAILY",,,,,,,,,,,,2021,Q2,Malignant anorectal neoplasm,,2021,Q2,7,F,20191016.0,20210602.0,20191024,20210604,EXP,,US-GILEAD-2019-0433605,GILEAD,,66.0,YR,E,M,Y,84.8,KG,20210604.0,,MD,US,US,2021,Q2,Elderly
169576847,16957684,4,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"12.5?1000,MG,DAILY",,,,,,,,,,,,2021,Q2,Pneumonia,,2021,Q2,7,F,20191016.0,20210602.0,20191024,20210604,EXP,,US-GILEAD-2019-0433605,GILEAD,,66.0,YR,E,M,Y,84.8,KG,20210604.0,,MD,US,US,2021,Q2,Elderly
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Anhedonia,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Anxiety,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Chronic kidney disease,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Emotional distress,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Glomerulonephritis membranous,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Nephrotic syndrome,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Pain,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Renal failure,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
171627934,17162793,31,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Tooth loss,,2021,Q2,4,F,2016.0,20210614.0,20191217,20210616,EXP,,US-GILEAD-2019-0442869,GILEAD,,54.0,YR,A,M,Y,92.98,KG,20210616.0,,LW,US,US,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Blood pressure increased,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Diabetic nephropathy,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Hypertension,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Oedema,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Oedema peripheral,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Protein urine present,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,15,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, QD",,,,,,,,,,,QD,2021,Q2,Renal impairment,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Blood pressure increased,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Diabetic nephropathy,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Hypertension,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Oedema,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Oedema peripheral,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Protein urine present,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
175539606,17553960,16,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q2,Renal impairment,,2021,Q2,6,F,20191119.0,20210426.0,20200317,20210430,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20210430.0,,MD,JP,JP,2021,Q2,Adult
177256659,17725665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,9,F,202002.0,20210414.0,20200429,20210414,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-021407",BOEHRINGER INGELHEIM,,39.0,YR,A,M,Y,109.8,KG,20210414.0,,MD,BR,BR,2021,Q2,Adult
177256659,17725665,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Renal failure,,2021,Q2,9,F,202002.0,20210414.0,20200429,20210414,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-021407",BOEHRINGER INGELHEIM,,39.0,YR,A,M,Y,109.8,KG,20210414.0,,MD,BR,BR,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Candida infection,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Candida sepsis,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Coagulation test abnormal,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Coagulopathy,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Emphysematous pyelonephritis,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Hypotension,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Oliguria,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Perinephric abscess,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Product use in unapproved indication,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Pyelonephritis fungal,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Renal impairment,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Septic shock,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Systemic candida,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Therapy non-responder,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Urinary tract candidiasis,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Urinary tract infection,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Urinary tract infection enterococcal,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180590728,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q2,Vesicoureteric reflux,,2021,Q2,8,F,,20210628.0,20200723,20210629,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210629.0,,HP,ES,ES,2021,Q2,Adult
180929889,18092988,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Urinary tract infection,,2021,Q2,9,F,20200720.0,20210521.0,20200730,20210602,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-037161",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,61.6,KG,20210602.0,,MD,KR,KR,2021,Q2,Elderly
180929889,18092988,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Urosepsis,,2021,Q2,9,F,20200720.0,20210521.0,20200730,20210602,EXP,,"KR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-037161",BOEHRINGER INGELHEIM,,78.0,YR,E,F,Y,61.6,KG,20210602.0,,MD,KR,KR,2021,Q2,Elderly
1810817311,18108173,20,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DATE OF LAST ADMINISTRATION PRIOR TO EVENT: 01?SEP?2020,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Acute kidney injury,,2021,Q2,11,F,20200309.0,20210409.0,20200803,20210416,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015702",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,88.2,KG,20210416.0,,MD,BR,BR,2021,Q2,Elderly
1810817311,18108173,20,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DATE OF LAST ADMINISTRATION PRIOR TO EVENT: 01?SEP?2020,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,COVID-19,,2021,Q2,11,F,20200309.0,20210409.0,20200803,20210416,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015702",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,88.2,KG,20210416.0,,MD,BR,BR,2021,Q2,Elderly
1810817311,18108173,20,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DATE OF LAST ADMINISTRATION PRIOR TO EVENT: 01?SEP?2020,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Cardiac failure,,2021,Q2,11,F,20200309.0,20210409.0,20200803,20210416,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015702",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,88.2,KG,20210416.0,,MD,BR,BR,2021,Q2,Elderly
1810817311,18108173,20,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DATE OF LAST ADMINISTRATION PRIOR TO EVENT: 01?SEP?2020,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Hyperkalaemia,,2021,Q2,11,F,20200309.0,20210409.0,20200803,20210416,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015702",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,88.2,KG,20210416.0,,MD,BR,BR,2021,Q2,Elderly
1810817311,18108173,20,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,DATE OF LAST ADMINISTRATION PRIOR TO EVENT: 01?SEP?2020,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Metabolic acidosis,,2021,Q2,11,F,20200309.0,20210409.0,20200803,20210416,EXP,,"BR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-015702",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,88.2,KG,20210416.0,,MD,BR,BR,2021,Q2,Elderly
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Candida infection,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Candida sepsis,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Coagulation test abnormal,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Emphysematous pyelonephritis,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Perinephric abscess,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Pyelonephritis fungal,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Septic shock,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
181117262,18111726,10,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q2,Systemic candida,,2021,Q2,2,F,,20200727.0,20200805,20210628,EXP,,ES-TEVA-2020-ES-1809860,TEVA,"CASES?CORONA C, SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT. NEPHRON 2020?144(6):304?309.",56.0,YR,A,F,Y,,,20210628.0,,MD,ES,ES,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Atrial fibrillation,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Dehydration,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Malaise,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Product dose omission issue,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182333473,18233347,10,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Pyrexia,,2021,Q2,3,F,,20210412.0,20200904,20210421,EXP,,CA-TEVA-2020-CA-1822259,TEVA,,58.0,YR,A,M,Y,98.0,KG,20210421.0,,PH,CA,CA,2021,Q2,Adult
182858076,18285807,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q2,Cardiac ventricular thrombosis,,2021,Q2,6,F,20200827.0,20210624.0,20200918,20210629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-045151",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,70.5,KG,20210629.0,,MD,JP,JP,2021,Q2,Elderly
182858076,18285807,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q2,Coronary artery stenosis,,2021,Q2,6,F,20200827.0,20210624.0,20200918,20210629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-045151",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,70.5,KG,20210629.0,,MD,JP,JP,2021,Q2,Elderly
182858076,18285807,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q2,Ventricular tachycardia,,2021,Q2,6,F,20200827.0,20210624.0,20200918,20210629,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-045151",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,70.5,KG,20210629.0,,MD,JP,JP,2021,Q2,Elderly
184331472,18433147,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Pulmonary embolism,,2021,Q2,2,F,20201008.0,20210428.0,20201027,20210507,EXP,,DE-BAUSCH-BL-2020-030717,BAUSCH AND LOMB,,71.0,YR,,M,Y,80.0,KG,20210507.0,,MD,DE,DE,2021,Q2,Elderly
184331472,18433147,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Thrombosis,,2021,Q2,2,F,20201008.0,20210428.0,20201027,20210507,EXP,,DE-BAUSCH-BL-2020-030717,BAUSCH AND LOMB,,71.0,YR,,M,Y,80.0,KG,20210507.0,,MD,DE,DE,2021,Q2,Elderly
184821755,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Arthralgia,,2021,Q2,5,F,20201019.0,20210601.0,20201110,20210605,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210604.0,,MD,JP,JP,2021,Q2,Adult
184821755,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Cataract,,2021,Q2,5,F,20201019.0,20210601.0,20201110,20210605,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210604.0,,MD,JP,JP,2021,Q2,Adult
184821755,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Eczema asteatotic,,2021,Q2,5,F,20201019.0,20210601.0,20201110,20210605,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210604.0,,MD,JP,JP,2021,Q2,Adult
184821755,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Rash pruritic,,2021,Q2,5,F,20201019.0,20210601.0,20201110,20210605,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20210604.0,,MD,JP,JP,2021,Q2,Adult
185800832,18580083,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Hyperkalaemia,,2021,Q2,2,F,20201124.0,20210514.0,20201204,20210521,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065004",BOEHRINGER INGELHEIM,,76.0,YR,E,F,Y,,,20210521.0,,MD,CN,CN,2021,Q2,Elderly
187182722,18718272,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q2,Diverticulitis,,2021,Q2,2,F,20200525.0,20210427.0,20210108,20210428,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210428.0,,HP,GB,GB,2021,Q2,Adult
187600072,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,,20210518.0,20210120,20210526,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG M, DE JESUS E, BELAL A, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863?863.",69.0,YR,E,F,Y,,,20210526.0,,HP,US,US,2021,Q2,Elderly
187600072,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,2,F,,20210518.0,20210120,20210526,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG M, DE JESUS E, BELAL A, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863?863.",69.0,YR,E,F,Y,,,20210526.0,,HP,US,US,2021,Q2,Elderly
187600072,18760007,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,25.0,MG,,,2021,Q2,Metabolic acidosis,,2021,Q2,2,F,,20210518.0,20210120,20210526,EXP,,US-DRREDDYS-USA/USA/21/0131048,DR REDDYS,"YANG M, DE JESUS E, BELAL A, KORATALA A. SGLT2 INHIBITORS ARE A NEW STRING FOR NEPHROLOGISTS^ BOW: TIME TO BE EXCITED YET EXERCISE CAUTION. J AM SOC NEPHROL. 2019?30:863?863.",69.0,YR,E,F,Y,,,20210526.0,,HP,US,US,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188004782,18800478,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10MG,,,D,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210128,20210617,EXP,DE-DCGMA-20187149,NVSC2021DE019358,NOVARTIS,,75.0,YR,,F,Y,,,20210617.0,,HP,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188088172,18808817,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10.0MG UNKNOWN,,,,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,2,F,20201203.0,20210616.0,20210129,20210621,EXP,,DE-ASTRAZENECA-2021A015188,ASTRAZENECA,,75.0,YR,,F,Y,,,20210621.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188122782,18812278,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,D,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210129,20210624,EXP,,DE-AUROBINDO-AUR-APL-2021-003472,AUROBINDO,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
188132703,18813270,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,U,,,,25.0,MG,,QD,2021,Q2,Cerebrovascular accident,,2021,Q2,3,F,,20210604.0,20210131,20210615,EXP,,CA-AUROBINDO-AUR-APL-2021-003684,AUROBINDO,,51.0,YR,,M,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Adult
188132703,18813270,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,U,,,,25.0,MG,,QD,2021,Q2,Lactic acidosis,,2021,Q2,3,F,,20210604.0,20210131,20210615,EXP,,CA-AUROBINDO-AUR-APL-2021-003684,AUROBINDO,,51.0,YR,,M,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Adult
188132703,18813270,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, ONCE A DAY",,,U,U,,,,25.0,MG,,QD,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,3,F,,20210604.0,20210131,20210615,EXP,,CA-AUROBINDO-AUR-APL-2021-003684,AUROBINDO,,51.0,YR,,M,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Adenocarcinoma,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Asthenia,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Decreased appetite,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Drug ineffective,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Dyspnoea,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Fatigue,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,General physical health deterioration,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Hyperkalaemia,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Hyponatraemia,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Lumbar vertebral fracture,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Malignant neoplasm of pleura,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Metastases to adrenals,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Metastases to bone,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Metastases to liver,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Neoplasm progression,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Oedema peripheral,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188203272,18820327,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG X 1.5, STARTED BEFORE 2017",,,U,,,,,25.0,MG,,,2021,Q2,Weight increased,,2021,Q2,2,F,20191116.0,20210601.0,20210202,20210604,EXP,,NVSC2020DE326484,NOVARTIS,,61.0,YR,,M,Y,,,20210604.0,,MD,DE,DE,2021,Q2,Adult
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188410683,18841068,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,3,F,20201203.0,20210617.0,20210204,20210626,EXP,,DE-TEVA-2021-DE-1875017,TEVA,,75.0,YR,E,F,Y,,,20210626.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188461894,18846189,6,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,4,F,20201203.0,20210622.0,20210204,20210628,EXP,DE-DCGMA-20187149,DE-TORRENT-00019529,TORRENT,,75.0,YR,E,F,Y,,,20210628.0,,MD,DE,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188494022,18849402,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-279139,RANBAXY,,75.0,YR,,F,Y,,,20210629.0,,HP,NL,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188504972,18850497,6,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,2,F,20201203.0,20210614.0,20210205,20210629,EXP,DE-DCGMA-20187149,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-00408,ALKEM,,75.0,YR,,F,Y,,,20210629.0,,HP,DE,DE,2021,Q2,Elderly
188543133,18854313,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Confusional state,,2021,Q2,3,F,20210122.0,20210211.0,20210205,20210409,EXP,,CA-KARYOPHARM-2021KPT000116,KARYOPHARM THERAPEUTICS,,71.0,YR,,F,Y,66.2,KG,20210409.0,,HP,CA,CA,2021,Q2,Elderly
188578112,18857811,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, EVERYDAY",,,,,,,,10.0,MG,,QD,2021,Q2,Bradycardia,,2021,Q2,2,F,2021.0,20210426.0,20210208,20210504,PER,,JP-AMGEN-JPNSP2021019946,AMGEN,,39.0,YR,A,F,Y,110.0,KG,20210504.0,,MD,JP,JP,2021,Q2,Adult
188578112,18857811,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, EVERYDAY",,,,,,,,10.0,MG,,QD,2021,Q2,Product use issue,,2021,Q2,2,F,2021.0,20210426.0,20210208,20210504,PER,,JP-AMGEN-JPNSP2021019946,AMGEN,,39.0,YR,A,F,Y,110.0,KG,20210504.0,,MD,JP,JP,2021,Q2,Adult
189063652,18906365,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Asthenia,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189063652,18906365,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Fatigue,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189063652,18906365,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Hypersomnia,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189227753,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY",,,,,,,,25.0,MG,,QD,2021,Q2,Product dispensing error,,2021,Q2,3,F,,20210413.0,20210222,20210428,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20210428.0,,CN,US,US,2021,Q2,Adult
189227753,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY",,,,,,,,25.0,MG,,QD,2021,Q2,Product distribution issue,,2021,Q2,3,F,,20210413.0,20210222,20210428,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20210428.0,,CN,US,US,2021,Q2,Adult
189227753,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY",,,,,,,,25.0,MG,,QD,2021,Q2,Thrombosis,,2021,Q2,3,F,,20210413.0,20210222,20210428,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20210428.0,,CN,US,US,2021,Q2,Adult
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Cardiac arrest,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Decreased appetite,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Gastric ulcer perforation,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Haematemesis,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Limb injury,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
189962212,18996221,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK QD,,,,, UNKNOWN,,,,,,,2021,Q2,Venous occlusion,,2021,Q2,2,F,202011.0,20210325.0,20210311,20210402,EXP,,CO-NOVOPROD-792877,NOVO NORDISK,,76.0,YR,,M,Y,62.0,KG,20210402.0,,CN,CO,CO,2021,Q2,Elderly
190113684,19011368,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Cytokine release syndrome,,2021,Q2,4,F,20201212.0,20210514.0,20210316,20210520,EXP,,US-ROCHE-2734786,ROCHE,,72.0,YR,,M,Y,82.5,KG,20210520.0,,MD,US,US,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Musculoskeletal disorder,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,N-terminal prohormone brain natriuretic peptide decreased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Weight increased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Musculoskeletal disorder,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,N-terminal prohormone brain natriuretic peptide decreased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190209692,19020969,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,, UNK,,,25.0,MG,,,2021,Q2,Weight increased,,2021,Q2,2,F,201811.0,20210329.0,20210317,20210405,EXP,,NVSC2021HU058596,NOVARTIS,,69.0,YR,,M,Y,,,20210405.0,,HP,HU,HU,2021,Q2,Elderly
190390432,19039043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,, UNKNOWN,,,10.0,MG,,QD,2021,Q2,Dyspnoea,,2021,Q2,2,F,20200817.0,20210330.0,20210322,20210412,EXP,,GB-PFIZER INC-2021267315,PFIZER,,66.0,YR,,M,Y,83.9,KG,20210412.0,,MD,GB,GB,2021,Q2,Elderly
190390432,19039043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,, UNKNOWN,,,10.0,MG,,QD,2021,Q2,Left ventricular failure,,2021,Q2,2,F,20200817.0,20210330.0,20210322,20210412,EXP,,GB-PFIZER INC-2021267315,PFIZER,,66.0,YR,,M,Y,83.9,KG,20210412.0,,MD,GB,GB,2021,Q2,Elderly
190390432,19039043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,, UNKNOWN,,,10.0,MG,,QD,2021,Q2,Oedema peripheral,,2021,Q2,2,F,20200817.0,20210330.0,20210322,20210412,EXP,,GB-PFIZER INC-2021267315,PFIZER,,66.0,YR,,M,Y,83.9,KG,20210412.0,,MD,GB,GB,2021,Q2,Elderly
190390432,19039043,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1X/DAY",,,,, UNKNOWN,,,10.0,MG,,QD,2021,Q2,Pulmonary oedema,,2021,Q2,2,F,20200817.0,20210330.0,20210322,20210412,EXP,,GB-PFIZER INC-2021267315,PFIZER,,66.0,YR,,M,Y,83.9,KG,20210412.0,,MD,GB,GB,2021,Q2,Elderly
190568203,19056820,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Renal impairment,,2021,Q2,3,F,20190730.0,20210407.0,20210325,20210414,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-091874",BOEHRINGER INGELHEIM,,91.0,YR,E,F,Y,65.5,KG,20210414.0,,MD,NL,NL,2021,Q2,Elderly
190663203,19066320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Fluid overload,,2021,Q2,3,F,20200206.0,20210330.0,20210328,20210407,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-091834",BOEHRINGER INGELHEIM,,29.0,YR,A,F,Y,64.2,KG,20210407.0,,MD,CA,CA,2021,Q2,Young Adult
190696063,19069606,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,3,F,20210220.0,20210331.0,20210329,20210407,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-092877",BOEHRINGER INGELHEIM,,87.0,YR,E,F,Y,78.3,KG,20210407.0,,MD,DE,DE,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Brain natriuretic peptide decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cardiac failure acute,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Carotid artery stenosis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cystitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Ejection fraction decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Electrocardiogram QRS complex prolonged,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Ischaemic stroke,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Left ventricular dysfunction,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Musculoskeletal discomfort,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Pneumonia,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Prostatitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Brain natriuretic peptide decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cardiac failure acute,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Carotid artery stenosis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cystitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Ejection fraction decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Electrocardiogram QRS complex prolonged,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Ischaemic stroke,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Left ventricular dysfunction,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Musculoskeletal discomfort,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Pneumonia,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Prostatitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Brain natriuretic peptide decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cardiac failure acute,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Carotid artery stenosis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Cystitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Ejection fraction decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Electrocardiogram QRS complex prolonged,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Ischaemic stroke,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Left ventricular dysfunction,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Musculoskeletal discomfort,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Pneumonia,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Prostatitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,, UNKNOWN,,,10.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Blood potassium increased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Brain natriuretic peptide decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cardiac failure acute,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cardiac failure chronic,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Carotid artery stenosis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Cystitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Dyspnoea paroxysmal nocturnal,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Ejection fraction decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Electrocardiogram QRS complex prolonged,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Fluid retention,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Iron deficiency,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Ischaemic stroke,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Left ventricular dysfunction,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Musculoskeletal discomfort,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Pneumonia,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Prostatitis,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190700482,19070048,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,25.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2015.0,20210329.0,20210329,20210406,EXP,,HU-PFIZER INC-2021318977,PFIZER,,69.0,YR,,M,Y,,,20210406.0,,MD,HU,HU,2021,Q2,Elderly
190849111,19084911,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2021,Q2,Coma,,2021,Q2,1,I,20190718.0,20210323.0,20210401,20210401,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000360,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT..JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210401.0,,MD,HU,HU,2021,Q2,Elderly
190849111,19084911,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2021,Q2,Haemorrhagic stroke,,2021,Q2,1,I,20190718.0,20210323.0,20210401,20210401,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000360,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT..JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210401.0,,MD,HU,HU,2021,Q2,Elderly
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,COVID-19,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,COVID-19 pneumonia,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Confusional state,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Dyspnoea,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Pyrexia,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870161,19087016,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,0.5,DF,TABLET,QD,2021,Q2,Tachypnoea,,2021,Q2,1,I,20201205.0,,20210401,20210401,DIR,,,FDA-CTU,,63.0,YR,,M,N,174.0,KG,20210218.0,N,HP,US,US,2021,Q2,Adult
190870791,19087079,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Acute kidney injury,,2021,Q2,1,I,,20210324.0,20210402,20210402,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, ET AL. ARNI + SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUR?GERIATR?MED 2020?11 (SUPPL.):S157 ABSTR. 103.",68.0,YR,,M,Y,,,20210402.0,,HP,IT,IT,2021,Q2,Elderly
190870791,19087079,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Hyperkalaemia,,2021,Q2,1,I,,20210324.0,20210402,20210402,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, ET AL. ARNI + SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUR?GERIATR?MED 2020?11 (SUPPL.):S157 ABSTR. 103.",68.0,YR,,M,Y,,,20210402.0,,HP,IT,IT,2021,Q2,Elderly
190870791,19087079,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Hypovolaemia,,2021,Q2,1,I,,20210324.0,20210402,20210402,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, ET AL. ARNI + SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUR?GERIATR?MED 2020?11 (SUPPL.):S157 ABSTR. 103.",68.0,YR,,M,Y,,,20210402.0,,HP,IT,IT,2021,Q2,Elderly
190870791,19087079,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,,20210324.0,20210402,20210402,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, ET AL. ARNI + SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUR?GERIATR?MED 2020?11 (SUPPL.):S157 ABSTR. 103.",68.0,YR,,M,Y,,,20210402.0,,HP,IT,IT,2021,Q2,Elderly
190870791,19087079,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210324.0,20210402,20210402,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, MIGLIORINI M, ORSO F, PRATESI A, VIRCIGLIO S, CAMARTINI V, ET AL. ARNI + SGLT2I: AN INTRIGUING AND PROMISING ASSOCIATION TO BE USED WITH CAUTION?A CLINICAL CASE REPORT. EUR?GERIATR?MED 2020?11 (SUPPL.):S157 ABSTR. 103.",68.0,YR,,M,Y,,,20210402.0,,HP,IT,IT,2021,Q2,Elderly
190874421,19087442,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Deep vein thrombosis,,2021,Q2,1,I,20181010.0,20210329.0,20210402,20210402,PER,,US-PFIZER INC-2021351773,PFIZER,,74.0,YR,,,Y,,,20210402.0,,LW,US,US,2021,Q2,Elderly
190881881,19088188,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190881881,19088188,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190881881,19088188,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Hypomagnesaemia,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190883032,19088303,5,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,2,F,20210218.0,20210519.0,20210402,20210524,EXP,,"NL-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-094338",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,106.8,KG,20210524.0,,MD,NL,NL,2021,Q2,Elderly
190917851,19091785,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q2,Metabolic encephalopathy,,2021,Q2,1,I,20201001.0,,20210405,20210405,DIR,,,FDA-CTU,,60.0,YR,,M,N,92.53,KG,20201218.0,N,PH,US,US,2021,Q2,Adult
190917851,19091785,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q2,Nausea,,2021,Q2,1,I,20201001.0,,20210405,20210405,DIR,,,FDA-CTU,,60.0,YR,,M,N,92.53,KG,20201218.0,N,PH,US,US,2021,Q2,Adult
190917851,19091785,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q2,Sepsis,,2021,Q2,1,I,20201001.0,,20210405,20210405,DIR,,,FDA-CTU,,60.0,YR,,M,N,92.53,KG,20201218.0,N,PH,US,US,2021,Q2,Adult
190917851,19091785,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20201001.0,,20210405,20210405,DIR,,,FDA-CTU,,60.0,YR,,M,N,92.53,KG,20201218.0,N,PH,US,US,2021,Q2,Adult
190923621,19092362,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q2,Drug dependence,,2021,Q2,1,I,,20210326.0,20210405,20210405,EXP,,PT-MYLANLABS-2021M1019386,MYLAN,"FERNANDES LN, SILVA D.. THE IMPORTANCE OF QUESTIONING THE DIAGNOSIS OF DIABETES MELLITUS TYPE 2: A CASE OF LADA. PORTUGUESE CONGRESS OF ENDOCRINOLOGY /72ND SPEDM ANNUAL MEETING? REVISTA PORTUGU. 2021?16 SUPPLEMENT:53",65.0,YR,,F,Y,,,20210405.0,,MD,PT,PT,2021,Q2,Elderly
190923621,19092362,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q2,Vomiting,,2021,Q2,1,I,,20210326.0,20210405,20210405,EXP,,PT-MYLANLABS-2021M1019386,MYLAN,"FERNANDES LN, SILVA D.. THE IMPORTANCE OF QUESTIONING THE DIAGNOSIS OF DIABETES MELLITUS TYPE 2: A CASE OF LADA. PORTUGUESE CONGRESS OF ENDOCRINOLOGY /72ND SPEDM ANNUAL MEETING? REVISTA PORTUGU. 2021?16 SUPPLEMENT:53",65.0,YR,,F,Y,,,20210405.0,,MD,PT,PT,2021,Q2,Elderly
190923621,19092362,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q2,Weight increased,,2021,Q2,1,I,,20210326.0,20210405,20210405,EXP,,PT-MYLANLABS-2021M1019386,MYLAN,"FERNANDES LN, SILVA D.. THE IMPORTANCE OF QUESTIONING THE DIAGNOSIS OF DIABETES MELLITUS TYPE 2: A CASE OF LADA. PORTUGUESE CONGRESS OF ENDOCRINOLOGY /72ND SPEDM ANNUAL MEETING? REVISTA PORTUGU. 2021?16 SUPPLEMENT:53",65.0,YR,,F,Y,,,20210405.0,,MD,PT,PT,2021,Q2,Elderly
190943301,19094330,2,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"12.5 MILLIGRAM, UNK",,,U,,,,,12.5,MG,,,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,,20210322.0,20210406,20210406,EXP,,IL-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-289502,RANBAXY,,64.0,YR,,M,Y,,,20210406.0,,HP,IL,IL,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Atelectasis,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Back pain,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Chest pain,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Cough,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Deep vein thrombosis,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Dyspnoea,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Fatigue,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Headache,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Hepatic mass,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Pleural effusion,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Pneumonia viral,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Pulmonary embolism,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
190977571,19097757,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Tachycardia,,2021,Q2,1,I,20210331.0,,20210406,20210406,DIR,,,FDA-CTU,,49.0,YR,,F,N,103.95,KG,20210406.0,Y,HP,US,US,2021,Q2,Adult
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Hyperkalaemia,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Hypotension,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Hypovolaemia,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Metabolic acidosis,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Toxicity to various agents,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Acute kidney injury,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Hyperkalaemia,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Hypotension,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Hypovolaemia,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Metabolic acidosis,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Toxicity to various agents,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191004352,19100435,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,U,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,2,F,2019.0,20210610.0,20210407,20210619,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210619.0,,HP,IT,IT,2021,Q2,Elderly
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Anxiety,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,COVID-19,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Hypophagia,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Myalgia,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Nausea,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Pyrexia,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191015601,19101560,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Vomiting,,2021,Q2,1,I,20210115.0,,20210407,20210407,DIR,,,FDA-CTU,,61.0,YR,,M,N,99.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191074031,19107403,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Anaemia,,2021,Q2,1,I,20210317.0,,20210408,20210408,DIR,,,FDA-CTU,,58.0,YR,,M,N,125.0,KG,20210405.0,N,PH,US,US,2021,Q2,Adult
191074031,19107403,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Atrial fibrillation,,2021,Q2,1,I,20210317.0,,20210408,20210408,DIR,,,FDA-CTU,,58.0,YR,,M,N,125.0,KG,20210405.0,N,PH,US,US,2021,Q2,Adult
191074031,19107403,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Ketoacidosis,,2021,Q2,1,I,20210317.0,,20210408,20210408,DIR,,,FDA-CTU,,58.0,YR,,M,N,125.0,KG,20210405.0,N,PH,US,US,2021,Q2,Adult
191074031,19107403,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,20210317.0,,20210408,20210408,DIR,,,FDA-CTU,,58.0,YR,,M,N,125.0,KG,20210405.0,N,PH,US,US,2021,Q2,Adult
191074031,19107403,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Pulmonary embolism,,2021,Q2,1,I,20210317.0,,20210408,20210408,DIR,,,FDA-CTU,,58.0,YR,,M,N,125.0,KG,20210405.0,N,PH,US,US,2021,Q2,Adult
191098283,19109828,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,COVID-19 pneumonia,,2021,Q2,3,F,,20210603.0,20210409,20210616,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-095500",BOEHRINGER INGELHEIM,"OSHIMA Y, NAGASAWA R. A CASE OF ACUTE EXACERBATION OF IPF DUE TO COVID?19 ?IN LIGHT OF TIME?DEPENDENT CHANGES IN SERUM HEME OXYGENASE (HO)?1?. THE 244TH KANTO REGIONAL MEETING OF THE JAPANESE RESPIRATORY SOCIETY. 2021 MAY 29? 16?",70.0,YR,E,M,Y,,,20210616.0,,MD,JP,JP,2021,Q2,Elderly
191098283,19109828,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Idiopathic pulmonary fibrosis,,2021,Q2,3,F,,20210603.0,20210409,20210616,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-095500",BOEHRINGER INGELHEIM,"OSHIMA Y, NAGASAWA R. A CASE OF ACUTE EXACERBATION OF IPF DUE TO COVID?19 ?IN LIGHT OF TIME?DEPENDENT CHANGES IN SERUM HEME OXYGENASE (HO)?1?. THE 244TH KANTO REGIONAL MEETING OF THE JAPANESE RESPIRATORY SOCIETY. 2021 MAY 29? 16?",70.0,YR,E,M,Y,,,20210616.0,,MD,JP,JP,2021,Q2,Elderly
191098283,19109828,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,COVID-19 pneumonia,,2021,Q2,3,F,,20210603.0,20210409,20210616,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-095500",BOEHRINGER INGELHEIM,"OSHIMA Y, NAGASAWA R. A CASE OF ACUTE EXACERBATION OF IPF DUE TO COVID?19 ?IN LIGHT OF TIME?DEPENDENT CHANGES IN SERUM HEME OXYGENASE (HO)?1?. THE 244TH KANTO REGIONAL MEETING OF THE JAPANESE RESPIRATORY SOCIETY. 2021 MAY 29? 16?",70.0,YR,E,M,Y,,,20210616.0,,MD,JP,JP,2021,Q2,Elderly
191098283,19109828,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Idiopathic pulmonary fibrosis,,2021,Q2,3,F,,20210603.0,20210409,20210616,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-095500",BOEHRINGER INGELHEIM,"OSHIMA Y, NAGASAWA R. A CASE OF ACUTE EXACERBATION OF IPF DUE TO COVID?19 ?IN LIGHT OF TIME?DEPENDENT CHANGES IN SERUM HEME OXYGENASE (HO)?1?. THE 244TH KANTO REGIONAL MEETING OF THE JAPANESE RESPIRATORY SOCIETY. 2021 MAY 29? 16?",70.0,YR,E,M,Y,,,20210616.0,,MD,JP,JP,2021,Q2,Elderly
191120881,19112088,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Anion gap increased,,2021,Q2,1,I,20201108.0,,20210409,20210409,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q2,Elderly
191120881,19112088,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20201108.0,,20210409,20210409,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q2,Elderly
191120881,19112088,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,20201108.0,,20210409,20210409,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q2,Elderly
191120881,19112088,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Renal tubular acidosis,,2021,Q2,1,I,20201108.0,,20210409,20210409,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q2,Elderly
191120881,19112088,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Sepsis,,2021,Q2,1,I,20201108.0,,20210409,20210409,DIR,,,FDA-CTU,,67.0,YR,,M,N,,,20210119.0,N,PH,US,US,2021,Q2,Elderly
191172881,19117288,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,, UNKNOWN,,,25.0,MG,,QD,2021,Q2,Acute myocardial infarction,,2021,Q2,1,I,,20200914.0,20210409,20210409,EXP,,BR-NOVOPROD-801712,NOVO NORDISK,,59.0,YR,,M,Y,,,20210409.0,,MD,BR,BR,2021,Q2,Adult
191198701,19119870,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Acute erythroid leukaemia,,2021,Q2,1,I,20201230.0,20201231.0,20210412,20210412,EXP,,US-ABBVIE-21K-163-3714419-00,ABBVIE,,75.0,YR,,M,Y,98.0,KG,20210412.0,,MD,US,US,2021,Q2,Elderly
191198701,19119870,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Anaemia,,2021,Q2,1,I,20201230.0,20201231.0,20210412,20210412,EXP,,US-ABBVIE-21K-163-3714419-00,ABBVIE,,75.0,YR,,M,Y,98.0,KG,20210412.0,,MD,US,US,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Cardiothoracic ratio,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Chest discomfort,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Drug interaction,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Dyspnoea,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Hypotension,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Ischaemia,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Peripheral circulatory failure,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Ventricular hypokinesia,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Ventricular internal diameter,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Volume blood decreased,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191204911,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q2,Weight decreased,,2021,Q2,1,I,20201105.0,20201118.0,20210412,20210412,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210412.0,,MD,JP,JP,2021,Q2,Elderly
191229001,19122900,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q2,Colon cancer metastatic,,2021,Q2,1,I,201804.0,20210406.0,20210412,20210412,EXP,,HU-FRESENIUS KABI-FK202103621,FRESENIUS KABI,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (125):.",66.0,YR,,M,Y,,,20210412.0,,HP,HU,HU,2021,Q2,Elderly
191267843,19126784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,3,F,2019.0,20210610.0,20210413,20210623,EXP,,IT-ACCORD-222405,ACCORD,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V,ET. AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020 NOV 28?17(11):728?732",68.0,YR,,M,Y,,,20210623.0,,HP,IT,IT,2021,Q2,Elderly
191267843,19126784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Hypovolaemia,,2021,Q2,3,F,2019.0,20210610.0,20210413,20210623,EXP,,IT-ACCORD-222405,ACCORD,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V,ET. AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020 NOV 28?17(11):728?732",68.0,YR,,M,Y,,,20210623.0,,HP,IT,IT,2021,Q2,Elderly
191267843,19126784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Metabolic acidosis,,2021,Q2,3,F,2019.0,20210610.0,20210413,20210623,EXP,,IT-ACCORD-222405,ACCORD,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V,ET. AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020 NOV 28?17(11):728?732",68.0,YR,,M,Y,,,20210623.0,,HP,IT,IT,2021,Q2,Elderly
191267843,19126784,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,3,F,2019.0,20210610.0,20210413,20210623,EXP,,IT-ACCORD-222405,ACCORD,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V,ET. AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020 NOV 28?17(11):728?732",68.0,YR,,M,Y,,,20210623.0,,HP,IT,IT,2021,Q2,Elderly
191268401,19126840,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Pancreatitis,,2021,Q2,1,I,20210216.0,,20210413,20210413,DIR,,,FDA-CTU,,70.0,YR,,M,N,99.0,KG,20210412.0,N,HP,US,US,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Arthritis,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Asphyxia,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Gait disturbance,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Hypertension,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Rectal haemorrhage,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191334711,19133471,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Speech disorder,,2021,Q2,1,I,2021.0,20210405.0,20210413,20210413,EXP,,CO-JNJFOC-20210410361,JOHNSON AND JOHNSON,,80.0,YR,E,F,Y,72.0,KG,20210414.0,,HP,CO,CO,2021,Q2,Elderly
191345851,19134585,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210406.0,20210414,20210414,EXP,,HU-MYLANLABS-2021M1022059,MYLAN,,66.0,YR,,M,Y,,,20210414.0,,HP,HU,HU,2021,Q2,Elderly
191345851,19134585,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,2018.0,20210406.0,20210414,20210414,EXP,,HU-MYLANLABS-2021M1022059,MYLAN,,66.0,YR,,M,Y,,,20210414.0,,HP,HU,HU,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,COVID-19,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Diverticulum,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Gastritis,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Hepatic cirrhosis,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Nephrolithiasis,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191385941,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Varices oesophageal,,2021,Q2,1,I,202102.0,20210409.0,20210415,20210415,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210415.0,,MD,BR,BR,2021,Q2,Elderly
191397401,19139740,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210406.0,20210408.0,20210415,20210415,EXP,GB-MHRA-TPP9810181C6372686YC1617693206695,NVSC2021GB080652,NOVARTIS,,74.0,YR,,M,Y,92.0,KG,20210415.0,,HP,GB,GB,2021,Q2,Elderly
191397401,19139740,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q2,Hypersensitivity,,2021,Q2,1,I,20210406.0,20210408.0,20210415,20210415,EXP,GB-MHRA-TPP9810181C6372686YC1617693206695,NVSC2021GB080652,NOVARTIS,,74.0,YR,,M,Y,92.0,KG,20210415.0,,HP,GB,GB,2021,Q2,Elderly
191443551,19144355,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q2,Acute kidney injury,,2021,Q2,1,I,,20210406.0,20210416,20210416,EXP,,IT-LEADINGPHARMA-IT-2021LEALIT00129,LEADING PHARMA,,68.0,YR,E,M,Y,,,20210416.0,,HP,IT,IT,2021,Q2,Elderly
191443551,19144355,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q2,Hyperkalaemia,,2021,Q2,1,I,,20210406.0,20210416,20210416,EXP,,IT-LEADINGPHARMA-IT-2021LEALIT00129,LEADING PHARMA,,68.0,YR,E,M,Y,,,20210416.0,,HP,IT,IT,2021,Q2,Elderly
191443551,19144355,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q2,Hypovolaemia,,2021,Q2,1,I,,20210406.0,20210416,20210416,EXP,,IT-LEADINGPHARMA-IT-2021LEALIT00129,LEADING PHARMA,,68.0,YR,E,M,Y,,,20210416.0,,HP,IT,IT,2021,Q2,Elderly
191443551,19144355,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,,20210406.0,20210416,20210416,EXP,,IT-LEADINGPHARMA-IT-2021LEALIT00129,LEADING PHARMA,,68.0,YR,E,M,Y,,,20210416.0,,HP,IT,IT,2021,Q2,Elderly
191443551,19144355,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210406.0,20210416,20210416,EXP,,IT-LEADINGPHARMA-IT-2021LEALIT00129,LEADING PHARMA,,68.0,YR,E,M,Y,,,20210416.0,,HP,IT,IT,2021,Q2,Elderly
191449001,19144900,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, 1 DOSE PER 1 D",,,,,,,,1.0,DF,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210406.0,20210408.0,20210416,20210416,EXP,GB-MHRA-ADR 25084485,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001166,EMCURE,,74.0,YR,,M,Y,92.0,KG,20210416.0,,MD,GB,GB,2021,Q2,Elderly
191449001,19144900,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, 1 DOSE PER 1 D",,,,,,,,1.0,DF,,QD,2021,Q2,Hypersensitivity,,2021,Q2,1,I,20210406.0,20210408.0,20210416,20210416,EXP,GB-MHRA-ADR 25084485,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001166,EMCURE,,74.0,YR,,M,Y,92.0,KG,20210416.0,,MD,GB,GB,2021,Q2,Elderly
191477731,19147773,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Blood glucose increased,,2021,Q2,1,I,202007.0,20201014.0,20210416,20210416,EXP,,BR-NOVOPROD-802030,NOVO NORDISK,,52.0,YR,,M,Y,110.6,KG,20210416.0,,MD,BR,BR,2021,Q2,Adult
191477731,19147773,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,COVID-19,,2021,Q2,1,I,202007.0,20201014.0,20210416,20210416,EXP,,BR-NOVOPROD-802030,NOVO NORDISK,,52.0,YR,,M,Y,110.6,KG,20210416.0,,MD,BR,BR,2021,Q2,Adult
191521021,19152102,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,1.0,DF,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210406.0,20210408.0,20210419,20210419,EXP,GB-MHRA-TPP9810181C6372686YC1617693206695,GB-EMD SERONO-E2B_90083140,EMD SERONO INC,,74.0,YR,E,M,Y,92.0,KG,20210419.0,,MD,GB,GB,2021,Q2,Elderly
191521021,19152102,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,1.0,DF,,QD,2021,Q2,Hypersensitivity,,2021,Q2,1,I,20210406.0,20210408.0,20210419,20210419,EXP,GB-MHRA-TPP9810181C6372686YC1617693206695,GB-EMD SERONO-E2B_90083140,EMD SERONO INC,,74.0,YR,E,M,Y,92.0,KG,20210419.0,,MD,GB,GB,2021,Q2,Elderly
191616951,19161695,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Syncope,,2021,Q2,1,I,20200901.0,,20210420,20210420,DIR,,,FDA-CTU,,60.0,YR,,M,N,,,20210331.0,N,PH,US,US,2021,Q2,Adult
191677811,19167781,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q2,Rash,,2021,Q2,1,I,20210206.0,,20210420,20210420,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q2,Elderly
191677811,19167781,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q2,Skin exfoliation,,2021,Q2,1,I,20210206.0,,20210420,20210420,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q2,Elderly
191677811,19167781,1,PS,EMPAGLIFLOZIN (EMPAGLIFOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,D,,,,,,,,2021,Q2,Skin ulcer,,2021,Q2,1,I,20210206.0,,20210420,20210420,DIR,,,FDA-CTU,,79.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Colon cancer metastatic,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hypomagnesaemia,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Rash,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191706484,19170648,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Respiratory failure,,2021,Q2,4,F,20210417.0,20210526.0,20210422,20210528,EXP,,"DE-PORTOLA PHARMACEUTICALS, INC.-A202104684",ALEXION,,82.0,YR,,M,Y,,,20210528.0,,HP,DE,DE,2021,Q2,Elderly
191737011,19173701,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Asthenia,,2021,Q2,1,I,20210411.0,20210417.0,20210423,20210423,EXP,,CN-009507513-2104CHN004684,MERCK,,47.0,YR,,M,Y,73.0,KG,20210423.0,,HP,CN,CN,2021,Q2,Adult
191737011,19173701,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Decreased appetite,,2021,Q2,1,I,20210411.0,20210417.0,20210423,20210423,EXP,,CN-009507513-2104CHN004684,MERCK,,47.0,YR,,M,Y,73.0,KG,20210423.0,,HP,CN,CN,2021,Q2,Adult
191737011,19173701,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Mental disorder,,2021,Q2,1,I,20210411.0,20210417.0,20210423,20210423,EXP,,CN-009507513-2104CHN004684,MERCK,,47.0,YR,,M,Y,73.0,KG,20210423.0,,HP,CN,CN,2021,Q2,Adult
191737011,19173701,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Seizure,,2021,Q2,1,I,20210411.0,20210417.0,20210423,20210423,EXP,,CN-009507513-2104CHN004684,MERCK,,47.0,YR,,M,Y,73.0,KG,20210423.0,,HP,CN,CN,2021,Q2,Adult
191737011,19173701,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Weight decreased,,2021,Q2,1,I,20210411.0,20210417.0,20210423,20210423,EXP,,CN-009507513-2104CHN004684,MERCK,,47.0,YR,,M,Y,73.0,KG,20210423.0,,HP,CN,CN,2021,Q2,Adult
191757722,19175772,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Cardiac failure,,2021,Q2,2,F,20201130.0,20210422.0,20210423,20210428,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-085035",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,50.7,KG,20210428.0,,MD,US,US,2021,Q2,Elderly
191757722,19175772,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Cardiac failure congestive,,2021,Q2,2,F,20201130.0,20210422.0,20210423,20210428,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-085035",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,50.7,KG,20210428.0,,MD,US,US,2021,Q2,Elderly
191757722,19175772,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q2,Chronic kidney disease,,2021,Q2,2,F,20201130.0,20210422.0,20210423,20210428,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-085035",BOEHRINGER INGELHEIM,,86.0,YR,E,F,Y,50.7,KG,20210428.0,,MD,US,US,2021,Q2,Elderly
191768141,19176814,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Haemarthrosis,,2021,Q2,1,I,,20210416.0,20210424,20210424,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-098504",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20210424.0,,MD,HU,HU,2021,Q2,Adult
191768141,19176814,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Joint injury,,2021,Q2,1,I,,20210416.0,20210424,20210424,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-098504",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20210424.0,,MD,HU,HU,2021,Q2,Adult
191803891,19180389,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850MG 2X1,,,U,,,,,,,,,2021,Q2,Angina pectoris,,2021,Q2,1,I,202005.0,20210413.0,20210426,20210426,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20210426.0,,MD,HR,HR,2021,Q2,Elderly
191803891,19180389,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850MG 2X1,,,U,,,,,,,,,2021,Q2,Cardiac failure chronic,,2021,Q2,1,I,202005.0,20210413.0,20210426,20210426,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20210426.0,,MD,HR,HR,2021,Q2,Elderly
191803891,19180389,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850MG 2X1,,,U,,,,,,,,,2021,Q2,Concomitant disease aggravated,,2021,Q2,1,I,202005.0,20210413.0,20210426,20210426,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20210426.0,,MD,HR,HR,2021,Q2,Elderly
191803891,19180389,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850MG 2X1,,,U,,,,,,,,,2021,Q2,Dyspnoea,,2021,Q2,1,I,202005.0,20210413.0,20210426,20210426,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20210426.0,,MD,HR,HR,2021,Q2,Elderly
191803891,19180389,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850MG 2X1,,,U,,,,,,,,,2021,Q2,Oedema peripheral,,2021,Q2,1,I,202005.0,20210413.0,20210426,20210426,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20210426.0,,MD,HR,HR,2021,Q2,Elderly
191861201,19186120,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q2,Cataract,,2021,Q2,1,I,,20201111.0,20210427,20210427,EXP,,BR-NOVOPROD-805370,NOVO NORDISK,,70.0,YR,,F,Y,78.1,KG,20210427.0,,MD,BR,BR,2021,Q2,Elderly
191870961,19187096,2,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, ONCE A DAY",161.958,DF,,,,,,1.0,DF,,QD,2021,Q2,Product substitution issue,,2021,Q2,1,I,20210415.0,20210420.0,20210428,20210428,EXP,,GB-AUROBINDO-AUR-APL-2021-017115,AUROBINDO,,58.0,YR,,M,Y,110.0,KG,20210428.0,,MD,GB,GB,2021,Q2,Adult
191870961,19187096,2,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, ONCE A DAY",161.958,DF,,,,,,1.0,DF,,QD,2021,Q2,Suicidal ideation,,2021,Q2,1,I,20210415.0,20210420.0,20210428,20210428,EXP,,GB-AUROBINDO-AUR-APL-2021-017115,AUROBINDO,,58.0,YR,,M,Y,110.0,KG,20210428.0,,MD,GB,GB,2021,Q2,Adult
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Bandaemia,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Glycosylated haemoglobin increased,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Hypoxia,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Lung opacity,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Pneumonia aspiration,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,Pyrexia,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191942291,19194229,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,,QD,2021,Q2,SARS-CoV-2 test positive,,2021,Q2,1,I,20201206.0,,20210429,20210429,DIR,,,FDA-CTU,,80.0,YR,,M,N,71.21,KG,20210418.0,N,PH,US,US,2021,Q2,Elderly
191960912,19196091,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,TABLET,,2021,Q2,Duodenal ulcer haemorrhage,,2021,Q2,2,F,20180614.0,20210609.0,20210429,20210617,EXP,,JP-AMERICAN REGENT INC-2021001065,AMERICAN REGENT,,78.0,YR,,M,Y,64.0,KG,20210617.0,,MD,JP,JP,2021,Q2,Elderly
191960912,19196091,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,TABLET,,2021,Q2,Intestinal ischaemia,,2021,Q2,2,F,20180614.0,20210609.0,20210429,20210617,EXP,,JP-AMERICAN REGENT INC-2021001065,AMERICAN REGENT,,78.0,YR,,M,Y,64.0,KG,20210617.0,,MD,JP,JP,2021,Q2,Elderly
191960912,19196091,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,TABLET,,2021,Q2,Pyrexia,,2021,Q2,2,F,20180614.0,20210609.0,20210429,20210617,EXP,,JP-AMERICAN REGENT INC-2021001065,AMERICAN REGENT,,78.0,YR,,M,Y,64.0,KG,20210617.0,,MD,JP,JP,2021,Q2,Elderly
191960912,19196091,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,TABLET,,2021,Q2,Thalamus haemorrhage,,2021,Q2,2,F,20180614.0,20210609.0,20210429,20210617,EXP,,JP-AMERICAN REGENT INC-2021001065,AMERICAN REGENT,,78.0,YR,,M,Y,64.0,KG,20210617.0,,MD,JP,JP,2021,Q2,Elderly
191993471,19199347,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210426.0,20210430,20210430,PER,,US-AMGEN INC.-USASP2021065652,AMGEN,DIAZ D. A HIDDEN ISSUE IN PLAIN SIGHT: A CASE OF EUGLYCEMIC DKA IN THE SETTING OF PANCREATITIS. CRITICAL CARE MEDICINE. 2021?49 (1 SUPPL 1):209,57.0,YR,A,F,Y,,,20210430.0,,HP,US,US,2021,Q2,Adult
191993471,19199347,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Pancreatitis,,2021,Q2,1,I,,20210426.0,20210430,20210430,PER,,US-AMGEN INC.-USASP2021065652,AMGEN,DIAZ D. A HIDDEN ISSUE IN PLAIN SIGHT: A CASE OF EUGLYCEMIC DKA IN THE SETTING OF PANCREATITIS. CRITICAL CARE MEDICINE. 2021?49 (1 SUPPL 1):209,57.0,YR,A,F,Y,,,20210430.0,,HP,US,US,2021,Q2,Adult
192001851,19200185,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,161.958,DF,U,,,,,1.0,DF,,QD,2021,Q2,Product substitution issue,,2021,Q2,1,I,20210415.0,20210420.0,20210430,20210430,EXP,GB-MHRA-TPP12102220C963889YC1618492773758,GB-TORRENT-00025526,TORRENT,,58.0,YR,A,M,Y,110.0,KG,20210430.0,,MD,GB,GB,2021,Q2,Adult
192001851,19200185,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,161.958,DF,U,,,,,1.0,DF,,QD,2021,Q2,Suicidal ideation,,2021,Q2,1,I,20210415.0,20210420.0,20210430,20210430,EXP,GB-MHRA-TPP12102220C963889YC1618492773758,GB-TORRENT-00025526,TORRENT,,58.0,YR,A,M,Y,110.0,KG,20210430.0,,MD,GB,GB,2021,Q2,Adult
192008561,19200856,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Acute kidney injury,,2021,Q2,1,I,20210413.0,20210418.0,20210430,20210430,EXP,GB-MHRA-EYC 00247949,GB-PFIZER INC-2021424665,PFIZER,,65.0,YR,,M,Y,90.0,KG,20210430.0,,PH,GB,GB,2021,Q2,Elderly
192008561,19200856,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Agitation,,2021,Q2,1,I,20210413.0,20210418.0,20210430,20210430,EXP,GB-MHRA-EYC 00247949,GB-PFIZER INC-2021424665,PFIZER,,65.0,YR,,M,Y,90.0,KG,20210430.0,,PH,GB,GB,2021,Q2,Elderly
192008561,19200856,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Blood creatinine increased,,2021,Q2,1,I,20210413.0,20210418.0,20210430,20210430,EXP,GB-MHRA-EYC 00247949,GB-PFIZER INC-2021424665,PFIZER,,65.0,YR,,M,Y,90.0,KG,20210430.0,,PH,GB,GB,2021,Q2,Elderly
192008561,19200856,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Confusional state,,2021,Q2,1,I,20210413.0,20210418.0,20210430,20210430,EXP,GB-MHRA-EYC 00247949,GB-PFIZER INC-2021424665,PFIZER,,65.0,YR,,M,Y,90.0,KG,20210430.0,,PH,GB,GB,2021,Q2,Elderly
192074874,19207487,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,4,F,20210220.0,20210519.0,20210503,20210520,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-100025",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,65.0,KG,20210520.0,,MD,HU,HU,2021,Q2,Elderly
192086272,19208627,5,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,2,F,20210220.0,20210505.0,20210503,20210510,EXP,,"HU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-100026",BOEHRINGER INGELHEIM,,85.0,YR,E,M,Y,82.0,KG,20210510.0,,MD,HU,HU,2021,Q2,Elderly
192094771,19209477,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Blood creatinine increased,,2021,Q2,1,I,,20200302.0,20210503,20210503,EXP,,US-ROCHE-2562362,ROCHE,"HANNA R, ABDELNOUR L, HASNAIN H, SELAMET U AND KURTZ I. INTRAVITREAL BEVACIZUMAB?INDUCED EXACERBATION OF PROTEINURIA IN DIABETIC NEPHROPATHY, AND AMELIORATION BY SWITCHING TO RANIBIZUMAB. SAGE OPEN MEDICAL CASE REPORTS 2020 FEB 16?8:1?5.",37.0,YR,,F,Y,,,20210504.0,,HP,US,US,2021,Q2,Adult
192094771,19209477,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Blood pressure increased,,2021,Q2,1,I,,20200302.0,20210503,20210503,EXP,,US-ROCHE-2562362,ROCHE,"HANNA R, ABDELNOUR L, HASNAIN H, SELAMET U AND KURTZ I. INTRAVITREAL BEVACIZUMAB?INDUCED EXACERBATION OF PROTEINURIA IN DIABETIC NEPHROPATHY, AND AMELIORATION BY SWITCHING TO RANIBIZUMAB. SAGE OPEN MEDICAL CASE REPORTS 2020 FEB 16?8:1?5.",37.0,YR,,F,Y,,,20210504.0,,HP,US,US,2021,Q2,Adult
192094771,19209477,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Proteinuria,,2021,Q2,1,I,,20200302.0,20210503,20210503,EXP,,US-ROCHE-2562362,ROCHE,"HANNA R, ABDELNOUR L, HASNAIN H, SELAMET U AND KURTZ I. INTRAVITREAL BEVACIZUMAB?INDUCED EXACERBATION OF PROTEINURIA IN DIABETIC NEPHROPATHY, AND AMELIORATION BY SWITCHING TO RANIBIZUMAB. SAGE OPEN MEDICAL CASE REPORTS 2020 FEB 16?8:1?5.",37.0,YR,,F,Y,,,20210504.0,,HP,US,US,2021,Q2,Adult
192116171,19211617,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Hyperglycaemia,,2021,Q2,1,I,20200902.0,,20210503,20210503,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q2,Elderly
192116261,19211626,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,,,,,,12.5,MG,,,2021,Q2,Pollakiuria,,2021,Q2,1,I,20200922.0,,20210503,20210503,DIR,,,FDA-CTU,,88.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q2,Elderly
192120181,19212018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Epididymitis,,2021,Q2,1,I,20191203.0,,20210503,20210503,DIR,,,FDA-CTU,,74.0,YR,,M,N,83.0,KG,20200217.0,N,PH,US,US,2021,Q2,Elderly
192120181,19212018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Therapy cessation,,2021,Q2,1,I,20191203.0,,20210503,20210503,DIR,,,FDA-CTU,,74.0,YR,,M,N,83.0,KG,20200217.0,N,PH,US,US,2021,Q2,Elderly
192120181,19212018,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20191203.0,,20210503,20210503,DIR,,,FDA-CTU,,74.0,YR,,M,N,83.0,KG,20200217.0,N,PH,US,US,2021,Q2,Elderly
192160993,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,U,,,,,,,TABLET,,2021,Q2,Abnormal loss of weight,,2021,Q2,3,F,2019.0,20210622.0,20210505,20210623,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20210624.0,,CN,US,US,2021,Q2,Elderly
192160993,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,U,,,,,,,TABLET,,2021,Q2,Diabetes mellitus,,2021,Q2,3,F,2019.0,20210622.0,20210505,20210623,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20210624.0,,CN,US,US,2021,Q2,Elderly
192160993,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,U,,,,,,,TABLET,,2021,Q2,Diarrhoea,,2021,Q2,3,F,2019.0,20210622.0,20210505,20210623,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20210624.0,,CN,US,US,2021,Q2,Elderly
192160993,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,U,,,,,,,TABLET,,2021,Q2,Nephrolithiasis,,2021,Q2,3,F,2019.0,20210622.0,20210505,20210623,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,71.0,YR,E,M,Y,,,20210624.0,,CN,US,US,2021,Q2,Elderly
192199361,19219936,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0, TABLETTEN",,,,,,,,,,TABLET,QD,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210427.0,20210506,20210506,PER,DE-ADRED-06353-01,DE-SHILPA MEDICARE LIMITED-SML-DE-2021-00536,SHILPA MEDICARE,,72.0,YR,E,M,Y,,,20210506.0,,MD,DE,DE,2021,Q2,Elderly
192199361,19219936,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0, TABLETTEN",,,,,,,,,,TABLET,QD,2021,Q2,Chills,,2021,Q2,1,I,,20210427.0,20210506,20210506,PER,DE-ADRED-06353-01,DE-SHILPA MEDICARE LIMITED-SML-DE-2021-00536,SHILPA MEDICARE,,72.0,YR,E,M,Y,,,20210506.0,,MD,DE,DE,2021,Q2,Elderly
192220211,19222021,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,US-EMD SERONO-9236010,EMD SERONO INC,"ADRIANZA A, DIAZ D. A HIDDEN ISSUE IN PLAIN SIGHT: A CASE OF EUGLYCEMIC DKA IN THE SETTING OF PANCREATITIS.. CRITICAL CARE MEDICINE. 2021 JAN 01?49(1 SUPPL 1):209?209.",57.0,YR,A,F,Y,,,20210505.0,,HP,US,US,2021,Q2,Adult
192220211,19222021,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q2,Hypertriglyceridaemia,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,US-EMD SERONO-9236010,EMD SERONO INC,"ADRIANZA A, DIAZ D. A HIDDEN ISSUE IN PLAIN SIGHT: A CASE OF EUGLYCEMIC DKA IN THE SETTING OF PANCREATITIS.. CRITICAL CARE MEDICINE. 2021 JAN 01?49(1 SUPPL 1):209?209.",57.0,YR,A,F,Y,,,20210505.0,,HP,US,US,2021,Q2,Adult
192220211,19222021,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q2,Pancreatitis,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,US-EMD SERONO-9236010,EMD SERONO INC,"ADRIANZA A, DIAZ D. A HIDDEN ISSUE IN PLAIN SIGHT: A CASE OF EUGLYCEMIC DKA IN THE SETTING OF PANCREATITIS.. CRITICAL CARE MEDICINE. 2021 JAN 01?49(1 SUPPL 1):209?209.",57.0,YR,A,F,Y,,,20210505.0,,HP,US,US,2021,Q2,Adult
192222391,19222239,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Fournier's gangrene,,2021,Q2,1,I,20210101.0,,20210506,20210506,DIR,,,FDA-CTU,,63.0,YR,,M,N,,,20210223.0,N,PH,US,US,2021,Q2,Adult
192223021,19222302,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q2,Acidosis,,2021,Q2,1,I,20210218.0,,20210506,20210506,DIR,,,FDA-CTU,,82.0,YR,,M,N,68.0,KG,20210409.0,N,PH,US,US,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Blood testosterone decreased,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Disturbance in attention,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Drug effective for unapproved indication,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,General physical health deterioration,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Malaise,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Off label use,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Pain in extremity,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Peripheral coldness,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Pruritus,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Temperature intolerance,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226611,19222661,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10,MG,DAILY",,,U,,,,,,,FILM-COATED TABLET,,2021,Q2,Weight decreased,,2021,Q2,1,I,201912.0,20210426.0,20210506,20210506,EXP,FI-FIMEA-20211052,FI-ACCORD-224331,ACCORD,,73.0,YR,E,M,Y,,,20210506.0,,MD,FI,FI,2021,Q2,Elderly
192226762,19222676,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, UNK",,,,,,,,25.0,MG,,,2021,Q2,Ventricular fibrillation,,2021,Q2,2,F,20210501.0,20210526.0,20210505,20210527,EXP,,"DE-PORTOLA PHARMACEUTICALS, INC.-A202105140",ALEXION,,68.0,YR,,M,Y,,,20210527.0,,MD,DE,DE,2021,Q2,Elderly
192245542,19224554,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,TABLET,QD,2021,Q2,Cerebrovascular accident,,2021,Q2,2,F,20210423.0,20210514.0,20210506,20210521,EXP,,US-JNJFOC-20210500081,JOHNSON AND JOHNSON,,72.0,YR,E,M,Y,80.81,KG,20210521.0,,CN,US,US,2021,Q2,Elderly
192260191,19226019,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,QD,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,DE-AUROBINDO-AUR-APL-2021-018099,AUROBINDO,,72.0,YR,,M,Y,,,20210506.0,,MD,DE,DE,2021,Q2,Elderly
192260191,19226019,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, ONCE A DAY, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,QD,2021,Q2,Chills,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,DE-AUROBINDO-AUR-APL-2021-018099,AUROBINDO,,72.0,YR,,M,Y,,,20210506.0,,MD,DE,DE,2021,Q2,Elderly
192306661,19230666,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2021,Q2,Acidosis,,2021,Q2,1,I,20200814.0,,20210507,20210507,DIR,,,FDA-CTU,,62.0,YR,,F,N,57.0,KG,20210507.0,N,MD,US,US,2021,Q2,Adult
192306661,19230666,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2021,Q2,Haemodialysis,,2021,Q2,1,I,20200814.0,,20210507,20210507,DIR,,,FDA-CTU,,62.0,YR,,F,N,57.0,KG,20210507.0,N,MD,US,US,2021,Q2,Adult
192306661,19230666,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2021,Q2,Myocardial ischaemia,,2021,Q2,1,I,20200814.0,,20210507,20210507,DIR,,,FDA-CTU,,62.0,YR,,F,N,57.0,KG,20210507.0,N,MD,US,US,2021,Q2,Adult
192306661,19230666,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2021,Q2,Renal failure,,2021,Q2,1,I,20200814.0,,20210507,20210507,DIR,,,FDA-CTU,,62.0,YR,,F,N,57.0,KG,20210507.0,N,MD,US,US,2021,Q2,Adult
192306661,19230666,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,10.0,MG,,QD,2021,Q2,Sepsis,,2021,Q2,1,I,20200814.0,,20210507,20210507,DIR,,,FDA-CTU,,62.0,YR,,F,N,57.0,KG,20210507.0,N,MD,US,US,2021,Q2,Adult
192370062,19237006,5,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,2,F,20200822.0,20210512.0,20210510,20210514,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-052415",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,85.6,KG,20210514.0,,MD,DE,DE,2021,Q2,Elderly
192370062,19237006,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,2,F,20200822.0,20210512.0,20210510,20210514,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-052415",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,85.6,KG,20210514.0,,MD,DE,DE,2021,Q2,Elderly
192400661,19240066,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Cardiac failure congestive,,2021,Q2,1,I,,20210430.0,20210511,20210511,EXP,,CA-APOTEX-2021AP011240,APOTEX,,86.0,YR,,F,Y,75.0,KG,20210511.0,,CN,CA,CA,2021,Q2,Elderly
192400661,19240066,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Hyperkalaemia,,2021,Q2,1,I,,20210430.0,20210511,20210511,EXP,,CA-APOTEX-2021AP011240,APOTEX,,86.0,YR,,F,Y,75.0,KG,20210511.0,,CN,CA,CA,2021,Q2,Elderly
192400661,19240066,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210430.0,20210511,20210511,EXP,,CA-APOTEX-2021AP011240,APOTEX,,86.0,YR,,F,Y,75.0,KG,20210511.0,,CN,CA,CA,2021,Q2,Elderly
192401342,19240134,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG DAILY WITH BREAKFAST,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Fall,,2021,Q2,2,F,20210501.0,20210610.0,20210510,20210617,EXP,,US-JNJFOC-20210505725,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,124.4,KG,20210617.0,,HP,US,US,2021,Q2,Elderly
192401342,19240134,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG DAILY WITH BREAKFAST,,,,,,,,10.0,MG,TABLET,QD,2021,Q2,Rib fracture,,2021,Q2,2,F,20210501.0,20210610.0,20210510,20210617,EXP,,US-JNJFOC-20210505725,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,124.4,KG,20210617.0,,HP,US,US,2021,Q2,Elderly
192411241,19241124,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,0.5,DF,TABLET,QD,2021,Q2,Hepatic encephalopathy,,2021,Q2,1,I,20210413.0,,20210510,20210510,DIR,,,FDA-CTU,,71.0,YR,,M,N,83.01,KG,20210506.0,N,PH,US,US,2021,Q2,Elderly
192411241,19241124,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,0.5,DF,TABLET,QD,2021,Q2,Urinary retention,,2021,Q2,1,I,20210413.0,,20210510,20210510,DIR,,,FDA-CTU,,71.0,YR,,M,N,83.01,KG,20210506.0,N,PH,US,US,2021,Q2,Elderly
192411241,19241124,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,0.5,DF,TABLET,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20210413.0,,20210510,20210510,DIR,,,FDA-CTU,,71.0,YR,,M,N,83.01,KG,20210506.0,N,PH,US,US,2021,Q2,Elderly
192426992,19242699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,TABLET,,2021,Q2,Blood creatinine increased,,2021,Q2,2,F,20210218.0,20210601.0,20210510,20210614,EXP,,NVSJ2021JP005562,NOVARTIS,,49.0,YR,,M,Y,,,20210614.0,,MD,JP,JP,2021,Q2,Adult
192426992,19242699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,TABLET,,2021,Q2,Brain natriuretic peptide increased,,2021,Q2,2,F,20210218.0,20210601.0,20210510,20210614,EXP,,NVSJ2021JP005562,NOVARTIS,,49.0,YR,,M,Y,,,20210614.0,,MD,JP,JP,2021,Q2,Adult
192426992,19242699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,TABLET,,2021,Q2,N-terminal prohormone brain natriuretic peptide increased,,2021,Q2,2,F,20210218.0,20210601.0,20210510,20210614,EXP,,NVSJ2021JP005562,NOVARTIS,,49.0,YR,,M,Y,,,20210614.0,,MD,JP,JP,2021,Q2,Adult
192426992,19242699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,TABLET,,2021,Q2,Urine output decreased,,2021,Q2,2,F,20210218.0,20210601.0,20210510,20210614,EXP,,NVSJ2021JP005562,NOVARTIS,,49.0,YR,,M,Y,,,20210614.0,,MD,JP,JP,2021,Q2,Adult
192460341,19246034,2,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210504.0,20210512,20210512,EXP,,DE-TEVA-2021-DE-1909043,TEVA,,72.0,YR,E,M,Y,,,20210512.0,,MD,DE,DE,2021,Q2,Elderly
192460341,19246034,2,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q2,Chills,,2021,Q2,1,I,,20210504.0,20210512,20210512,EXP,,DE-TEVA-2021-DE-1909043,TEVA,,72.0,YR,E,M,Y,,,20210512.0,,MD,DE,DE,2021,Q2,Elderly
192484541,19248454,2,C,empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLETTEN",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210504.0,20210512,20210512,EXP,,DE-DRREDDYS-GER/GER/21/0135163,DR REDDYS,,72.0,YR,E,M,Y,,,20210512.0,,MD,DE,DE,2021,Q2,Elderly
192484541,19248454,2,C,empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLETTEN",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q2,Chills,,2021,Q2,1,I,,20210504.0,20210512,20210512,EXP,,DE-DRREDDYS-GER/GER/21/0135163,DR REDDYS,,72.0,YR,E,M,Y,,,20210512.0,,MD,DE,DE,2021,Q2,Elderly
192489481,19248948,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210429.0,20210512,20210512,EXP,DE-ADRED-06353-01,NVSC2021DE096979,NOVARTIS,,72.0,YR,,M,Y,,,20210512.0,,HP,DE,DE,2021,Q2,Elderly
192489481,19248948,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q2,Chills,,2021,Q2,1,I,,20210429.0,20210512,20210512,EXP,DE-ADRED-06353-01,NVSC2021DE096979,NOVARTIS,,72.0,YR,,M,Y,,,20210512.0,,HP,DE,DE,2021,Q2,Elderly
192633581,19263358,2,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, 10 MG, 1?0?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q2,C-reactive protein increased,,2021,Q2,1,I,,20210504.0,20210517,20210517,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-296690,RANBAXY,,72.0,YR,,M,Y,,,20210517.0,,HP,NL,DE,2021,Q2,Elderly
192633581,19263358,2,C,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK, 10 MG, 1?0?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q2,Chills,,2021,Q2,1,I,,20210504.0,20210517,20210517,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-296690,RANBAXY,,72.0,YR,,M,Y,,,20210517.0,,HP,NL,DE,2021,Q2,Elderly
192644481,19264448,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D, 957396,20201120.0,,25.0,MG,,QD,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,20200224.0,,20210517,20210517,DIR,,,FDA-CTU,,53.0,YR,,M,N,106.0,KG,20200325.0,N,PH,US,US,2021,Q2,Adult
192651871,19265187,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, UNKNOWN",,,,,,,,10.0,MG,,,2021,Q2,Blood pressure decreased,,2021,Q2,1,I,2021.0,20210506.0,20210517,20210517,PER,,JP-AMGEN-JPNSP2021074308,AMGEN,,63.0,YR,A,M,Y,,,20210517.0,,MD,JP,JP,2021,Q2,Adult
192651871,19265187,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, UNKNOWN",,,,,,,,10.0,MG,,,2021,Q2,Renal impairment,,2021,Q2,1,I,2021.0,20210506.0,20210517,20210517,PER,,JP-AMGEN-JPNSP2021074308,AMGEN,,63.0,YR,A,M,Y,,,20210517.0,,MD,JP,JP,2021,Q2,Adult
192722511,19272251,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q2,Cystitis haemorrhagic,,2021,Q2,1,I,,20210509.0,20210519,20210519,EXP,,ES-NOVOPROD-812516,NOVO NORDISK,,73.0,YR,,F,Y,59.0,KG,20210519.0,,MD,ES,ES,2021,Q2,Elderly
192733521,19273352,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210517.0,20210519,20210519,EXP,,NVSC2021ES111602,NOVARTIS,,53.0,YR,,M,Y,,,20210519.0,,HP,ES,ES,2021,Q2,Adult
192733521,19273352,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210517.0,20210519,20210519,EXP,,NVSC2021ES111602,NOVARTIS,,53.0,YR,,M,Y,,,20210519.0,,HP,ES,ES,2021,Q2,Adult
192733521,19273352,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Sleep apnoea syndrome,,2021,Q2,1,I,,20210517.0,20210519,20210519,EXP,,NVSC2021ES111602,NOVARTIS,,53.0,YR,,M,Y,,,20210519.0,,HP,ES,ES,2021,Q2,Adult
192760291,19276029,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Cardiac failure,,2021,Q2,1,I,2018.0,20210511.0,20210519,20210519,EXP,,NVSC2021PL112038,NOVARTIS,,69.0,YR,,M,Y,,,20210519.0,,MD,PL,PL,2021,Q2,Elderly
192760291,19276029,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pneumonia,,2021,Q2,1,I,2018.0,20210511.0,20210519,20210519,EXP,,NVSC2021PL112038,NOVARTIS,,69.0,YR,,M,Y,,,20210519.0,,MD,PL,PL,2021,Q2,Elderly
192783371,19278337,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Fluid overload,,2021,Q2,1,I,20210504.0,,20210520,20210520,DIR,,,FDA-CTU,,78.0,YR,,M,N,,,20210519.0,N,PH,US,US,2021,Q2,Elderly
192783371,19278337,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20210504.0,,20210520,20210520,DIR,,,FDA-CTU,,78.0,YR,,M,N,,,20210519.0,N,PH,US,US,2021,Q2,Elderly
192783931,19278393,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,,2021,Q2,Blood creatinine increased,,2021,Q2,1,I,20210326.0,,20210520,20210520,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.0,KG,20210512.0,N,PH,US,US,2021,Q2,Elderly
192783931,19278393,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,,2021,Q2,Blood urea increased,,2021,Q2,1,I,20210326.0,,20210520,20210520,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.0,KG,20210512.0,N,PH,US,US,2021,Q2,Elderly
192783931,19278393,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,,2021,Q2,Renal impairment,,2021,Q2,1,I,20210326.0,,20210520,20210520,DIR,,,FDA-CTU,,72.0,YR,,M,N,102.0,KG,20210512.0,N,PH,US,US,2021,Q2,Elderly
192833912,19283391,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,2,F,,20210521.0,20210520,20210526,EXP,,TR-GILEAD-2021-0531908,GILEAD,,59.0,YR,A,M,Y,,,20210526.0,,MD,TR,TR,2021,Q2,Adult
192833912,19283391,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Febrile neutropenia,,2021,Q2,2,F,,20210521.0,20210520,20210526,EXP,,TR-GILEAD-2021-0531908,GILEAD,,59.0,YR,A,M,Y,,,20210526.0,,MD,TR,TR,2021,Q2,Adult
192833912,19283391,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Nausea,,2021,Q2,2,F,,20210521.0,20210520,20210526,EXP,,TR-GILEAD-2021-0531908,GILEAD,,59.0,YR,A,M,Y,,,20210526.0,,MD,TR,TR,2021,Q2,Adult
192833912,19283391,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Pyrexia,,2021,Q2,2,F,,20210521.0,20210520,20210526,EXP,,TR-GILEAD-2021-0531908,GILEAD,,59.0,YR,A,M,Y,,,20210526.0,,MD,TR,TR,2021,Q2,Adult
192833912,19283391,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Vomiting,,2021,Q2,2,F,,20210521.0,20210520,20210526,EXP,,TR-GILEAD-2021-0531908,GILEAD,,59.0,YR,A,M,Y,,,20210526.0,,MD,TR,TR,2021,Q2,Adult
192834372,19283437,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Cardiac failure,,2021,Q2,2,F,20190513.0,20210519.0,20210520,20210521,EXP,,"IN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-104429",BOEHRINGER INGELHEIM,,70.0,YR,E,F,Y,45.8,KG,20210521.0,,MD,IN,IN,2021,Q2,Elderly
192836631,19283663,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210512.0,20210521,20210521,EXP,,ES-AUROBINDO-AUR-APL-2021-020436,AUROBINDO,,53.0,YR,,M,Y,,,20210521.0,,MD,ES,ES,2021,Q2,Adult
192836631,19283663,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210512.0,20210521,20210521,EXP,,ES-AUROBINDO-AUR-APL-2021-020436,AUROBINDO,,53.0,YR,,M,Y,,,20210521.0,,MD,ES,ES,2021,Q2,Adult
192836631,19283663,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Sleep apnoea syndrome,,2021,Q2,1,I,,20210512.0,20210521,20210521,EXP,,ES-AUROBINDO-AUR-APL-2021-020436,AUROBINDO,,53.0,YR,,M,Y,,,20210521.0,,MD,ES,ES,2021,Q2,Adult
192881292,19288129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,2,F,202101.0,20210524.0,20210521,20210604,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202105005025,ELI LILLY AND CO,,63.0,YR,,M,Y,53.0,KG,20210604.0,,CN,CN,CN,2021,Q2,Adult
192881292,19288129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Blood glucose increased,,2021,Q2,2,F,202101.0,20210524.0,20210521,20210604,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202105005025,ELI LILLY AND CO,,63.0,YR,,M,Y,53.0,KG,20210604.0,,CN,CN,CN,2021,Q2,Adult
192881292,19288129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Cholangiocarcinoma,,2021,Q2,2,F,202101.0,20210524.0,20210521,20210604,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202105005025,ELI LILLY AND CO,,63.0,YR,,M,Y,53.0,KG,20210604.0,,CN,CN,CN,2021,Q2,Adult
192881292,19288129,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,2,F,202101.0,20210524.0,20210521,20210604,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202105005025,ELI LILLY AND CO,,63.0,YR,,M,Y,53.0,KG,20210604.0,,CN,CN,CN,2021,Q2,Adult
192893651,19289365,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Abdominal pain,,2021,Q2,1,I,20200806.0,20210510.0,20210521,20210521,EXP,,NVSC2021GB105308,NOVARTIS,,51.0,YR,,F,Y,78.5,KG,20210521.0,,HP,GB,GB,2021,Q2,Adult
192893651,19289365,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Bacterial infection,,2021,Q2,1,I,20200806.0,20210510.0,20210521,20210521,EXP,,NVSC2021GB105308,NOVARTIS,,51.0,YR,,F,Y,78.5,KG,20210521.0,,HP,GB,GB,2021,Q2,Adult
192893651,19289365,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,20200806.0,20210510.0,20210521,20210521,EXP,,NVSC2021GB105308,NOVARTIS,,51.0,YR,,F,Y,78.5,KG,20210521.0,,HP,GB,GB,2021,Q2,Adult
192893651,19289365,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Dizziness,,2021,Q2,1,I,20200806.0,20210510.0,20210521,20210521,EXP,,NVSC2021GB105308,NOVARTIS,,51.0,YR,,F,Y,78.5,KG,20210521.0,,HP,GB,GB,2021,Q2,Adult
192893651,19289365,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Inflammatory bowel disease,,2021,Q2,1,I,20200806.0,20210510.0,20210521,20210521,EXP,,NVSC2021GB105308,NOVARTIS,,51.0,YR,,F,Y,78.5,KG,20210521.0,,HP,GB,GB,2021,Q2,Adult
192895621,19289562,6,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q2,Vasculitis,,2021,Q2,1,I,20210330.0,20210516.0,20210521,20210521,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-104314",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20210521.0,,MD,CN,CN,2021,Q2,Adult
192914271,19291427,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,UNKNOWN,,2021,Q2,Pruritus,,2021,Q2,1,I,20210507.0,20210511.0,20210523,20210523,PER,,US-CELGENEUS-USA-20210503220,CELGENE,,72.0,YR,,M,Y,68.1,KG,20210523.0,,CN,US,US,2021,Q2,Elderly
192932631,19293263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q2,Blood creatinine increased,,2021,Q2,1,I,,20210511.0,20210524,20210524,EXP,,NVSC2021HR110216,NOVARTIS,,64.0,YR,,M,Y,80.0,KG,20210524.0,,MD,HR,HR,2021,Q2,Adult
192932631,19293263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q2,Blood urea increased,,2021,Q2,1,I,,20210511.0,20210524,20210524,EXP,,NVSC2021HR110216,NOVARTIS,,64.0,YR,,M,Y,80.0,KG,20210524.0,,MD,HR,HR,2021,Q2,Adult
192932631,19293263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q2,Glomerular filtration rate decreased,,2021,Q2,1,I,,20210511.0,20210524,20210524,EXP,,NVSC2021HR110216,NOVARTIS,,64.0,YR,,M,Y,80.0,KG,20210524.0,,MD,HR,HR,2021,Q2,Adult
192932631,19293263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q2,Hypotension,,2021,Q2,1,I,,20210511.0,20210524,20210524,EXP,,NVSC2021HR110216,NOVARTIS,,64.0,YR,,M,Y,80.0,KG,20210524.0,,MD,HR,HR,2021,Q2,Adult
192932631,19293263,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210511.0,20210524,20210524,EXP,,NVSC2021HR110216,NOVARTIS,,64.0,YR,,M,Y,80.0,KG,20210524.0,,MD,HR,HR,2021,Q2,Adult
192993871,19299387,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG/MG,,QD,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210522.0,,20210524,20210524,DIR,,,FDA-CTU,,54.0,YR,,M,N,105.7,KG,20210524.0,N,PH,US,US,2021,Q2,Adult
193007411,19300741,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20210420.0,,20210525,20210525,DIR,,,FDA-CTU,,57.0,YR,,M,N,84.0,KG,20210522.0,N,PH,US,US,2021,Q2,Adult
193007411,19300741,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q2,Perineal abscess,,2021,Q2,1,I,20210420.0,,20210525,20210525,DIR,,,FDA-CTU,,57.0,YR,,M,N,84.0,KG,20210522.0,N,PH,US,US,2021,Q2,Adult
193032811,19303281,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,2021.0,20210517.0,20210525,20210525,PER,,ES-AMGEN-ESPSP2021079395,AMGEN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28",53.0,YR,A,M,Y,,,20210525.0,,MD,ES,ES,2021,Q2,Adult
193032811,19303281,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Renal impairment,,2021,Q2,1,I,2021.0,20210517.0,20210525,20210525,PER,,ES-AMGEN-ESPSP2021079395,AMGEN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28",53.0,YR,A,M,Y,,,20210525.0,,MD,ES,ES,2021,Q2,Adult
193032811,19303281,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Sleep apnoea syndrome,,2021,Q2,1,I,2021.0,20210517.0,20210525,20210525,PER,,ES-AMGEN-ESPSP2021079395,AMGEN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28",53.0,YR,A,M,Y,,,20210525.0,,MD,ES,ES,2021,Q2,Adult
193133411,19313341,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Cervical vertebral fracture,,2021,Q2,1,I,20210522.0,,20210527,20210527,DIR,,,FDA-CTU,,74.0,YR,,F,N,,,20210527.0,N,PH,US,US,2021,Q2,Elderly
193133411,19313341,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210522.0,,20210527,20210527,DIR,,,FDA-CTU,,74.0,YR,,F,N,,,20210527.0,N,PH,US,US,2021,Q2,Elderly
193161311,19316131,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Coronary artery disease,,2021,Q2,1,I,,20210521.0,20210527,20210527,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-050117,BRISTOL MYERS SQUIBB,,82.0,YR,,M,Y,72.0,KG,20210527.0,,CN,US,US,2021,Q2,Elderly
193161311,19316131,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pulmonary thrombosis,,2021,Q2,1,I,,20210521.0,20210527,20210527,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-050117,BRISTOL MYERS SQUIBB,,82.0,YR,,M,Y,72.0,KG,20210527.0,,CN,US,US,2021,Q2,Elderly
193212501,19321250,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,N,,,,12.5,MG,TABLET,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20210412.0,,20210528,20210528,DIR,,,FDA-CTU,,70.0,YR,,M,N,104.0,KG,20210526.0,N,PH,US,US,2021,Q2,Elderly
193225471,19322547,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,QD,2021,Q2,Abdominal pain,,2021,Q2,1,I,20210516.0,20210521.0,20210527,20210527,EXP,DE-BFARM-21004858,DE-EMD SERONO-E2B_90083660,EMD SERONO INC,,41.0,YR,A,F,Y,120.0,KG,20210528.0,,MD,DE,DE,2021,Q2,Adult
193225471,19322547,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,QD,2021,Q2,Flatulence,,2021,Q2,1,I,20210516.0,20210521.0,20210527,20210527,EXP,DE-BFARM-21004858,DE-EMD SERONO-E2B_90083660,EMD SERONO INC,,41.0,YR,A,F,Y,120.0,KG,20210528.0,,MD,DE,DE,2021,Q2,Adult
193225471,19322547,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,100.0,MG,,QD,2021,Q2,Lactic acidosis,,2021,Q2,1,I,20210516.0,20210521.0,20210527,20210527,EXP,DE-BFARM-21004858,DE-EMD SERONO-E2B_90083660,EMD SERONO INC,,41.0,YR,A,F,Y,120.0,KG,20210528.0,,MD,DE,DE,2021,Q2,Adult
193466121,19346612,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20210315.0,,20210528,20210528,DIR,,,FDA-CTU,,90.0,YR,,M,N,,,20210519.0,N,PH,US,US,2021,Q2,Elderly
193501871,19350187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Acidosis,,2021,Q2,1,I,20201224.0,,20210601,20210601,DIR,,,FDA-CTU,,75.0,YR,,M,N,,,20210420.0,N,PH,US,US,2021,Q2,Elderly
193501871,19350187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Hyperglycaemia,,2021,Q2,1,I,20201224.0,,20210601,20210601,DIR,,,FDA-CTU,,75.0,YR,,M,N,,,20210420.0,N,PH,US,US,2021,Q2,Elderly
193501871,19350187,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Ketosis,,2021,Q2,1,I,20201224.0,,20210601,20210601,DIR,,,FDA-CTU,,75.0,YR,,M,N,,,20210420.0,N,PH,US,US,2021,Q2,Elderly
193550011,19355001,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"1 DOSAGE FORM, ONCE A DAY",82.0,DF,,,,,,1.0,DF,,QD,2021,Q2,Angioedema,,2021,Q2,1,I,20201120.0,20210523.0,20210602,20210602,EXP,,GB-AUROBINDO-AUR-APL-2021-022142,AUROBINDO,,80.0,YR,,M,Y,93.0,KG,20210602.0,,MD,GB,GB,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Abdominal discomfort,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Constipation,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Dizziness,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Fungal infection,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193567921,19356792,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Pollakiuria,,2021,Q2,1,I,20201007.0,,20210602,20210602,DIR,,,FDA-CTU,,71.0,YR,,M,N,123.0,KG,20201218.0,N,HP,US,US,2021,Q2,Elderly
193573551,19357355,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Erythema multiforme,,2021,Q2,1,I,20180524.0,,20210602,20210602,DIR,,,FDA-CTU,,67.0,YR,,M,N,90.81,KG,20181118.0,N,PH,US,US,2021,Q2,Elderly
193573551,19357355,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Osteomyelitis,,2021,Q2,1,I,20180524.0,,20210602,20210602,DIR,,,FDA-CTU,,67.0,YR,,M,N,90.81,KG,20181118.0,N,PH,US,US,2021,Q2,Elderly
193573551,19357355,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Osteonecrosis,,2021,Q2,1,I,20180524.0,,20210602,20210602,DIR,,,FDA-CTU,,67.0,YR,,M,N,90.81,KG,20181118.0,N,PH,US,US,2021,Q2,Elderly
193573551,19357355,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Toe amputation,,2021,Q2,1,I,20180524.0,,20210602,20210602,DIR,,,FDA-CTU,,67.0,YR,,M,N,90.81,KG,20181118.0,N,PH,US,US,2021,Q2,Elderly
193575151,19357515,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Cardiac failure,,2021,Q2,1,I,2018.0,20210521.0,20210601,20210601,EXP,,PL-AUROBINDO-AUR-APL-2021-022178,AUROBINDO,,69.0,YR,,M,Y,,,20210601.0,,MD,PL,PL,2021,Q2,Elderly
193575151,19357515,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pneumonia,,2021,Q2,1,I,2018.0,20210521.0,20210601,20210601,EXP,,PL-AUROBINDO-AUR-APL-2021-022178,AUROBINDO,,69.0,YR,,M,Y,,,20210601.0,,MD,PL,PL,2021,Q2,Elderly
193577031,19357703,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q2,Rash,,2021,Q2,1,I,20201222.0,,20210602,20210602,DIR,,,FDA-CTU,,72.0,YR,,M,N,110.0,KG,20210218.0,N,PH,US,US,2021,Q2,Elderly
193578141,19357814,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q2,Urinary tract infection,,2021,Q2,1,I,20200522.0,,20210602,20210602,DIR,,,FDA-CTU,,82.0,YR,,M,N,,,20200718.0,N,PH,US,US,2021,Q2,Elderly
193595741,19359574,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,100 MG X1 PERMANENTLY,,,,,,,,100.0,MG,,QD,2021,Q2,Abdominal pain,,2021,Q2,1,I,20210516.0,20210520.0,20210602,20210602,EXP,DE-BFARM-21004858,DE-BAUSCH-BL-2021-018352,BAUSCH AND LOMB,,41.0,YR,,F,Y,120.0,KG,20210602.0,,MD,DE,DE,2021,Q2,Adult
193595741,19359574,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,100 MG X1 PERMANENTLY,,,,,,,,100.0,MG,,QD,2021,Q2,Flatulence,,2021,Q2,1,I,20210516.0,20210520.0,20210602,20210602,EXP,DE-BFARM-21004858,DE-BAUSCH-BL-2021-018352,BAUSCH AND LOMB,,41.0,YR,,F,Y,120.0,KG,20210602.0,,MD,DE,DE,2021,Q2,Adult
193595741,19359574,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,100 MG X1 PERMANENTLY,,,,,,,,100.0,MG,,QD,2021,Q2,Lactic acidosis,,2021,Q2,1,I,20210516.0,20210520.0,20210602,20210602,EXP,DE-BFARM-21004858,DE-BAUSCH-BL-2021-018352,BAUSCH AND LOMB,,41.0,YR,,F,Y,120.0,KG,20210602.0,,MD,DE,DE,2021,Q2,Adult
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Blood glucose abnormal,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Breast cancer,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Breast cancer metastatic,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Coronary artery disease,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Deep vein thrombosis,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Diabetic retinopathy,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Oral disorder,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193623753,19362375,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Pancreatitis,,2021,Q2,3,F,2009.0,20210517.0,20210601,20210618,EXP,,BR-NOVOPROD-816729,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210618.0,,CN,BR,BR,2021,Q2,Elderly
193697041,19369704,7,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5/1000 MG, QD",,,,,,,,,,,QD,2021,Q2,Angina pectoris,,2021,Q2,1,I,2021.0,20210527.0,20210602,20210602,EXP,,HR-JNJFOC-20210604378,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20210603.0,,MD,HR,HR,2021,Q2,Elderly
193697041,19369704,7,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5/1000 MG, QD",,,,,,,,,,,QD,2021,Q2,Coronary artery disease,,2021,Q2,1,I,2021.0,20210527.0,20210602,20210602,EXP,,HR-JNJFOC-20210604378,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20210603.0,,MD,HR,HR,2021,Q2,Elderly
193697041,19369704,7,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,"12.5/1000 MG, QD",,,,,,,,,,,QD,2021,Q2,Coronary artery stenosis,,2021,Q2,1,I,2021.0,20210527.0,20210602,20210602,EXP,,HR-JNJFOC-20210604378,JOHNSON AND JOHNSON,,76.0,YR,E,M,Y,,,20210603.0,,MD,HR,HR,2021,Q2,Elderly
193701611,19370161,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM OM,,,,U,,,,25.0,MG,,QD,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210603,20210603,EXP,GB-MHRA-EYC 00252118,GB-009507513-2106GBR000651,MERCK,,69.0,YR,,M,Y,,,20210603.0,,PH,GB,GB,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Aortic aneurysm,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Aortic valve sclerosis,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,COVID-19,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Decreased appetite,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Hyperglycaemia,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Urinary tract infection,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193716421,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,202005.0,20210525.0,20210604,20210604,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20210604.0,,CN,BR,BR,2021,Q2,Elderly
193719861,19371986,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Cardiac failure,,2021,Q2,1,I,2018.0,20210524.0,20210603,20210603,EXP,,PL-PFIZER INC-2021588605,PFIZER,,69.0,YR,,M,Y,,,20210603.0,,MD,PL,PL,2021,Q2,Elderly
193719861,19371986,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Pneumonia,,2021,Q2,1,I,2018.0,20210524.0,20210603,20210603,EXP,,PL-PFIZER INC-2021588605,PFIZER,,69.0,YR,,M,Y,,,20210603.0,,MD,PL,PL,2021,Q2,Elderly
193749101,19374910,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, AM (25MG OM)",,,D,,,,,25.0,MG,,QD,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210604,20210604,EXP,GB-MHRA-EYC 00252118,GB-MYLANLABS-2021M1032779,MYLAN,,69.0,YR,,M,Y,,,20210604.0,,PH,GB,GB,2021,Q2,Elderly
193764621,19376462,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG (OM),,,D,,,,,25.0,MG,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210604,20210604,EXP,GB-MHRA-EYC 00252118,NVSC2021GB124400,NOVARTIS,,69.0,YR,,M,Y,,,20210604.0,,HP,GB,GB,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Apnoea,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Arterial occlusive disease,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Arteriosclerosis,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Cataract operation,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Dysuria,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Orthostatic hypotension,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Peripheral artery stenosis,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Peripheral venous disease,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193765051,19376505,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Urinary tract infection,,2021,Q2,1,I,2018.0,20210522.0,20210604,20210604,EXP,,BR-NOVOPROD-816336,NOVO NORDISK,,74.0,YR,,F,Y,74.0,KG,20210604.0,,MD,BR,BR,2021,Q2,Elderly
193825691,19382569,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD, AFTER BREAKFAST",,,,,,,,10.0,MG,,QD,2021,Q2,Acute coronary syndrome,,2021,Q2,1,I,,20210528.0,20210607,20210607,EXP,,JP-DSJP-DSJ-2021-116305,DAIICHI,,85.0,YR,,F,Y,,,20210607.0,,MD,JP,JP,2021,Q2,Elderly
193825691,19382569,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD, AFTER BREAKFAST",,,,,,,,10.0,MG,,QD,2021,Q2,Blood pressure increased,,2021,Q2,1,I,,20210528.0,20210607,20210607,EXP,,JP-DSJP-DSJ-2021-116305,DAIICHI,,85.0,YR,,F,Y,,,20210607.0,,MD,JP,JP,2021,Q2,Elderly
193825691,19382569,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD, AFTER BREAKFAST",,,,,,,,10.0,MG,,QD,2021,Q2,Neoplasm malignant,,2021,Q2,1,I,,20210528.0,20210607,20210607,EXP,,JP-DSJP-DSJ-2021-116305,DAIICHI,,85.0,YR,,F,Y,,,20210607.0,,MD,JP,JP,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Hepatotoxicity,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Hypertension,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Myocardial ischaemia,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Off label use,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Pulmonary fibrosis,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193958661,19395866,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,, UNK,,,,,,,2021,Q2,Type 2 diabetes mellitus,,2021,Q2,1,I,,20210602.0,20210609,20210609,EXP,GB-MHRA-ADR 25397062,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-001820,EMCURE,,69.0,YR,,M,Y,,,20210609.0,,PH,GB,GB,2021,Q2,Elderly
193968711,19396871,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,,,,,,,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GB-AUROBINDO-AUR-APL-2021-023820,AUROBINDO,,69.0,YR,,M,Y,,,20210610.0,,PH,GB,GB,2021,Q2,Elderly
193974291,19397429,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q2,Varices oesophageal,,2021,Q2,1,I,20200717.0,20210604.0,20210609,20210609,EXP,,GB-JNJFOC-20210618943,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,,,20210610.0,,MD,GB,GB,2021,Q2,Adult
193989801,19398980,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Osteomyelitis,,2021,Q2,1,I,20210601.0,,20210610,20210610,DIR,,,FDA-CTU,,72.0,YR,,M,N,97.2,KG,20210610.0,N,MD,US,US,2021,Q2,Elderly
193989801,19398980,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Skin discolouration,,2021,Q2,1,I,20210601.0,,20210610,20210610,DIR,,,FDA-CTU,,72.0,YR,,M,N,97.2,KG,20210610.0,N,MD,US,US,2021,Q2,Elderly
193989801,19398980,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Toe amputation,,2021,Q2,1,I,20210601.0,,20210610,20210610,DIR,,,FDA-CTU,,72.0,YR,,M,N,97.2,KG,20210610.0,N,MD,US,US,2021,Q2,Elderly
193994741,19399474,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Abdominal distension,,2021,Q2,1,I,,20210530.0,20210610,20210610,EXP,GB-MHRA-EYC 00251623,GB-NOVOPROD-817258,NOVO NORDISK,,37.0,YR,,F,Y,122.5,KG,20210610.0,,HP,GB,GB,2021,Q2,Adult
193994741,19399474,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Abdominal pain upper,,2021,Q2,1,I,,20210530.0,20210610,20210610,EXP,GB-MHRA-EYC 00251623,GB-NOVOPROD-817258,NOVO NORDISK,,37.0,YR,,F,Y,122.5,KG,20210610.0,,HP,GB,GB,2021,Q2,Adult
193994741,19399474,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Pancreatitis acute,,2021,Q2,1,I,,20210530.0,20210610,20210610,EXP,GB-MHRA-EYC 00251623,GB-NOVOPROD-817258,NOVO NORDISK,,37.0,YR,,F,Y,122.5,KG,20210610.0,,HP,GB,GB,2021,Q2,Adult
193994741,19399474,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Vomiting,,2021,Q2,1,I,,20210530.0,20210610,20210610,EXP,GB-MHRA-EYC 00251623,GB-NOVOPROD-817258,NOVO NORDISK,,37.0,YR,,F,Y,122.5,KG,20210610.0,,HP,GB,GB,2021,Q2,Adult
194020471,19402047,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Chest pain,,2021,Q2,1,I,20210228.0,20210608.0,20210611,20210611,EXP,,GB-ABBVIE-21K-167-3944548-00,ABBVIE,,60.0,YR,,F,Y,74.8,KG,20210611.0,,HP,GB,GB,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Brain natriuretic peptide increased,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Cardiac failure,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Dyspnoea exertional,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Left ventricular dilatation,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Oxygen saturation decreased,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194020721,19402072,3,C,METFORMIN/EMPAGLIFLOZIN,,2,,10/1.700 MG,,,,,,,,,,,,2021,Q2,Rhonchi,,2021,Q2,1,I,,20210602.0,20210610,20210610,EXP,,GR-ASTRAZENECA-2021A500668,ASTRAZENECA,,60.0,YR,,F,Y,78.0,KG,20210610.0,,MD,GR,GR,2021,Q2,Adult
194022061,19402206,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,U,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210207.0,20210601.0,20210611,20210611,EXP,DE-DCGMA-21187985,DE-NOVOPROD-819073,NOVO NORDISK,,54.0,YR,,M,Y,91.0,KG,20210611.0,,MD,DE,DE,2021,Q2,Adult
194038531,19403853,7,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210329.0,20210528.0,20210611,20210611,EXP,,AU-QED THERAPEUTICS-2112606,QED THERAPEUTICS,,69.0,YR,,F,Y,93.8,KG,20210611.0,,MD,AU,AU,2021,Q2,Elderly
194038531,19403853,7,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Eye pain,,2021,Q2,1,I,20210329.0,20210528.0,20210611,20210611,EXP,,AU-QED THERAPEUTICS-2112606,QED THERAPEUTICS,,69.0,YR,,F,Y,93.8,KG,20210611.0,,MD,AU,AU,2021,Q2,Elderly
194076511,19407651,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,,U,,,,25.0,MG,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210611,20210611,EXP,GB-MHRA-EYC 00252118,GB-EMD SERONO-E2B_90083776,EMD SERONO INC,,69.0,YR,E,M,Y,,,20210611.0,,PH,GB,GB,2021,Q2,Elderly
194076511,19407651,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,,U,,,,25.0,MG,,,2021,Q2,Drug-induced liver injury,,2021,Q2,1,I,,20210602.0,20210611,20210611,EXP,GB-MHRA-EYC 00252118,GB-EMD SERONO-E2B_90083776,EMD SERONO INC,,69.0,YR,E,M,Y,,,20210611.0,,PH,GB,GB,2021,Q2,Elderly
194076511,19407651,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,,U,,,,25.0,MG,,,2021,Q2,Jaundice,,2021,Q2,1,I,,20210602.0,20210611,20210611,EXP,GB-MHRA-EYC 00252118,GB-EMD SERONO-E2B_90083776,EMD SERONO INC,,69.0,YR,E,M,Y,,,20210611.0,,PH,GB,GB,2021,Q2,Elderly
194076511,19407651,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,,U,,,,25.0,MG,,,2021,Q2,Myocardial ischaemia,,2021,Q2,1,I,,20210602.0,20210611,20210611,EXP,GB-MHRA-EYC 00252118,GB-EMD SERONO-E2B_90083776,EMD SERONO INC,,69.0,YR,E,M,Y,,,20210611.0,,PH,GB,GB,2021,Q2,Elderly
194076511,19407651,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,,U,,,,25.0,MG,,,2021,Q2,Pulmonary fibrosis,,2021,Q2,1,I,,20210602.0,20210611,20210611,EXP,GB-MHRA-EYC 00252118,GB-EMD SERONO-E2B_90083776,EMD SERONO INC,,69.0,YR,E,M,Y,,,20210611.0,,PH,GB,GB,2021,Q2,Elderly
194078131,19407813,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Myocardial infarction,,2021,Q2,1,I,20210527.0,20210604.0,20210611,20210611,EXP,,RU-ASTRAZENECA-2021A504760,ASTRAZENECA,,59.0,YR,,M,Y,,,20210611.0,,,RU,RU,2021,Q2,Adult
194078131,19407813,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Vascular stent thrombosis,,2021,Q2,1,I,20210527.0,20210604.0,20210611,20210611,EXP,,RU-ASTRAZENECA-2021A504760,ASTRAZENECA,,59.0,YR,,M,Y,,,20210611.0,,,RU,RU,2021,Q2,Adult
194088871,19408887,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY; 25MG OM,,,,U,,,,25.0,MG,,QD,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210613,20210613,EXP,GB-MHRA-EYC 00252118,GB-TEVA-2021-GB-1920383,TEVA,,69.0,YR,E,M,Y,,,20210613.0,,PH,GB,GB,2021,Q2,Elderly
194108141,19410814,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MG OM,,,D,,,,,,,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210614,20210614,EXP,GB-MHRA-EYC 00252118,GB-MICRO LABS LIMITED-ML2021-01832,MICRO LABS,,69.0,YR,,M,Y,,,20210614.0,,PH,GB,GB,2021,Q2,Elderly
194126081,19412608,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1 EVERY 24 HOURS",,,U,,,,,25.0,MG,,,2021,Q2,Cerebrovascular accident,,2021,Q2,1,I,,20210609.0,20210614,20210614,EXP,,CA-009507513-2106CAN003183,MERCK,,51.0,YR,,M,Y,,,20210614.0,,HP,CA,CA,2021,Q2,Adult
194126081,19412608,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1 EVERY 24 HOURS",,,U,,,,,25.0,MG,,,2021,Q2,Lactic acidosis,,2021,Q2,1,I,,20210609.0,20210614,20210614,EXP,,CA-009507513-2106CAN003183,MERCK,,51.0,YR,,M,Y,,,20210614.0,,HP,CA,CA,2021,Q2,Adult
194126081,19412608,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1 EVERY 24 HOURS",,,U,,,,,25.0,MG,,,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,1,I,,20210609.0,20210614,20210614,EXP,,CA-009507513-2106CAN003183,MERCK,,51.0,YR,,M,Y,,,20210614.0,,HP,CA,CA,2021,Q2,Adult
194155121,19415512,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,GR-MYLANLABS-2021M1034208,MYLAN,"A.STAVRATI, I. ZARIFIS, K. POLYMEROPOULOS. PATIENT WITH ARTERIAL HYPERTENSION AND CORONARY ARTERY DISEASE. ARTERIAL HYPERTENSION. 2021?30:81?85",60.0,YR,,F,Y,78.0,KG,20210614.0,,MD,GR,GR,2021,Q2,Adult
194175001,19417500,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MG, DAILY",,,,,,,,10.0,MG,,QD,2021,Q2,Hypercalcaemia,,2021,Q2,1,I,,20210603.0,20210614,20210614,EXP,,US-GLAND PHARMA LIMITED-2021US004247,GLAND PHARMA,,64.0,YR,,M,Y,85.0,KG,20210614.0,,MD,US,US,2021,Q2,Adult
194175001,19417500,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MG, DAILY",,,,,,,,10.0,MG,,QD,2021,Q2,Hyperthyroidism,,2021,Q2,1,I,,20210603.0,20210614,20210614,EXP,,US-GLAND PHARMA LIMITED-2021US004247,GLAND PHARMA,,64.0,YR,,M,Y,85.0,KG,20210614.0,,MD,US,US,2021,Q2,Adult
194188751,19418875,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG OM,,,D,,,,,,,,,2021,Q2,Acute hepatic failure,,2021,Q2,1,I,,20210602.0,20210615,20210615,EXP,GB-MHRA-ADR 25397062,GB-ACCORD-227816,ACCORD,,69.0,YR,,M,Y,,,20210615.0,,PH,GB,GB,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure decreased,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood sodium increased,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Cardiomegaly,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Dyspnoea,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,N-terminal prohormone brain natriuretic peptide increased,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194207931,19420793,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Ventricular tachycardia,,2021,Q2,1,I,,20210602.0,20210616,20210616,EXP,,NVSC2021HR128448,NOVARTIS,,67.0,YR,,M,Y,,,20210616.0,,MD,HR,HR,2021,Q2,Elderly
194219101,19421910,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Fournier's gangrene,,2021,Q2,1,I,20210511.0,,20210615,20210615,DIR,,,FDA-CTU,,59.0,YR,,M,N,,,20210614.0,N,PH,US,US,2021,Q2,Adult
194231551,19423155,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Abdominal pain,,2021,Q2,1,I,20210614.0,,20210616,20210616,DIR,,,FDA-CTU,,57.0,YR,,M,N,105.7,KG,20210616.0,N,PH,US,US,2021,Q2,Adult
194231551,19423155,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20210614.0,,20210616,20210616,DIR,,,FDA-CTU,,57.0,YR,,M,N,105.7,KG,20210616.0,N,PH,US,US,2021,Q2,Adult
194231551,19423155,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,20210614.0,,20210616,20210616,DIR,,,FDA-CTU,,57.0,YR,,M,N,105.7,KG,20210616.0,N,PH,US,US,2021,Q2,Adult
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Asthenia,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Dropped head syndrome,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Dysphagia,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Gait disturbance,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Gastrointestinal tube insertion,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194236091,19423609,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q2,Muscular weakness,,2021,Q2,1,I,,20210604.0,20210616,20210616,EXP,,CA-APOTEX-2021AP013960,APOTEX,,79.0,YR,,M,Y,,,20210616.0,,CN,CA,CA,2021,Q2,Elderly
194290971,19429097,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q2,Diarrhoea,,2021,Q2,1,I,20210310.0,,20210617,20210617,DIR,,,FDA-CTU,,88.0,YR,,M,N,113.4,KG,20210519.0,N,PH,US,US,2021,Q2,Elderly
194290971,19429097,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q2,Urinary retention,,2021,Q2,1,I,20210310.0,,20210617,20210617,DIR,,,FDA-CTU,,88.0,YR,,M,N,113.4,KG,20210519.0,N,PH,US,US,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Asthenia,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Dropped head syndrome,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Dysphagia,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Gait disturbance,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Gastrointestinal tube insertion,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194305641,19430564,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q2,Muscular weakness,,2021,Q2,1,I,,20210607.0,20210617,20210617,EXP,,CA-TEVA-2021-CA-1921335,TEVA,,79.0,YR,E,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Elderly
194308071,19430807,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,COVID-19,,2021,Q2,1,I,,20200928.0,20210617,20210617,EXP,,BR-NOVOPROD-818851,NOVO NORDISK,,55.0,YR,,F,Y,,,20210617.0,,MD,BR,BR,2021,Q2,Adult
194308071,19430807,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Myalgia,,2021,Q2,1,I,,20200928.0,20210617,20210617,EXP,,BR-NOVOPROD-818851,NOVO NORDISK,,55.0,YR,,F,Y,,,20210617.0,,MD,BR,BR,2021,Q2,Adult
194308071,19430807,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Pyrexia,,2021,Q2,1,I,,20200928.0,20210617,20210617,EXP,,BR-NOVOPROD-818851,NOVO NORDISK,,55.0,YR,,F,Y,,,20210617.0,,MD,BR,BR,2021,Q2,Adult
194329151,19432915,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Diabetic neuropathy,Diabetic neuropathy,2021,Q2,1,I,,20210607.0,20210618,20210618,EXP,,GB-ALS-000306,ALIGNSCIENCE PHARMA,,65.0,YR,E,M,Y,,,20210618.0,,HP,GB,GB,2021,Q2,Elderly
194329151,19432915,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Diverticulitis,Diverticulitis,2021,Q2,1,I,,20210607.0,20210618,20210618,EXP,,GB-ALS-000306,ALIGNSCIENCE PHARMA,,65.0,YR,E,M,Y,,,20210618.0,,HP,GB,GB,2021,Q2,Elderly
194329151,19432915,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Peripheral motor neuropathy,Peripheral motor neuropathy,2021,Q2,1,I,,20210607.0,20210618,20210618,EXP,,GB-ALS-000306,ALIGNSCIENCE PHARMA,,65.0,YR,E,M,Y,,,20210618.0,,HP,GB,GB,2021,Q2,Elderly
194329151,19432915,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Spondylolysis,Spondylolysis,2021,Q2,1,I,,20210607.0,20210618,20210618,EXP,,GB-ALS-000306,ALIGNSCIENCE PHARMA,,65.0,YR,E,M,Y,,,20210618.0,,HP,GB,GB,2021,Q2,Elderly
194329151,19432915,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Weight increased,Weight increased,2021,Q2,1,I,,20210607.0,20210618,20210618,EXP,,GB-ALS-000306,ALIGNSCIENCE PHARMA,,65.0,YR,E,M,Y,,,20210618.0,,HP,GB,GB,2021,Q2,Elderly
194333881,19433388,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Cardiac failure,,2021,Q2,1,I,20210402.0,20210607.0,20210618,20210618,EXP,,NVSJ2021JP009099,NOVARTIS,,52.0,YR,,M,Y,,,20210618.0,,CN,JP,JP,2021,Q2,Adult
194333881,19433388,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q2,Ventricular tachycardia,,2021,Q2,1,I,20210402.0,20210607.0,20210618,20210618,EXP,,NVSJ2021JP009099,NOVARTIS,,52.0,YR,,M,Y,,,20210618.0,,CN,JP,JP,2021,Q2,Adult
194371652,19437165,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Hypercalcaemia,,2021,Q2,2,F,,20210621.0,20210619,20210630,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,,64.0,YR,,M,Y,,,20210630.0,,HP,US,US,2021,Q2,Adult
194371652,19437165,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Hyperthyroidism,,2021,Q2,2,F,,20210621.0,20210619,20210630,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,,64.0,YR,,M,Y,,,20210630.0,,HP,US,US,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Cardiac failure acute,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Cardiac ventricular thrombosis,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Dyspnoea,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Oedema peripheral,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Pleural effusion,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Underdose,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194386011,19438601,13,C,EMPAGLIFLOZIN;METFORMIN,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,,QD,2021,Q2,Wrong technique in product usage process,,2021,Q2,1,I,202012.0,20210607.0,20210619,20210619,EXP,,NVSC2021VN130220,NOVARTIS,,62.0,YR,,M,Y,,,20210619.0,,MD,VN,VN,2021,Q2,Adult
194418151,19441815,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2021,Q2,Acute kidney injury,,2021,Q2,1,I,20210208.0,20210329.0,20210621,20210621,PER,,NVSC2021US076375,NOVARTIS,,45.0,YR,,M,Y,,,20210621.0,,CN,US,US,2021,Q2,Adult
194418151,19441815,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2021,Q2,Oedema peripheral,,2021,Q2,1,I,20210208.0,20210329.0,20210621,20210621,PER,,NVSC2021US076375,NOVARTIS,,45.0,YR,,M,Y,,,20210621.0,,CN,US,US,2021,Q2,Adult
194418151,19441815,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK, QD",,,U,,,,,,,,QD,2021,Q2,Venous pressure jugular increased,,2021,Q2,1,I,20210208.0,20210329.0,20210621,20210621,PER,,NVSC2021US076375,NOVARTIS,,45.0,YR,,M,Y,,,20210621.0,,CN,US,US,2021,Q2,Adult
194469891,19446989,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Blood creatinine increased,,2021,Q2,1,I,20210519.0,,20210621,20210621,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20210616.0,N,PH,US,US,2021,Q2,Elderly
194469891,19446989,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,12.5,MG,,QD,2021,Q2,Blood urea increased,,2021,Q2,1,I,20210519.0,,20210621,20210621,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20210616.0,N,PH,US,US,2021,Q2,Elderly
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Abdominal discomfort,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Acute kidney injury,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Constipation,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Fatigue,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Somnolence,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194474161,19447416,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MG, BID",,,U,U,,,,5.0,MG,,BID,2021,Q2,Vomiting,,2021,Q2,1,I,202101.0,20210121.0,20210622,20210622,EXP,,AU-NOVOPROD-783744,NOVO NORDISK,,46.0,YR,,M,Y,113.2,KG,20210622.0,,MD,AU,AU,2021,Q2,Adult
194550801,19455080,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q2,Lactic acidosis,,2021,Q2,1,I,,20210608.0,20210623,20210623,EXP,,IT-EMD SERONO-9244299,EMD SERONO INC,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, UNGAR A, BALDASSERONI S, PRATESI A, FATTIROLLI F, MARCHIONNI N. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION.. JOURNAL OF GERIATRIC CARDIOLOGY. 2020 JAN 01?17(11):728?732. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210623.0,,MD,IT,IT,2021,Q2,Elderly
194550801,19455080,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210608.0,20210623,20210623,EXP,,IT-EMD SERONO-9244299,EMD SERONO INC,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, UNGAR A, BALDASSERONI S, PRATESI A, FATTIROLLI F, MARCHIONNI N. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION.. JOURNAL OF GERIATRIC CARDIOLOGY. 2020 JAN 01?17(11):728?732. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210623.0,,MD,IT,IT,2021,Q2,Elderly
194550801,19455080,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2021,Q2,Lactic acidosis,,2021,Q2,1,I,,20210608.0,20210623,20210623,EXP,,IT-EMD SERONO-9244299,EMD SERONO INC,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, UNGAR A, BALDASSERONI S, PRATESI A, FATTIROLLI F, MARCHIONNI N. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION.. JOURNAL OF GERIATRIC CARDIOLOGY. 2020 JAN 01?17(11):728?732. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210623.0,,MD,IT,IT,2021,Q2,Elderly
194550801,19455080,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,5.0,MG,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210608.0,20210623,20210623,EXP,,IT-EMD SERONO-9244299,EMD SERONO INC,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, UNGAR A, BALDASSERONI S, PRATESI A, FATTIROLLI F, MARCHIONNI N. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION.. JOURNAL OF GERIATRIC CARDIOLOGY. 2020 JAN 01?17(11):728?732. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210623.0,,MD,IT,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Fatigue,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Hyperkalaemia,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Hypotension,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Nausea,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194567071,19456707,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,,,,,Y,,,,,10.0,MG,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210611.0,20210624,20210624,EXP,,IT-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000558,UNICHEM,"ORSO F, HERBST A, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2020?17(11):728?32. DOI:10.11909/J.ISSN.1671?5411.2020.11.005",68.0,YR,E,M,Y,,,20210624.0,,,COUNTRY NOT SPECIFIED,IT,2021,Q2,Elderly
194581231,19458123,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,U,,,,10.0,MG,,QD,2021,Q2,Blood pressure decreased,,2021,Q2,1,I,,20210614.0,20210624,20210624,EXP,,US-MYLANLABS-2021M1036658,MYLAN,,64.0,YR,,M,Y,,,20210624.0,,MD,US,US,2021,Q2,Adult
194581231,19458123,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,U,,,,10.0,MG,,QD,2021,Q2,Hypercalcaemia,,2021,Q2,1,I,,20210614.0,20210624,20210624,EXP,,US-MYLANLABS-2021M1036658,MYLAN,,64.0,YR,,M,Y,,,20210624.0,,MD,US,US,2021,Q2,Adult
194581231,19458123,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,U,,,,10.0,MG,,QD,2021,Q2,Hyperthyroidism,,2021,Q2,1,I,,20210614.0,20210624,20210624,EXP,,US-MYLANLABS-2021M1036658,MYLAN,,64.0,YR,,M,Y,,,20210624.0,,MD,US,US,2021,Q2,Adult
194581231,19458123,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD",,,U,U,,,,10.0,MG,,QD,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210614.0,20210624,20210624,EXP,,US-MYLANLABS-2021M1036658,MYLAN,,64.0,YR,,M,Y,,,20210624.0,,MD,US,US,2021,Q2,Adult
194584781,19458478,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, 2101115,,202293.0,,,TABLET,,2021,Q2,Ketosis,,2021,Q2,1,I,20210524.0,20210616.0,20210624,20210624,EXP,,CN-ASTRAZENECA-2021A545244,ASTRAZENECA,,52.0,YR,,F,Y,76.0,KG,20210624.0,,HP,CN,CN,2021,Q2,Adult
194584781,19458478,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, 2101115,,202293.0,,,TABLET,,2021,Q2,Ketosis,,2021,Q2,1,I,20210524.0,20210616.0,20210624,20210624,EXP,,CN-ASTRAZENECA-2021A545244,ASTRAZENECA,,52.0,YR,,F,Y,76.0,KG,20210624.0,,HP,CN,CN,2021,Q2,Adult
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Acute kidney injury,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Crush syndrome,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Hyperparathyroidism secondary,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Hyperphosphataemia,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Language disorder,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Myalgia,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194587691,19458769,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q2,Sensorimotor disorder,,2021,Q2,1,I,20201203.0,20210127.0,20210624,20210624,EXP,,DE-ORGANON-2101DEU012565,ORGANON,,75.0,YR,,F,Y,,,20210624.0,,MD,DE,DE,2021,Q2,Elderly
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Constipation,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Decreased appetite,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Dyspnoea exertional,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Hypercalcaemia,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Hyperthyroidism,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Hypotension,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Nausea,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Orthopnoea,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Vomiting,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194626411,19462641,6,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210603.0,20210625,20210625,EXP,,US-UNICHEM PHARMACEUTICALS (USA) INC-UCM202106-000535,UNICHEM,"SOLOMON S, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021 MAY 17?. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,,,20210625.0,,,COUNTRY NOT SPECIFIED,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Acute kidney injury,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Dyspnoea,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Hyperglycaemia,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Metabolic acidosis,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Nausea,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194676251,19467625,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,,QD,2021,Q2,Vomiting,,2021,Q2,1,I,20200911.0,,20210628,20210628,DIR,,,FDA-CTU,,61.0,YR,,M,N,84.0,KG,20201119.0,N,PH,US,US,2021,Q2,Adult
194701061,19470106,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNK,,,,,,,2021,Q2,Haemorrhage,,2021,Q2,1,I,,20210618.0,20210629,20210629,EXP,,BR-NOVOPROD-823553,NOVO NORDISK,,82.0,YR,,M,Y,79.9,KG,20210629.0,,MD,BR,BR,2021,Q2,Elderly
194735601,19473560,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Altered state of consciousness,,2021,Q2,1,I,,20210624.0,20210629,20210629,EXP,,JP-009507513-2106JPN002242J,MERCK,,72.0,YR,,M,Y,,,20210629.0,,MD,JP,JP,2021,Q2,Elderly
194735601,19473560,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Oedema,,2021,Q2,1,I,,20210624.0,20210629,20210629,EXP,,JP-009507513-2106JPN002242J,MERCK,,72.0,YR,,M,Y,,,20210629.0,,MD,JP,JP,2021,Q2,Elderly
194735601,19473560,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,,,,,10.0,MG,,,2021,Q2,Oliguria,,2021,Q2,1,I,,20210624.0,20210629,20210629,EXP,,JP-009507513-2106JPN002242J,MERCK,,72.0,YR,,M,Y,,,20210629.0,,MD,JP,JP,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Asthenia,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Colectomy,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Gastrointestinal bacterial infection,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Off label use,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
194795731,19479573,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,20160226.0,20210210.0,20210630,20210630,EXP,,IL-TAKEDA-2021TUS009784,TAKEDA,,67.0,YR,,M,Y,,,20210630.0,,CN,IL,IL,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Atrial fibrillation,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure decreased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure diastolic increased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure fluctuation,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure increased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Blood pressure systolic increased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Bronchitis,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Cardiac failure congestive,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Cough,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Dizziness,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Dyspnoea,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Fall,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Fatigue,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Heart rate decreased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Heart rate increased,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Inappropriate schedule of product administration,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Influenza,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Joint injury,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Limb injury,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Malaise,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Oedema peripheral,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Orthopnoea,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Palpitations,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pericardial effusion,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pneumonia,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Pulmonary oedema,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Rales,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
902813620,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Vital functions abnormal,,2021,Q2,20,F,201212.0,20210526.0,20130123,20210604,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20210604.0,,CN,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Anxiety,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Arthralgia,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Basal cell carcinoma,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Blood pressure diastolic decreased,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Blood pressure increased,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Blood pressure systolic increased,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Cataract,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Cough,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Dyspepsia,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Gastrooesophageal reflux disease,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Malaise,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Nasal congestion,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Nasopharyngitis,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Neck pain,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Pancreatic carcinoma,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Pyrexia,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Second primary malignancy,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Skin mass,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
946404951,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,U,,,,,25.0,MG,,QD,2021,Q2,Vision blurred,,2021,Q2,51,F,20141127.0,20210602.0,20130819,20210614,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210614.0,,MD,CA,CA,2021,Q2,Elderly
162879193,16287919,67,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q3,Acute kidney injury,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,67,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q3,Chronic kidney disease,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,67,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q3,End stage renal disease,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,67,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q3,Nephrogenic anaemia,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,67,C,EMPAGLIFLOZIN+METFORMIN,,2,Unknown,,,,,,,,,,,,,2021,Q3,Renal failure,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
175106752,17510675,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Chills,,2021,Q3,2,F,,20210706.0,20200306,20210714,EXP,,CA-CELGENEUS-CAN-20200210550,CELGENE,,66.0,YR,,M,Y,,,20210714.0,,HP,CA,CA,2021,Q3,Elderly
175106752,17510675,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Sepsis,,2021,Q3,2,F,,20210706.0,20200306,20210714,EXP,,CA-CELGENEUS-CAN-20200210550,CELGENE,,66.0,YR,,M,Y,,,20210714.0,,HP,CA,CA,2021,Q3,Elderly
175106752,17510675,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Vomiting,,2021,Q3,2,F,,20210706.0,20200306,20210714,EXP,,CA-CELGENEUS-CAN-20200210550,CELGENE,,66.0,YR,,M,Y,,,20210714.0,,HP,CA,CA,2021,Q3,Elderly
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Abdominal distension,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Cellulitis,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Chills,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Device infusion issue,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Device leakage,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Headache,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Influenza like illness,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Injection site erythema,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Injection site swelling,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Palpitations,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Pyrexia,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
180201545,18020154,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Dermatitis exfoliative generalised,,2021,Q3,5,F,20200609.0,20210706.0,20200714,20210708,EXP,,JP-ABBVIE-20K-087-3477884-00,ABBVIE,,70.0,YR,,M,Y,,,20210708.0,,MD,JP,JP,2021,Q3,Elderly
180201545,18020154,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Sepsis,,2021,Q3,5,F,20200609.0,20210706.0,20200714,20210708,EXP,,JP-ABBVIE-20K-087-3477884-00,ABBVIE,,70.0,YR,,M,Y,,,20210708.0,,MD,JP,JP,2021,Q3,Elderly
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Candida infection,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Candida sepsis,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Coagulation test abnormal,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Coagulopathy,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Emphysematous pyelonephritis,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Oliguria,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Perinephric abscess,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Product use in unapproved indication,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Pyelonephritis fungal,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Renal impairment,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Septic shock,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Systemic candida,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Therapy non-responder,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Urinary tract candidiasis,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Urinary tract infection,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Urinary tract infection enterococcal,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
180590729,18059072,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2021,Q3,Vesicoureteric reflux,,2021,Q3,9,F,,20210719.0,20200723,20210722,EXP,,NVSC2020ES206671,NOVARTIS,,56.0,YR,,F,Y,,,20210722.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Candida infection,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Candida sepsis,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Coagulation test abnormal,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Coagulopathy,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Emphysematous pyelonephritis,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Hypotension,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Oliguria,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Perinephric abscess,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Pyelonephritis fungal,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Renal impairment,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Septic shock,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Systemic candida,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Therapy non-responder,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Urinary tract candidiasis,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Urinary tract infection enterococcal,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
181423284,18142328,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,,2021,Q3,Vesicoureteric reflux,,2021,Q3,4,F,,20210720.0,20200813,20210728,EXP,,ES-ROCHE-2657950,ROCHE,", SHABAKA A, GONZALEZ?LOPEZ A, MARTIN?SEGARRA O, MORENO DE LA HIGUERA MA, LUCENA R, ET AL. FULMINANT EMPHYSEMATOUS PYELONEPHRITIS BY CANDIDA GLABRATA IN A KIDNEY ALLOGRAFT.. NEPHRON CLINICAL PRACTICE. 2020?144(6):304?309.",56.0,YR,,F,Y,,,20210728.0,,HP,ES,ES,2021,Q3,Adult
182168622,18216862,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Abdominal pain,,2021,Q3,2,F,,20210726.0,20200901,20210804,EXP,CA-MHPD-000912710,CA-ACCORD-198289,ACCORD,,61.0,YR,,F,Y,,,20210804.0,,HP,CA,CA,2021,Q3,Adult
182168622,18216862,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Dehydration,,2021,Q3,2,F,,20210726.0,20200901,20210804,EXP,CA-MHPD-000912710,CA-ACCORD-198289,ACCORD,,61.0,YR,,F,Y,,,20210804.0,,HP,CA,CA,2021,Q3,Adult
182168622,18216862,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,2,F,,20210726.0,20200901,20210804,EXP,CA-MHPD-000912710,CA-ACCORD-198289,ACCORD,,61.0,YR,,F,Y,,,20210804.0,,HP,CA,CA,2021,Q3,Adult
182168622,18216862,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,2,F,,20210726.0,20200901,20210804,EXP,CA-MHPD-000912710,CA-ACCORD-198289,ACCORD,,61.0,YR,,F,Y,,,20210804.0,,HP,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Atrial fibrillation,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Dehydration,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Diarrhoea,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Malaise,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Product dose omission issue,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,LINAGLIPTIN,,,,,,,,,,UNSPECIFIED,,2021,Q3,Pyrexia,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Atrial fibrillation,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Dehydration,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Diarrhoea,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Malaise,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Product dose omission issue,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
183118972,18311897,23,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,,,,,,,,,,2021,Q3,Pyrexia,,2021,Q3,2,F,,20210826.0,20200925,20210904,EXP,CA-MHPD-000914081,CA-ACCORD-202269,ACCORD,,58.0,YR,,M,Y,98.0,KG,20210904.0,,PH,CA,CA,2021,Q3,Adult
184552647,18455264,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Chronic obstructive pulmonary disease,,2021,Q3,7,F,20200423.0,20210914.0,20201102,20210917,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20210917.0,,CN,CO,CO,2021,Q3,Elderly
184552647,18455264,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Expired product administered,,2021,Q3,7,F,20200423.0,20210914.0,20201102,20210917,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20210917.0,,CN,CO,CO,2021,Q3,Elderly
184552647,18455264,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Hypothyroidism,,2021,Q3,7,F,20200423.0,20210914.0,20201102,20210917,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20210917.0,,CN,CO,CO,2021,Q3,Elderly
184552647,18455264,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,7,F,20200423.0,20210914.0,20201102,20210917,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20210917.0,,CN,CO,CO,2021,Q3,Elderly
184552647,18455264,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,7,F,20200423.0,20210914.0,20201102,20210917,EXP,,CO-TAKEDA-CO202019165,TAKEDA,,78.0,YR,,M,Y,69.0,KG,20210917.0,,CN,CO,CO,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Anxiety,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Arrhythmia,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Arthralgia,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Back pain,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Bacterial test positive,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Balanoposthitis,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Blood glucose abnormal,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Diabetes mellitus inadequate control,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Disturbance in attention,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Dizziness,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Dysuria,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Emotional distress,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Erectile dysfunction,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Fall,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Fatigue,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Feeling hot,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Flank pain,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Gastrointestinal disorder,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Glycosylated haemoglobin abnormal,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Groin pain,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Haematoma,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Headache,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Herpes zoster,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Hyperhidrosis,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Hypoaesthesia,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Incontinence,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Leukocyturia,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Loss of libido,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Malaise,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Muscle tightness,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Nausea,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Osteoarthritis,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Pain in extremity,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Peripheral coldness,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Phimosis,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Plantar fasciitis,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Pollakiuria,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Pruritus,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Quality of life decreased,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Renal cyst,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Restlessness,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Sacroiliac joint dysfunction,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Sense of oppression,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Sleep disorder,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Stress urinary incontinence,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Urinary tract infection bacterial,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186179864,18617986,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD ((1?0?0?0), IN MORNING)",,,U,U,,,,,,TABLET,QD,2021,Q3,Urine flow decreased,,2021,Q3,4,F,20140414.0,20210812.0,20201215,20210826,EXP,,DE-MYLANLABS-2020M1100563,MYLAN,,65.0,YR,,M,Y,134.0,KG,20210826.0,,MD,DE,DE,2021,Q3,Elderly
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Arrhythmia,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Intracardiac thrombus,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Palpitations,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Supraventricular extrasystoles,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Tachycardia,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
186646866,18664686,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 DF, QD",,,U,,,,,1.0,DF,,QD,2021,Q3,Ventricular extrasystoles,,2021,Q3,6,F,20201216.0,20210630.0,20201225,20210710,EXP,,NVSC2020KE338503,NOVARTIS,,36.0,YR,,F,Y,,,20210710.0,,CN,COUNTRY NOT SPECIFIED,KE,2021,Q3,Adult
188578113,18857811,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, EVERYDAY",,,,,,,,10.0,MG,,QD,2021,Q3,Bradycardia,,2021,Q3,3,F,2021.0,20210818.0,20210208,20210830,PER,,JP-AMGEN-JPNSP2021019946,AMGEN,,39.0,YR,A,F,Y,110.0,KG,20210830.0,,MD,JP,JP,2021,Q3,Adult
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Crush syndrome,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Hyperparathyroidism secondary,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Hyperphosphataemia,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Language disorder,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Myalgia,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Rhabdomyolysis,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
188916512,18891651,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,,,,10.0,MG,,,2021,Q3,Sensorimotor disorder,,2021,Q3,2,F,20201203.0,20210701.0,20210215,20210714,EXP,DE-BFARM-21000617,DE-ACCORD-217142,ACCORD,,75.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dropped head syndrome,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dysphagia,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Gait disturbance,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Gastrointestinal tube insertion,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189204082,18920408,4,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,2,F,,20210716.0,20210222,20210731,EXP,,CA-AUROBINDO-AUR-APL-2021-007133,AUROBINDO,,79.0,YR,,M,Y,,,20210731.0,,HP,CA,CA,2021,Q3,Elderly
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Arthritis,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Coronary artery occlusion,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Diabetic coma,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Diabetic metabolic decompensation,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Inflammation,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
189245422,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q3,Tonsillitis,,2021,Q3,2,F,20210307.0,20210707.0,20210222,20210714,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,60.0,YR,,F,Y,,,20210714.0,,CN,CL,CL,2021,Q3,Adult
190840095,19084009,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q3,Acute kidney injury,,2021,Q3,5,F,20210318.0,20210602.0,20210401,20210708,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-092826",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,76.3,KG,20210708.0,,MD,CA,CA,2021,Q3,Elderly
190840095,19084009,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q3,Cardiac failure,,2021,Q3,5,F,20210318.0,20210602.0,20210401,20210708,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-092826",BOEHRINGER INGELHEIM,,73.0,YR,E,M,Y,76.3,KG,20210708.0,,MD,CA,CA,2021,Q3,Elderly
190870792,19087079,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,2,F,,20210707.0,20210402,20210719,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J?GERIATR?CARDIOL 2020?17(11):728?732.",68.0,YR,,M,Y,,,20210719.0,,HP,IT,IT,2021,Q3,Elderly
190870792,19087079,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hypovolaemia,,2021,Q3,2,F,,20210707.0,20210402,20210719,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J?GERIATR?CARDIOL 2020?17(11):728?732.",68.0,YR,,M,Y,,,20210719.0,,HP,IT,IT,2021,Q3,Elderly
190870792,19087079,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,2,F,,20210707.0,20210402,20210719,EXP,,IT-MYLANLABS-2021M1019609,MYLAN,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J?GERIATR?CARDIOL 2020?17(11):728?732.",68.0,YR,,M,Y,,,20210719.0,,HP,IT,IT,2021,Q3,Elderly
190874422,19087442,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Deep vein thrombosis,,2021,Q3,2,F,20181010.0,20210723.0,20210402,20210803,PER,,US-PFIZER INC-2021351773,PFIZER,,74.0,YR,,M,Y,,,20210803.0,,LW,US,US,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hypovolaemia,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Toxicity to various agents,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,12,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Hypovolaemia,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Toxicity to various agents,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191004353,19100435,13,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,Y,U,,,,10.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,3,F,2019.0,20210719.0,20210407,20210729,EXP,,IT-AUROBINDO-AUR-APL-2021-013897,AUROBINDO,,68.0,YR,,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Angina pectoris,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Cardiac failure congestive,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Cardiothoracic ratio,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Chest discomfort,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Drug interaction,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Dyspnoea,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Hypotension,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Myocardial ischaemia,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Peripheral circulatory failure,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Ventricular hypokinesia,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Ventricular internal diameter,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Volume blood decreased,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191204912,19120491,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DF, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Weight decreased,,2021,Q3,2,F,20201105.0,20210820.0,20210412,20210830,EXP,,NVSJ2020JP012470,NOVARTIS,,82.0,YR,,F,Y,38.1,KG,20210830.0,,MD,JP,JP,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,COVID-19,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,Diverticulum,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,Gastritis,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,Hepatic cirrhosis,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,Nephrolithiasis,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
191385942,19138594,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,, UNKNOWN,,,,,,,2021,Q3,Varices oesophageal,,2021,Q3,2,F,202102.0,20210629.0,20210415,20210903,EXP,,BR-NOVOPROD-803188,NOVO NORDISK,,68.0,YR,,M,Y,107.0,KG,20210903.0,,MD,BR,BR,2021,Q3,Elderly
192160995,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,,,,,,,,TABLET,,2021,Q3,Abnormal loss of weight,,2021,Q3,5,F,2019.0,20210921.0,20210505,20210922,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20210922.0,,CN,US,US,2021,Q3,Elderly
192160995,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,,,,,,,,TABLET,,2021,Q3,Atrioventricular block,,2021,Q3,5,F,2019.0,20210921.0,20210505,20210922,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20210922.0,,CN,US,US,2021,Q3,Elderly
192160995,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,,,,,,,,TABLET,,2021,Q3,Diabetes mellitus,,2021,Q3,5,F,2019.0,20210921.0,20210505,20210922,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20210922.0,,CN,US,US,2021,Q3,Elderly
192160995,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,,,,,,,,TABLET,,2021,Q3,Diarrhoea,,2021,Q3,5,F,2019.0,20210921.0,20210505,20210922,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20210922.0,,CN,US,US,2021,Q3,Elderly
192160995,19216099,5,C,EMPAGLIFLOZIN;LINAGLIPTIN;METFORMIN,,2,Oral,,,,,,,,,,,TABLET,,2021,Q3,Nephrolithiasis,,2021,Q3,5,F,2019.0,20210921.0,20210505,20210922,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101442",BOEHRINGER INGELHEIM,,69.0,YR,E,M,Y,,,20210922.0,,CN,US,US,2021,Q3,Elderly
192226763,19222676,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, UNK",,,,,,,,25.0,MG,,,2021,Q3,Ventricular fibrillation,,2021,Q3,3,F,20210501.0,20210803.0,20210505,20210804,EXP,,"DE-PORTOLA PHARMACEUTICALS, INC.-A202105140",ALEXION,,68.0,YR,,M,Y,,,20210804.0,,MD,DE,DE,2021,Q3,Elderly
192895622,19289562,6,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,N,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,,2021,Q3,Vasculitis,,2021,Q3,2,F,20210329.0,20210517.0,20210521,20210924,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-104314",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20210924.0,,MD,CN,CN,2021,Q3,Adult
193233582,19323358,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,2,F,,20210623.0,20210528,20210701,EXP,,ES-BAUSCH-BL-2021-017759,BAUSCH AND LOMB,"SOLER C, GARRIDO?LESTACHE E, GUTIERREZ A, MAYORDOMO P, ABIZANDA A, CONTRERAS I. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28.",53.0,YR,,M,Y,,,20210701.0,,MD,ES,ES,2021,Q3,Adult
193233582,19323358,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Renal impairment,,2021,Q3,2,F,,20210623.0,20210528,20210701,EXP,,ES-BAUSCH-BL-2021-017759,BAUSCH AND LOMB,"SOLER C, GARRIDO?LESTACHE E, GUTIERREZ A, MAYORDOMO P, ABIZANDA A, CONTRERAS I. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28.",53.0,YR,,M,Y,,,20210701.0,,MD,ES,ES,2021,Q3,Adult
193233582,19323358,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Sleep apnoea syndrome,,2021,Q3,2,F,,20210623.0,20210528,20210701,EXP,,ES-BAUSCH-BL-2021-017759,BAUSCH AND LOMB,"SOLER C, GARRIDO?LESTACHE E, GUTIERREZ A, MAYORDOMO P, ABIZANDA A, CONTRERAS I. TRIPLE TERAPIA EN UN PACIENTE CON INSUFICIENCIA CARDIACA, FEVI REDUCIDA Y ENFERMEDAD RENAL CRONICA. MINICARDIO. 2021?11:28.",53.0,YR,,M,Y,,,20210701.0,,MD,ES,ES,2021,Q3,Adult
1935159215,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"CAPSULE,HARD",,,Y,U, UNKNOWN,,102145.0,,,FILM-COATED TABLET,,2021,Q3,Arm amputation,,2021,Q3,15,F,20210525.0,20210928.0,20210531,20210930,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20210930.0,,MD,US,US,2021,Q3,Youth
1935159215,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"CAPSULE,HARD",,,Y,U, UNKNOWN,,102145.0,,,FILM-COATED TABLET,,2021,Q3,Peripheral ischaemia,,2021,Q3,15,F,20210525.0,20210928.0,20210531,20210930,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20210930.0,,MD,US,US,2021,Q3,Youth
1935159215,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"CAPSULE,HARD",,,Y,U, UNKNOWN,,102145.0,,,FILM-COATED TABLET,,2021,Q3,Pulmonary embolism,,2021,Q3,15,F,20210525.0,20210928.0,20210531,20210930,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20210930.0,,MD,US,US,2021,Q3,Youth
193602493,19360249,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25MG,,,,,,,,,,,,2021,Q3,Breast cancer metastatic,,2021,Q3,3,F,20200610.0,20210517.0,20210601,20210708,EXP,,BR-NOVOPROD-816988,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210708.0,,CN,BR,BR,2021,Q3,Elderly
193602493,19360249,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25MG,,,,,,,,,,,,2021,Q3,Breast cancer recurrent,,2021,Q3,3,F,20200610.0,20210517.0,20210601,20210708,EXP,,BR-NOVOPROD-816988,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210708.0,,CN,BR,BR,2021,Q3,Elderly
193602493,19360249,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25MG,,,,,,,,,,,,2021,Q3,Diastolic dysfunction,,2021,Q3,3,F,20200610.0,20210517.0,20210601,20210708,EXP,,BR-NOVOPROD-816988,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210708.0,,CN,BR,BR,2021,Q3,Elderly
193602493,19360249,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25MG,,,,,,,,,,,,2021,Q3,Orthostatic hypotension,,2021,Q3,3,F,20200610.0,20210517.0,20210601,20210708,EXP,,BR-NOVOPROD-816988,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210708.0,,CN,BR,BR,2021,Q3,Elderly
193602493,19360249,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25MG,,,,,,,,,,,,2021,Q3,Thoracic vertebral fracture,,2021,Q3,3,F,20200610.0,20210517.0,20210601,20210708,EXP,,BR-NOVOPROD-816988,NOVO NORDISK,,75.0,YR,,F,Y,83.8,KG,20210708.0,,CN,BR,BR,2021,Q3,Elderly
193669973,19366997,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,,,2021,Q3,Abdominal abscess,,2021,Q3,3,F,,20210618.0,20210603,20210702,EXP,,JP-PFIZER INC-2021580210,PFIZER,"MOTOMURA, Y.. A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118 (5):455?461",8.0,DEC,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Child
193669973,19366997,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,,,2021,Q3,Amoebic colitis,,2021,Q3,3,F,,20210618.0,20210603,20210702,EXP,,JP-PFIZER INC-2021580210,PFIZER,"MOTOMURA, Y.. A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118 (5):455?461",8.0,DEC,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Child
193669973,19366997,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, DAILY",,,,,,,,10.0,MG,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,3,F,,20210618.0,20210603,20210702,EXP,,JP-PFIZER INC-2021580210,PFIZER,"MOTOMURA, Y.. A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118 (5):455?461",8.0,DEC,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Child
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Abdominal pain,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Alcohol abuse,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Allergy to animal,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Anxiety,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Asthma,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Back pain,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Depression,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Drug hypersensitivity,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Generalised tonic-clonic seizure,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Heart rate increased,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Limb injury,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Memory impairment,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Mobility decreased,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Product dose omission issue,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Seasonal allergy,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Sleep apnoea syndrome,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Sleep disorder,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Staphylococcal bacteraemia,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Staphylococcal sepsis,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Toxic encephalopathy,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194141293,19414129,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Weight decreased,,2021,Q3,3,F,2018.0,20210714.0,20210614,20210728,EXP,,NVSC2021US124162,NOVARTIS,,65.0,YR,,M,Y,121.0,KG,20210728.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194177563,19417756,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q3,Amoebic colitis,,2021,Q3,3,F,,20210618.0,20210615,20210701,EXP,,JP-PFIZER INC-2021631889,PFIZER,"KATO, A.. A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118(5):455?461",8.0,DEC,,M,Y,,,20210701.0,,MD,JP,JP,2021,Q3,Child
194177563,19417756,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG,,,,,,,,10.0,MG,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,3,F,,20210618.0,20210615,20210701,EXP,,JP-PFIZER INC-2021631889,PFIZER,"KATO, A.. A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118(5):455?461",8.0,DEC,,M,Y,,,20210701.0,,MD,JP,JP,2021,Q3,Child
194264042,19426404,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,UNKNOWN,,2021,Q3,Hypercalcaemia,,2021,Q3,2,F,,20210713.0,20210617,20210720,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-21-54654,HIKMA,"GANESAN K, BRADLEY B, JONES DW, SOLOMON DS. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021. DOI:10.1016/J.AMJMS.2021.05.010.",64.0,YR,,M,Y,85.0,KG,20210720.0,,,COUNTRY NOT SPECIFIED,US,2021,Q3,Adult
194264042,19426404,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,UNKNOWN,,2021,Q3,Hyperthyroidism,,2021,Q3,2,F,,20210713.0,20210617,20210720,EXP,,US-HIKMA PHARMACEUTICALS USA INC.-US-H14001-21-54654,HIKMA,"GANESAN K, BRADLEY B, JONES DW, SOLOMON DS. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. THE AMERICAN JOURNAL OF THE MEDICAL SCIENCES. 2021. DOI:10.1016/J.AMJMS.2021.05.010.",64.0,YR,,M,Y,85.0,KG,20210720.0,,,COUNTRY NOT SPECIFIED,US,2021,Q3,Adult
194333882,19433388,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q3,Cardiac failure,,2021,Q3,2,F,20210402.0,20210716.0,20210618,20210729,EXP,,NVSJ2021JP009099,NOVARTIS,,52.0,YR,,M,Y,,,20210729.0,,CN,JP,JP,2021,Q3,Adult
194333882,19433388,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,,,,,10.0,MG,,,2021,Q3,Ventricular tachycardia,,2021,Q3,2,F,20210402.0,20210716.0,20210618,20210729,EXP,,NVSJ2021JP009099,NOVARTIS,,52.0,YR,,M,Y,,,20210729.0,,CN,JP,JP,2021,Q3,Adult
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Abdominal pain,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Atrial fibrillation,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Cardiac failure acute,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Cardiac failure chronic,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Colitis ischaemic,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194438713,19443871,21,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,,,FILM-COATED TABLET,QD,2021,Q3,Left ventricular failure,,2021,Q3,3,F,20201120.0,20210701.0,20210621,20210705,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-065804",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,77.1,KG,20210705.0,,MD,US,US,2021,Q3,Elderly
194482592,19448259,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2021,Q3,Hypercalcaemia,,2021,Q3,2,F,,20210713.0,20210622,20210723,EXP,,US-DRREDDYS-SPO/USA/21/0136627,DR REDDYS,"SOLOMON D, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. AM J MED SCI. 2021?UNKNOWN:UNKNOWN?UNKNOWN. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,85.0,KG,20210723.0,,MD,US,US,2021,Q3,Adult
194482592,19448259,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,,,2021,Q3,Hyperthyroidism,,2021,Q3,2,F,,20210713.0,20210622,20210723,EXP,,US-DRREDDYS-SPO/USA/21/0136627,DR REDDYS,"SOLOMON D, GANESAN K, BRADLEY B, JONES D. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. AM J MED SCI. 2021?UNKNOWN:UNKNOWN?UNKNOWN. DOI:10.1016/J.AMJMS.2021.05.010",64.0,YR,A,M,Y,85.0,KG,20210723.0,,MD,US,US,2021,Q3,Adult
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Abdominal distension,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Anxiety,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Atrial fibrillation,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Bundle branch block left,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Chest discomfort,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Chronic left ventricular failure,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Claustrophobia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Coronary artery disease,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Diabetic dyslipidaemia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Diabetic nephropathy,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Diabetic neuropathy,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dyspnoea exertional,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Haematochezia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Hyperthyroidism,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Insomnia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Ischaemic cardiomyopathy,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Left ventricular failure,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Myocardial infarction,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Obesity,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Orthopnoea,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194733223,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Psychophysiologic insomnia,,2021,Q3,3,F,202001.0,20210812.0,20210629,20210825,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20210825.0,,CN,COUNTRY NOT SPECIFIED,US,2021,Q3,Elderly
194824911,19482491,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210522.0,,20210701,20210701,DIR,,,FDA-CTU,,71.0,YR,,M,N,111.58,KG,20210609.0,N,PH,US,US,2021,Q3,Elderly
194824911,19482491,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Dehydration,,2021,Q3,1,I,20210522.0,,20210701,20210701,DIR,,,FDA-CTU,,71.0,YR,,M,N,111.58,KG,20210609.0,N,PH,US,US,2021,Q3,Elderly
194824911,19482491,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,20210522.0,,20210701,20210701,DIR,,,FDA-CTU,,71.0,YR,,M,N,111.58,KG,20210609.0,N,PH,US,US,2021,Q3,Elderly
194825802,19482580,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Cardiac failure,Cardiac failure,2021,Q3,2,F,,20210621.0,20210701,20210702,EXP,,JP-ALVOGEN-2021-ALVOGEN-117141,ALVOGEN,,88.0,YR,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Elderly
194825802,19482580,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Chronic kidney disease,Chronic kidney disease,2021,Q3,2,F,,20210621.0,20210701,20210702,EXP,,JP-ALVOGEN-2021-ALVOGEN-117141,ALVOGEN,,88.0,YR,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Elderly
194832532,19483253,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,U,,,,,10.0,MG,,QD,2021,Q3,Hypercalcaemia,,2021,Q3,2,F,,20210831.0,20210701,20210908,EXP,,US-TEVA-2021-US-1927393,TEVA,"GANESAN K, BRADLEY B, JONES DW, SOLOMON DS. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. AM?J?MED?SCI 2021?:.",64.0,YR,A,M,Y,,,20210908.0,,MD,US,US,2021,Q3,Adult
194832532,19483253,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,U,,,,,10.0,MG,,QD,2021,Q3,Hyperthyroidism,,2021,Q3,2,F,,20210831.0,20210701,20210908,EXP,,US-TEVA-2021-US-1927393,TEVA,"GANESAN K, BRADLEY B, JONES DW, SOLOMON DS. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. AM?J?MED?SCI 2021?:.",64.0,YR,A,M,Y,,,20210908.0,,MD,US,US,2021,Q3,Adult
194832532,19483253,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM DAILY;,,,U,,,,,10.0,MG,,QD,2021,Q3,Weight decreased,,2021,Q3,2,F,,20210831.0,20210701,20210908,EXP,,US-TEVA-2021-US-1927393,TEVA,"GANESAN K, BRADLEY B, JONES DW, SOLOMON DS. A CASE REPORT ON TYPE 2 AMIODARONE INDUCED THYROTOXICOSIS AND HYPERCALCEMIA. AM?J?MED?SCI 2021?:.",64.0,YR,A,M,Y,,,20210908.0,,MD,US,US,2021,Q3,Adult
194855081,19485508,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q3,Cerebrovascular accident,,2021,Q3,1,I,20200525.0,20210223.0,20210702,20210702,EXP,,NO-ROCHE-2777394,ROCHE,,59.0,YR,,,Y,,,20210702.0,,MD,NO,NO,2021,Q3,Adult
194862451,19486245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Abscess,,2021,Q3,1,I,20201128.0,,20210701,20210701,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
194862451,19486245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Epididymitis,,2021,Q3,1,I,20201128.0,,20210701,20210701,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
194862451,19486245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Scrotal cellulitis,,2021,Q3,1,I,20201128.0,,20210701,20210701,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
194868521,19486852,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q3,Chest pain,,2021,Q3,1,I,20210617.0,,20210701,20210701,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210701.0,N,PH,US,US,2021,Q3,Adult
194868521,19486852,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q3,Diarrhoea,,2021,Q3,1,I,20210617.0,,20210701,20210701,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210701.0,N,PH,US,US,2021,Q3,Adult
194868521,19486852,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210617.0,,20210701,20210701,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210701.0,N,PH,US,US,2021,Q3,Adult
194868521,19486852,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210617.0,,20210701,20210701,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210701.0,N,PH,US,US,2021,Q3,Adult
194868521,19486852,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,,QD,2021,Q3,Vomiting,,2021,Q3,1,I,20210617.0,,20210701,20210701,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210701.0,N,PH,US,US,2021,Q3,Adult
194872961,19487296,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,2.0,DF,,QD,2021,Q3,Diabetic metabolic decompensation,,2021,Q3,1,I,201605.0,20210622.0,20210702,20210702,EXP,,SK-EMD SERONO-9247559,EMD SERONO INC,UNKNOWN. PRACTICAL EXPERIENCE CONFIRMS THE RESULTS OF THE RCT AND RWE STUDIES WITH EMPAGLIFLOSIN: CASE REPORTS. FORUM DIABETOLOGICUM. 2021?10(1):53?61.,53.0,YR,A,M,Y,,,20210702.0,,MD,SK,SK,2021,Q3,Adult
194872961,19487296,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,2.0,DF,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,201605.0,20210622.0,20210702,20210702,EXP,,SK-EMD SERONO-9247559,EMD SERONO INC,UNKNOWN. PRACTICAL EXPERIENCE CONFIRMS THE RESULTS OF THE RCT AND RWE STUDIES WITH EMPAGLIFLOSIN: CASE REPORTS. FORUM DIABETOLOGICUM. 2021?10(1):53?61.,53.0,YR,A,M,Y,,,20210702.0,,MD,SK,SK,2021,Q3,Adult
194872961,19487296,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,2.0,DF,,QD,2021,Q3,Weight increased,,2021,Q3,1,I,201605.0,20210622.0,20210702,20210702,EXP,,SK-EMD SERONO-9247559,EMD SERONO INC,UNKNOWN. PRACTICAL EXPERIENCE CONFIRMS THE RESULTS OF THE RCT AND RWE STUDIES WITH EMPAGLIFLOSIN: CASE REPORTS. FORUM DIABETOLOGICUM. 2021?10(1):53?61.,53.0,YR,A,M,Y,,,20210702.0,,MD,SK,SK,2021,Q3,Adult
194891041,19489104,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM,1?0?0?0, TABLET",,,,,,,,10.0,MG,TABLET,,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20210703.0,,PH,DE,DE,2021,Q3,Elderly
194891041,19489104,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM,1?0?0?0, TABLET",,,,,,,,10.0,MG,TABLET,,2021,Q3,Erythema,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20210703.0,,PH,DE,DE,2021,Q3,Elderly
194891041,19489104,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM,1?0?0?0, TABLET",,,,,,,,10.0,MG,TABLET,,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20210703.0,,PH,DE,DE,2021,Q3,Elderly
194891041,19489104,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM,1?0?0?0, TABLET",,,,,,,,10.0,MG,TABLET,,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20210703.0,,PH,DE,DE,2021,Q3,Elderly
194891041,19489104,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM,1?0?0?0, TABLET",,,,,,,,10.0,MG,TABLET,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027373,AUROBINDO,,70.0,YR,,M,Y,95.0,KG,20210703.0,,PH,DE,DE,2021,Q3,Elderly
194893391,19489339,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210628.0,20210703,20210703,EXP,,DE-TEVA-2021-DE-1928412,TEVA,,74.0,YR,E,M,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194893391,19489339,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Dehydration,,2021,Q3,1,I,,20210628.0,20210703,20210703,EXP,,DE-TEVA-2021-DE-1928412,TEVA,,74.0,YR,E,M,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194893391,19489339,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210628.0,20210703,20210703,EXP,,DE-TEVA-2021-DE-1928412,TEVA,,74.0,YR,E,M,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194893391,19489339,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210628.0,20210703,20210703,EXP,,DE-TEVA-2021-DE-1928412,TEVA,,74.0,YR,E,M,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194893391,19489339,9,C,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY; 1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210628.0,20210703,20210703,EXP,,DE-TEVA-2021-DE-1928412,TEVA,,74.0,YR,E,M,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194903591,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210622.0,20210705,20210705,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194903591,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Erythema,,2021,Q3,1,I,,20210622.0,20210705,20210705,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194903591,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210622.0,20210705,20210705,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194903591,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210622.0,20210705,20210705,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194903591,19490359,1,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210622.0,20210705,20210705,EXP,DE-BFARM-21006057,DE-NOVOPROD-823249,NOVO NORDISK,,70.0,YR,,M,Y,95.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194913521,19491352,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000011,MERCK,,70.0,YR,,M,Y,89.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194913521,19491352,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000011,MERCK,,70.0,YR,,M,Y,89.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194930481,19493048,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Product used for unknown indication,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000027,MERCK,,55.0,YR,,M,Y,70.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Adult
194930481,19493048,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Proteinuria,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000027,MERCK,,55.0,YR,,M,Y,70.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Adult
194930481,19493048,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000027,MERCK,,55.0,YR,,M,Y,70.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Adult
194974971,19497497,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-TEVA-2021-DE-1929533,TEVA,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194974971,19497497,8,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-TEVA-2021-DE-1929533,TEVA,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194983391,19498339,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-SA-2021SA218615,SANOFI AVENTIS,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194983391,19498339,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-SA-2021SA218615,SANOFI AVENTIS,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194991521,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20210706.0,,HP,COUNTRY NOT SPECIFIED,DE,2021,Q3,Elderly
194991521,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Erythema,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20210706.0,,HP,COUNTRY NOT SPECIFIED,DE,2021,Q3,Elderly
194991521,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20210706.0,,HP,COUNTRY NOT SPECIFIED,DE,2021,Q3,Elderly
194991521,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20210706.0,,HP,COUNTRY NOT SPECIFIED,DE,2021,Q3,Elderly
194991521,19499152,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,NVSC2021DE148696,NOVARTIS,,70.0,YR,,M,Y,95.0,KG,20210706.0,,HP,COUNTRY NOT SPECIFIED,DE,2021,Q3,Elderly
194999941,19499994,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1?0?0?0, TABLETTEN",,,U,U,,,,,,,,2021,Q3,Arrhythmia,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06673-01,DE-NOVOPROD-824134,NOVO NORDISK,,88.0,YR,,F,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
194999941,19499994,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1?0?0?0, TABLETTEN",,,U,U,,,,,,,,2021,Q3,Blood glucose fluctuation,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06673-01,DE-NOVOPROD-824134,NOVO NORDISK,,88.0,YR,,F,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
194999941,19499994,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1?0?0?0, TABLETTEN",,,U,U,,,,,,,,2021,Q3,Fatigue,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06673-01,DE-NOVOPROD-824134,NOVO NORDISK,,88.0,YR,,F,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
194999941,19499994,12,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1?0?0?0, TABLETTEN",,,U,U,,,,,,,,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06673-01,DE-NOVOPROD-824134,NOVO NORDISK,,88.0,YR,,F,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
194999951,19499995,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,U,,,,,,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06617-01,DE-NOVOPROD-824135,NOVO NORDISK,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999951,19499995,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,U,,,,,,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06617-01,DE-NOVOPROD-824135,NOVO NORDISK,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195005711,19500571,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,30 MILLIGRAM DAILY; 1?1?1?0,,,,, UNKNOWN,,,10.0,MG,TABLET,TID,2021,Q3,Abdominal pain,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929840,TEVA,,82.0,YR,E,M,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
195005711,19500571,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,30 MILLIGRAM DAILY; 1?1?1?0,,,,, UNKNOWN,,,10.0,MG,TABLET,TID,2021,Q3,Constipation,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929840,TEVA,,82.0,YR,E,M,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
195005711,19500571,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,30 MILLIGRAM DAILY; 1?1?1?0,,,,, UNKNOWN,,,10.0,MG,TABLET,TID,2021,Q3,Flatulence,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929840,TEVA,,82.0,YR,E,M,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
195005711,19500571,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,30 MILLIGRAM DAILY; 1?1?1?0,,,,, UNKNOWN,,,10.0,MG,TABLET,TID,2021,Q3,Haematuria,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929840,TEVA,,82.0,YR,E,M,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
195005711,19500571,16,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,30 MILLIGRAM DAILY; 1?1?1?0,,,,, UNKNOWN,,,10.0,MG,TABLET,TID,2021,Q3,Micturition disorder,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929840,TEVA,,82.0,YR,E,M,Y,,,20210707.0,,MD,DE,DE,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195012561,19501256,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-TEVA-2021-GB-1930355,TEVA,,65.0,YR,E,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195023091,19502309,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929446,TEVA,,70.0,YR,E,M,Y,95.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195023091,19502309,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Erythema,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929446,TEVA,,70.0,YR,E,M,Y,95.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195023091,19502309,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929446,TEVA,,70.0,YR,E,M,Y,95.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195023091,19502309,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929446,TEVA,,70.0,YR,E,M,Y,95.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195023091,19502309,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210630.0,20210707,20210707,EXP,,DE-TEVA-2021-DE-1929446,TEVA,,70.0,YR,E,M,Y,95.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Diabetes mellitus inadequate control,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039051,19503905,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210707,20210707,EXP,,GB-MYLANLABS-2021M1040177,MYLAN,,65.0,YR,,M,Y,,,20210707.0,,MD,GB,GB,2021,Q3,Elderly
195039141,19503914,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202106013456,ELI LILLY AND CO,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195039141,19503914,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202106013456,ELI LILLY AND CO,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195044741,19504474,1,PS,EMPAGLIFLOZIN/METFORMIN (EMPAGLIFLOZIN 5MG/METFORMIN 1000MG TAB.ORAL),EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,2.0,DF,COATED TABLET,QD,2021,Q3,Hypotension,,2021,Q3,1,I,20210415.0,,20210707,20210707,DIR,,,FDA-CTU,,70.0,YR,,M,N,127.0,KG,20210617.0,N,PH,US,US,2021,Q3,Elderly
195044741,19504474,1,PS,EMPAGLIFLOZIN/METFORMIN (EMPAGLIFLOZIN 5MG/METFORMIN 1000MG TAB.ORAL),EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,D,,,,2.0,DF,COATED TABLET,QD,2021,Q3,Urosepsis,,2021,Q3,1,I,20210415.0,,20210707,20210707,DIR,,,FDA-CTU,,70.0,YR,,M,N,127.0,KG,20210617.0,N,PH,US,US,2021,Q3,Elderly
195044811,19504481,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,Y,,,,12.5,MG,,,2021,Q3,Myalgia,,2021,Q3,1,I,20210401.0,,20210707,20210707,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20210429.0,N,PH,US,US,2021,Q3,Adult
195044811,19504481,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,Y,,,,12.5,MG,,,2021,Q3,Peripheral ischaemia,,2021,Q3,1,I,20210401.0,,20210707,20210707,DIR,,,FDA-CTU,,57.0,YR,,M,N,,,20210429.0,N,PH,US,US,2021,Q3,Adult
195055121,19505512,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM DAILY;  1?0?0?0,",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Bradycardia,,2021,Q3,1,I,20210412.0,20210630.0,20210708,20210708,EXP,,DE-TEVA-2021-DE-1929626,TEVA,,95.0,YR,E,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195055121,19505512,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM DAILY;  1?0?0?0,",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Hypotension,,2021,Q3,1,I,20210412.0,20210630.0,20210708,20210708,EXP,,DE-TEVA-2021-DE-1929626,TEVA,,95.0,YR,E,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195055121,19505512,9,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MILLIGRAM DAILY;  1?0?0?0,",,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Wrong product administered,,2021,Q3,1,I,20210412.0,20210630.0,20210708,20210708,EXP,,DE-TEVA-2021-DE-1929626,TEVA,,95.0,YR,E,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195063011,19506301,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,20210504.0,,20210708,20210708,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20210603.0,N,PH,US,US,2021,Q3,Elderly
195063011,19506301,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,1,I,20210504.0,,20210708,20210708,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20210603.0,N,PH,US,US,2021,Q3,Elderly
195086741,19508674,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLET",,,,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06282-01,DE-PFIZER INC-2021770582,PFIZER,,74.0,YR,,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195086741,19508674,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLET",,,,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Dehydration,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06282-01,DE-PFIZER INC-2021770582,PFIZER,,74.0,YR,,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195086741,19508674,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLET",,,,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06282-01,DE-PFIZER INC-2021770582,PFIZER,,74.0,YR,,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195086741,19508674,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLET",,,,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06282-01,DE-PFIZER INC-2021770582,PFIZER,,74.0,YR,,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195086741,19508674,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0, TABLET",,,,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06282-01,DE-PFIZER INC-2021770582,PFIZER,,74.0,YR,,M,Y,,,20210708.0,,MD,DE,DE,2021,Q3,Elderly
195106231,19510623,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-EMD SERONO-E2B_90084138,EMD SERONO INC,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195106231,19510623,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Erythema,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-EMD SERONO-E2B_90084138,EMD SERONO INC,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195106231,19510623,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-EMD SERONO-E2B_90084138,EMD SERONO INC,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195106231,19510623,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-EMD SERONO-E2B_90084138,EMD SERONO INC,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195106231,19510623,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-EMD SERONO-E2B_90084138,EMD SERONO INC,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195109111,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195109111,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Erythema,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195109111,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195109111,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195109111,19510911,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210629.0,20210709,20210709,EXP,,DE-SA-2021SA216364,SANOFI AVENTIS,,70.0,YR,E,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195111573,19511157,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM (1?0?0?0),,,U,,,,,10.0,MG,TABLET,,2021,Q3,Bradycardia,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111573,19511157,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM (1?0?0?0),,,U,,,,,10.0,MG,TABLET,,2021,Q3,Hypotension,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111573,19511157,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM (1?0?0?0),,,U,,,,,10.0,MG,TABLET,,2021,Q3,Wrong product administered,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111573,19511157,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, ONCE A DAY (10 MG, 1?0?0?0, TABLETS)",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Bradycardia,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111573,19511157,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, ONCE A DAY (10 MG, 1?0?0?0, TABLETS)",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Hypotension,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111573,19511157,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, ONCE A DAY (10 MG, 1?0?0?0, TABLETS)",,,U,,,,,1.0,DF,TABLET,QD,2021,Q3,Wrong product administered,,2021,Q3,3,F,20210412.0,20210714.0,20210709,20210727,EXP,,DE-AUROBINDO-AUR-APL-2021-028055,AUROBINDO,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195111671,19511167,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM (1?0?0?0),,,U,U,,,,10.0,MG,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,,DE-AUROBINDO-AUR-APL-2021-028067,AUROBINDO,,70.0,YR,,M,Y,89.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195111671,19511167,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM (1?0?0?0),,,U,U,,,,10.0,MG,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,,DE-AUROBINDO-AUR-APL-2021-028067,AUROBINDO,,70.0,YR,,M,Y,89.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195120982,19512098,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Abdominal abscess,,2021,Q3,2,F,,20210818.0,20210709,20210826,EXP,JP-MLMSERVICE-20210609-2941326-1,JP-MYLANLABS-2021M1039659,MYLAN,,8.0,DEC,,M,Y,,,20210826.0,,PH,COUNTRY NOT SPECIFIED,JP,2021,Q3,Child
195120982,19512098,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Amoebiasis,,2021,Q3,2,F,,20210818.0,20210709,20210826,EXP,JP-MLMSERVICE-20210609-2941326-1,JP-MYLANLABS-2021M1039659,MYLAN,,8.0,DEC,,M,Y,,,20210826.0,,PH,COUNTRY NOT SPECIFIED,JP,2021,Q3,Child
195120982,19512098,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Enterocolitis,,2021,Q3,2,F,,20210818.0,20210709,20210826,EXP,JP-MLMSERVICE-20210609-2941326-1,JP-MYLANLABS-2021M1039659,MYLAN,,8.0,DEC,,M,Y,,,20210826.0,,PH,COUNTRY NOT SPECIFIED,JP,2021,Q3,Child
195120982,19512098,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,2,F,,20210818.0,20210709,20210826,EXP,JP-MLMSERVICE-20210609-2941326-1,JP-MYLANLABS-2021M1039659,MYLAN,,8.0,DEC,,M,Y,,,20210826.0,,PH,COUNTRY NOT SPECIFIED,JP,2021,Q3,Child
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195131101,19513110,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210702.0,20210709,20210709,EXP,,GB-TAKEDA-2021TEU006055,TAKEDA,,65.0,YR,,M,Y,,,20210709.0,,MD,GB,GB,2021,Q3,Elderly
195133282,19513328,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1 DF, QD)",,,U,, UNK,,,10.0,MG,TABLET,QD,2021,Q3,Bradycardia,,2021,Q3,2,F,20210412.0,20210714.0,20210709,20210726,EXP,,NVSC2021DE145176,NOVARTIS,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195133282,19513328,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1 DF, QD)",,,U,, UNK,,,10.0,MG,TABLET,QD,2021,Q3,Hypotension,,2021,Q3,2,F,20210412.0,20210714.0,20210709,20210726,EXP,,NVSC2021DE145176,NOVARTIS,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195133282,19513328,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1 DF, QD)",,,U,, UNK,,,10.0,MG,TABLET,QD,2021,Q3,Wrong product administered,,2021,Q3,2,F,20210412.0,20210714.0,20210709,20210726,EXP,,NVSC2021DE145176,NOVARTIS,,95.0,YR,,M,Y,,,20210727.0,,HP,DE,DE,2021,Q3,Elderly
195140031,19514003,15,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Contraindicated product administered,,2021,Q3,1,I,20200930.0,20210628.0,20210709,20210709,EXP,DE-ADRED-06574-01,DE-TORRENT-00020641,TORRENT,,75.0,YR,E,M,Y,110.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195140031,19514003,15,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,U,,,,,10.0,MG,TABLET,,2021,Q3,Haematuria,,2021,Q3,1,I,20200930.0,20210628.0,20210709,20210709,EXP,DE-ADRED-06574-01,DE-TORRENT-00020641,TORRENT,,75.0,YR,E,M,Y,110.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195153631,19515363,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETTEN",,,U,, UNK,,,,,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210710,20210710,EXP,,NVSC2021DE145323,NOVARTIS,,70.0,YR,,M,Y,89.0,KG,20210710.0,,HP,DE,DE,2021,Q3,Elderly
195153631,19515363,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETTEN",,,U,, UNK,,,,,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210710,20210710,EXP,,NVSC2021DE145323,NOVARTIS,,70.0,YR,,M,Y,89.0,KG,20210710.0,,HP,DE,DE,2021,Q3,Elderly
195155251,19515525,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1?0?0?0,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210626.0,20210709,20210709,EXP,DE-ADRED-05826-01,DE-BAUSCH-BL-2021-022615,BAUSCH AND LOMB,,70.0,YR,,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195155251,19515525,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1?0?0?0,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Erythema,,2021,Q3,1,I,,20210626.0,20210709,20210709,EXP,DE-ADRED-05826-01,DE-BAUSCH-BL-2021-022615,BAUSCH AND LOMB,,70.0,YR,,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195155251,19515525,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1?0?0?0,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210626.0,20210709,20210709,EXP,DE-ADRED-05826-01,DE-BAUSCH-BL-2021-022615,BAUSCH AND LOMB,,70.0,YR,,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195155251,19515525,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1?0?0?0,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210626.0,20210709,20210709,EXP,DE-ADRED-05826-01,DE-BAUSCH-BL-2021-022615,BAUSCH AND LOMB,,70.0,YR,,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195155251,19515525,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1?0?0?0,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210626.0,20210709,20210709,EXP,DE-ADRED-05826-01,DE-BAUSCH-BL-2021-022615,BAUSCH AND LOMB,,70.0,YR,,M,Y,95.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195158381,19515838,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210702.0,20210710,20210710,EXP,,NVSC2021GB153010,NOVARTIS,,65.0,YR,,M,Y,,,20210710.0,,HP,GB,GB,2021,Q3,Elderly
195177462,19517746,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Abdominal abscess,,2021,Q3,2,F,,20210709.0,20210712,20210722,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-11380,LUPIN,,8.0,DEC,,M,Y,,,20210722.0,,HP,JP,JP,2021,Q3,Child
195177462,19517746,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Amoebiasis,,2021,Q3,2,F,,20210709.0,20210712,20210722,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-11380,LUPIN,,8.0,DEC,,M,Y,,,20210722.0,,HP,JP,JP,2021,Q3,Child
195177462,19517746,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Enterocolitis,,2021,Q3,2,F,,20210709.0,20210712,20210722,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-11380,LUPIN,,8.0,DEC,,M,Y,,,20210722.0,,HP,JP,JP,2021,Q3,Child
195177462,19517746,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,2,F,,20210709.0,20210712,20210722,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-11380,LUPIN,,8.0,DEC,,M,Y,,,20210722.0,,HP,JP,JP,2021,Q3,Child
195177462,19517746,12,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Rebound effect,,2021,Q3,2,F,,20210709.0,20210712,20210722,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-11380,LUPIN,,8.0,DEC,,M,Y,,,20210722.0,,HP,JP,JP,2021,Q3,Child
195189231,19518923,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETTEN",,,U,,,,,,,TABLET,,2021,Q3,Contraindicated product administered,,2021,Q3,1,I,20200930.0,20210628.0,20210712,20210712,EXP,,DE-AUROBINDO-AUR-APL-2021-028056,AUROBINDO,,75.0,YR,,M,Y,110.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195189231,19518923,7,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETTEN",,,U,,,,,,,TABLET,,2021,Q3,Haematuria,,2021,Q3,1,I,20200930.0,20210628.0,20210712,20210712,EXP,,DE-AUROBINDO-AUR-APL-2021-028056,AUROBINDO,,75.0,YR,,M,Y,110.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Diabetic neuropathy,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Lethargy,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Muscle spasms,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195191131,19519113,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,IN EARLY AUGUST,,,U,, UNK,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210702.0,20210712,20210712,EXP,GB-MHRA-ADR 25580909,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002223,EMCURE,,65.0,YR,,M,Y,,,20210712.0,,MD,GB,GB,2021,Q3,Elderly
195192341,19519234,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210627.0,,20210712,20210712,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210708.0,N,PH,US,US,2021,Q3,Elderly
195192451,19519245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Epididymitis,,2021,Q3,1,I,20201128.0,,20210712,20210712,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
195192451,19519245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Scrotal abscess,,2021,Q3,1,I,20201128.0,,20210712,20210712,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
195192451,19519245,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Scrotal cellulitis,,2021,Q3,1,I,20201128.0,,20210712,20210712,DIR,,,FDA-CTU,,52.0,YR,,M,N,119.0,KG,20210519.0,N,PH,US,US,2021,Q3,Adult
195193091,19519309,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210216.0,,20210712,20210712,DIR,,,FDA-CTU,,79.0,YR,,M,N,75.0,KG,20210418.0,N,PH,US,US,2021,Q3,Elderly
195193091,19519309,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,20210216.0,,20210712,20210712,DIR,,,FDA-CTU,,79.0,YR,,M,N,75.0,KG,20210418.0,N,PH,US,US,2021,Q3,Elderly
195195711,19519571,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210711.0,,20210712,20210712,DIR,,,FDA-CTU,,51.0,YR,,M,N,85.1,KG,20210712.0,N,PH,US,US,2021,Q3,Adult
195195711,19519571,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q3,Tibia fracture,,2021,Q3,1,I,20210711.0,,20210712,20210712,DIR,,,FDA-CTU,,51.0,YR,,M,N,85.1,KG,20210712.0,N,PH,US,US,2021,Q3,Adult
195203731,19520373,18,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS ()",,,U,,,,,,,TABLET,,2021,Q3,Contraindicated product administered,,2021,Q3,1,I,20200930.0,20210628.0,20210712,20210712,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-304103,RANBAXY,,75.0,YR,,M,Y,110.0,KG,20210712.0,,HP,NL,DE,2021,Q3,Elderly
195203731,19520373,18,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS ()",,,U,,,,,,,TABLET,,2021,Q3,Haematuria,,2021,Q3,1,I,20200930.0,20210628.0,20210712,20210712,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-304103,RANBAXY,,75.0,YR,,M,Y,110.0,KG,20210712.0,,HP,NL,DE,2021,Q3,Elderly
195217131,19521713,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210712,20210712,EXP,,DE-PFIZER INC-2021795618,PFIZER,,70.0,YR,,M,Y,89.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195217131,19521713,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,,10.0,MG,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210712,20210712,EXP,,DE-PFIZER INC-2021795618,PFIZER,,70.0,YR,,M,Y,89.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Candida infection,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Candida sepsis,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Coagulation test abnormal,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Coagulopathy,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Emphysematous pyelonephritis,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Hypotension,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Off label use,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Oliguria,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Perinephric abscess,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Renal impairment,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Septic shock,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Systemic candida,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Therapy non-responder,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Urinary tract candidiasis,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Urinary tract infection,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Urinary tract infection enterococcal,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195327701,19532770,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, ASKED BUT UNKNOWN,,,,,,Q3W,2021,Q3,Vesicoureteric reflux,,2021,Q3,1,I,,20200729.0,20210713,20210713,EXP,,ES-ROCHE-2650818,ROCHE,,56.0,YR,,F,Y,,,20210713.0,,HP,ES,ES,2021,Q3,Adult
195348342,19534834,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Swelling face,,2021,Q3,2,F,20210615.0,20210718.0,20210713,20210720,EXP,GB-MHRA-INP4C9C9754-0CB8-4B8B-9191-CC240531071C,GB-ORION CORPORATION ORION PHARMA-21_00015151,ORION,,74.0,YR,,M,Y,91.0,KG,20210720.0,,HP,GB,GB,2021,Q3,Elderly
195348342,19534834,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,25.0,MG,TABLET,QD,2021,Q3,Swelling face,,2021,Q3,2,F,20210615.0,20210718.0,20210713,20210720,EXP,GB-MHRA-INP4C9C9754-0CB8-4B8B-9191-CC240531071C,GB-ORION CORPORATION ORION PHARMA-21_00015151,ORION,,74.0,YR,,M,Y,91.0,KG,20210720.0,,HP,GB,GB,2021,Q3,Elderly
195365301,19536530,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Fungal infection,,2021,Q3,1,I,20210614.0,,20210714,20210714,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20210712.0,N,PH,US,US,2021,Q3,Elderly
195365301,19536530,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Skin candida,,2021,Q3,1,I,20210614.0,,20210714,20210714,DIR,,,FDA-CTU,,74.0,YR,,M,N,,,20210712.0,N,PH,US,US,2021,Q3,Elderly
195382461,19538246,9,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Bradycardia,,2021,Q3,1,I,20210412.0,20210705.0,20210714,20210714,PER,,DE-DRREDDYS-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195382461,19538246,9,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Hypotension,,2021,Q3,1,I,20210412.0,20210705.0,20210714,20210714,PER,,DE-DRREDDYS-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195382461,19538246,9,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Wrong product administered,,2021,Q3,1,I,20210412.0,20210705.0,20210714,20210714,PER,,DE-DRREDDYS-SPO/GER/21/0137549,DR REDDYS,,95.0,YR,E,M,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195434581,19543458,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,1 DOSAGE FORMS DAILY; 1?0?0?0,,,U,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Arrhythmia,,2021,Q3,1,I,,20210707.0,20210714,20210714,EXP,,DE-TEVA-2021-DE-1931675,TEVA,,88.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195434581,19543458,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,1 DOSAGE FORMS DAILY; 1?0?0?0,,,U,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Blood glucose fluctuation,,2021,Q3,1,I,,20210707.0,20210714,20210714,EXP,,DE-TEVA-2021-DE-1931675,TEVA,,88.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195434581,19543458,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,1 DOSAGE FORMS DAILY; 1?0?0?0,,,U,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Fatigue,,2021,Q3,1,I,,20210707.0,20210714,20210714,EXP,,DE-TEVA-2021-DE-1931675,TEVA,,88.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195434581,19543458,3,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,1 DOSAGE FORMS DAILY; 1?0?0?0,,,U,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210707.0,20210714,20210714,EXP,,DE-TEVA-2021-DE-1931675,TEVA,,88.0,YR,E,F,Y,,,20210714.0,,MD,DE,DE,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195460701,19546070,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210702.0,20210714,20210714,EXP,,GB-AUROBINDO-AUR-APL-2021-029416,AUROBINDO,,65.0,YR,,M,Y,,,20210714.0,,MD,GB,GB,2021,Q3,Elderly
195470292,19547029,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Abdominal abscess,,2021,Q3,2,F,,20210802.0,20210714,20210803,EXP,,JP-TEVA-2021-JP-1931246,TEVA,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL. [A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT]. [JAPANESE]. NIHON?SHOKAKIBYO?GAKKAI?ZASSHI 2021?118(5):455?461.",8.0,DEC,E,M,Y,,,20210803.0,,HP,JP,JP,2021,Q3,Child
195470292,19547029,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Amoebiasis,,2021,Q3,2,F,,20210802.0,20210714,20210803,EXP,,JP-TEVA-2021-JP-1931246,TEVA,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL. [A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT]. [JAPANESE]. NIHON?SHOKAKIBYO?GAKKAI?ZASSHI 2021?118(5):455?461.",8.0,DEC,E,M,Y,,,20210803.0,,HP,JP,JP,2021,Q3,Child
195470292,19547029,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Enterocolitis,,2021,Q3,2,F,,20210802.0,20210714,20210803,EXP,,JP-TEVA-2021-JP-1931246,TEVA,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL. [A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT]. [JAPANESE]. NIHON?SHOKAKIBYO?GAKKAI?ZASSHI 2021?118(5):455?461.",8.0,DEC,E,M,Y,,,20210803.0,,HP,JP,JP,2021,Q3,Child
195470292,19547029,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,2,F,,20210802.0,20210714,20210803,EXP,,JP-TEVA-2021-JP-1931246,TEVA,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL. [A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT]. [JAPANESE]. NIHON?SHOKAKIBYO?GAKKAI?ZASSHI 2021?118(5):455?461.",8.0,DEC,E,M,Y,,,20210803.0,,HP,JP,JP,2021,Q3,Child
195470292,19547029,11,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,10.0,MG,,,2021,Q3,Rebound effect,,2021,Q3,2,F,,20210802.0,20210714,20210803,EXP,,JP-TEVA-2021-JP-1931246,TEVA,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL. [A CASE OF AMEBIC COLITIS THAT DEVELOPED AFTER CORTICOSTEROID THERAPY IN WHICH PERFORATION OCCURRED DURING METRONIDAZOLE TREATMENT]. [JAPANESE]. NIHON?SHOKAKIBYO?GAKKAI?ZASSHI 2021?118(5):455?461.",8.0,DEC,E,M,Y,,,20210803.0,,HP,JP,JP,2021,Q3,Child
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Candida infection,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Candida sepsis,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Coagulopathy,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Emphysematous pyelonephritis,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Oliguria,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Perinephric abscess,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Product use in unapproved indication,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Pyelonephritis fungal,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Septic shock,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Systemic candida,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Therapy non-responder,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Urinary tract candidiasis,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Urinary tract infection,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Urinary tract infection enterococcal,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195673521,19567352,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,, UNKNOWN,,,,,,,2021,Q3,Vesicoureteric reflux,,2021,Q3,1,I,,20200727.0,20210716,20210716,EXP,,ES-VELOXIS PHARMACEUTICALS-2020VELES-000672,VELOXIS PHARMACEUTICALS,,56.0,YR,,F,Y,,,20210716.0,,CN,ES,ES,2021,Q3,Adult
195699932,19569993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,,QD,2021,Q3,Diabetic metabolic decompensation,,2021,Q3,2,F,201605.0,20210713.0,20210715,20210721,EXP,,SK-ASTRAZENECA-2021A601970,ASTRAZENECA,,53.0,YR,,M,Y,,,20210721.0,,HP,SK,SK,2021,Q3,Adult
195699932,19569993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,,QD,2021,Q3,Drug ineffective,,2021,Q3,2,F,201605.0,20210713.0,20210715,20210721,EXP,,SK-ASTRAZENECA-2021A601970,ASTRAZENECA,,53.0,YR,,M,Y,,,20210721.0,,HP,SK,SK,2021,Q3,Adult
195699932,19569993,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,,QD,2021,Q3,Injection site nodule,,2021,Q3,2,F,201605.0,20210713.0,20210715,20210721,EXP,,SK-ASTRAZENECA-2021A601970,ASTRAZENECA,,53.0,YR,,M,Y,,,20210721.0,,HP,SK,SK,2021,Q3,Adult
195725301,19572530,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Chills,,2021,Q3,1,I,,20210708.0,20210716,20210716,EXP,,CA-ASTRAZENECA-2021A606794,ASTRAZENECA,,66.0,YR,,M,Y,,,20210716.0,,HP,CA,CA,2021,Q3,Elderly
195725301,19572530,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Sepsis,,2021,Q3,1,I,,20210708.0,20210716,20210716,EXP,,CA-ASTRAZENECA-2021A606794,ASTRAZENECA,,66.0,YR,,M,Y,,,20210716.0,,HP,CA,CA,2021,Q3,Elderly
195725301,19572530,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210708.0,20210716,20210716,EXP,,CA-ASTRAZENECA-2021A606794,ASTRAZENECA,,66.0,YR,,M,Y,,,20210716.0,,HP,CA,CA,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Affective disorder,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Cachexia,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Change of bowel habit,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Constipation,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Diverticulum,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Hyporeflexia,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Impaired quality of life,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Lethargy,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Lumbosacral radiculoplexus neuropathy,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Muscle atrophy,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Muscle spasms,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Sleep disorder,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Spondylolysis,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195735881,19573588,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,, UNKNOWN,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210705.0,20210717,20210717,EXP,GB-2021-MED-LIT-001,GB-LUPIN PHARMACEUTICALS INC.-2021-11879,LUPIN,,65.0,YR,,M,Y,,,20210717.0,,CN,GB,GB,2021,Q3,Elderly
195820092,19582009,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Amoebic dysentery,,2021,Q3,2,F,,20210719.0,20210719,20210730,EXP,,JP-ENDO PHARMACEUTICALS INC-2021-010193,ENDO,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL.. ONE CASE OF AMEBIC ENTERITIS DEVELOPED UNDER THE USE OF STEROIDS WHICH INDUCED GASTROINTESTINAL PERFORATION IN SPITE OF TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118(5):455?461",8.0,DEC,,M,Y,,,20210730.0,,HP,JP,JP,2021,Q3,Child
195820092,19582009,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Gastrointestinal perforation,,2021,Q3,2,F,,20210719.0,20210719,20210730,EXP,,JP-ENDO PHARMACEUTICALS INC-2021-010193,ENDO,"KATO A, IWATA F, HIGASHINO M, MIYAGAKI A, YAMAGUCHI E, OKAMOTO R, ET AL.. ONE CASE OF AMEBIC ENTERITIS DEVELOPED UNDER THE USE OF STEROIDS WHICH INDUCED GASTROINTESTINAL PERFORATION IN SPITE OF TREATMENT. JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY. 2021?118(5):455?461",8.0,DEC,,M,Y,,,20210730.0,,HP,JP,JP,2021,Q3,Child
195823171,19582317,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,D,,,,10.0,MG,,,2021,Q3,Urinary retention,,2021,Q3,1,I,20201217.0,,20210719,20210719,DIR,,,FDA-CTU,,58.0,YR,,M,N,103.42,KG,20210125.0,N,PH,US,US,2021,Q3,Adult
195834001,19583400,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,10.0,MG,,,2021,Q3,Dry mouth,,2021,Q3,1,I,20210630.0,,20210720,20210720,DIR,,,FDA-CTU,,65.0,YR,,M,N,,,20210715.0,N,PH,US,US,2021,Q3,Elderly
195834001,19583400,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,10.0,MG,,,2021,Q3,Fungal infection,,2021,Q3,1,I,20210630.0,,20210720,20210720,DIR,,,FDA-CTU,,65.0,YR,,M,N,,,20210715.0,N,PH,US,US,2021,Q3,Elderly
195834001,19583400,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,10.0,MG,,,2021,Q3,Pollakiuria,,2021,Q3,1,I,20210630.0,,20210720,20210720,DIR,,,FDA-CTU,,65.0,YR,,M,N,,,20210715.0,N,PH,US,US,2021,Q3,Elderly
195834001,19583400,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;?,,,Y,,,,,10.0,MG,,,2021,Q3,Polydipsia,,2021,Q3,1,I,20210630.0,,20210720,20210720,DIR,,,FDA-CTU,,65.0,YR,,M,N,,,20210715.0,N,PH,US,US,2021,Q3,Elderly
195867481,19586748,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210707.0,20210721,20210721,EXP,,IT-LUPIN PHARMACEUTICALS INC.-2021-12267,LUPIN,,68.0,YR,,M,Y,,,20210721.0,,HP,IT,IT,2021,Q3,Elderly
195867481,19586748,17,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,,,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210707.0,20210721,20210721,EXP,,IT-LUPIN PHARMACEUTICALS INC.-2021-12267,LUPIN,,68.0,YR,,M,Y,,,20210721.0,,HP,IT,IT,2021,Q3,Elderly
195872051,19587205,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 TO 25 MG;?,,,,,,,,,,,QD,2021,Q3,Dry mouth,,2021,Q3,1,I,20190310.0,,20210720,20210720,DIR,,,FDA-CTU,,63.0,YR,,M,N,96.0,KG,20190827.0,N,PH,US,US,2021,Q3,Adult
195872051,19587205,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:12.5 TO 25 MG;?,,,,,,,,,,,QD,2021,Q3,Thirst,,2021,Q3,1,I,20190310.0,,20210720,20210720,DIR,,,FDA-CTU,,63.0,YR,,M,N,96.0,KG,20190827.0,N,PH,US,US,2021,Q3,Adult
195876181,19587618,13,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Medication error,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116215",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,70.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Adult
195876181,19587618,13,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Product used for unknown indication,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116215",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,70.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Adult
195876181,19587618,13,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Proteinuria,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116215",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,70.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Adult
195876181,19587618,13,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116215",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,70.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Adult
195912931,19591293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",92.0,DF,U,,,,,1.0,DF,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210708.0,20210713.0,20210721,20210721,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-SA-2021SA230625,SANOFI AVENTIS,,60.0,YR,A,F,Y,75.0,KG,20210721.0,,HP,GB,GB,2021,Q3,Adult
195912931,19591293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",92.0,DF,U,,,,,1.0,DF,,QD,2021,Q3,Drug hypersensitivity,,2021,Q3,1,I,20210708.0,20210713.0,20210721,20210721,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-SA-2021SA230625,SANOFI AVENTIS,,60.0,YR,A,F,Y,75.0,KG,20210721.0,,HP,GB,GB,2021,Q3,Adult
195912931,19591293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",92.0,DF,U,,,,,1.0,DF,,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210708.0,20210713.0,20210721,20210721,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-SA-2021SA230625,SANOFI AVENTIS,,60.0,YR,A,F,Y,75.0,KG,20210721.0,,HP,GB,GB,2021,Q3,Adult
195912931,19591293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",92.0,DF,U,,,,,1.0,DF,,QD,2021,Q3,Headache,,2021,Q3,1,I,20210708.0,20210713.0,20210721,20210721,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-SA-2021SA230625,SANOFI AVENTIS,,60.0,YR,A,F,Y,75.0,KG,20210721.0,,HP,GB,GB,2021,Q3,Adult
195912931,19591293,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, QD",92.0,DF,U,,,,,1.0,DF,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210708.0,20210713.0,20210721,20210721,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-SA-2021SA230625,SANOFI AVENTIS,,60.0,YR,A,F,Y,75.0,KG,20210721.0,,HP,GB,GB,2021,Q3,Adult
195928071,19592807,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-TEVA-2021-GB-1933738,TEVA,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195928071,19592807,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Drug hypersensitivity,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-TEVA-2021-GB-1933738,TEVA,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195928071,19592807,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-TEVA-2021-GB-1933738,TEVA,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195928071,19592807,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Headache,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-TEVA-2021-GB-1933738,TEVA,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195928071,19592807,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-TEVA-2021-GB-1933738,TEVA,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195937861,19593786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,92.0,DF,,, UNKNOWN,,,1.0,DF,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-DRREDDYS-SPO/UKI/21/0137911,DR REDDYS,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195937861,19593786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,92.0,DF,,, UNKNOWN,,,1.0,DF,,QD,2021,Q3,Drug hypersensitivity,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-DRREDDYS-SPO/UKI/21/0137911,DR REDDYS,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195937861,19593786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,92.0,DF,,, UNKNOWN,,,1.0,DF,,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-DRREDDYS-SPO/UKI/21/0137911,DR REDDYS,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195937861,19593786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,92.0,DF,,, UNKNOWN,,,1.0,DF,,QD,2021,Q3,Headache,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-DRREDDYS-SPO/UKI/21/0137911,DR REDDYS,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195937861,19593786,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,92.0,DF,,, UNKNOWN,,,1.0,DF,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210708.0,20210713.0,20210722,20210722,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-DRREDDYS-SPO/UKI/21/0137911,DR REDDYS,,60.0,YR,A,F,Y,75.0,KG,20210722.0,,HP,GB,GB,2021,Q3,Adult
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Fatigue,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Therapeutic product effect incomplete,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195941451,19594145,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210324.0,20210722,20210722,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-290082,RANBAXY,"HERBST A, ORSO F, MIGLIORINI M, VIRCIGLIO S, TOGNELLI S, CAMARTINI V, ET AL. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. J GERIATR CARDIOL. 2020?17(11):728?732",68.0,YR,,M,Y,,,20210722.0,,HP,IT,IT,2021,Q3,Elderly
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Diabetic neuropathy,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Glycosylated haemoglobin increased,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Hypoaesthesia,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Muscle spasms,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Pain in extremity,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Peripheral artery occlusion,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Peripheral ischaemia,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Skin ulcer,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Staphylococcal bacteraemia,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Staphylococcal infection,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982031,19598203,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,,,,,25.0,MG,,QD,2021,Q3,Toe amputation,,2021,Q3,1,I,20210706.0,,20210722,20210722,DIR,,,FDA-CTU,,63.0,YR,,M,N,97.0,KG,20210720.0,N,PH,US,US,2021,Q3,Adult
195982611,19598261,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Cystitis,,2021,Q3,1,I,20210524.0,,20210722,20210722,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20210720.0,N,PH,US,US,2021,Q3,Elderly
195982611,19598261,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210524.0,,20210722,20210722,DIR,,,FDA-CTU,,68.0,YR,,M,N,,,20210720.0,N,PH,US,US,2021,Q3,Elderly
195991871,19599187,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Rash,,2021,Q3,1,I,20210513.0,,20210722,20210722,DIR,,,FDA-CTU,,76.0,YR,,M,N,,,20210621.0,N,PH,US,US,2021,Q3,Elderly
195991921,19599192,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Myalgia,,2021,Q3,1,I,20210504.0,,20210722,20210722,DIR,,,FDA-CTU,,56.0,YR,,M,N,,,20210621.0,N,PH,US,US,2021,Q3,Adult
195991921,19599192,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Pollakiuria,,2021,Q3,1,I,20210504.0,,20210722,20210722,DIR,,,FDA-CTU,,56.0,YR,,M,N,,,20210621.0,N,PH,US,US,2021,Q3,Adult
196008911,19600891,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Contraindicated product administered,,2021,Q3,1,I,20200930.0,20210713.0,20210723,20210723,EXP,DE-BFARM-21006331,DE-ACCORD-232665,ACCORD,,75.0,YR,E,M,Y,110.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196008911,19600891,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Haematuria,,2021,Q3,1,I,20200930.0,20210713.0,20210723,20210723,EXP,DE-BFARM-21006331,DE-ACCORD-232665,ACCORD,,75.0,YR,E,M,Y,110.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Diabetic nephropathy,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Dyspnoea,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Hyperkalaemia,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Labelled drug-drug interaction medication error,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Medication error,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Metabolic acidosis,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Product monitoring error,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Product prescribing error,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Renal failure,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Renal impairment,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196009482,19600948,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,,,,,,,TABLET,,2021,Q3,Therapeutic drug monitoring analysis not performed,,2021,Q3,2,F,,20210906.0,20210723,20210917,EXP,DE-BFARM-21006323,DE-ACCORD-232639,ACCORD,,82.0,YR,E,M,Y,72.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
196016032,19601603,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2021,Q3,Blood glucose abnormal,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2021,Q3,COVID-19,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,U,,,,,,,,2021,Q3,Pneumonia,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,U,,,,10.0,MG,,,2021,Q3,Blood glucose abnormal,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,U,,,,10.0,MG,,,2021,Q3,COVID-19,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,U,,,,10.0,MG,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196016032,19601603,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG,,,,U,,,,10.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,2,F,,20210826.0,20210723,20210831,EXP,,HR-009507513-2107HRV006798,MERCK,,65.0,YR,,,Y,,,20210831.0,,MD,HR,HR,2021,Q3,Elderly
196018221,19601822,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210713.0,20210723,20210723,EXP,DE-BFARM-21006294,DE-ACCORD-232689,ACCORD,,70.0,YR,E,M,Y,89.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196018221,19601822,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210713.0,20210723,20210723,EXP,DE-BFARM-21006294,DE-ACCORD-232689,ACCORD,,70.0,YR,E,M,Y,89.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196036341,19603634,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Bradycardia,,2021,Q3,1,I,20210412.0,20210713.0,20210724,20210724,EXP,DE-BFARM-21006368,DE-ACCORD-232706,ACCORD,,95.0,YR,E,M,Y,,,20210724.0,,MD,DE,DE,2021,Q3,Elderly
196036341,19603634,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Hypotension,,2021,Q3,1,I,20210412.0,20210713.0,20210724,20210724,EXP,DE-BFARM-21006368,DE-ACCORD-232706,ACCORD,,95.0,YR,E,M,Y,,,20210724.0,,MD,DE,DE,2021,Q3,Elderly
196036341,19603634,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Medication error,,2021,Q3,1,I,20210412.0,20210713.0,20210724,20210724,EXP,DE-BFARM-21006368,DE-ACCORD-232706,ACCORD,,95.0,YR,E,M,Y,,,20210724.0,,MD,DE,DE,2021,Q3,Elderly
196036341,19603634,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Wrong product administered,,2021,Q3,1,I,20210412.0,20210713.0,20210724,20210724,EXP,DE-BFARM-21006368,DE-ACCORD-232706,ACCORD,,95.0,YR,E,M,Y,,,20210724.0,,MD,DE,DE,2021,Q3,Elderly
196083015,19608301,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5,MG,",,,,,,,,,,,,2021,Q3,Cholecystitis,,2021,Q3,5,F,20210708.0,20210823.0,20210726,20210830,EXP,,IL-NOVOPROD-828509,NOVO NORDISK,,47.0,YR,,M,Y,86.0,KG,20210830.0,,MD,IL,IL,2021,Q3,Adult
196083015,19608301,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5,MG,",,,,,,,,,,,,2021,Q3,Cholelithiasis,,2021,Q3,5,F,20210708.0,20210823.0,20210726,20210830,EXP,,IL-NOVOPROD-828509,NOVO NORDISK,,47.0,YR,,M,Y,86.0,KG,20210830.0,,MD,IL,IL,2021,Q3,Adult
196100921,19610092,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, QD, 0.1 MG/KG/DAY; DAY 0 (AHOSPITAL DAY 16)",,,,,,,,5.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196100921,19610092,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, QD, 0.1 MG/KG/DAY; DAY 0 (AHOSPITAL DAY 16)",,,,,,,,5.0,MG,,QD,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196100921,19610092,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, BID, 0.2 MG/KG/DAY; DAY 3",,,,,,,,5.0,MG,,BID,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196100921,19610092,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"5 MILLIGRAM, BID, 0.2 MG/KG/DAY; DAY 3",,,,,,,,5.0,MG,,BID,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196100921,19610092,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD, 0.4 MG/KG/DAY; DAY 7",,,,,,,,10.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196100921,19610092,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM, QD, 0.4 MG/KG/DAY; DAY 7",,,,,,,,10.0,MG,,QD,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210720.0,20210726,20210726,EXP,,IT-MYLANLABS-2021M1046179,MYLAN,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?NULL:NULL.",9.0,YR,,M,Y,,,20210726.0,,HP,IT,IT,2021,Q3,Child
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Blood glucose increased,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Dizziness,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Nausea,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Palpitations,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Rash,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196103591,19610359,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QAM",,,,,,,,25.0,MG,TABLET,,2021,Q3,Syncope,,2021,Q3,1,I,20190807.0,20210714.0,20210726,20210726,EXP,,US-AMERICAN REGENT INC-2021001964,AMERICAN REGENT,,46.0,YR,,F,Y,,,20210726.0,,MD,US,US,2021,Q3,Adult
196116691,19611669,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q3,Hepatic cirrhosis,,2021,Q3,1,I,20210123.0,20210721.0,20210726,20210726,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20210726.0,,MD,CN,CN,2021,Q3,Elderly
196116691,19611669,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,QD,2021,Q3,Liver injury,,2021,Q3,1,I,20210123.0,20210721.0,20210726,20210726,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116779",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20210726.0,,MD,CN,CN,2021,Q3,Elderly
196118612,19611861,7,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Delirium,,2021,Q3,2,F,,20210803.0,20210727,20210816,EXP,,US-AUROBINDO-AUR-APL-2021-031617,AUROBINDO,,89.0,YR,,M,Y,,,20210816.0,,HP,US,US,2021,Q3,Elderly
196160551,19616055,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,,,,,,,,,2021,Q3,Cardiomyopathy,,2021,Q3,1,I,20210620.0,20210722.0,20210727,20210727,EXP,,DE-ABBVIE-21K-062-4012331-00,ABBVIE,,85.0,YR,,F,Y,76.0,KG,20210727.0,,MD,DE,DE,2021,Q3,Elderly
196193072,19619307,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Pneumonia,,2021,Q3,2,F,,20210810.0,20210728,20210812,EXP,,NVSJ2021JP011286,NOVARTIS,,92.0,YR,,F,Y,,,20210812.0,,MD,JP,JP,2021,Q3,Elderly
196214031,19621403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q3,Blood glucose abnormal,,2021,Q3,1,I,,20210727.0,20210728,20210728,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-117818",BOEHRINGER INGELHEIM,,65.0,YR,E,,Y,,,20210728.0,,MD,HR,HR,2021,Q3,Elderly
196214031,19621403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q3,COVID-19,,2021,Q3,1,I,,20210727.0,20210728,20210728,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-117818",BOEHRINGER INGELHEIM,,65.0,YR,E,,Y,,,20210728.0,,MD,HR,HR,2021,Q3,Elderly
196214031,19621403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,1,I,,20210727.0,20210728,20210728,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-117818",BOEHRINGER INGELHEIM,,65.0,YR,E,,Y,,,20210728.0,,MD,HR,HR,2021,Q3,Elderly
196214031,19621403,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,, UNKNOWN,,204629.0,10.0,MG,,QD,2021,Q3,Pneumonia,,2021,Q3,1,I,,20210727.0,20210728,20210728,EXP,,"HR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-117818",BOEHRINGER INGELHEIM,,65.0,YR,E,,Y,,,20210728.0,,MD,HR,HR,2021,Q3,Elderly
196246291,19624629,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Swelling face,,2021,Q3,1,I,20210615.0,20210720.0,20210728,20210728,EXP,GB-MHRA-INP4C9C9754-0CB8-4B8B-9191-CC240531071C,GB-MYLANLABS-2021M1045095,MYLAN,,74.0,YR,,M,Y,91.0,KG,20210728.0,,CN,GB,GB,2021,Q3,Elderly
196246291,19624629,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Swelling face,,2021,Q3,1,I,20210615.0,20210720.0,20210728,20210728,EXP,GB-MHRA-INP4C9C9754-0CB8-4B8B-9191-CC240531071C,GB-MYLANLABS-2021M1045095,MYLAN,,74.0,YR,,M,Y,91.0,KG,20210728.0,,CN,GB,GB,2021,Q3,Elderly
196271081,19627108,9,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,,,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210329.0,20210729,20210729,EXP,,IT-TEVA-2021-IT-1898284,TEVA,ORSO F. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2021 JAN?17:728?732.,68.0,YR,E,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
196271081,19627108,9,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,,,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210329.0,20210729,20210729,EXP,,IT-TEVA-2021-IT-1898284,TEVA,ORSO F. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2021 JAN?17:728?732.,68.0,YR,E,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
196271081,19627108,9,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,,,,,2021,Q3,Hypovolaemia,,2021,Q3,1,I,,20210329.0,20210729,20210729,EXP,,IT-TEVA-2021-IT-1898284,TEVA,ORSO F. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2021 JAN?17:728?732.,68.0,YR,E,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
196271081,19627108,9,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,,,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210329.0,20210729,20210729,EXP,,IT-TEVA-2021-IT-1898284,TEVA,ORSO F. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2021 JAN?17:728?732.,68.0,YR,E,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
196271081,19627108,9,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210329.0,20210729,20210729,EXP,,IT-TEVA-2021-IT-1898284,TEVA,ORSO F. ARNI AND SGLT2I: A PROMISING ASSOCIATION TO BE USED WITH CAUTION. JOURNAL OF GERIATRIC CARDIOLOGY. 2021 JAN?17:728?732.,68.0,YR,E,M,Y,,,20210729.0,,HP,IT,IT,2021,Q3,Elderly
196301191,19630119,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210708.0,20210720.0,20210729,20210729,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-MYLANLABS-2021M1045350,MYLAN,,60.0,YR,,F,Y,75.0,KG,20210729.0,,HP,GB,GB,2021,Q3,Adult
196301191,19630119,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Drug hypersensitivity,,2021,Q3,1,I,20210708.0,20210720.0,20210729,20210729,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-MYLANLABS-2021M1045350,MYLAN,,60.0,YR,,F,Y,75.0,KG,20210729.0,,HP,GB,GB,2021,Q3,Adult
196301191,19630119,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210708.0,20210720.0,20210729,20210729,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-MYLANLABS-2021M1045350,MYLAN,,60.0,YR,,F,Y,75.0,KG,20210729.0,,HP,GB,GB,2021,Q3,Adult
196301191,19630119,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Headache,,2021,Q3,1,I,20210708.0,20210720.0,20210729,20210729,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-MYLANLABS-2021M1045350,MYLAN,,60.0,YR,,F,Y,75.0,KG,20210729.0,,HP,GB,GB,2021,Q3,Adult
196301191,19630119,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DOSAGE FORM, QD",92.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210708.0,20210720.0,20210729,20210729,EXP,GB-MHRA-TPP32950498C7088271YC1625747641645,GB-MYLANLABS-2021M1045350,MYLAN,,60.0,YR,,F,Y,75.0,KG,20210729.0,,HP,GB,GB,2021,Q3,Adult
196341041,19634104,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG MID,,,,,,,,,,,,2021,Q3,Cardiac failure,,2021,Q3,1,I,,20210719.0,20210730,20210730,EXP,,BR-NOVOPROD-831863,NOVO NORDISK,,65.0,YR,,F,Y,82.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Elderly
196341041,19634104,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG MID,,,,,,,,,,,,2021,Q3,Diabetes mellitus inadequate control,,2021,Q3,1,I,,20210719.0,20210730,20210730,EXP,,BR-NOVOPROD-831863,NOVO NORDISK,,65.0,YR,,F,Y,82.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Elderly
196341041,19634104,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG MID,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,,20210719.0,20210730,20210730,EXP,,BR-NOVOPROD-831863,NOVO NORDISK,,65.0,YR,,F,Y,82.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Elderly
196341041,19634104,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG MID,,,,,,,,,,,,2021,Q3,Neuropathy peripheral,,2021,Q3,1,I,,20210719.0,20210730,20210730,EXP,,BR-NOVOPROD-831863,NOVO NORDISK,,65.0,YR,,F,Y,82.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Elderly
196341041,19634104,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG MID,,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210719.0,20210730,20210730,EXP,,BR-NOVOPROD-831863,NOVO NORDISK,,65.0,YR,,F,Y,82.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Elderly
196361141,19636114,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210311.0,20210730,20210730,EXP,,US-SCIEGENPHARMA-2021SCILIT00271,SCIEGEN,,77.0,YR,E,M,Y,,,20210730.0,,HP,US,US,2021,Q3,Elderly
196361141,19636114,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210311.0,20210730,20210730,EXP,,US-SCIEGENPHARMA-2021SCILIT00271,SCIEGEN,,77.0,YR,E,M,Y,,,20210730.0,,HP,US,US,2021,Q3,Elderly
196402151,19640215,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20201123.0,20210730,20210730,EXP,,BR-NOVOPROD-814031,NOVO NORDISK,,57.0,YR,,F,Y,78.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Adult
196402151,19640215,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Severe acute respiratory syndrome,,2021,Q3,1,I,,20201123.0,20210730,20210730,EXP,,BR-NOVOPROD-814031,NOVO NORDISK,,57.0,YR,,F,Y,78.0,KG,20210730.0,,MD,BR,BR,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Candida infection,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Candida sepsis,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Coagulopathy,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Emphysematous pyelonephritis,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Oliguria,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Perinephric abscess,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Pyelonephritis fungal,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Septic shock,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Systemic candida,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Therapy non-responder,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Urinary tract candidiasis,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Urinary tract infection,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Urinary tract infection enterococcal,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196467621,19646762,14,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,U, UNKNOWN,,,,,,,2021,Q3,Vesicoureteric reflux,,2021,Q3,1,I,,20210719.0,20210802,20210802,EXP,,ES-PFIZER INC-202100913656,PFIZER,,56.0,YR,,F,Y,,,20210802.0,,CN,ES,ES,2021,Q3,Adult
196504041,19650404,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210529.0,,20210802,20210802,DIR,,,FDA-CTU,,61.0,YR,,F,N,100.7,KG,20210728.0,N,PH,US,US,2021,Q3,Adult
196504041,19650404,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Hallucination,,2021,Q3,1,I,20210529.0,,20210802,20210802,DIR,,,FDA-CTU,,61.0,YR,,F,N,100.7,KG,20210728.0,N,PH,US,US,2021,Q3,Adult
196504951,19650495,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,IN AM,,,,,,,,12.5,MG,,QD,2021,Q3,Genital swelling,,2021,Q3,1,I,20210623.0,,20210802,20210802,DIR,,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20210726.0,N,PH,US,US,2021,Q3,Elderly
196504951,19650495,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,IN AM,,,,,,,,12.5,MG,,QD,2021,Q3,Glycosylated haemoglobin increased,,2021,Q3,1,I,20210623.0,,20210802,20210802,DIR,,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20210726.0,N,PH,US,US,2021,Q3,Elderly
196504951,19650495,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,IN AM,,,,,,,,12.5,MG,,QD,2021,Q3,Rash,,2021,Q3,1,I,20210623.0,,20210802,20210802,DIR,,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20210726.0,N,PH,US,US,2021,Q3,Elderly
196504951,19650495,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,IN AM,,,,,,,,12.5,MG,,QD,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210623.0,,20210802,20210802,DIR,,,FDA-CTU,,75.0,YR,,M,N,83.0,KG,20210726.0,N,PH,US,US,2021,Q3,Elderly
196508474,19650847,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q3,Gastric mucosal lesion,,2021,Q3,4,F,20210705.0,20210813.0,20210803,20210819,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107006194,ELI LILLY AND CO,,67.0,YR,,F,Y,56.0,KG,20210819.0,,MD,CN,CN,2021,Q3,Elderly
196512791,19651279,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,5 MILLIGRAM DAILY; 0.1 MG/KG/DAY; DAY 0 (HOSPITAL DAY 16),,,D,,,,,5.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,5 MILLIGRAM DAILY; 0.1 MG/KG/DAY; DAY 0 (HOSPITAL DAY 16),,,D,,,,,5.0,MG,,QD,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,4,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,5 MILLIGRAM DAILY; 0.1 MG/KG/DAY; DAY 0 (HOSPITAL DAY 16),,,D,,,,,5.0,MG,,QD,2021,Q3,Off label use,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.2 MG/KG/DAY; DAY 3,,,D,,,,,5.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.2 MG/KG/DAY; DAY 3,,,D,,,,,5.0,MG,,QD,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.2 MG/KG/DAY; DAY 3,,,D,,,,,5.0,MG,,QD,2021,Q3,Off label use,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.4 MG/KG/DAY; DAY 7,,,D,,,,,10.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.4 MG/KG/DAY; DAY 7,,,D,,,,,10.0,MG,,QD,2021,Q3,Drug specific antibody present,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196512791,19651279,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,0.4 MG/KG/DAY; DAY 7,,,D,,,,,10.0,MG,,QD,2021,Q3,Off label use,,2021,Q3,1,I,,20210726.0,20210803,20210803,EXP,,IT-TEVA-2021-IT-1938119,TEVA,"ROSSI A, MIELE E, FECAROTTA S, VEIGA?DA?CUNHA M, MARTINELLI M, MOLLICA C, ET AL. CROHN DISEASE?LIKE ENTEROCOLITIS REMISSION AFTER EMPAGLIFLOZIN TREATMENT IN A CHILD WITH GLYCOGEN STORAGE DISEASE TYPE IB: A CASE REPORT. ITAL?J?PEDIATR 2021?:.",9.0,YR,C,M,Y,,,20210803.0,,HP,IT,IT,2021,Q3,Child
196515932,19651593,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q3,Blood glucose abnormal,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q3,COVID-19,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,,,,,,10.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Blood glucose abnormal,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,COVID-19,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196515932,19651593,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Pneumonia,,2021,Q3,2,F,,20210903.0,20210803,20210906,EXP,,NVSC2021HR170588,NOVARTIS,,65.0,YR,,,Y,,,20210906.0,,HP,HR,HR,2021,Q3,Elderly
196521052,19652105,5,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,102145.0,10.0,MG,FILM-COATED TABLET,,2021,Q3,Hepatitis acute,,2021,Q3,2,F,20210727.0,20210803.0,20210803,20210804,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-118094",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,65.0,KG,20210804.0,,MD,JP,JP,2021,Q3,Elderly
196544581,19654458,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,10.0,MG,UNK,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210721.0,20210804,20210804,EXP,,IT-GRANULES-IT-2021GRALIT00429,GRANULES INDIA,,68.0,YR,A,M,Y,,,20210804.0,,HP,IT,IT,2021,Q3,Elderly
196544581,19654458,21,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,10.0,MG,UNK,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210721.0,20210804,20210804,EXP,,IT-GRANULES-IT-2021GRALIT00429,GRANULES INDIA,,68.0,YR,A,M,Y,,,20210804.0,,HP,IT,IT,2021,Q3,Elderly
196544581,19654458,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKOWN,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210721.0,20210804,20210804,EXP,,IT-GRANULES-IT-2021GRALIT00429,GRANULES INDIA,,68.0,YR,A,M,Y,,,20210804.0,,HP,IT,IT,2021,Q3,Elderly
196544581,19654458,22,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,, UNKOWN,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210721.0,20210804,20210804,EXP,,IT-GRANULES-IT-2021GRALIT00429,GRANULES INDIA,,68.0,YR,A,M,Y,,,20210804.0,,HP,IT,IT,2021,Q3,Elderly
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Drug withdrawal syndrome,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Gastrointestinal sounds abnormal,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Product adhesion issue,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Product solubility abnormal,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196568861,19656886,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNKNOWN, UNKNOWN",,,,,,,,,,,,2021,Q3,Therapeutic response decreased,,2021,Q3,1,I,202105.0,20210604.0,20210804,20210804,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2021BDSI0229,BIODELIVERY SCIENCES INTERNATIONAL,,60.0,YR,A,F,Y,95.34,KG,20210804.0,,MD,US,US,2021,Q3,Adult
196588821,19658882,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196588821,19658882,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196588821,19658882,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196588821,19658882,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196588821,19658882,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196588821,19658882,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210722.0,20210805,20210805,EXP,,IT-SCIEGENPHARMA-2021SCILIT00632,SCIEGEN,,68.0,YR,A,M,Y,,,20210805.0,,HP,IT,IT,2021,Q3,Elderly
196593701,19659370,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,,20210727.0,20210805,20210805,EXP,GB-MHRA-EYC 00257067,GB-NOVOPROD-833327,NOVO NORDISK,,46.0,YR,,F,Y,,,20210805.0,,PH,GB,GB,2021,Q3,Adult
196593701,19659370,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210727.0,20210805,20210805,EXP,GB-MHRA-EYC 00257067,GB-NOVOPROD-833327,NOVO NORDISK,,46.0,YR,,F,Y,,,20210805.0,,PH,GB,GB,2021,Q3,Adult
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Fall,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Language disorder,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Restlessness,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196700831,19670083,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0",,,U,,,,,,,TABLET,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210730.0,20210806,20210806,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-075227,BRISTOL MYERS SQUIBB,,79.0,YR,,M,Y,76.0,KG,20210806.0,,PH,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Fall,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Language disorder,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Restlessness,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196718701,19671870,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD (1?0?0?0)",,,U,,,,,10.0,MG,TABLET,QD,2021,Q3,Vomiting,,2021,Q3,1,I,,20210802.0,20210806,20210806,EXP,,NVSC2021DE175288,NOVARTIS,,79.0,YR,,M,Y,76.0,KG,20210807.0,,HP,DE,DE,2021,Q3,Elderly
196741961,19674196,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210726.0,20210809,20210809,EXP,,IT-EPICPHARMA-IT-2021EPCLIT00830,EPIC PHARM,,68.0,YR,A,M,Y,,,20210809.0,,HP,IT,IT,2021,Q3,Elderly
196741961,19674196,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,, UNKNOWN,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210726.0,20210809,20210809,EXP,,IT-EPICPHARMA-IT-2021EPCLIT00830,EPIC PHARM,,68.0,YR,A,M,Y,,,20210809.0,,HP,IT,IT,2021,Q3,Elderly
196741961,19674196,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210726.0,20210809,20210809,EXP,,IT-EPICPHARMA-IT-2021EPCLIT00830,EPIC PHARM,,68.0,YR,A,M,Y,,,20210809.0,,HP,IT,IT,2021,Q3,Elderly
196741961,19674196,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,10.0,MG,,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210726.0,20210809,20210809,EXP,,IT-EPICPHARMA-IT-2021EPCLIT00830,EPIC PHARM,,68.0,YR,A,M,Y,,,20210809.0,,HP,IT,IT,2021,Q3,Elderly
196742731,19674273,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,1,I,202011.0,20210609.0,20210809,20210809,EXP,,CO-NOVOPROD-822149,NOVO NORDISK,,56.0,YR,,F,Y,,,20210809.0,,CN,CO,CO,2021,Q3,Adult
196742731,19674273,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,202011.0,20210609.0,20210809,20210809,EXP,,CO-NOVOPROD-822149,NOVO NORDISK,,56.0,YR,,F,Y,,,20210809.0,,CN,CO,CO,2021,Q3,Adult
196742731,19674273,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Hypoglycaemic seizure,,2021,Q3,1,I,202011.0,20210609.0,20210809,20210809,EXP,,CO-NOVOPROD-822149,NOVO NORDISK,,56.0,YR,,F,Y,,,20210809.0,,CN,CO,CO,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Bladder discomfort,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Dysuria,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Malaise,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Pollakiuria,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196749391,19674939,1,PS,empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Urine ketone body present,,2021,Q3,1,I,20210701.0,,20210809,20210809,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20210809.0,N,PH,US,US,2021,Q3,Adult
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Acute respiratory failure,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Bradycardia,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Cardiac arrest,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196773271,19677327,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"UNK (10 MG, 1?0?0?0)",,,,,,,,,,,,2021,Q3,Wound,,2021,Q3,1,I,,20210730.0,20210810,20210810,EXP,,DE-AUROBINDO-AUR-APL-2021-033879,AUROBINDO,,79.0,YR,,M,Y,,,20210810.0,,PH,DE,DE,2021,Q3,Elderly
196788121,19678812,1,PS,EMPAGLIFLOZIN AND LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q3,Abnormal loss of weight,,2021,Q3,1,I,20210707.0,,20210809,20210809,DIR,,,FDA-CTU,,72.0,YR,,M,N,66.0,KG,20210809.0,N,PH,US,US,2021,Q3,Elderly
196788121,19678812,1,PS,EMPAGLIFLOZIN AND LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210707.0,,20210809,20210809,DIR,,,FDA-CTU,,72.0,YR,,M,N,66.0,KG,20210809.0,N,PH,US,US,2021,Q3,Elderly
196788121,19678812,1,PS,EMPAGLIFLOZIN AND LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,D,,,,10.0,MG,,QD,2021,Q3,Pancreatitis,,2021,Q3,1,I,20210707.0,,20210809,20210809,DIR,,,FDA-CTU,,72.0,YR,,M,N,66.0,KG,20210809.0,N,PH,US,US,2021,Q3,Elderly
196816221,19681622,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,COVID-19,,2021,Q3,1,I,20170215.0,20201201.0,20210810,20210810,EXP,,BR-NOVOPROD-814125,NOVO NORDISK,,58.0,YR,,M,Y,79.75,KG,20210810.0,,MD,BR,BR,2021,Q3,Adult
196816221,19681622,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Catheterisation cardiac,,2021,Q3,1,I,20170215.0,20201201.0,20210810,20210810,EXP,,BR-NOVOPROD-814125,NOVO NORDISK,,58.0,YR,,M,Y,79.75,KG,20210810.0,,MD,BR,BR,2021,Q3,Adult
196816221,19681622,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Diabetes mellitus inadequate control,,2021,Q3,1,I,20170215.0,20201201.0,20210810,20210810,EXP,,BR-NOVOPROD-814125,NOVO NORDISK,,58.0,YR,,M,Y,79.75,KG,20210810.0,,MD,BR,BR,2021,Q3,Adult
196816221,19681622,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Hepatic steatosis,,2021,Q3,1,I,20170215.0,20201201.0,20210810,20210810,EXP,,BR-NOVOPROD-814125,NOVO NORDISK,,58.0,YR,,M,Y,79.75,KG,20210810.0,,MD,BR,BR,2021,Q3,Adult
196827321,19682732,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,,,,,10.0,MG,,,2021,Q3,Blood glucose abnormal,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,,,,,10.0,MG,,,2021,Q3,COVID-19,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,,,,,10.0,MG,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG (WITH URINE AND URINE SEDIMENT CONTROL),,,,,,,,10.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Blood glucose abnormal,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,COVID-19,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Glomerular filtration rate abnormal,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196827321,19682732,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Pneumonia,,2021,Q3,1,I,,20210727.0,20210810,20210810,EXP,,HR-BAUSCH-BL-2021-026508,BAUSCH AND LOMB,,65.0,YR,,,Y,,,20210810.0,,MD,HR,HR,2021,Q3,Elderly
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Anaemia,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Atrial fibrillation,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Pallor,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196869071,19686907,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MG, QD",,,,,,,,10.0,MG,,QD,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210806.0,20210811,20210811,EXP,DE-ADRED-06982-01,DE-DSJP-DSE-2021-125249,DAIICHI,,53.0,YR,,M,Y,74.0,KG,20210811.0,,PH,DE,DE,2021,Q3,Adult
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Acute respiratory failure,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Bradycardia,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Cardiac arrest,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Fall,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196940371,19694037,8,C,empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,,,,,,10.0,MG,,QD,2021,Q3,Wound,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940761,TEVA,,79.0,YR,E,M,Y,,,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Acute respiratory failure,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Bradycardia,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Cardiac arrest,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Fall,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196943681,19694368,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Wound,,2021,Q3,1,I,,20210802.0,20210812,20210812,EXP,,NVSC2021DE175454,NOVARTIS,,79.0,YR,,M,Y,,,20210812.0,,HP,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Fall,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Language disorder,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Restlessness,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
196947931,19694793,5,C,empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Vomiting,,2021,Q3,1,I,,20210805.0,20210813,20210813,EXP,,DE-TEVA-2021-DE-1940757,TEVA,,79.0,YR,E,M,Y,76.0,KG,20210813.0,,PH,DE,DE,2021,Q3,Elderly
197067341,19706734,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210713.0,,20210816,20210816,DIR,,,FDA-CTU,,64.0,YR,,M,N,108.86,KG,20210813.0,N,PH,US,US,2021,Q3,Adult
197067341,19706734,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Pain,,2021,Q3,1,I,20210713.0,,20210816,20210816,DIR,,,FDA-CTU,,64.0,YR,,M,N,108.86,KG,20210813.0,N,PH,US,US,2021,Q3,Adult
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Diarrhoea,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197070451,19707045,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,12.5,MG,,QD,2021,Q3,Vomiting,,2021,Q3,1,I,20210227.0,,20210816,20210816,DIR,,,FDA-CTU,,71.0,YR,,M,N,,,20210418.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Blood creatinine increased,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Blood urea increased,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Hypotension,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197071701,19707170,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,N,D,,,,12.5,MG,,QD,2021,Q3,Urosepsis,,2021,Q3,1,I,20210402.0,,20210816,20210816,DIR,,,FDA-CTU,,73.0,YR,,M,N,,,20210617.0,N,PH,US,US,2021,Q3,Elderly
197079941,19707994,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,,,,,2021,Q3,Balance disorder,,2021,Q3,1,I,,20210803.0,20210817,20210817,EXP,,BR-NOVOPROD-836634,NOVO NORDISK,,72.0,YR,,M,Y,78.0,KG,20210817.0,,MD,BR,BR,2021,Q3,Elderly
197079941,19707994,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210803.0,20210817,20210817,EXP,,BR-NOVOPROD-836634,NOVO NORDISK,,72.0,YR,,M,Y,78.0,KG,20210817.0,,MD,BR,BR,2021,Q3,Elderly
197079941,19707994,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,,,,,2021,Q3,Sensory disturbance,,2021,Q3,1,I,,20210803.0,20210817,20210817,EXP,,BR-NOVOPROD-836634,NOVO NORDISK,,72.0,YR,,M,Y,78.0,KG,20210817.0,,MD,BR,BR,2021,Q3,Elderly
197079941,19707994,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,,,,,2021,Q3,Visual field defect,,2021,Q3,1,I,,20210803.0,20210817,20210817,EXP,,BR-NOVOPROD-836634,NOVO NORDISK,,72.0,YR,,M,Y,78.0,KG,20210817.0,,MD,BR,BR,2021,Q3,Elderly
197079941,19707994,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 MG,,,,,,,,,,,,2021,Q3,Walking aid user,,2021,Q3,1,I,,20210803.0,20210817,20210817,EXP,,BR-NOVOPROD-836634,NOVO NORDISK,,72.0,YR,,M,Y,78.0,KG,20210817.0,,MD,BR,BR,2021,Q3,Elderly
197134881,19713488,1,PS,"EMPAGLIFLOZIN/ METFORMIN (EMPAGLIFLOZIN 12.5MG/METFORMIN 1000MG TAB, O",EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Polyuria,,2021,Q3,1,I,20201222.0,,20210817,20210817,DIR,,,FDA-CTU,,78.0,YR,,M,N,150.0,KG,20210512.0,N,PH,US,US,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Fall,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Language disorder,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Restlessness,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197198501,19719850,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,,,TABLET,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210803.0,20210818,20210818,EXP,DE-ADRED-06892-01,DE-PFIZER INC-202100987896,PFIZER,,79.0,YR,,M,Y,76.0,KG,20210818.0,,PH,DE,DE,2021,Q3,Elderly
197241751,19724175,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,, UNKNOWN,,204629.0,10.0,MG,,,2021,Q3,Death,,2021,Q3,1,I,202108.0,20210817.0,20210820,20210820,EXP,,"RO-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-122343",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20210820.0,,CN,RO,RO,2021,Q3,Adult
197241751,19724175,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,, UNKNOWN,,204629.0,10.0,MG,,,2021,Q3,Hepatic cirrhosis,,2021,Q3,1,I,202108.0,20210817.0,20210820,20210820,EXP,,"RO-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-122343",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,,,20210820.0,,CN,RO,RO,2021,Q3,Adult
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Dropped head syndrome,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Dysphagia,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Gait disturbance,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Gastrointestinal tube insertion,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197283771,19728377,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,,,,U,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210807.0,20210820,20210820,EXP,CA-MHPD-000924219,CA-ACCORD-235280,ACCORD,,79.0,YR,,M,Y,,,20210820.0,,HP,CA,CA,2021,Q3,Elderly
197319141,19731914,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210721.0,,20210820,20210820,DIR,,,FDA-CTU,,52.0,YR,,M,N,,,20210818.0,N,PH,US,US,2021,Q3,Adult
197332691,19733269,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 MG, BID",,,,,,,,12.5,MG,,BID,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,,20210809.0,20210823,20210823,EXP,,US-NOVOPROD-840139,NOVO NORDISK,"CHAUDHRY A, BIGGIANI C, AFZAL M, ET AL.. ACUTE PANCREATITIS?INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS. CUREUS. 2021?13(6):E15949",41.0,YR,,M,Y,,,20210823.0,,MD,US,US,2021,Q3,Adult
197332691,19733269,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"12.5 MG, BID",,,,,,,,12.5,MG,,BID,2021,Q3,Pancreatitis acute,,2021,Q3,1,I,,20210809.0,20210823,20210823,EXP,,US-NOVOPROD-840139,NOVO NORDISK,"CHAUDHRY A, BIGGIANI C, AFZAL M, ET AL.. ACUTE PANCREATITIS?INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS. CUREUS. 2021?13(6):E15949",41.0,YR,,M,Y,,,20210823.0,,MD,US,US,2021,Q3,Adult
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Fall,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Language disorder,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Restlessness,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197344961,19734496,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 1?0?0?0, TABLET",,,,,,,,,,TABLET,,2021,Q3,Vomiting,,2021,Q3,1,I,,20210811.0,20210824,20210824,EXP,DE-BFARM-21007381,DE-ACCORD-235831,ACCORD,,79.0,YR,E,M,Y,76.0,KG,20210824.0,,PH,DE,DE,2021,Q3,Elderly
197360071,19736007,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210816.0,20210823,20210823,EXP,,ES-MYLANLABS-2021M1053247,MYLAN,,63.0,YR,,F,Y,,,20210823.0,,MD,ES,ES,2021,Q3,Adult
197360071,19736007,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q3,Renal failure,,2021,Q3,1,I,,20210816.0,20210823,20210823,EXP,,ES-MYLANLABS-2021M1053247,MYLAN,,63.0,YR,,F,Y,,,20210823.0,,MD,ES,ES,2021,Q3,Adult
197368391,19736839,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Anaemia,,2021,Q3,1,I,20201027.0,20210716.0,20210824,20210824,EXP,,US-GILEAD-2021-0541502,GILEAD,,62.0,YR,A,F,Y,125.62,KG,20210824.0,,HP,US,US,2021,Q3,Adult
197368391,19736839,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Disease progression,,2021,Q3,1,I,20201027.0,20210716.0,20210824,20210824,EXP,,US-GILEAD-2021-0541502,GILEAD,,62.0,YR,A,F,Y,125.62,KG,20210824.0,,HP,US,US,2021,Q3,Adult
197368391,19736839,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Hypokalaemia,,2021,Q3,1,I,20201027.0,20210716.0,20210824,20210824,EXP,,US-GILEAD-2021-0541502,GILEAD,,62.0,YR,A,F,Y,125.62,KG,20210824.0,,HP,US,US,2021,Q3,Adult
197368391,19736839,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Metastases to central nervous system,,2021,Q3,1,I,20201027.0,20210716.0,20210824,20210824,EXP,,US-GILEAD-2021-0541502,GILEAD,,62.0,YR,A,F,Y,125.62,KG,20210824.0,,HP,US,US,2021,Q3,Adult
197368391,19736839,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Neutropenia,,2021,Q3,1,I,20201027.0,20210716.0,20210824,20210824,EXP,,US-GILEAD-2021-0541502,GILEAD,,62.0,YR,A,F,Y,125.62,KG,20210824.0,,HP,US,US,2021,Q3,Adult
197378741,19737874,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,0.5,DF,COATED TABLET,QD,2021,Q3,Chest pain,,2021,Q3,1,I,20210512.0,,20210820,20210820,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20210719.0,N,PH,US,US,2021,Q3,Adult
197378741,19737874,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,0.5,DF,COATED TABLET,QD,2021,Q3,Therapy cessation,,2021,Q3,1,I,20210512.0,,20210820,20210820,DIR,,,FDA-CTU,,50.0,YR,,M,N,,,20210719.0,N,PH,US,US,2021,Q3,Adult
197379021,19737902,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210823,20210823,EXP,GB-MHRA-EYC 00258659,NVSC2021GB189326,NOVARTIS,,47.0,YR,,M,Y,115.0,KG,20210823.0,,HP,GB,GB,2021,Q3,Adult
197379021,19737902,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,D,,,,,25.0,MG,,QD,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210823,20210823,EXP,GB-MHRA-EYC 00258659,NVSC2021GB189326,NOVARTIS,,47.0,YR,,M,Y,115.0,KG,20210823.0,,HP,GB,GB,2021,Q3,Adult
197385581,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,D,,,,,25.0,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210823,20210823,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20210823.0,,MD,GB,GB,2021,Q3,Adult
197385581,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, QD",,,D,,,,,25.0,MG,,QD,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210823,20210823,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20210823.0,,MD,GB,GB,2021,Q3,Adult
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Acute respiratory distress syndrome,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Atrial fibrillation,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Bacterial infection,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Cardiogenic shock,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Cardiomyopathy,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Ischaemic cardiomyopathy,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Multiple organ dysfunction syndrome,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197385871,19738587,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD (10 MG, QD)",,,,,,,,10.0,MG,,QD,2021,Q3,Septic shock,,2021,Q3,1,I,,20210819.0,20210823,20210823,EXP,,DE-MYLANLABS-2021M1054580,MYLAN,"HINTERSEER M, ZENS M, WIMMER RJ, DELLADIO S, LEDERLE S, KUPATT C, ET AL... ACUTE MYOCARDIAL INFARCTION DUE TO CORONARY STENT THROMBOSIS IN A SYMPTOMATIC COVID?19 PATIENT.. CLINICAL RESEARCH IN CARDIOLOGY. 2021?110:302?306",65.0,YR,,M,Y,,,20210823.0,,MD,DE,DE,2021,Q3,Elderly
197393063,19739306,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,3,F,20210811.0,20210924.0,20210824,20210928,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-083340,BRISTOL MYERS SQUIBB,,73.0,YR,,F,Y,69.0,KG,20210928.0,,HP,ES,ES,2021,Q3,Elderly
197393063,19739306,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Sepsis,,2021,Q3,3,F,20210811.0,20210924.0,20210824,20210928,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-083340,BRISTOL MYERS SQUIBB,,73.0,YR,,F,Y,69.0,KG,20210928.0,,HP,ES,ES,2021,Q3,Elderly
197434941,19743494,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM,,,,, UNK,,,25.0,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210813.0,20210819.0,20210825,20210825,EXP,GB-MHRA-ADR 25810686,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002734,EMCURE,,47.0,YR,,M,Y,115.0,KG,20210825.0,,MD,GB,GB,2021,Q3,Adult
197434941,19743494,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM,,,,, UNK,,,25.0,MG,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210825,20210825,EXP,GB-MHRA-ADR 25810686,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002734,EMCURE,,47.0,YR,,M,Y,115.0,KG,20210825.0,,MD,GB,GB,2021,Q3,Adult
197434941,19743494,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM,,,,, UNK,,,25.0,MG,,,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210825,20210825,EXP,GB-MHRA-ADR 25810686,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-002734,EMCURE,,47.0,YR,,M,Y,115.0,KG,20210825.0,,MD,GB,GB,2021,Q3,Adult
197445561,19744556,4,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Cerebral mass effect,,2021,Q3,1,I,20210811.0,,20210823,20210823,DIR,,,FDA-CTU,,71.0,YR,,F,N,101.0,KG,20210823.0,N,PH,US,US,2021,Q3,Elderly
197445561,19744556,4,C,Empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Haemorrhagic stroke,,2021,Q3,1,I,20210811.0,,20210823,20210823,DIR,,,FDA-CTU,,71.0,YR,,F,N,101.0,KG,20210823.0,N,PH,US,US,2021,Q3,Elderly
197514381,19751438,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG DAILY,,,,U,,,,25.0,MG,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210827,20210827,EXP,GB-MHRA-EYC 00258659,GB-EMD SERONO-E2B_90084795,EMD SERONO INC,,47.0,YR,A,M,Y,115.0,KG,20210827.0,,MD,GB,GB,2021,Q3,Adult
197514381,19751438,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25MG DAILY,,,,U,,,,25.0,MG,,,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210827,20210827,EXP,GB-MHRA-EYC 00258659,GB-EMD SERONO-E2B_90084795,EMD SERONO INC,,47.0,YR,A,M,Y,115.0,KG,20210827.0,,MD,GB,GB,2021,Q3,Adult
197559601,19755960,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,,U,,,,,,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210827,20210827,EXP,GB-MHRA-EYC 00258659,GB-TEVA-2021-GB-1945883,TEVA,,47.0,YR,A,M,Y,115.0,KG,20210827.0,,MD,GB,GB,2021,Q3,Adult
197559601,19755960,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,,U,,,,,,,,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210827,20210827,EXP,GB-MHRA-EYC 00258659,GB-TEVA-2021-GB-1945883,TEVA,,47.0,YR,A,M,Y,115.0,KG,20210827.0,,MD,GB,GB,2021,Q3,Adult
197584591,19758459,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,TAKE ONE DAILY,,,U,,,,,,,,QD,2021,Q3,Vulvovaginal discomfort,,2021,Q3,1,I,20210826.0,20210827.0,20210827,20210827,EXP,GB-MHRA-TPP1743640C579002YC1629992033121,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-123973",BOEHRINGER INGELHEIM,,75.0,YR,E,F,Y,61.0,KG,20210827.0,,MD,GB,GB,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Dropped head syndrome,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Dysphagia,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Gait disturbance,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Gastrointestinal tube insertion,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197631431,19763143,4,C,EMPAGLIFLOZIN;LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210819.0,20210830,20210830,EXP,,CA-APOTEX-2021AP039385,APOTEX,,79.0,YR,,M,Y,,,20210830.0,,CN,CA,CA,2021,Q3,Elderly
197641401,19764140,1,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210831,20210831,EXP,,GB-AUROBINDO-AUR-APL-2021-036793,AUROBINDO,,47.0,YR,,M,Y,115.0,KG,20210831.0,,MD,GB,GB,2021,Q3,Adult
197641401,19764140,1,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MILLIGRAM, DAILY",,,D,,,,,25.0,MG,,,2021,Q3,Lactic acidosis,,2021,Q3,1,I,20210813.0,20210819.0,20210831,20210831,EXP,,GB-AUROBINDO-AUR-APL-2021-036793,AUROBINDO,,47.0,YR,,M,Y,115.0,KG,20210831.0,,MD,GB,GB,2021,Q3,Adult
197650201,19765020,2,C,Empagliflozin;Linagliptin,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"1 DOSAGE FORM, QD",,,,,,,,1.0,DF,,QD,2021,Q3,Off label use,,2021,Q3,1,I,2020.0,20210818.0,20210831,20210831,PER,,BR-LUPIN PHARMACEUTICALS INC.-2021-15993,LUPIN,,56.0,YR,,M,Y,72.0,KG,20210831.0,,HP,BR,BR,2021,Q3,Adult
197684881,19768488,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Adrenal insufficiency,,2021,Q3,1,I,,20210819.0,20210831,20210831,EXP,E2B_03639641,CA-USP-000128,USPHARMA,,75.0,YR,E,,Y,,,20210831.0,,MD,CA,CA,2021,Q3,Elderly
197684881,19768488,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hyperthyroidism,,2021,Q3,1,I,,20210819.0,20210831,20210831,EXP,E2B_03639641,CA-USP-000128,USPHARMA,,75.0,YR,E,,Y,,,20210831.0,,MD,CA,CA,2021,Q3,Elderly
197684881,19768488,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20210819.0,20210831,20210831,EXP,E2B_03639641,CA-USP-000128,USPHARMA,,75.0,YR,E,,Y,,,20210831.0,,MD,CA,CA,2021,Q3,Elderly
197684881,19768488,11,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Troponin increased,,2021,Q3,1,I,,20210819.0,20210831,20210831,EXP,E2B_03639641,CA-USP-000128,USPHARMA,,75.0,YR,E,,Y,,,20210831.0,,MD,CA,CA,2021,Q3,Elderly
197698371,19769837,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,U,,,,25.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210824.0,20210831,20210831,EXP,,IN-MYLANLABS-2021M1057401,MYLAN,"KUCHAY MS, MISHRA SK, MEHTA Y. EMPAGLIFLOZIN INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT UNDERGOING CORONARY ARTERY BYPASS GRAFT DESPITE DISCONTINUATION OF THE DRUG 48 HOURS PRIOR TO THE SURGERY. DIABETES?METAB?SYNDR 2021?15(3):909?911.",53.0,YR,,F,Y,,,20210831.0,,HP,IN,IN,2021,Q3,Adult
197706824,19770682,23,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,COVID-19,,2021,Q3,4,F,20210820.0,20210927.0,20210831,20210930,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-124049",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,42.0,KG,20210930.0,,MD,GB,GB,2021,Q3,Adult
197706824,19770682,23,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Diabetic ketosis,,2021,Q3,4,F,20210820.0,20210927.0,20210831,20210930,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-124049",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,42.0,KG,20210930.0,,MD,GB,GB,2021,Q3,Adult
197706824,19770682,23,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Respiratory failure,,2021,Q3,4,F,20210820.0,20210927.0,20210831,20210930,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-124049",BOEHRINGER INGELHEIM,,60.0,YR,A,F,Y,42.0,KG,20210930.0,,MD,GB,GB,2021,Q3,Adult
197708891,19770889,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,12.5,MG,,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,20210610.0,,20210830,20210830,DIR,,,FDA-CTU,,61.0,YR,,M,N,,,20210818.0,N,PH,US,US,2021,Q3,Adult
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Cardiac failure chronic,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Musculoskeletal disorder,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,N-terminal prohormone brain natriuretic peptide decreased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,U,U,,,,25.0,MG,,,2021,Q3,Weight increased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Cardiac failure chronic,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Musculoskeletal disorder,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,N-terminal prohormone brain natriuretic peptide decreased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197745891,19774589,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MG,,,U,U,,,,10.0,MG,,,2021,Q3,Weight increased,,2021,Q3,1,I,201811.0,20210827.0,20210901,20210901,EXP,,HU-MYLANLABS-2021M1056950,MYLAN,,69.0,YR,,M,Y,,,20210901.0,,MD,HU,HU,2021,Q3,Elderly
197870722,19787072,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 MILLIGRAM, ONCE DAILY",,,U,,,,,25.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,2,F,,20210830.0,20210903,20210909,EXP,,CA-009507513-2109CAN000534,MERCK,"PAPASTERGIOU J, SMILEY T. AIDER LES PATIENTS ? MA?TRISER LEUR GLYC?MIE AU MOYEN DE TECHNOLOGIES NUM?RIQUES ET DE STRAT?GIES DE CHANGEMENT COMPORTEMENTAL [HELPING PATIENTS CONTROL THEIR BLOOD SUGAR LEVELS THROUGH DIGITAL TECHNOLOGIES AND BEHAVIOR CHANGE STRATEGIES]. PROFESSION SANT?. 2021?7(6):39?45",49.0,YR,,M,Y,,,20210909.0,,PH,CA,CA,2021,Q3,Adult
197949701,19794970,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"25 MILLIGRAM, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210824.0,20210907,20210907,PER,,IN-LUPIN LIMITED-2021-16567,LUPIN,,53.0,YR,,F,Y,,,20210907.0,,HP,IN,IN,2021,Q3,Adult
197955021,19795502,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Angina pectoris,,2021,Q3,1,I,2021.0,20210831.0,20210907,20210907,PER,DE-BFARM-21008377,DE-AMGEN-DEUSP2021137804,AMGEN,,79.0,YR,E,F,Y,,,20210907.0,,MD,DE,DE,2021,Q3,Elderly
197955021,19795502,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Cough,,2021,Q3,1,I,2021.0,20210831.0,20210907,20210907,PER,DE-BFARM-21008377,DE-AMGEN-DEUSP2021137804,AMGEN,,79.0,YR,E,F,Y,,,20210907.0,,MD,DE,DE,2021,Q3,Elderly
197955021,19795502,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,2021.0,20210831.0,20210907,20210907,PER,DE-BFARM-21008377,DE-AMGEN-DEUSP2021137804,AMGEN,,79.0,YR,E,F,Y,,,20210907.0,,MD,DE,DE,2021,Q3,Elderly
197955021,19795502,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, QD",,,,,,,,25.0,MG,,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,2021.0,20210831.0,20210907,20210907,PER,DE-BFARM-21008377,DE-AMGEN-DEUSP2021137804,AMGEN,,79.0,YR,E,F,Y,,,20210907.0,,MD,DE,DE,2021,Q3,Elderly
198012302,19801230,3,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MG,,,,,,,,25.0,MG,UNKNOWN,QD,2021,Q3,COVID-19,,2021,Q3,2,F,20210826.0,20210903.0,20210907,20210908,EXP,,BR-CELGENEUS-BRA-20210901360,CELGENE,,78.0,YR,,F,Y,59.0,KG,20210908.0,,HP,BR,BR,2021,Q3,Elderly
198068691,19806869,3,SS,empagliflozin,EMPAGLIFLOZIN,1,,,,,U,, UNKNOWN,,,,,,,2021,Q3,Delirium,,2021,Q3,1,I,,20210713.0,20210909,20210909,EXP,,MX-MICRO LABS LIMITED-ML2021-02150,MICRO LABS,"ZAVALA?JONGUITUD LF, PEREZ?GARCIA CC. DELIRIUM TRIGGERED BY COVID?19 VACCINE IN AN ELDERLYPATIENT. GERIATR?GERONTOL?INT 2021?21(6):540.",89.0,YR,,M,Y,,,20210909.0,,HP,MX,MX,2021,Q3,Elderly
198071311,19807131,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM (1?0?0?0),,,,,,,,25.0,MG,TABLET,,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038057,AUROBINDO,,79.0,YR,,F,Y,,,20210909.0,,MD,DE,DE,2021,Q3,Elderly
198071311,19807131,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM (1?0?0?0),,,,,,,,25.0,MG,TABLET,,2021,Q3,Cough,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038057,AUROBINDO,,79.0,YR,,F,Y,,,20210909.0,,MD,DE,DE,2021,Q3,Elderly
198071311,19807131,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM (1?0?0?0),,,,,,,,25.0,MG,TABLET,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038057,AUROBINDO,,79.0,YR,,F,Y,,,20210909.0,,MD,DE,DE,2021,Q3,Elderly
198071311,19807131,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM (1?0?0?0),,,,,,,,25.0,MG,TABLET,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038057,AUROBINDO,,79.0,YR,,F,Y,,,20210909.0,,MD,DE,DE,2021,Q3,Elderly
198078471,19807847,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, QD",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Pharyngeal swelling,,2021,Q3,1,I,20210619.0,20210901.0,20210908,20210908,EXP,GB-MHRA-TPP26691140C947265YC1630064308604,GB-MYLANLABS-2021M1058732,MYLAN,,48.0,YR,,F,Y,96.0,KG,20210908.0,,MD,GB,GB,2021,Q3,Adult
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Anuria,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Apnoea,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Bradypnoea,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Cyanosis,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Dehydration,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Disorientation,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Electrolyte imbalance,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Hypotension,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Hypotonia,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Loss of consciousness,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Nuchal rigidity,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Pupils unequal,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Skin irritation,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Skin pressure mark,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Systemic infection,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Tachycardia,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198084381,19808438,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"10 MILLIGRAM (10 MG, 1?0?0?0 ), ONCE A DAY",,,U,U,,,,10.0,MG,,QD,2021,Q3,Tachypnoea,,2021,Q3,1,I,,20210831.0,20210909,20210909,EXP,,DE-AUROBINDO-AUR-APL-2021-038117,AUROBINDO,,76.0,YR,,M,Y,,,20210909.0,,PH,DE,DE,2021,Q3,Elderly
198135771,19813577,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,N,,,,,,,,,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210831.0,20210903.0,20210909,20210909,EXP,GB-MHRA-EYC 00259728,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125373",BOEHRINGER INGELHEIM,,55.0,YR,A,M,Y,76.0,KG,20210909.0,,PH,GB,GB,2021,Q3,Adult
198143131,19814313,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2021,Q3,Pancreatitis,,2021,Q3,1,I,20191101.0,20210901.0,20210909,20210909,EXP,,CN-EMD SERONO-9263454,EMD SERONO INC,"ZHIHUI T, KAI Z, YINGCHAO T, BINGQING Z. ACUTE PANCREATITIS CAUSED BY THE COMBINED USE OF LIRAGLUTIDE AND EMPAGLIFLOZIN. ADVERSE DRUG REACTIONS JOURNAL. 2020 OCT?10:601?602.",26.0,YR,A,M,Y,,,20210909.0,,PH,CN,CN,2021,Q3,Young Adult
198143131,19814313,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,10.0,MG,TABLET,QD,2021,Q3,Therapeutic response decreased,,2021,Q3,1,I,20191101.0,20210901.0,20210909,20210909,EXP,,CN-EMD SERONO-9263454,EMD SERONO INC,"ZHIHUI T, KAI Z, YINGCHAO T, BINGQING Z. ACUTE PANCREATITIS CAUSED BY THE COMBINED USE OF LIRAGLUTIDE AND EMPAGLIFLOZIN. ADVERSE DRUG REACTIONS JOURNAL. 2020 OCT?10:601?602.",26.0,YR,A,M,Y,,,20210909.0,,PH,CN,CN,2021,Q3,Young Adult
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Anuria,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Apnoea,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Bradypnoea,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Condition aggravated,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Cyanosis,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Decubitus ulcer,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Dehydration,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Disorientation,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Dyspnoea,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Electrocardiogram abnormal,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Electrolyte imbalance,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,General physical health deterioration,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Hyperglycaemia,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Hypotension,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Hypotonia,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Loss of consciousness,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Nuchal rigidity,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Oedema peripheral,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Pupils unequal,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Renal impairment,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Skin irritation,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Skin pressure mark,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Systemic infection,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Tachycardia,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198144162,19814416,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 MG, QD (10 MG, 1?0?0?0)",,,U,,,,,10.0,MG,,QD,2021,Q3,Tachypnoea,,2021,Q3,2,F,,20210902.0,20210909,20210915,EXP,DE-ADRED-07036-02,NVSC2021DE199737,NOVARTIS,,76.0,YR,,M,Y,,,20210915.0,,HP,DE,DE,2021,Q3,Elderly
198150881,19815088,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,U,,,,,25.0,MG,TABLET,,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20210910.0,,MD,DE,DE,2021,Q3,Elderly
198150881,19815088,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,U,,,,,25.0,MG,TABLET,,2021,Q3,Cough,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20210910.0,,MD,DE,DE,2021,Q3,Elderly
198150881,19815088,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,U,,,,,25.0,MG,TABLET,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20210910.0,,MD,DE,DE,2021,Q3,Elderly
198150881,19815088,4,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,U,,,,,25.0,MG,TABLET,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07051-01,DE-TORRENT-00021058,TORRENT,,79.0,YR,E,F,Y,,,20210910.0,,MD,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Anuria,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Apnoea,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Bradypnoea,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Cyanosis,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Dehydration,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Disorientation,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Electrolyte imbalance,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Hypotonia,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Loss of consciousness,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Nuchal rigidity,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Pupils unequal,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Skin irritation,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Skin pressure mark,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Systemic infection,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Tachycardia,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198150911,19815091,6,SS,Empagliflozin,EMPAGLIFLOZIN,1,,"10 MG, 1?0?0?0",,,U,,,,,10.0,MG,,,2021,Q3,Tachypnoea,,2021,Q3,1,I,,20210901.0,20210910,20210910,EXP,DE-ADRED-07036-02,DE-TORRENT-00021096,TORRENT,,76.0,YR,E,M,Y,,,20210910.0,,PH,DE,DE,2021,Q3,Elderly
198154631,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETTEN",,,U,,,,,25.0,MG,TABLET,QD,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210902.0,20210910,20210910,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20210910.0,,HP,DE,DE,2021,Q3,Elderly
198154631,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETTEN",,,U,,,,,25.0,MG,TABLET,QD,2021,Q3,Cough,,2021,Q3,1,I,,20210902.0,20210910,20210910,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20210910.0,,HP,DE,DE,2021,Q3,Elderly
198154631,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETTEN",,,U,,,,,25.0,MG,TABLET,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210902.0,20210910,20210910,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20210910.0,,HP,DE,DE,2021,Q3,Elderly
198154631,19815463,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETTEN",,,U,,,,,25.0,MG,TABLET,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210902.0,20210910,20210910,EXP,,NVSC2021DE199854,NOVARTIS,,79.0,YR,,F,Y,,,20210910.0,,HP,DE,DE,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Brain natriuretic peptide decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Cardiac failure acute,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Carotid artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Coronary artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Cystitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Electrocardiogram QRS complex prolonged,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Ischaemic stroke,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Left ventricular dysfunction,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Loss of personal independence in daily activities,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Musculoskeletal discomfort,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Prostatitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,22,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Brain natriuretic peptide decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Cardiac failure acute,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Carotid artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Coronary artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Cystitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Electrocardiogram QRS complex prolonged,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Ischaemic stroke,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Left ventricular dysfunction,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Loss of personal independence in daily activities,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Musculoskeletal discomfort,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Prostatitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Brain natriuretic peptide decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Cardiac failure acute,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Carotid artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Coronary artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Cystitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Electrocardiogram QRS complex prolonged,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Ischaemic stroke,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Left ventricular dysfunction,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Loss of personal independence in daily activities,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Musculoskeletal discomfort,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Prostatitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,24,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 MILLIGRAM,,,U,U,,,,10.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Blood potassium increased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Brain natriuretic peptide decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Cardiac failure acute,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Carotid artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Coronary artery stenosis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Cystitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Dyspnoea paroxysmal nocturnal,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Electrocardiogram QRS complex prolonged,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Fluid retention,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Hypotension,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Iron deficiency,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Ischaemic stroke,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Left ventricular dysfunction,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Loss of personal independence in daily activities,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Musculoskeletal discomfort,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Pneumonia,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Prostatitis,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198172021,19817202,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MILLIGRAM,,,U,U,,,,25.0,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,2015.0,20210823.0,20210910,20210910,EXP,,HU-MYLANLABS-2021M1055695,MYLAN,,69.0,YR,,M,Y,,,20210910.0,,MD,HU,HU,2021,Q3,Elderly
198173061,19817306,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,1 DOSAGE FORMS DAILY;,,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Pharyngeal swelling,,2021,Q3,1,I,20210619.0,20210901.0,20210910,20210910,EXP,GB-MHRA-TPP26691140C947265YC1630064308604,GB-TEVA-2021-GB-1950766,TEVA,,48.0,YR,A,F,Y,96.0,KG,20210910.0,,MD,GB,GB,2021,Q3,Adult
198185941,19818594,8,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,"1 DOSAGE FORM, ONCE A DAY",,,,,,,,1.0,DF,TABLET,QD,2021,Q3,Pharyngeal swelling,,2021,Q3,1,I,20210619.0,20210901.0,20210912,20210912,EXP,,GB-AUROBINDO-AUR-APL-2021-037996,AUROBINDO,,48.0,YR,,F,Y,96.0,KG,20210912.0,,MD,GB,GB,2021,Q3,Adult
198254651,19825465,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Anaphylactic reaction,,2021,Q3,1,I,20210823.0,20210903.0,20210914,20210914,EXP,GB-MHRA-EYC 00259589,GB-NOVOPROD-844577,NOVO NORDISK,,40.0,YR,,F,Y,75.0,KG,20210914.0,,HP,GB,GB,2021,Q3,Adult
198254651,19825465,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,20210823.0,20210903.0,20210914,20210914,EXP,GB-MHRA-EYC 00259589,GB-NOVOPROD-844577,NOVO NORDISK,,40.0,YR,,F,Y,75.0,KG,20210914.0,,HP,GB,GB,2021,Q3,Adult
198254651,19825465,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,20210823.0,20210903.0,20210914,20210914,EXP,GB-MHRA-EYC 00259589,GB-NOVOPROD-844577,NOVO NORDISK,,40.0,YR,,F,Y,75.0,KG,20210914.0,,HP,GB,GB,2021,Q3,Adult
198262361,19826236,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210601.0,,20210913,20210913,DIR,,,FDA-CTU,,66.0,YR,,M,N,85.0,KG,20210818.0,N,HP,US,US,2021,Q3,Elderly
198265181,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q3,Contusion,,2021,Q3,1,I,,20210822.0,20210914,20210914,EXP,,ES-ACCORD-237521,ACCORD,"MARIN AS, CENDROS M, CIUDAD CJ, SABATER A. CASE REPORT: FATIGUE AND BLEEDING IN A POLYMEDICATED PATIENT USING SEVERAL HERBAL SUPPLEMENTATIONS, DETECTED WITH G?NOMIC? SOFTWARE, PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2021? 14:963?70.",65.0,YR,,M,Y,,,20210914.0,,HP,ES,ES,2021,Q3,Elderly
198265181,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210822.0,20210914,20210914,EXP,,ES-ACCORD-237521,ACCORD,"MARIN AS, CENDROS M, CIUDAD CJ, SABATER A. CASE REPORT: FATIGUE AND BLEEDING IN A POLYMEDICATED PATIENT USING SEVERAL HERBAL SUPPLEMENTATIONS, DETECTED WITH G?NOMIC? SOFTWARE, PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2021? 14:963?70.",65.0,YR,,M,Y,,,20210914.0,,HP,ES,ES,2021,Q3,Elderly
198265181,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q3,Fatigue,,2021,Q3,1,I,,20210822.0,20210914,20210914,EXP,,ES-ACCORD-237521,ACCORD,"MARIN AS, CENDROS M, CIUDAD CJ, SABATER A. CASE REPORT: FATIGUE AND BLEEDING IN A POLYMEDICATED PATIENT USING SEVERAL HERBAL SUPPLEMENTATIONS, DETECTED WITH G?NOMIC? SOFTWARE, PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2021? 14:963?70.",65.0,YR,,M,Y,,,20210914.0,,HP,ES,ES,2021,Q3,Elderly
198265181,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q3,Gingival bleeding,,2021,Q3,1,I,,20210822.0,20210914,20210914,EXP,,ES-ACCORD-237521,ACCORD,"MARIN AS, CENDROS M, CIUDAD CJ, SABATER A. CASE REPORT: FATIGUE AND BLEEDING IN A POLYMEDICATED PATIENT USING SEVERAL HERBAL SUPPLEMENTATIONS, DETECTED WITH G?NOMIC? SOFTWARE, PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2021? 14:963?70.",65.0,YR,,M,Y,,,20210914.0,,HP,ES,ES,2021,Q3,Elderly
198265181,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q3,Hypertension,,2021,Q3,1,I,,20210822.0,20210914,20210914,EXP,,ES-ACCORD-237521,ACCORD,"MARIN AS, CENDROS M, CIUDAD CJ, SABATER A. CASE REPORT: FATIGUE AND BLEEDING IN A POLYMEDICATED PATIENT USING SEVERAL HERBAL SUPPLEMENTATIONS, DETECTED WITH G?NOMIC? SOFTWARE, PHARMACOGENOMICS AND PERSONALIZED MEDICINE. 2021? 14:963?70.",65.0,YR,,M,Y,,,20210914.0,,HP,ES,ES,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Diabetic nephropathy,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Labelled drug-drug interaction medication error,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Medication error,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Product monitoring error,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198270301,19827030,7,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, 0?1?0?0, TABLETS",,,U,, UNKNOWN,,204629.0,10.0,MG,TABLET,QD,2021,Q3,Renal failure,,2021,Q3,1,I,,20210906.0,20210914,20210914,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-125403",BOEHRINGER INGELHEIM,,82.0,YR,E,M,Y,82.0,KG,20210914.0,,PH,DE,DE,2021,Q3,Elderly
198354281,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,,,,,,,,TABLET,,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210903.0,20210915,20210915,EXP,DE-BFARM-21008377,DE-ACCORD-238399,ACCORD,,79.0,YR,E,F,Y,,,20210915.0,,MD,DE,DE,2021,Q3,Elderly
198354281,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,,,,,,,,TABLET,,2021,Q3,Cough,,2021,Q3,1,I,,20210903.0,20210915,20210915,EXP,DE-BFARM-21008377,DE-ACCORD-238399,ACCORD,,79.0,YR,E,F,Y,,,20210915.0,,MD,DE,DE,2021,Q3,Elderly
198354281,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,,,,,,,,TABLET,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210903.0,20210915,20210915,EXP,DE-BFARM-21008377,DE-ACCORD-238399,ACCORD,,79.0,YR,E,F,Y,,,20210915.0,,MD,DE,DE,2021,Q3,Elderly
198354281,19835428,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1?0?0?0, TABLETS",,,,,,,,,,TABLET,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210903.0,20210915,20210915,EXP,DE-BFARM-21008377,DE-ACCORD-238399,ACCORD,,79.0,YR,E,F,Y,,,20210915.0,,MD,DE,DE,2021,Q3,Elderly
198372692,19837269,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,2,F,,20210922.0,20210915,20210924,EXP,,GR-EMD SERONO-9264894,EMD SERONO INC,"MOUSTAKI M, KALOGERIS N, KATSAFYLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L, ANGELOPOULOS T, KALANTZIS G, VRYONIDOU A. A CASE OF SIMULTANEOUS OCCURRENCE OF EUGLYCEMIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM DIABETES MELLITUS CONGRESS. 2021 JUL?48:1?3.",50.0,YR,A,M,Y,,,20210924.0,,HP,GR,GR,2021,Q3,Adult
198372692,19837269,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q3,Pancreatitis acute,,2021,Q3,2,F,,20210922.0,20210915,20210924,EXP,,GR-EMD SERONO-9264894,EMD SERONO INC,"MOUSTAKI M, KALOGERIS N, KATSAFYLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L, ANGELOPOULOS T, KALANTZIS G, VRYONIDOU A. A CASE OF SIMULTANEOUS OCCURRENCE OF EUGLYCEMIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM DIABETES MELLITUS CONGRESS. 2021 JUL?48:1?3.",50.0,YR,A,M,Y,,,20210924.0,,HP,GR,GR,2021,Q3,Adult
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Anuria,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Apnoea,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Bradypnoea,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Condition aggravated,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Cyanosis,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Decubitus ulcer,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Dehydration,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Disorientation,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Electrocardiogram abnormal,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Electrolyte imbalance,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,General physical health deterioration,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Hypotension,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Hypotonia,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Loss of consciousness,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Nuchal rigidity,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Pupils unequal,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Skin irritation,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Skin pressure mark,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Systemic infection,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Tachycardia,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198379121,19837912,2,SS,Empagliflozin,EMPAGLIFLOZIN,1,,10 MILLIGRAM DAILY;  1?0?0?0,,,U,, UNKNOWN,,,10.0,MG,,QD,2021,Q3,Tachypnoea,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951461,TEVA,,76.0,YR,E,M,Y,,,20210916.0,,PH,DE,DE,2021,Q3,Elderly
198380611,19838061,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951513,TEVA,,79.0,YR,E,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198380611,19838061,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Cough,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951513,TEVA,,79.0,YR,E,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198380611,19838061,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951513,TEVA,,79.0,YR,E,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198380611,19838061,5,C,Empagliflozin,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;  1?0?0?0,,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,DE-TEVA-2021-DE-1951513,TEVA,,79.0,YR,E,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198382961,19838296,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Chills,,2021,Q3,1,I,20210622.0,,20210914,20210914,DIR,,,FDA-CTU,,68.0,YR,,M,N,115.0,KG,20210818.0,N,PH,US,US,2021,Q3,Elderly
198382961,19838296,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210622.0,,20210914,20210914,DIR,,,FDA-CTU,,68.0,YR,,M,N,115.0,KG,20210818.0,N,PH,US,US,2021,Q3,Elderly
198382961,19838296,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Tremor,,2021,Q3,1,I,20210622.0,,20210914,20210914,DIR,,,FDA-CTU,,68.0,YR,,M,N,115.0,KG,20210818.0,N,PH,US,US,2021,Q3,Elderly
198382961,19838296,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210622.0,,20210914,20210914,DIR,,,FDA-CTU,,68.0,YR,,M,N,115.0,KG,20210818.0,N,PH,US,US,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Dropped head syndrome,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Dysphagia,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Gait disturbance,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Gastrointestinal tube insertion,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198395341,19839534,4,C,EMPAGLIFLOZIN/LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Muscular weakness,,2021,Q3,1,I,,20210906.0,20210915,20210915,EXP,,CA-TEVA-2021-CA-1952145,TEVA,,79.0,YR,E,M,Y,,,20210915.0,,HP,CA,CA,2021,Q3,Elderly
198397261,19839726,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,Y,, C88613,20230901.0,,12.5,MG,,QD,2021,Q3,Palpitations,,2021,Q3,1,I,20210315.0,,20210914,20210914,DIR,,,FDA-CTU,,72.0,YR,,M,N,68.0,KG,20210719.0,N,PH,US,US,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Aneurysm,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Aphasia,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Asthenia,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Balance disorder,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Cerebrovascular accident,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Disorientation,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Fall,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Feeling abnormal,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Inappropriate schedule of product administration,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Loss of consciousness,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Multiple sclerosis,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198402671,19840267,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 MG, QD",,,U,,,,,10.0,MG,,QD,2021,Q3,Muscular weakness,,2021,Q3,1,I,20200219.0,20181030.0,20210915,20210915,EXP,,PHHY2018CO148578,NOVARTIS,,72.0,YR,,M,Y,67.0,KG,20210915.0,,CN,COUNTRY NOT SPECIFIED,CO,2021,Q3,Elderly
198409371,19840937,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,U,,,,,25.0,MG,,,2021,Q3,Cerebrovascular accident,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,CA-TEVA-2021-CA-1952165,TEVA,,51.0,YR,A,M,Y,,,20210916.0,,HP,CA,CA,2021,Q3,Adult
198409371,19840937,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,U,,,,,25.0,MG,,,2021,Q3,Lactic acidosis,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,CA-TEVA-2021-CA-1952165,TEVA,,51.0,YR,A,M,Y,,,20210916.0,,HP,CA,CA,2021,Q3,Adult
198409371,19840937,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,25 MILLIGRAM DAILY;,,,U,,,,,25.0,MG,,,2021,Q3,Therapeutic product effect incomplete,,2021,Q3,1,I,,20210906.0,20210916,20210916,EXP,,CA-TEVA-2021-CA-1952165,TEVA,,51.0,YR,A,M,Y,,,20210916.0,,HP,CA,CA,2021,Q3,Adult
198419871,19841987,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY  (1?0?0?0)",,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Angina pectoris,,2021,Q3,1,I,,20210902.0,20210916,20210916,EXP,DE-ADRED-07051-01,DE-PFIZER INC-202101143189,PFIZER,,79.0,YR,,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198419871,19841987,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY  (1?0?0?0)",,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Cough,,2021,Q3,1,I,,20210902.0,20210916,20210916,EXP,DE-ADRED-07051-01,DE-PFIZER INC-202101143189,PFIZER,,79.0,YR,,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198419871,19841987,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY  (1?0?0?0)",,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210902.0,20210916,20210916,EXP,DE-ADRED-07051-01,DE-PFIZER INC-202101143189,PFIZER,,79.0,YR,,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198419871,19841987,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 MG, 1X/DAY  (1?0?0?0)",,,,, UNKNOWN,,,25.0,MG,TABLET,QD,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210902.0,20210916,20210916,EXP,DE-ADRED-07051-01,DE-PFIZER INC-202101143189,PFIZER,,79.0,YR,,F,Y,,,20210916.0,,MD,DE,DE,2021,Q3,Elderly
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Acidosis,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Chest pain,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Hypertriglyceridaemia,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198465081,19846508,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 25MG TAB),EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q3,Pain in extremity,,2021,Q3,1,I,20210501.0,,20210915,20210915,DIR,,,FDA-CTU,,50.0,YR,,M,N,155.58,KG,20210719.0,N,PH,US,US,2021,Q3,Adult
198473291,19847329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD, 1?0?0?0",,,,,,,,10.0,MG,TABLET,QD,2021,Q3,C-reactive protein increased,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-MYLANLABS-2021M1062151,MYLAN,,72.0,YR,,M,Y,,,20210917.0,,MD,DE,DE,2021,Q3,Elderly
198473291,19847329,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 MILLIGRAM, QD, 1?0?0?0",,,,,,,,10.0,MG,TABLET,QD,2021,Q3,Chills,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-MYLANLABS-2021M1062151,MYLAN,,72.0,YR,,M,Y,,,20210917.0,,MD,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Diabetic nephropathy,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Labelled drug-drug interaction medication error,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Medication error,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product monitoring error,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198494191,19849419,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,10 MILLIGRAM DAILY; 0?1?0?0:MEDICATION ERRORS,,,U,, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Renal failure,,2021,Q3,1,I,,20210908.0,20210917,20210917,EXP,,DE-TEVA-2021-DE-1953018,TEVA,,82.0,YR,E,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Diabetic nephropathy,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Labelled drug-drug interaction medication error,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Medication error,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Product monitoring error,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198496841,19849684,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 MG QD,,,U,N,,,,,,TABLET,,2021,Q3,Renal failure,,2021,Q3,1,I,,20210913.0,20210917,20210917,EXP,,DE-ANIPHARMA-2021-DE-000206,ANI,,82.0,YR,,M,Y,82.0,KG,20210917.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Diabetic nephropathy,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Hyperkalaemia,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Labelled drug-drug interaction medication error,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Medication error,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Metabolic acidosis,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product monitoring error,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Product prescribing error,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198576121,19857612,5,SS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,U,U, UNKNOWN,,,10.0,MG,TABLET,QD,2021,Q3,Renal failure,,2021,Q3,1,I,,20210914.0,20210921,20210921,EXP,,DE-DRREDDYS-SPO/GER/21/0140103,DR REDDYS,,82.0,YR,E,M,Y,82.0,KG,20210920.0,,PH,DE,DE,2021,Q3,Elderly
198590161,19859016,7,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, 40 MG/D",,,U,,,,,40.0,MG,,,2021,Q3,Coagulopathy,,2021,Q3,1,I,,20210906.0,20210921,20210921,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,,65.0,YR,,M,Y,,,20210921.0,,MD,ES,ES,2021,Q3,Elderly
198590161,19859016,7,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, 40 MG/D",,,U,,,,,40.0,MG,,,2021,Q3,Contusion,,2021,Q3,1,I,,20210906.0,20210921,20210921,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,,65.0,YR,,M,Y,,,20210921.0,,MD,ES,ES,2021,Q3,Elderly
198590161,19859016,7,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, 40 MG/D",,,U,,,,,40.0,MG,,,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210906.0,20210921,20210921,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,,65.0,YR,,M,Y,,,20210921.0,,MD,ES,ES,2021,Q3,Elderly
198590161,19859016,7,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, 40 MG/D",,,U,,,,,40.0,MG,,,2021,Q3,Gingival bleeding,,2021,Q3,1,I,,20210906.0,20210921,20210921,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,,65.0,YR,,M,Y,,,20210921.0,,MD,ES,ES,2021,Q3,Elderly
198590161,19859016,7,SS,empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, 40 MG/D",,,U,,,,,40.0,MG,,,2021,Q3,Sensory disturbance,,2021,Q3,1,I,,20210906.0,20210921,20210921,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,,65.0,YR,,M,Y,,,20210921.0,,MD,ES,ES,2021,Q3,Elderly
198601371,19860137,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Anion gap increased,,2021,Q3,1,I,20210917.0,,20210921,20210921,DIR,,,FDA-CTU,,50.0,YR,,M,N,186.7,KG,20210921.0,N,PH,US,US,2021,Q3,Adult
198601371,19860137,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Blood bicarbonate increased,,2021,Q3,1,I,20210917.0,,20210921,20210921,DIR,,,FDA-CTU,,50.0,YR,,M,N,186.7,KG,20210921.0,N,PH,US,US,2021,Q3,Adult
198601371,19860137,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Fournier's gangrene,,2021,Q3,1,I,20210917.0,,20210921,20210921,DIR,,,FDA-CTU,,50.0,YR,,M,N,186.7,KG,20210921.0,N,PH,US,US,2021,Q3,Adult
198601371,19860137,1,PS,Empagliflozin,EMPAGLIFLOZIN,1,Oral,,,,Y,D,,,,25.0,MG,,QD,2021,Q3,Necrotising fasciitis,,2021,Q3,1,I,20210917.0,,20210921,20210921,DIR,,,FDA-CTU,,50.0,YR,,M,N,186.7,KG,20210921.0,N,PH,US,US,2021,Q3,Adult
198645511,19864551,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q3,Cardiac failure congestive,,2021,Q3,1,I,20201127.0,20210106.0,20210921,20210921,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-074441",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,132.0,KG,20210921.0,,MD,US,US,2021,Q3,Adult
198645511,19864551,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q3,Fournier's gangrene,,2021,Q3,1,I,20201127.0,20210106.0,20210921,20210921,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-074441",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,132.0,KG,20210921.0,,MD,US,US,2021,Q3,Adult
198645511,19864551,9,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U, UNKNOWN,,204629.0,10.0,MG,FILM-COATED TABLET,,2021,Q3,Septic shock,,2021,Q3,1,I,20201127.0,20210106.0,20210921,20210921,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-074441",BOEHRINGER INGELHEIM,,57.0,YR,A,M,Y,132.0,KG,20210921.0,,MD,US,US,2021,Q3,Adult
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Cataract operation,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Glaucoma,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Hypoglycaemia,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Retinopathy,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700061,19870006,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 MG,,,,,,,,,,,,2021,Q3,Visual impairment,,2021,Q3,1,I,,20210911.0,20210923,20210923,EXP,,BR-NOVOPROD-847312,NOVO NORDISK,,79.0,YR,,F,Y,52.5,KG,20210923.0,,MD,BR,BR,2021,Q3,Elderly
198700451,19870045,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Partial seizures,,2021,Q3,1,I,20210606.0,20210914.0,20210923,20210923,EXP,GB-MHRA-EYC 00260495,GB-NOVOPROD-847237,NOVO NORDISK,,63.0,YR,,M,Y,,,20210923.0,,MD,GB,GB,2021,Q3,Adult
198700451,19870045,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Visual impairment,,2021,Q3,1,I,20210606.0,20210914.0,20210923,20210923,EXP,GB-MHRA-EYC 00260495,GB-NOVOPROD-847237,NOVO NORDISK,,63.0,YR,,M,Y,,,20210923.0,,MD,GB,GB,2021,Q3,Adult
198767611,19876761,9,I,Empagliflozin,EMPAGLIFLOZIN,1,Unknown,"40 MILLIGRAM, QD",,,,,,,,40.0,MG,,QD,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210906.0,20210924,20210924,PER,,ES-LUPIN PHARMACEUTICALS INC.-2021-17742,LUPIN,,65.0,YR,,M,Y,,,20210924.0,,HP,ES,ES,2021,Q3,Elderly
198836771,19883677,1,PS,EMPAGLIFLOZIN (EMPAGLIFLOZIN 10MG TAB),EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,10.0,MG,,QD,2021,Q3,Weight increased,,2021,Q3,1,I,20210316.0,,20210923,20210923,DIR,,,FDA-CTU,,54.0,YR,,M,N,,,20210719.0,N,PH,US,US,2021,Q3,Adult
198867291,19886729,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210920.0,20210927,20210927,EXP,,ES-MYLANLABS-2021M1064627,MYLAN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P.. TRIPLE THERAPY IN A PATIENT WITH HEART FAILURE, REDUCED LVEF, AND CHRONIC KIDNEY DISEASE.. MINICARDIO. 2021?11:28",53.0,YR,,M,Y,,,20210927.0,,MD,ES,ES,2021,Q3,Adult
198867291,19886729,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210920.0,20210927,20210927,EXP,,ES-MYLANLABS-2021M1064627,MYLAN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P.. TRIPLE THERAPY IN A PATIENT WITH HEART FAILURE, REDUCED LVEF, AND CHRONIC KIDNEY DISEASE.. MINICARDIO. 2021?11:28",53.0,YR,,M,Y,,,20210927.0,,MD,ES,ES,2021,Q3,Adult
198867291,19886729,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Sleep apnoea syndrome,,2021,Q3,1,I,,20210920.0,20210927,20210927,EXP,,ES-MYLANLABS-2021M1064627,MYLAN,"BENAVENTE SOLER C, BARRIOS GARRIDO?LESTACHE E, MIGUEL GUTIERREZ A, SANZ MAYORDOMO P.. TRIPLE THERAPY IN A PATIENT WITH HEART FAILURE, REDUCED LVEF, AND CHRONIC KIDNEY DISEASE.. MINICARDIO. 2021?11:28",53.0,YR,,M,Y,,,20210927.0,,MD,ES,ES,2021,Q3,Adult
198885471,19888547,6,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Back pain,,2021,Q3,1,I,20210919.0,,20210927,20210927,DIR,,,FDA-CTU,,46.0,YR,,M,N,128.25,KG,20210927.0,Y,HP,US,US,2021,Q3,Adult
198885471,19888547,6,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Cough,,2021,Q3,1,I,20210919.0,,20210927,20210927,DIR,,,FDA-CTU,,46.0,YR,,M,N,128.25,KG,20210927.0,Y,HP,US,US,2021,Q3,Adult
198885471,19888547,6,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Headache,,2021,Q3,1,I,20210919.0,,20210927,20210927,DIR,,,FDA-CTU,,46.0,YR,,M,N,128.25,KG,20210927.0,Y,HP,US,US,2021,Q3,Adult
198885471,19888547,6,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Paranasal sinus discomfort,,2021,Q3,1,I,20210919.0,,20210927,20210927,DIR,,,FDA-CTU,,46.0,YR,,M,N,128.25,KG,20210927.0,Y,HP,US,US,2021,Q3,Adult
199025071,19902507,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Fungal infection,,2021,Q3,1,I,,20210924.0,20210930,20210930,PER,,US-SA-2021SA321370,SANOFI AVENTIS,,60.0,YR,A,F,Y,,,20210930.0,,CN,US,US,2021,Q3,Adult
199051751,19905175,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Injection site erythema,,2021,Q3,1,I,20210825.0,,20210930,20210930,DIR,,,FDA-CTU,,38.0,YR,,F,N,110.7,KG,20210930.0,N,PH,US,US,2021,Q3,Adult
199051751,19905175,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Injection site mass,,2021,Q3,1,I,20210825.0,,20210930,20210930,DIR,,,FDA-CTU,,38.0,YR,,F,N,110.7,KG,20210930.0,N,PH,US,US,2021,Q3,Adult
199051751,19905175,4,C,empagliflozin,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Injection site pruritus,,2021,Q3,1,I,20210825.0,,20210930,20210930,DIR,,,FDA-CTU,,38.0,YR,,F,N,110.7,KG,20210930.0,N,PH,US,US,2021,Q3,Adult
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Anxiety,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Arthralgia,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Basal cell carcinoma,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Blood pressure diastolic decreased,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Blood pressure increased,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Blood pressure systolic increased,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Blood urine present,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Cataract,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Cough,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Dyspepsia,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Malaise,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Nasal congestion,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Nasopharyngitis,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Neck pain,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Pancreatic carcinoma,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Pyrexia,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Second primary malignancy,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Skin mass,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
946404952,9464049,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,U,,,,,,,,QD,2021,Q3,Vision blurred,,2021,Q3,52,F,20141127.0,20210922.0,20130819,20210927,EXP,,PHHY2013CA085730,NOVARTIS,,67.0,YR,,M,Y,,,20210928.0,,CN,COUNTRY NOT SPECIFIED,CA,2021,Q3,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Pulmonary congestion,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Skin disorder,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Arrhythmia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Presyncope,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Drug interaction,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Dizziness,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Dehydration,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Renal disorder,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Heart rate irregular,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Mucosal dryness,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Hypovolaemia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Syncope,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Haematocrit increased,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Haemoglobin increased,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Left atrial dilatation,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,14,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2021,Q4,Bradycardia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Pulmonary congestion,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Atrial fibrillation,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Skin disorder,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Arrhythmia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Presyncope,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Drug interaction,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Dizziness,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Dehydration,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Renal disorder,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Heart rate irregular,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Mucosal dryness,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Hypovolaemia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Syncope,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Haematocrit increased,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Haemoglobin increased,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Left atrial dilatation,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Hypotension,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Oedema peripheral,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
161236889,16123688,15,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,D,,,,,10.0,MG,,QD,2021,Q4,Bradycardia,,2021,Q4,9,F,20180101.0,20211112.0,20190327,20211117,EXP,,PT-MYLANLABS-2019M1028062,MYLAN,"Gouveia C., Duque S., Campos L.. Lipothymia by hypovolemia- A case of empagliflozin iatrogeny?. Revista Portuguesa de Diabetes. 2019;14 (1) Suppl:Sup: 47-122",71.0,YR,,M,Y,,,20211117.0,,HP,PT,PT,2021,Q4,Elderly
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Schizophrenia,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastroenteritis,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Electrocardiogram abnormal,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Diabetes mellitus,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Pruritus genital,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Bronchitis,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Insomnia,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Stomatitis,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
1652766611,16527666,37,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,,2021,Q4,Enuresis,,2021,Q4,11,F,20170929.0,20211220.0,20190703,20211223,EXP,,JP-GILEAD-2018-0382287,GILEAD,,31.0,YR,A,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Young Adult
171589302,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 qd,,,,,,,,,,,,2021,Q4,Abdominal discomfort,,2021,Q4,2,F,,20191203.0,20191216,20211206,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20211206.0,,HP,GB,GB,2021,Q4,Elderly
171589302,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 qd,,,,,,,,,,,,2021,Q4,Eructation,,2021,Q4,2,F,,20191203.0,20191216,20211206,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20211206.0,,HP,GB,GB,2021,Q4,Elderly
171589302,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 qd,,,,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20191203.0,20191216,20211206,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20211206.0,,HP,GB,GB,2021,Q4,Elderly
171589302,17158930,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 qd,,,,,,,,,,,,2021,Q4,Loss of consciousness,,2021,Q4,2,F,,20191203.0,20191216,20211206,EXP,GB-MHRA-TPP34673888C1753076YC1574330452715,GB-NOVOPROD-700210,NOVO NORDISK,,69.0,YR,,F,Y,69.0,KG,20211206.0,,HP,GB,GB,2021,Q4,Elderly
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Blood pressure increased,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Oedema peripheral,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Hypertension,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Renal impairment,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Protein urine present,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Diabetic nephropathy,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,11,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,,,,,,,,,QD,2021,Q4,Oedema,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Blood pressure increased,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Oedema peripheral,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Hypertension,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Renal impairment,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Protein urine present,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Diabetic nephropathy,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
175539607,17553960,12,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,UNK,,,,,,,,,,,QD,2021,Q4,Oedema,,2021,Q4,7,F,20191119.0,20211119.0,20200317,20211129,EXP,,JP-BEH-2020114465,CSL BEHRING,,36.0,YR,A,M,Y,95.6,KG,20211129.0,,MD,JP,JP,2021,Q4,Adult
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve sclerosis,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lipase increased,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Arteriosclerosis coronary artery,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve stenosis,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Infection,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pulmonary hypertension,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Mitral valve incompetence,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Tricuspid valve incompetence,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178773077,17877307,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic obstructive pulmonary disease,,2021,Q4,7,F,20200303.0,20211021.0,20200609,20211028,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-021514,BRISTOL MYERS SQUIBB,,69.0,YR,,M,Y,,,20211028.0,,PH,DE,DE,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Haemoglobin decreased,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,COVID-19,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Platelet count decreased,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Thrombosis,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Drug ineffective,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Contusion,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Ecchymosis,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Product use in unapproved indication,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
178919103,17891910,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"UNK, QD (1 of 12.5 mg/1000 mg)",,,D,,,,,,,,QD,2021,Q4,Red blood cell count decreased,,2021,Q4,3,F,20200201.0,20210929.0,20200612,20211004,EXP,,NVSC2020CO076213,NOVARTIS,,80.0,YR,,M,Y,73.0,KG,20211004.0,,CN,CO,CO,2021,Q4,Elderly
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Candida infection,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Emphysematous pyelonephritis,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Coagulation test abnormal,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Candida sepsis,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Systemic candida,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Septic shock,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Pyelonephritis fungal,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
180976082,18097608,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2021,Q4,Perinephric abscess,,2021,Q4,2,F,,20211013.0,20200731,20211025,EXP,,ES-MYLANLABS-2020M1067951,MYLAN,"Cases-Corona C, Shabaka A, Gonzalez-Lopez A, Martin-Segarra O, Moreno De La Higuera MA, Lucena R, et al. Fulminant Emphysematous Pyelonephritis by Candida glabrata in a Kidney Allograft. Nephron 2020;144(6):304-309.",56.0,YR,,F,Y,,,20211025.0,,MD,ES,ES,2021,Q4,Adult
182842912,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,20180530.0,20211123.0,20200918,20211201,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20211201.0,,MD,CA,,2021,Q4,Elderly
182842912,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2021,Q4,Sepsis,,2021,Q4,2,F,20180530.0,20211123.0,20200918,20211201,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20211201.0,,MD,CA,,2021,Q4,Elderly
182842912,18284291,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,unknown,,,,,,,,,,,,2021,Q4,Chills,,2021,Q4,2,F,20180530.0,20211123.0,20200918,20211201,EXP,,CA-AstraZeneca-2020SF17007,ASTRAZENECA,,66.0,YR,,M,Y,,,20211201.0,,MD,CA,,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve stenosis,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Mitral valve incompetence,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Infection,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pulmonary hypertension,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Arteriosclerosis coronary artery,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Tricuspid valve incompetence,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic obstructive pulmonary disease,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve sclerosis,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lipase increased,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
183641943,18364194,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,3,F,20200303.0,20211102.0,20201009,20211116,EXP,,DE-AUROBINDO-AUR-APL-2020-051429,AUROBINDO,,69.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve stenosis,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lipase increased,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Tricuspid valve incompetence,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Aortic valve sclerosis,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Mitral valve incompetence,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic obstructive pulmonary disease,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Infection,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pulmonary hypertension,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184180253,18418025,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Arteriosclerosis coronary artery,,2021,Q4,3,F,20200303.0,20211103.0,20201022,20211117,EXP,,DE-PFIZER INC-2020411017,PFIZER,,69.0,YR,,M,Y,,,20211117.0,,HP,DE,DE,2021,Q4,Elderly
184821756,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Arthralgia,,2021,Q4,6,F,20201019.0,20211015.0,20201110,20211020,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20211020.0,,MD,COUNTRY NOT SPECIFIED,JP,2021,Q4,Adult
184821756,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Eczema asteatotic,,2021,Q4,6,F,20201019.0,20211015.0,20201110,20211020,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20211020.0,,MD,COUNTRY NOT SPECIFIED,JP,2021,Q4,Adult
184821756,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Rash pruritic,,2021,Q4,6,F,20201019.0,20211015.0,20201110,20211020,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20211020.0,,MD,COUNTRY NOT SPECIFIED,JP,2021,Q4,Adult
184821756,18482175,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Cataract,,2021,Q4,6,F,20201019.0,20211015.0,20201110,20211020,EXP,,JP-ABBVIE-20K-087-3639069-00,ABBVIE,,61.0,YR,,F,Y,,,20211020.0,,MD,COUNTRY NOT SPECIFIED,JP,2021,Q4,Adult
186417058,18641705,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Malignant neoplasm progression,,2021,Q4,8,F,20200720.0,20211005.0,20201221,20211012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, et al. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 486th Meeting of Osaka Dermatology Association. 2021;9",73.0,YR,,M,Y,,,20211012.0,,MD,JP,JP,2021,Q4,Elderly
186417058,18641705,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Colitis,,2021,Q4,8,F,20200720.0,20211005.0,20201221,20211012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, et al. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 486th Meeting of Osaka Dermatology Association. 2021;9",73.0,YR,,M,Y,,,20211012.0,,MD,JP,JP,2021,Q4,Elderly
186417058,18641705,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Pyrexia,,2021,Q4,8,F,20200720.0,20211005.0,20201221,20211012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, et al. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 486th Meeting of Osaka Dermatology Association. 2021;9",73.0,YR,,M,Y,,,20211012.0,,MD,JP,JP,2021,Q4,Elderly
186417058,18641705,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Acute generalised exanthematous pustulosis,,2021,Q4,8,F,20200720.0,20211005.0,20201221,20211012,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-108892,BRISTOL MYERS SQUIBB,"Goto A, et al. A case of acute generalized exanthematous pustulosis during administration of immune checkpoint inhibitors. The 486th Meeting of Osaka Dermatology Association. 2021;9",73.0,YR,,M,Y,,,20211012.0,,MD,JP,JP,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Drug dose titration not performed,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Incorrect dose administered,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Intentional product use issue,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Drug dose titration not performed,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Syncope,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Blood pressure decreased,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Product dose omission issue,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
187420644,18742064,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Product prescribing issue,,2021,Q4,4,F,20200101.0,20211201.0,20210114,20211206,EXP,,CO-BAYER-2020-276785,BAYER,,79.0,YR,E,F,Y,,,20211206.0,,CN,CO,CO,2021,Q4,Elderly
188172302,18817230,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, QD",,,,,,,,25.0,MG,,QD,2021,Q4,Nausea,,2021,Q4,2,F,20201209.0,20211029.0,20210201,20211108,EXP,,US-KARYOPHARM-2020KPT001550,KARYOPHARM THERAPEUTICS,,65.0,YR,,F,Y,,,20211108.0,,MD,US,US,2021,Q4,Elderly
188543134,18854313,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,,,,,,10.0,MG,,QD,2021,Q4,Confusional state,,2021,Q4,4,F,20210122.0,20211103.0,20210205,20211112,EXP,,CA-KARYOPHARM-2021KPT000116,KARYOPHARM THERAPEUTICS,,71.0,YR,,F,Y,66.2,KG,20211112.0,,MD,CA,CA,2021,Q4,Elderly
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Stress,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Chest discomfort,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Dizziness,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Pyrexia,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Malaria,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Eating disorder,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Amnesia,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Malaise,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Abdominal pain,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Vomiting,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Dyspnoea,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Heavy menstrual bleeding,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Oedema peripheral,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
1886105611,18861056,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD  (for 2 weeks)",,,U,,,,,10.0,MG,,QD,2021,Q4,Nasopharyngitis,,2021,Q4,11,F,20201201.0,20211211.0,20210208,20211218,EXP,,NVSC2021NG023994,NOVARTIS,,41.0,YR,,F,Y,,,20211218.0,,HP,NG,NG,2021,Q4,Adult
189227754,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2021,Q4,Product dispensing error,,2021,Q4,4,F,,20211115.0,20210222,20211129,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20211129.0,,MD,US,US,2021,Q4,Adult
189227754,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2021,Q4,Thrombosis,,2021,Q4,4,F,,20211115.0,20210222,20211129,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20211129.0,,MD,US,US,2021,Q4,Adult
189227754,18922775,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, 1x/day",,,,,,,,25.0,MG,,QD,2021,Q4,Product distribution issue,,2021,Q4,4,F,,20211115.0,20210222,20211129,EXP,,US-PFIZER INC-2019538078,PFIZER,,61.0,YR,,F,Y,,,20211129.0,,MD,US,US,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Diabetic coma,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Diabetic metabolic decompensation,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Arthritis,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Coronary artery occlusion,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Inflammation,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
189245423,18924542,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Tonsillitis,,2021,Q4,3,F,20210307.0,20211203.0,20210222,20211208,EXP,,CL-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015453,BRISTOL MYERS SQUIBB,,62.0,YR,,F,Y,,,20211208.0,,CN,CL,CL,2021,Q4,Adult
191098284,19109828,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Idiopathic pulmonary fibrosis,,2021,Q4,4,F,,20211216.0,20210409,20211223,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-095500",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Elderly
191098284,19109828,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,COVID-19 pneumonia,,2021,Q4,4,F,,20211216.0,20210409,20211223,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-095500",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Cardiac failure congestive,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Magnetic resonance imaging heart,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Chronic left ventricular failure,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Ischaemic cardiomyopathy,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Sleep apnoea syndrome,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Renal impairment,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Sinus node dysfunction,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191242915,19124291,26,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, daily",,,,,,,,10.0,MG,,,2021,Q4,Ventricular extrasystoles,,2021,Q4,5,F,20210405.0,20211129.0,20210412,20211208,EXP,,US-VERTEX PHARMACEUTICALS-2021-005668,VERTEX,,79.0,YR,,M,Y,94.3,KG,20211208.0,,MD,US,US,2021,Q4,Elderly
191803892,19180389,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850mg 2x1,,,U,,,,,,,,,2021,Q4,Concomitant disease aggravated,,2021,Q4,2,F,20200501.0,20210413.0,20210426,20211229,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20211229.0,,MD,HR,HR,2021,Q4,Elderly
191803892,19180389,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850mg 2x1,,,U,,,,,,,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,20200501.0,20210413.0,20210426,20211229,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20211229.0,,MD,HR,HR,2021,Q4,Elderly
191803892,19180389,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850mg 2x1,,,U,,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,2,F,20200501.0,20210413.0,20210426,20211229,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20211229.0,,MD,HR,HR,2021,Q4,Elderly
191803892,19180389,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850mg 2x1,,,U,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,2,F,20200501.0,20210413.0,20210426,20211229,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20211229.0,,MD,HR,HR,2021,Q4,Elderly
191803892,19180389,13,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,12.5/850mg 2x1,,,U,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,2,F,20200501.0,20210413.0,20210426,20211229,EXP,,NVSC2021HR087253,NOVARTIS,,80.0,YR,,M,Y,96.0,KG,20211229.0,,MD,HR,HR,2021,Q4,Elderly
1922421510,19224215,7,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 DF, qd",,,U,,,,,,,,QD,2021,Q4,Pneumonia,,2021,Q4,10,F,20210408.0,20211202.0,20210506,20211209,EXP,,KR-GLAXOSMITHKLINE-KR2021085580,GLAXOSMITHKLINE,,67.0,YR,,M,Y,64.0,KG,20211209.0,,MD,KR,KR,2021,Q4,Elderly
192895623,19289562,6,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Vasculitis,,2021,Q4,3,F,20210329.0,20211023.0,20210521,20211026,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-104314",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20211026.0,,MD,CN,CN,2021,Q4,Adult
192895623,19289562,6,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Neutropenia,,2021,Q4,3,F,20210329.0,20211023.0,20210521,20211026,EXP,,"CN-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-104314",BOEHRINGER INGELHEIM,,62.0,YR,A,M,Y,,,20211026.0,,MD,CN,CN,2021,Q4,Adult
1935159218,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,102145.0,,,Film-coated tablet,QD,2021,Q4,Pulmonary embolism,,2021,Q4,18,F,20210525.0,20211217.0,20210531,20211222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20211222.0,,MD,US,US,2021,Q4,Youth
1935159218,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,102145.0,,,Film-coated tablet,QD,2021,Q4,Peripheral ischaemia,,2021,Q4,18,F,20210525.0,20211217.0,20210531,20211222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20211222.0,,MD,US,US,2021,Q4,Youth
1935159218,19351592,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,102145.0,,,Film-coated tablet,QD,2021,Q4,Arm amputation,,2021,Q4,18,F,20210525.0,20211217.0,20210531,20211222,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-106387",BOEHRINGER INGELHEIM,,17.0,YR,T,F,Y,103.6,KG,20211222.0,,MD,US,US,2021,Q4,Youth
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Meningitis,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Scan abnormal,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Diverticulum intestinal,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Bladder diverticulum,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Renal cyst,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Cholelithiasis,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Hepatic cyst,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Hepatic steatosis,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Pneumonia pneumococcal,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Neutropenia,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Splenomegaly,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193546172,19354617,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Platelet count decreased,,2021,Q4,2,F,20180918.0,20211020.0,20210602,20211025,EXP,,JP-TAKEDA-2021TJP031369,TAKEDA,,69.0,YR,,M,Y,70.0,KG,20211025.0,,MD,JP,JP,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Decreased appetite,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Pulmonary arterial hypertension,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Aortic valve sclerosis,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,COVID-19,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
193716422,19371642,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25,,,,,,,,,,,,2021,Q4,Aortic aneurysm,,2021,Q4,2,F,20200501.0,20211004.0,20210604,20211013,EXP,,BR-NOVOPROD-817162,NOVO NORDISK,,80.0,YR,,F,Y,83.6,KG,20211013.0,,CN,BR,BR,2021,Q4,Elderly
194109142,19410914,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,0.005,MG,,BID,2021,Q4,Chest discomfort,,2021,Q4,2,F,20210603.0,20211026.0,20210614,20211104,EXP,,AU-BAXTER-2021BAX015110,BAXTER,,73.0,YR,,F,Y,52.3,KG,20211104.0,,PH,AU,AU,2021,Q4,Elderly
194109142,19410914,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,0.005,MG,,BID,2021,Q4,Dizziness,,2021,Q4,2,F,20210603.0,20211026.0,20210614,20211104,EXP,,AU-BAXTER-2021BAX015110,BAXTER,,73.0,YR,,F,Y,52.3,KG,20211104.0,,PH,AU,AU,2021,Q4,Elderly
194109142,19410914,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,0.005,MG,,BID,2021,Q4,Flushing,,2021,Q4,2,F,20210603.0,20211026.0,20210614,20211104,EXP,,AU-BAXTER-2021BAX015110,BAXTER,,73.0,YR,,F,Y,52.3,KG,20211104.0,,PH,AU,AU,2021,Q4,Elderly
194109142,19410914,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,0.005,MG,,BID,2021,Q4,Somnolence,,2021,Q4,2,F,20210603.0,20211026.0,20210614,20211104,EXP,,AU-BAXTER-2021BAX015110,BAXTER,,73.0,YR,,F,Y,52.3,KG,20211104.0,,PH,AU,AU,2021,Q4,Elderly
194109142,19410914,6,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,,,,,,0.005,MG,,BID,2021,Q4,Cough,,2021,Q4,2,F,20210603.0,20211026.0,20210614,20211104,EXP,,AU-BAXTER-2021BAX015110,BAXTER,,73.0,YR,,F,Y,52.3,KG,20211104.0,,PH,AU,AU,2021,Q4,Elderly
194199763,19419976,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Jardiance duo form strenght: 12.5/1000 mg at night.,,,Y,U,Asked But Unknown,,206111.0,,,Tablet,QD,2021,Q4,Balanoposthitis,,2021,Q4,3,F,20210606.0,20211025.0,20210616,20211029,EXP,,"PE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-109509",BOEHRINGER INGELHEIM,,35.0,YR,A,M,Y,70.0,KG,20211029.0,,MD,PE,PE,2021,Q4,Adult
194199763,19419976,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,Jardiance duo form strenght: 12.5/1000 mg at night.,,,Y,U,Asked But Unknown,,206111.0,,,Tablet,QD,2021,Q4,Diabetic ketoacidosis,,2021,Q4,3,F,20210606.0,20211025.0,20210616,20211029,EXP,,"PE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-109509",BOEHRINGER INGELHEIM,,35.0,YR,A,M,Y,70.0,KG,20211029.0,,MD,PE,PE,2021,Q4,Adult
194264043,19426404,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,,2021,Q4,Hyperthyroidism,,2021,Q4,3,F,,20211104.0,20210617,20211117,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-21-54654,HIKMA,,64.0,YR,,M,Y,85.0,KG,20211117.0,,HP,US,,2021,Q4,Adult
194264043,19426404,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,10.0,MG,Unknown,,2021,Q4,Hypercalcaemia,,2021,Q4,3,F,,20211104.0,20210617,20211117,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-21-54654,HIKMA,,64.0,YR,,M,Y,85.0,KG,20211117.0,,HP,US,,2021,Q4,Adult
194371654,19437165,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hyperthyroidism,,2021,Q4,4,F,,20210918.0,20210619,20211001,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,"Ganesan K, Bradley B, Jones DW, Solomon DS.. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia.. The American journal of the medical sciences.. 2021;1-6",64.0,YR,,M,Y,85.0,KG,20211001.0,,MD,US,US,2021,Q4,Adult
194371654,19437165,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hypercalcaemia,,2021,Q4,4,F,,20210918.0,20210619,20211001,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,"Ganesan K, Bradley B, Jones DW, Solomon DS.. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia.. The American journal of the medical sciences.. 2021;1-6",64.0,YR,,M,Y,85.0,KG,20211001.0,,MD,US,US,2021,Q4,Adult
194371654,19437165,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Hyperthyroidism,,2021,Q4,4,F,,20210918.0,20210619,20211001,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,"Ganesan K, Bradley B, Jones DW, Solomon DS.. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia.. The American journal of the medical sciences.. 2021;1-6",64.0,YR,,M,Y,85.0,KG,20211001.0,,MD,US,US,2021,Q4,Adult
194371654,19437165,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Hypercalcaemia,,2021,Q4,4,F,,20210918.0,20210619,20211001,EXP,,US-AUROBINDO-AUR-APL-2021-025197,AUROBINDO,"Ganesan K, Bradley B, Jones DW, Solomon DS.. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia.. The American journal of the medical sciences.. 2021;1-6",64.0,YR,,M,Y,85.0,KG,20211001.0,,MD,US,US,2021,Q4,Adult
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Abdominal distension,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diabetic neuropathy,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Myocardial infarction,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Orthopnoea,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure abnormal,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hyperthyroidism,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diabetic dyslipidaemia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Psychophysiologic insomnia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Muscle atrophy,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Left ventricular failure,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Asthenia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diabetic nephropathy,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Claustrophobia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chest discomfort,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dizziness,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Anxiety,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Bundle branch block left,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Haematochezia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Obesity,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chronic left ventricular failure,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Insomnia,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dyspnoea exertional,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Coronary artery disease,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
194733224,19473322,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Ischaemic cardiomyopathy,,2021,Q4,4,F,20200101.0,20211208.0,20210629,20211218,EXP,,NVSC2021US139002,NOVARTIS,,67.0,YR,,M,Y,,,20211218.0,,CN,US,US,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Hyperparathyroidism secondary,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Hyperphosphataemia,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Crush syndrome,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Rhabdomyolysis,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Myalgia,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Language disorder,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195211213,19521121,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Sensorimotor disorder,,2021,Q4,3,F,20201203.0,20211004.0,20210712,20211007,EXP,,DE-MYLANLABS-2021M1041685,MYLAN,,75.0,YR,,F,Y,,,20211007.0,,MD,DE,DE,2021,Q4,Elderly
195748173,19574817,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,Tablet,,2021,Q4,Adrenal disorder,,2021,Q4,3,F,20210601.0,20211214.0,20210719,20211220,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,,,20211220.0,,MD,JP,JP,2021,Q4,Elderly
195748173,19574817,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,Tablet,,2021,Q4,Drug eruption,,2021,Q4,3,F,20210601.0,20211214.0,20210719,20211220,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,,,20211220.0,,MD,JP,JP,2021,Q4,Elderly
195748173,19574817,3,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,D,,,,,,,Tablet,,2021,Q4,Interstitial lung disease,,2021,Q4,3,F,20210601.0,20211214.0,20210719,20211220,EXP,,JP-009507513-2107JPN001290J,MERCK,,67.0,YR,,M,Y,,,20211220.0,,MD,JP,JP,2021,Q4,Elderly
196083017,19608301,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5,mg,",,,,,,,,,,,,2021,Q4,Cholelithiasis,,2021,Q4,7,F,20210708.0,20211114.0,20210726,20211119,EXP,,IL-NOVOPROD-828509,NOVO NORDISK,,47.0,YR,,M,Y,86.0,KG,20211119.0,,MD,IL,IL,2021,Q4,Adult
196083017,19608301,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"12.5,mg,",,,,,,,,,,,,2021,Q4,Cholecystitis,,2021,Q4,7,F,20210708.0,20211114.0,20210726,20211119,EXP,,IL-NOVOPROD-828509,NOVO NORDISK,,47.0,YR,,M,Y,86.0,KG,20211119.0,,MD,IL,IL,2021,Q4,Adult
196091443,19609144,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, qd",,,U,,,,,,,Tablet,QD,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,3,F,20210720.0,20211013.0,20210726,20211119,EXP,,JP-009507513-2107JPN001874J,MERCK,,60.0,YR,,M,Y,,,20211119.0,,PH,JP,JP,2021,Q4,Adult
197385582,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,QD,2021,Q4,Vomiting,,2021,Q4,2,F,20210813.0,20211018.0,20210823,20211021,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20211021.0,,MD,GB,GB,2021,Q4,Adult
197385582,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,2,F,20210813.0,20211018.0,20210823,20211021,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20211021.0,,MD,GB,GB,2021,Q4,Adult
197385582,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,2,F,20210813.0,20211018.0,20210823,20211021,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20211021.0,,MD,GB,GB,2021,Q4,Adult
197385582,19738558,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,D,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,20210813.0,20211018.0,20210823,20211021,EXP,GB-MHRA-EYC 00258659,GB-MYLANLABS-2021M1054401,MYLAN,,47.0,YR,,M,Y,115.0,KG,20211021.0,,MD,GB,GB,2021,Q4,Adult
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Medication error,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Diabetic nephropathy,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Renal failure,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Metabolic acidosis,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198231232,19823123,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg,QD (10 MG, DAILY)",,,U,,Unk,,,10.0,MG,Tablet,QD,2021,Q4,Labelled drug-drug interaction medication error,,2021,Q4,2,F,,20210924.0,20210913,20211003,EXP,DE-ADRED-07117-01,NVSC2021DE202203,NOVARTIS,,82.0,YR,,M,Y,82.0,KG,20211003.0,,PH,DE,DE,2021,Q4,Elderly
198265182,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q4,Hypertension,,2021,Q4,2,F,,20211008.0,20210914,20211018,EXP,,ES-ACCORD-237521,ACCORD,"Saldarreaga Marin A, Cendros M, Ciudad CJ, Sabater A. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic Software. Pharmgenomics Pers Med. 2021 Aug 12;14:963-970.",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
198265182,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q4,Fatigue,,2021,Q4,2,F,,20211008.0,20210914,20211018,EXP,,ES-ACCORD-237521,ACCORD,"Saldarreaga Marin A, Cendros M, Ciudad CJ, Sabater A. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic Software. Pharmgenomics Pers Med. 2021 Aug 12;14:963-970.",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
198265182,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q4,Gingival bleeding,,2021,Q4,2,F,,20211008.0,20210914,20211018,EXP,,ES-ACCORD-237521,ACCORD,"Saldarreaga Marin A, Cendros M, Ciudad CJ, Sabater A. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic Software. Pharmgenomics Pers Med. 2021 Aug 12;14:963-970.",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
198265182,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q4,Contusion,,2021,Q4,2,F,,20211008.0,20210914,20211018,EXP,,ES-ACCORD-237521,ACCORD,"Saldarreaga Marin A, Cendros M, Ciudad CJ, Sabater A. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic Software. Pharmgenomics Pers Med. 2021 Aug 12;14:963-970.",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
198265182,19826518,7,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,40.0,MG,,,2021,Q4,Drug interaction,,2021,Q4,2,F,,20211008.0,20210914,20211018,EXP,,ES-ACCORD-237521,ACCORD,"Saldarreaga Marin A, Cendros M, Ciudad CJ, Sabater A. Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic Software. Pharmgenomics Pers Med. 2021 Aug 12;14:963-970.",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
198304612,19830461,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,2,F,,20210923.0,20210915,20211008,EXP,,CZ-BAUSCH-BL-2021-029949,BAUSCH AND LOMB,"Kristlova H, Bockova J, Horazdovsky J, Kadlecova M, Korinkova H, Rosolova A, Peskova M, Rendlova M. Apremilast v lecbe ulceraci pri suspektni non-uremick kealcifylaxi. Popis pripadu. Cesko-Slovenia dermatologie. 2021;96(3):142-148.",55.0,YR,,F,Y,115.0,KG,20211008.0,,MD,CZ,CZ,2021,Q4,Adult
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Labelled drug-drug interaction medication error,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Renal failure,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Metabolic acidosis,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Hyperkalaemia,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Diabetic nephropathy,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Product prescribing error,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198467523,19846752,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, Daily",,,D,,,,,10.0,MG,Tablet,QD,2021,Q4,Medication error,,2021,Q4,3,F,,20210930.0,20210917,20211122,EXP,,DE-009507513-2109DEU003028,MERCK,,82.0,YR,,M,Y,82.0,KG,20211122.0,,PH,DE,DE,2021,Q4,Elderly
198590162,19859016,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, 40 mg/d",,,U,,,,,40.0,MG,,,2021,Q4,Contusion,,2021,Q4,2,F,,20211011.0,20210921,20211026,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic software. Pharmacog Pers Med. 2021;14:963-970",65.0,YR,,M,Y,,,20211026.0,,MD,ES,ES,2021,Q4,Elderly
198590162,19859016,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, 40 mg/d",,,U,,,,,40.0,MG,,,2021,Q4,Sensory disturbance,,2021,Q4,2,F,,20211011.0,20210921,20211026,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic software. Pharmacog Pers Med. 2021;14:963-970",65.0,YR,,M,Y,,,20211026.0,,MD,ES,ES,2021,Q4,Elderly
198590162,19859016,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, 40 mg/d",,,U,,,,,40.0,MG,,,2021,Q4,Coagulopathy,,2021,Q4,2,F,,20211011.0,20210921,20211026,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic software. Pharmacog Pers Med. 2021;14:963-970",65.0,YR,,M,Y,,,20211026.0,,MD,ES,ES,2021,Q4,Elderly
198590162,19859016,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, 40 mg/d",,,U,,,,,40.0,MG,,,2021,Q4,Drug interaction,,2021,Q4,2,F,,20211011.0,20210921,20211026,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic software. Pharmacog Pers Med. 2021;14:963-970",65.0,YR,,M,Y,,,20211026.0,,MD,ES,ES,2021,Q4,Elderly
198590162,19859016,7,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, 40 mg/d",,,U,,,,,40.0,MG,,,2021,Q4,Gingival bleeding,,2021,Q4,2,F,,20211011.0,20210921,20211026,EXP,,ES-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-311994,RANBAXY,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic software. Pharmacog Pers Med. 2021;14:963-970",65.0,YR,,M,Y,,,20211026.0,,MD,ES,ES,2021,Q4,Elderly
198873663,19887366,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,Y,U,Unknown,,206073.0,,,Tablet,,2021,Q4,Metabolic acidosis,,2021,Q4,3,F,20210823.0,20211105.0,20210928,20211110,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-129363",BOEHRINGER INGELHEIM,,68.0,YR,E,M,Y,76.4,KG,20211110.0,,MD,JP,JP,2021,Q4,Elderly
198904882,19890488,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Oesophagitis,,2021,Q4,2,F,20210831.0,20211215.0,20210927,20211222,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-095697,BRISTOL MYERS SQUIBB,,56.0,YR,,M,Y,138.0,KG,20211222.0,,HP,US,US,2021,Q4,Adult
199030612,19903061,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,unknown,,,,,,,2021,Q4,Pancreatitis acute,,2021,Q4,2,F,20210809.0,20211018.0,20211001,20211028,EXP,,ES-NOVOPROD-849719,NOVO NORDISK,,66.0,YR,,F,Y,,,20211028.0,,MD,ES,ES,2021,Q4,Elderly
199030612,19903061,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,unknown,,,,,,,2021,Q4,Hepatitis viral,,2021,Q4,2,F,20210809.0,20211018.0,20211001,20211028,EXP,,ES-NOVOPROD-849719,NOVO NORDISK,,66.0,YR,,F,Y,,,20211028.0,,MD,ES,ES,2021,Q4,Elderly
199030612,19903061,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,unknown,,,,,,,2021,Q4,Pulmonary oedema,,2021,Q4,2,F,20210809.0,20211018.0,20211001,20211028,EXP,,ES-NOVOPROD-849719,NOVO NORDISK,,66.0,YR,,F,Y,,,20211028.0,,MD,ES,ES,2021,Q4,Elderly
199030612,19903061,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,unknown,,,,,,,2021,Q4,Renal failure,,2021,Q4,2,F,20210809.0,20211018.0,20211001,20211028,EXP,,ES-NOVOPROD-849719,NOVO NORDISK,,66.0,YR,,F,Y,,,20211028.0,,MD,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Drug interaction,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Contusion,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Hypertension,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Gingival bleeding,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199031292,19903129,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 milligram, Once a Day",,,U,,,,,40.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,2,F,,20211004.0,20211001,20211018,EXP,,ES-AUROBINDO-AUR-APL-2021-038065,AUROBINDO,"Sabater A, Marin AS, Cendros M, Ciudad CJ .. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software.. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199082031,19908203,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"60 mg, QD",,,U,,,,,60.0,MG,,QD,2021,Q4,Pyoderma gangrenosum,,2021,Q4,1,I,20210730.0,20210924.0,20211001,20211001,EXP,,AR-SA-2021SA321372,SANOFI AVENTIS,,76.0,YR,E,M,Y,,,20211001.0,,MD,AR,AR,2021,Q4,Elderly
199083761,19908376,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1 dosage form, unknown",,,,,,,,,,,,2021,Q4,Hyperinsulinaemic hypoglycaemia,,2021,Q4,1,I,20210809.0,20210920.0,20211001,20211001,EXP,IT-MINISAL02-788593,IT-ELI_LILLY_AND_COMPANY-IT202109007673,ELI LILLY AND CO,,69.0,YR,,M,Y,106.0,KG,20211001.0,,CN,IT,IT,2021,Q4,Elderly
199211831,19921183,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q4,Neurotoxicity,,2021,Q4,1,I,,20210924.0,20211006,20211006,EXP,,US-BAXTER-2021BAX030793,BAXTER,"BEHAL M, THOMAS J, THOMPSON BASTIN M, Mefford B. CEFEPIME INDUCED NEUROTOXICITY FOLLOWING A REGIMEN DOSE-ADJUSTED FOR RENAL FUNCTION: CASE REPORT AND REVIEW OF THE LITERATURE. HOSPITAL PHARMACY. 2021;1-7.",43.0,YR,,F,Y,,,20211006.0,,HP,US,US,2021,Q4,Adult
199211831,19921183,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q4,Mean arterial pressure increased,,2021,Q4,1,I,,20210924.0,20211006,20211006,EXP,,US-BAXTER-2021BAX030793,BAXTER,"BEHAL M, THOMAS J, THOMPSON BASTIN M, Mefford B. CEFEPIME INDUCED NEUROTOXICITY FOLLOWING A REGIMEN DOSE-ADJUSTED FOR RENAL FUNCTION: CASE REPORT AND REVIEW OF THE LITERATURE. HOSPITAL PHARMACY. 2021;1-7.",43.0,YR,,F,Y,,,20211006.0,,HP,US,US,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Toxicity to various agents,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Renal impairment,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Atrial flutter,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Blood pressure decreased,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199225231,19922523,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 mg, qd, After breakfast",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Weight decreased,,2021,Q4,1,I,,20210928.0,20211005,20211005,EXP,,JP-DSJP-DSJ-2021-131729,DAIICHI,"Tsuji H, Mantani T, Yamamoto Y. A case of severe obesity patient with bipolar affective disorder complicated with acute lithium poisoning during hospitalization for low calorie diet therapy. Journal of Japan Society for the Study of Obesity. 2021;27(2):99-102",56.0,YR,,M,Y,119.0,KG,20211005.0,,MD,JP,JP,2021,Q4,Adult
199235951,19923595,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,NVSC2021PL221800,NOVARTIS,,71.0,YR,,,Y,,,20211006.0,,MD,PL,PL,2021,Q4,Elderly
199235951,19923595,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,NVSC2021PL221800,NOVARTIS,,71.0,YR,,,Y,,,20211006.0,,MD,PL,PL,2021,Q4,Elderly
199235951,19923595,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Pneumonia,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,NVSC2021PL221800,NOVARTIS,,71.0,YR,,,Y,,,20211006.0,,MD,PL,PL,2021,Q4,Elderly
199235951,19923595,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Ventricular tachycardia,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,NVSC2021PL221800,NOVARTIS,,71.0,YR,,,Y,,,20211006.0,,MD,PL,PL,2021,Q4,Elderly
199235951,19923595,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,NVSC2021PL221800,NOVARTIS,,71.0,YR,,,Y,,,20211006.0,,MD,PL,PL,2021,Q4,Elderly
199256821,19925682,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,10.0,MG,Tablet,QD,2021,Q4,COVID-19,,2021,Q4,1,I,20210701.0,20210928.0,20211007,20211007,EXP,,GB-ROCHE-2925504,ROCHE,,52.0,YR,,F,Y,,,20211007.0,,MD,GB,GB,2021,Q4,Adult
199282541,19928254,9,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"25/5 milligram, qam",,,,,,,,,,,,2021,Q4,Eye pain,,2021,Q4,1,I,20210329.0,20210330.0,20211007,20211007,EXP,,AU-HTU-2021AU023421,HELSINN HEALTHCARE,,69.0,YR,,F,Y,93.8,KG,20211007.0,,MD,AU,AU,2021,Q4,Elderly
199301804,19930180,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,Tablets,,2021,Q4,Cellulitis,,2021,Q4,4,F,20210911.0,20211105.0,20211007,20211112,EXP,,CN-Eisai Medical Research-EC-2021-100765,EISAI,,51.0,YR,A,F,Y,47.0,KG,20211112.0,,MD,CN,,2021,Q4,Adult
199435611,19943561,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Diarrhoea,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070718,MYLAN,,74.0,YR,,M,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199435611,19943561,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Dehydration,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070718,MYLAN,,74.0,YR,,M,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199435611,19943561,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070718,MYLAN,,74.0,YR,,M,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199435611,19943561,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070718,MYLAN,,74.0,YR,,M,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199435611,19943561,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070718,MYLAN,,74.0,YR,,M,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199437352,19943735,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q4,Off label use,,2021,Q4,2,F,,20211008.0,20211011,20211019,EXP,,RU-EMD SERONO-9269464,EMD SERONO INC,"Demidova T, Gritskevich E, Izmaylova M. Features of differential diagnosis of diabetes mellitus in the modern world: clinical observation. Endocrinology: news, opinions, training. 2021;10 (2):112-117. doi:https://doi.org/10.33029/2304- 9529-2021-10-2-112-117",19.0,YR,A,M,Y,90.0,KG,20211019.0,,MD,RU,RU,2021,Q4,Youth
199437352,19943735,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,,QD,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,2,F,,20211008.0,20211011,20211019,EXP,,RU-EMD SERONO-9269464,EMD SERONO INC,"Demidova T, Gritskevich E, Izmaylova M. Features of differential diagnosis of diabetes mellitus in the modern world: clinical observation. Endocrinology: news, opinions, training. 2021;10 (2):112-117. doi:https://doi.org/10.33029/2304- 9529-2021-10-2-112-117",19.0,YR,A,M,Y,90.0,KG,20211019.0,,MD,RU,RU,2021,Q4,Youth
199456061,19945606,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"0.25 mg, qd",,,,,,,,0.25,MG,Tablet,QD,2021,Q4,Urinary tract infection,,2021,Q4,1,I,20210924.0,20210924.0,20211012,20211012,EXP,,JP-DSJP-DSJ-2021-131401,DAIICHI,,49.0,YR,,F,Y,71.0,KG,20211012.0,,MD,JP,JP,2021,Q4,Adult
199460542,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Erythema,,2021,Q4,2,F,,20211007.0,20211012,20211018,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20211018.0,,PH,DE,DE,2021,Q4,Elderly
199460542,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Decubitus ulcer,,2021,Q4,2,F,,20211007.0,20211012,20211018,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20211018.0,,PH,DE,DE,2021,Q4,Elderly
199460542,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Peripheral swelling,,2021,Q4,2,F,,20211007.0,20211012,20211018,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20211018.0,,PH,DE,DE,2021,Q4,Elderly
199460542,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Pyrexia,,2021,Q4,2,F,,20211007.0,20211012,20211018,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20211018.0,,PH,DE,DE,2021,Q4,Elderly
199460542,19946054,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,,,,,,10.0,MG,Tablet,QD,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211007.0,20211012,20211018,EXP,,DE-MYLANLABS-2021M1070977,MYLAN,,70.0,YR,,M,Y,95.0,KG,20211018.0,,PH,DE,DE,2021,Q4,Elderly
199486441,19948644,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,,,,U,,Unknown,,206111.0,,,,,2021,Q4,Vulval abscess,,2021,Q4,1,I,,20211011.0,20211013,20211013,EXP,,"AU-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-131748",BOEHRINGER INGELHEIM,,66.0,YR,E,F,Y,,,20211013.0,,HP,AU,AU,2021,Q4,Elderly
199491941,19949194,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK (10 mg, 1-0-0-0, Tabletten)",,,,,,,,,,Tablet,,2021,Q4,Contraindicated product administered,,2021,Q4,1,I,20200930.0,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071251,MYLAN,,75.0,YR,,M,Y,110.0,KG,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199491941,19949194,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK (10 mg, 1-0-0-0, Tabletten)",,,,,,,,,,Tablet,,2021,Q4,Haematuria,,2021,Q4,1,I,20200930.0,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071251,MYLAN,,75.0,YR,,M,Y,110.0,KG,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199533161,19953316,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,1,I,20210714.0,,20211012,20211012,DIR,FDA-CDER-CTU-2021-75547,,FDA-CTU,,76.0,YR,,M,N,,,20210902.0,N,PH,US,US,2021,Q4,Elderly
199533791,19953379,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q4,Groin infection,,2021,Q4,1,I,,,20211012,20211012,DIR,FDA-CDER-CTU-2021-75568,,FDA-CTU,,70.0,YR,,M,N,128.0,KG,20210826.0,N,PH,US,US,2021,Q4,Elderly
199533791,19953379,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,,,,,25.0,MG,,QD,2021,Q4,Rash,,2021,Q4,1,I,,,20211012,20211012,DIR,FDA-CDER-CTU-2021-75568,,FDA-CTU,,70.0,YR,,M,N,128.0,KG,20210826.0,N,PH,US,US,2021,Q4,Elderly
199541931,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, Tabletten)",,,,,,,,10.0,MG,Tablet,,2021,Q4,Flatulence,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20211013.0,,MD,DE,DE,2021,Q4,Elderly
199541931,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, Tabletten)",,,,,,,,10.0,MG,Tablet,,2021,Q4,Haematuria,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20211013.0,,MD,DE,DE,2021,Q4,Elderly
199541931,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, Tabletten)",,,,,,,,10.0,MG,Tablet,,2021,Q4,Abdominal pain,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20211013.0,,MD,DE,DE,2021,Q4,Elderly
199541931,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, Tabletten)",,,,,,,,10.0,MG,Tablet,,2021,Q4,Micturition disorder,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20211013.0,,MD,DE,DE,2021,Q4,Elderly
199541931,19954193,16,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram (1-1-1-0, Tabletten)",,,,,,,,10.0,MG,Tablet,,2021,Q4,Constipation,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071377,MYLAN,,82.0,YR,,M,Y,,,20211013.0,,MD,DE,DE,2021,Q4,Elderly
199552131,19955213,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,U,,Unknown,,206111.0,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,,20211013.0,20211013,20211013,EXP,,"EC-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-132373",BOEHRINGER INGELHEIM,,56.0,YR,A,F,Y,,,20211013.0,,MD,EC,EC,2021,Q4,Adult
199562291,19956229,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211010.0,20211014,20211014,EXP,,PL-TEVA-2021-PL-1967320,TEVA,,71.0,YR,E,,Y,,,20211014.0,,MD,PL,PL,2021,Q4,Elderly
199562291,19956229,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2021,Q4,Ventricular tachycardia,,2021,Q4,1,I,,20211010.0,20211014,20211014,EXP,,PL-TEVA-2021-PL-1967320,TEVA,,71.0,YR,E,,Y,,,20211014.0,,MD,PL,PL,2021,Q4,Elderly
199562291,19956229,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211010.0,20211014,20211014,EXP,,PL-TEVA-2021-PL-1967320,TEVA,,71.0,YR,E,,Y,,,20211014.0,,MD,PL,PL,2021,Q4,Elderly
199562291,19956229,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211010.0,20211014,20211014,EXP,,PL-TEVA-2021-PL-1967320,TEVA,,71.0,YR,E,,Y,,,20211014.0,,MD,PL,PL,2021,Q4,Elderly
199562291,19956229,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10 Milligram Daily;,,,,,,,,,,,,2021,Q4,Cardiac failure chronic,,2021,Q4,1,I,,20211010.0,20211014,20211014,EXP,,PL-TEVA-2021-PL-1967320,TEVA,,71.0,YR,E,,Y,,,20211014.0,,MD,PL,PL,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Impaired quality of life,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Gastrointestinal disorder,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Drug intolerance,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Hypophagia,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Fall,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Inappropriate schedule of product administration,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Incorrect product formulation administered,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Hypoglycaemia,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Nausea,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Arthralgia,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199562942,19956294,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Back pain,,2021,Q4,2,F,,20211011.0,20211014,20211018,EXP,,DE-IPCA LABORATORIES LIMITED-IPC-2021-DE-001758,IPCA,"Heitmann L, Dartsch D and  Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161 (31):12-53",70.0,YR,,F,Y,80.0,KG,20211018.0,,MD,DE,DE,2021,Q4,Elderly
199569771,19956977,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 10 mg, 1-0-0-0, TabletS",,,U,,,,,10.0,MG,,QD,2021,Q4,Cellulitis,,2021,Q4,1,I,,20211008.0,20211014,20211014,EXP,,DE-MYLANLABS-2021M1071409,MYLAN,,70.0,YR,,M,Y,89.0,KG,20211014.0,,PH,DE,DE,2021,Q4,Elderly
199569771,19956977,13,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, 10 mg, 1-0-0-0, TabletS",,,U,,,,,10.0,MG,,QD,2021,Q4,Skin ulcer,,2021,Q4,1,I,,20211008.0,20211014,20211014,EXP,,DE-MYLANLABS-2021M1071409,MYLAN,,70.0,YR,,M,Y,89.0,KG,20211014.0,,PH,DE,DE,2021,Q4,Elderly
199587041,19958704,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1/2;,,,,,,,,,,Tablet,QD,2021,Q4,Blood creatinine increased,,2021,Q4,1,I,20210525.0,,20211012,20211012,DIR,FDA-CDER-CTU-2021-75620,,FDA-CTU,,68.0,YR,,M,N,104.0,KG,20210709.0,N,PH,US,US,2021,Q4,Elderly
199587041,19958704,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER DOSE:1/2;,,,,,,,,,,Tablet,QD,2021,Q4,Blood urea increased,,2021,Q4,1,I,20210525.0,,20211012,20211012,DIR,FDA-CDER-CTU-2021-75620,,FDA-CTU,,68.0,YR,,M,N,104.0,KG,20210709.0,N,PH,US,US,2021,Q4,Elderly
199587321,19958732,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,,,unk,,,10.0,MG,,QD,2021,Q4,COVID-19 pneumonia,,2021,Q4,1,I,20210601.0,20211005.0,20211015,20211015,EXP,,BR-NOVOPROD-855008,NOVO NORDISK,,82.0,YR,,F,Y,74.4,KG,20211015.0,,MD,BR,BR,2021,Q4,Elderly
199587321,19958732,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,,,unk,,,10.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210601.0,20211005.0,20211015,20211015,EXP,,BR-NOVOPROD-855008,NOVO NORDISK,,82.0,YR,,F,Y,74.4,KG,20211015.0,,MD,BR,BR,2021,Q4,Elderly
199587321,19958732,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,,,unk,,,10.0,MG,,QD,2021,Q4,Blood glucose abnormal,,2021,Q4,1,I,20210601.0,20211005.0,20211015,20211015,EXP,,BR-NOVOPROD-855008,NOVO NORDISK,,82.0,YR,,F,Y,74.4,KG,20211015.0,,MD,BR,BR,2021,Q4,Elderly
199587321,19958732,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,,,unk,,,10.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210601.0,20211005.0,20211015,20211015,EXP,,BR-NOVOPROD-855008,NOVO NORDISK,,82.0,YR,,F,Y,74.4,KG,20211015.0,,MD,BR,BR,2021,Q4,Elderly
199587321,19958732,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, qd",,,,,unk,,,10.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210601.0,20211005.0,20211015,20211015,EXP,,BR-NOVOPROD-855008,NOVO NORDISK,,82.0,YR,,F,Y,74.4,KG,20211015.0,,MD,BR,BR,2021,Q4,Elderly
199591631,19959163,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd (1-0-0-0, Tabletten)",,,U,U,,,,,,Tablet,QD,2021,Q4,Blood glucose fluctuation,,2021,Q4,1,I,,20211009.0,20211015,20211015,EXP,,DE-MYLANLABS-2021M1071636,MYLAN,,88.0,YR,,F,Y,,,20211015.0,,MD,DE,DE,2021,Q4,Elderly
199591631,19959163,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd (1-0-0-0, Tabletten)",,,U,U,,,,,,Tablet,QD,2021,Q4,Arrhythmia,,2021,Q4,1,I,,20211009.0,20211015,20211015,EXP,,DE-MYLANLABS-2021M1071636,MYLAN,,88.0,YR,,F,Y,,,20211015.0,,MD,DE,DE,2021,Q4,Elderly
199591631,19959163,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd (1-0-0-0, Tabletten)",,,U,U,,,,,,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211009.0,20211015,20211015,EXP,,DE-MYLANLABS-2021M1071636,MYLAN,,88.0,YR,,F,Y,,,20211015.0,,MD,DE,DE,2021,Q4,Elderly
199591631,19959163,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"UNK UNK, qd (1-0-0-0, Tabletten)",,,U,U,,,,,,Tablet,QD,2021,Q4,Fatigue,,2021,Q4,1,I,,20211009.0,20211015,20211015,EXP,,DE-MYLANLABS-2021M1071636,MYLAN,,88.0,YR,,F,Y,,,20211015.0,,MD,DE,DE,2021,Q4,Elderly
199605092,19960509,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Glaucoma,,2021,Q4,2,F,20210823.0,20211026.0,20211015,20211029,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-131968",BOEHRINGER INGELHEIM,,80.0,YR,E,M,Y,84.7,KG,20211029.0,,MD,JP,JP,2021,Q4,Elderly
199644021,19964402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Bradycardia,,2021,Q4,1,I,20211009.0,20211012.0,20211018,20211018,EXP,GB-MHRA-MIDB-9534E6A1-A309-4ED5-AE07-4FBAF960E8B8,GB-MYLANLABS-2021M1072639,MYLAN,,59.0,YR,,M,Y,,,20211018.0,,PH,GB,GB,2021,Q4,Adult
199644021,19964402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Dizziness,,2021,Q4,1,I,20211009.0,20211012.0,20211018,20211018,EXP,GB-MHRA-MIDB-9534E6A1-A309-4ED5-AE07-4FBAF960E8B8,GB-MYLANLABS-2021M1072639,MYLAN,,59.0,YR,,M,Y,,,20211018.0,,PH,GB,GB,2021,Q4,Adult
199644021,19964402,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Hypotension,,2021,Q4,1,I,20211009.0,20211012.0,20211018,20211018,EXP,GB-MHRA-MIDB-9534E6A1-A309-4ED5-AE07-4FBAF960E8B8,GB-MYLANLABS-2021M1072639,MYLAN,,59.0,YR,,M,Y,,,20211018.0,,PH,GB,GB,2021,Q4,Adult
199655841,19965584,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 iU,,,U,,,,,60.0,IU,,,2021,Q4,Bile duct stone,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 iU,,,U,,,,,60.0,IU,,,2021,Q4,Balanoposthitis,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 iU,,,U,,,,,60.0,IU,,,2021,Q4,Diabetic neuropathy,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,20,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 iU,,,U,,,,,60.0,IU,,,2021,Q4,Diabetic retinopathy,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Bile duct stone,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Balanoposthitis,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Diabetic neuropathy,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655841,19965584,21,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Diabetic retinopathy,,2021,Q4,1,I,,20211011.0,20211018,20211018,EXP,,SK-SA-2021SA338452,SANOFI AVENTIS,,66.0,YR,E,M,Y,93.0,KG,20211018.0,,MD,SK,SK,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Gingival bleeding,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Increased tendency to bruise,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Haemorrhage,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Drug interaction,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Hypertension,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199655881,19965588,9,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"40 mg, QD",,,U,,,,,40.0,MG,,QD,2021,Q4,Coagulopathy,,2021,Q4,1,I,,20210826.0,20211018,20211018,EXP,,ES-SAKK-2021SA284537AA,SANOFI AVENTIS,"Marin AS, Cendros M, Ciudad CJ, Sabater A. Case report: Fatigue and bleeding in a polymedicated patient using several herbal supplementations, detected with g-nomic? software. Pharmacogenomics and Personalized Medicine. 2021;14:963-970",65.0,YR,E,M,Y,,,20211018.0,,HP,ES,ES,2021,Q4,Elderly
199687521,19968752,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,Malaise,,2021,Q4,1,I,20211012.0,20211013.0,20211019,20211019,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-MYLANLABS-2021M1073093,MYLAN,,82.0,YR,,M,Y,118.0,KG,20211019.0,,MD,GB,GB,2021,Q4,Elderly
199687521,19968752,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 dosage form, qd",,,,,,,,,,Tablet,QD,2021,Q4,"Hallucination, visual",,2021,Q4,1,I,20211012.0,20211013.0,20211019,20211019,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-MYLANLABS-2021M1073093,MYLAN,,82.0,YR,,M,Y,118.0,KG,20211019.0,,MD,GB,GB,2021,Q4,Elderly
199687521,19968752,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2021,Q4,Malaise,,2021,Q4,1,I,20211012.0,20211013.0,20211019,20211019,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-MYLANLABS-2021M1073093,MYLAN,,82.0,YR,,M,Y,118.0,KG,20211019.0,,MD,GB,GB,2021,Q4,Elderly
199687521,19968752,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,Tablet,,2021,Q4,"Hallucination, visual",,2021,Q4,1,I,20211012.0,20211013.0,20211019,20211019,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-MYLANLABS-2021M1073093,MYLAN,,82.0,YR,,M,Y,118.0,KG,20211019.0,,MD,GB,GB,2021,Q4,Elderly
199691971,19969197,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2021,Q4,Spontaneous bacterial peritonitis,,2021,Q4,1,I,20210908.0,20211014.0,20211019,20211019,EXP,CH-SM-2021-24150,CH-ELI_LILLY_AND_COMPANY-CH202110005961,ELI LILLY AND CO,,70.0,YR,,M,Y,,,20211019.0,,CN,CH,CH,2021,Q4,Elderly
199691971,19969197,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2021,Q4,Septic shock,,2021,Q4,1,I,20210908.0,20211014.0,20211019,20211019,EXP,CH-SM-2021-24150,CH-ELI_LILLY_AND_COMPANY-CH202110005961,ELI LILLY AND CO,,70.0,YR,,M,Y,,,20211019.0,,CN,CH,CH,2021,Q4,Elderly
199691971,19969197,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,"UNK, unknown",,,,,,,,,,,,2021,Q4,Pancytopenia,,2021,Q4,1,I,20210908.0,20211014.0,20211019,20211019,EXP,CH-SM-2021-24150,CH-ELI_LILLY_AND_COMPANY-CH202110005961,ELI LILLY AND CO,,70.0,YR,,M,Y,,,20211019.0,,CN,CH,CH,2021,Q4,Elderly
199697532,19969753,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Spontaneous bacterial peritonitis,,2021,Q4,2,F,20210908.0,20211014.0,20211019,20211021,EXP,CH-SM-2021-24150,CH-MYLANLABS-2021M1073129,MYLAN,,70.0,YR,,M,Y,,,20211021.0,,PH,CH,CH,2021,Q4,Elderly
199697532,19969753,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Pancytopenia,,2021,Q4,2,F,20210908.0,20211014.0,20211019,20211021,EXP,CH-SM-2021-24150,CH-MYLANLABS-2021M1073129,MYLAN,,70.0,YR,,M,Y,,,20211021.0,,PH,CH,CH,2021,Q4,Elderly
199697532,19969753,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Septic shock,,2021,Q4,2,F,20210908.0,20211014.0,20211019,20211021,EXP,CH-SM-2021-24150,CH-MYLANLABS-2021M1073129,MYLAN,,70.0,YR,,M,Y,,,20211021.0,,PH,CH,CH,2021,Q4,Elderly
199706471,19970647,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211012.0,20211019,20211019,EXP,,US-EMD SERONO-9272833,EMD SERONO INC,"Byrd M, Fang M, Khan U, Bouchonville M, Argyropoulos C, Teixeira J. EUGLYCEMIC DIABETIC KETOACIDOSIS MASQUERADING AS TOXIC ALCOHOL INGESTION.. Chest.. 2021 OCT 01;160(4):A683.",53.0,YR,A,F,Y,,,20211019.0,,HP,US,US,2021,Q4,Adult
199706471,19970647,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q4,Pancreatitis,,2021,Q4,1,I,,20211012.0,20211019,20211019,EXP,,US-EMD SERONO-9272833,EMD SERONO INC,"Byrd M, Fang M, Khan U, Bouchonville M, Argyropoulos C, Teixeira J. EUGLYCEMIC DIABETIC KETOACIDOSIS MASQUERADING AS TOXIC ALCOHOL INGESTION.. Chest.. 2021 OCT 01;160(4):A683.",53.0,YR,A,F,Y,,,20211019.0,,HP,US,US,2021,Q4,Adult
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Impaired quality of life,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Drug intolerance,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Back pain,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Fall,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Hypophagia,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Gastrointestinal disorder,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Incorrect product formulation administered,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Arthralgia,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Inappropriate schedule of product administration,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Hypoglycaemia,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199713052,19971305,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day (1-0-0)",,,,,,,,,,Tablet,QD,2021,Q4,Nausea,,2021,Q4,2,F,,20211028.0,20211020,20211110,EXP,,DE-AUROBINDO-AUR-APL-2021-042939,AUROBINDO,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211111.0,,PH,DE,DE,2021,Q4,Elderly
199751442,19975144,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"1 DF, 1x/day(1-0-0).",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Nausea,,2021,Q4,2,F,,20211018.0,20211020,20211101,EXP,,DE-PFIZER INC-202101361236,PFIZER,"Rose, O.. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches.. Deutsche Apotheker Zeitung. 2021;161(31)",70.0,YR,,F,Y,80.0,KG,20211101.0,,HP,DE,DE,2021,Q4,Elderly
199772042,19977204,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,Unknown,,206073.0,,,Tablet,,2021,Q4,Pneumonia viral,,2021,Q4,2,F,20211019.0,20211102.0,20211021,20211109,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-133774",BOEHRINGER INGELHEIM,,72.0,YR,E,M,Y,,,20211109.0,,MD,JP,JP,2021,Q4,Elderly
199808701,19980870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211006.0,20211022,20211022,PER,,US-LUPIN PHARMACEUTICALS INC.-2021-20024,LUPIN,"Jones A, Mospan C. Successful concomitant use of oral semaglutide with levothyroxine to achieve glycemic control: A case report. Journal of the American College of Clinical Pharmacy. 2021;4(9):1251",52.0,YR,,F,Y,,,20211022.0,,PH,US,US,2021,Q4,Adult
199808701,19980870,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Drug interaction,,2021,Q4,1,I,,20211006.0,20211022,20211022,PER,,US-LUPIN PHARMACEUTICALS INC.-2021-20024,LUPIN,"Jones A, Mospan C. Successful concomitant use of oral semaglutide with levothyroxine to achieve glycemic control: A case report. Journal of the American College of Clinical Pharmacy. 2021;4(9):1251",52.0,YR,,F,Y,,,20211022.0,,PH,US,US,2021,Q4,Adult
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Incorrect product formulation administered,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Hyperthyroidism,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Fall,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Inappropriate schedule of product administration,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Drug intolerance,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Gastrointestinal disorder,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Impaired quality of life,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Arthralgia,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Back pain,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199843281,19984328,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"1 dosage form, qd (1-0-0)",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Hypophagia,,2021,Q4,1,I,,20211007.0,20211022,20211022,EXP,,DE-LUPIN PHARMACEUTICALS INC.-2021-19637,LUPIN,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. Deutsche Apotheker Zeitung. 2021;161(31):161",70.0,YR,,F,Y,80.0,KG,20211022.0,,HP,DE,DE,2021,Q4,Elderly
199850012,19985001,15,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,2,F,20200607.0,20211020.0,20211022,20211022,EXP,,NVSC2021AU085120,NOVARTIS,,57.0,YR,,F,Y,98.0,KG,20211022.0,,MD,AU,AU,2021,Q4,Adult
199862651,19986265,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1 Dosage forms Daily;,,,,,,,,,,Tablet,QD,2021,Q4,"Hallucination, visual",,2021,Q4,1,I,20211012.0,20211013.0,20211022,20211022,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-TEVA-2021-GB-1967310,TEVA,,82.0,YR,E,M,Y,118.0,KG,20211022.0,,MD,GB,GB,2021,Q4,Elderly
199862651,19986265,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,"Hallucination, visual",,2021,Q4,1,I,20211012.0,20211013.0,20211022,20211022,EXP,GB-MHRA-TPP20367134C2335742YC1634028614505,GB-TEVA-2021-GB-1967310,TEVA,,82.0,YR,E,M,Y,118.0,KG,20211022.0,,MD,GB,GB,2021,Q4,Elderly
199873183,19987318,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,5 milligram,,,,,,,,5.0,MG,,,2021,Q4,Pancytopenia,,2021,Q4,3,F,20210908.0,20211119.0,20211022,20211201,EXP,,CH-PFIZER INC-202101404367,PFIZER,,70.0,YR,,M,Y,,,20211201.0,,PH,CH,CH,2021,Q4,Elderly
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Weight increased,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Therapeutic product effect incomplete,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Diabetic metabolic decompensation,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199914802,19991480,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,2 dosage form,,,,,,,,,,,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,2,F,20160501.0,20211026.0,20211025,20211103,EXP,,SK-MYLANLABS-2021M1046357,MYLAN,"Kollarova D, Martinka E, Urbanova M et al.. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211103.0,,MD,SK,SK,2021,Q4,Adult
199934601,19993460,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Acute pulmonary oedema,,2021,Q4,1,I,,20211013.0,20211025,20211025,EXP,,BR-NOVOPROD-857570,NOVO NORDISK,,76.0,YR,,F,Y,77.0,KG,20211025.0,,MD,BR,BR,2021,Q4,Elderly
199934601,19993460,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Coronary artery occlusion,,2021,Q4,1,I,,20211013.0,20211025,20211025,EXP,,BR-NOVOPROD-857570,NOVO NORDISK,,76.0,YR,,F,Y,77.0,KG,20211025.0,,MD,BR,BR,2021,Q4,Elderly
199934601,19993460,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Acute pulmonary oedema,,2021,Q4,1,I,,20211013.0,20211025,20211025,EXP,,BR-NOVOPROD-857570,NOVO NORDISK,,76.0,YR,,F,Y,77.0,KG,20211025.0,,MD,BR,BR,2021,Q4,Elderly
199934601,19993460,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Coronary artery occlusion,,2021,Q4,1,I,,20211013.0,20211025,20211025,EXP,,BR-NOVOPROD-857570,NOVO NORDISK,,76.0,YR,,F,Y,77.0,KG,20211025.0,,MD,BR,BR,2021,Q4,Elderly
199937621,19993762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,Unknown,,,10.0,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211011.0,20211025,20211025,EXP,,PL-PFIZER INC-202101346123,PFIZER,,71.0,YR,,,Y,,,20211025.0,,MD,PL,PL,2021,Q4,Elderly
199937621,19993762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,Unknown,,,10.0,MG,,,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211011.0,20211025,20211025,EXP,,PL-PFIZER INC-202101346123,PFIZER,,71.0,YR,,,Y,,,20211025.0,,MD,PL,PL,2021,Q4,Elderly
199937621,19993762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,Unknown,,,10.0,MG,,,2021,Q4,Ventricular tachycardia,,2021,Q4,1,I,,20211011.0,20211025,20211025,EXP,,PL-PFIZER INC-202101346123,PFIZER,,71.0,YR,,,Y,,,20211025.0,,MD,PL,PL,2021,Q4,Elderly
199937621,19993762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,Unknown,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,1,I,,20211011.0,20211025,20211025,EXP,,PL-PFIZER INC-202101346123,PFIZER,,71.0,YR,,,Y,,,20211025.0,,MD,PL,PL,2021,Q4,Elderly
199937621,19993762,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,,,Unknown,,,10.0,MG,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211011.0,20211025,20211025,EXP,,PL-PFIZER INC-202101346123,PFIZER,,71.0,YR,,,Y,,,20211025.0,,MD,PL,PL,2021,Q4,Elderly
199937911,19993791,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,Jardiance duo form strength: 1000/12.5 mg,,,,,Unknown,,206111.0,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211001.0,20211022.0,20211026,20211026,EXP,,"PE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-134380",BOEHRINGER INGELHEIM,,47.0,YR,A,M,Y,,,20211026.0,,MD,PE,PE,2021,Q4,Adult
199948021,19994802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,1,I,20211025.0,,20211025,20211025,DIR,588067,,FDA-CTU,,66.0,YR,,F,N,106.2,KG,20211025.0,N,MD,US,US,2021,Q4,Elderly
199948021,19994802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2021,Q4,Sepsis,,2021,Q4,1,I,20211025.0,,20211025,20211025,DIR,588067,,FDA-CTU,,66.0,YR,,F,N,106.2,KG,20211025.0,N,MD,US,US,2021,Q4,Elderly
199948021,19994802,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,D,D,,,,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211025.0,,20211025,20211025,DIR,588067,,FDA-CTU,,66.0,YR,,F,N,106.2,KG,20211025.0,N,MD,US,US,2021,Q4,Elderly
200008711,20000871,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,12.5,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210810.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-79945,,FDA-CTU,,76.0,YR,,M,N,65.32,KG,20211021.0,N,PH,US,US,2021,Q4,Elderly
200016981,20001698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q4,Pancreatitis,,2021,Q4,1,I,20210513.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80001,,FDA-CTU,,65.0,YR,,M,N,80.29,KG,20210719.0,N,PH,US,US,2021,Q4,Elderly
200016981,20001698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q4,Vomiting,,2021,Q4,1,I,20210513.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80001,,FDA-CTU,,65.0,YR,,M,N,80.29,KG,20210719.0,N,PH,US,US,2021,Q4,Elderly
200016981,20001698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210513.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80001,,FDA-CTU,,65.0,YR,,M,N,80.29,KG,20210719.0,N,PH,US,US,2021,Q4,Elderly
200016981,20001698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,20210513.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80001,,FDA-CTU,,65.0,YR,,M,N,80.29,KG,20210719.0,N,PH,US,US,2021,Q4,Elderly
200016981,20001698,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,D,,,,25.0,MG,,QD,2021,Q4,Renal impairment,,2021,Q4,1,I,20210513.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80001,,FDA-CTU,,65.0,YR,,M,N,80.29,KG,20210719.0,N,PH,US,US,2021,Q4,Elderly
200018251,20001825,21,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK (stop date- 07-AUG-2021),,,,,,,,,,,,2021,Q4,Pancytopenia,,2021,Q4,1,I,20210908.0,20211014.0,20211027,20211027,EXP,,CH-VALIDUS PHARMACEUTICALS LLC-CH-VDP-2021-008102,VALIDUS,,70.0,YR,,M,Y,,,20211027.0,,PH,CH,CH,2021,Q4,Elderly
200018261,20001826,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,?          OTHER FREQUENCY:AM;,,,Y,Y,,,,12.5,MG,,,2021,Q4,Abdominal pain,,2021,Q4,1,I,20210125.0,,20211027,20211027,DIR,FDA-CDER-CTU-2021-80005,,FDA-CTU,,59.0,YR,,M,N,84.0,KG,20210318.0,N,PH,US,US,2021,Q4,Adult
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Pneumonia,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Weight decreased,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Rectal ulcer,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Spondylitis,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Postresuscitation encephalopathy,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Myocardial infarction,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Endocarditis,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Pyrexia,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200066602,20006660,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,"1 DF, qd",,,,,,,,,,Tablet,QD,2021,Q4,Cardiac arrest,,2021,Q4,2,F,20201027.0,20211111.0,20211028,20211112,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN222886,VIIV,Suzuki M. The Eastern Japan Regional Meeting of The Eastern Japanese Association for Infectious Diseases Poster presentation 034 2 cases of HIV infection requiring treatment for infective endocarditis,66.0,YR,,M,Y,,,20211112.0,,MD,JP,JP,2021,Q4,Elderly
200069501,20006950,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2021,Q4,Diabetes with hyperosmolarity,,2021,Q4,1,I,20211011.0,20211021.0,20211028,20211028,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-134480",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20211028.0,,MD,GB,GB,2021,Q4,Adult
200069501,20006950,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,Y,U,Unknown,,204629.0,10.0,MG,Tablet,QD,2021,Q4,Ketosis,,2021,Q4,1,I,20211011.0,20211021.0,20211028,20211028,EXP,,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-134480",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20211028.0,,MD,GB,GB,2021,Q4,Adult
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Nausea,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Dizziness,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Overdose,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Congestive cardiomyopathy,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Symptom masked,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Hot flush,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Hypotension,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Fall,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Drug withdrawal syndrome,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Mood swings,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Product administration error,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Insomnia,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200093112,20009311,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 Milligram Daily; given in morning,,,U,,,,,10.0,MG,,QD,2021,Q4,Hyperthyroidism,,2021,Q4,2,F,,20211111.0,20211028,20211119,EXP,,DE-TEVA-2021-DE-1969094,TEVA,"Heitmann L, Dartsch D, Rose O. A female geriatric patient with muscle cramps, nausea and tendency to fall: Help for involuntary muscle twitches. [German]. Dtsch-Apoth-Ztg 2021;161(31):no pagination.",70.0,YR,E,F,Y,80.0,KG,20211119.0,,PH,DE,DE,2021,Q4,Elderly
200131451,20013145,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2021,Q4,Hypercalcaemia,,2021,Q4,1,I,,20211018.0,20211029,20211029,EXP,,"US-UPSHER-SMITH LABORATORIES, LLC-2021USL00743",UPSHER-SMITH,"Ganesan K, Bradley B, Jones DW, Solomon DS. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia. Am J Med Sci. 2021;362(3):308-313",64.0,YR,,M,Y,85.0,KG,20211029.0,,MD,US,US,2021,Q4,Adult
200131451,20013145,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2021,Q4,Hyperthyroidism,,2021,Q4,1,I,,20211018.0,20211029,20211029,EXP,,"US-UPSHER-SMITH LABORATORIES, LLC-2021USL00743",UPSHER-SMITH,"Ganesan K, Bradley B, Jones DW, Solomon DS. A Case Report on Type 2 Amiodarone Induced Thyrotoxicosis and Hypercalcemia. Am J Med Sci. 2021;362(3):308-313",64.0,YR,,M,Y,85.0,KG,20211029.0,,MD,US,US,2021,Q4,Adult
200154551,20015455,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,20210805.0,,20211029,20211029,DIR,FDA-CDER-CTU-2021-80712,,FDA-CTU,,44.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Adult
200154551,20015455,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Presyncope,,2021,Q4,1,I,20210805.0,,20211029,20211029,DIR,FDA-CDER-CTU-2021-80712,,FDA-CTU,,44.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Adult
200154551,20015455,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20210805.0,,20211029,20211029,DIR,FDA-CDER-CTU-2021-80712,,FDA-CTU,,44.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Adult
200154551,20015455,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Azotaemia,,2021,Q4,1,I,20210805.0,,20211029,20211029,DIR,FDA-CDER-CTU-2021-80712,,FDA-CTU,,44.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Adult
200154551,20015455,1,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Ventricular dysfunction,,2021,Q4,1,I,20210805.0,,20211029,20211029,DIR,FDA-CDER-CTU-2021-80712,,FDA-CTU,,44.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Adult
200158101,20015810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,20210816.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81412,,FDA-CTU,,73.0,YR,,M,N,79.0,KG,20211021.0,N,PH,US,,2021,Q4,Elderly
200158101,20015810,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Diarrhoea,,2021,Q4,1,I,20210816.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81412,,FDA-CTU,,73.0,YR,,M,N,79.0,KG,20211021.0,N,PH,US,,2021,Q4,Elderly
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Clostridium difficile colitis,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Oropharyngeal pain,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Hypovolaemia,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Metabolic alkalosis,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Tachycardia,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Acid base balance abnormal,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Dehydration,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200158121,20015812,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,25.0,MG,,QD,2021,Q4,Myalgia,,2021,Q4,1,I,20211003.0,,20211101,20211101,DIR,FDA-CDER-CTU-2021-81417,,FDA-CTU,,52.0,YR,,M,N,76.0,KG,20211005.0,N,PH,US,,2021,Q4,Adult
200161631,20016163,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,10.0,MG,,QD,2021,Q4,Amputation,,2021,Q4,1,I,20211028.0,,20211103,20211103,DIR,FDA-CDER-CTU-2021-81862,,FDA-CTU,,60.0,YR,,M,N,,,20211102.0,N,HP,US,,2021,Q4,Adult
200163201,20016320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Dizziness,,2021,Q4,1,I,20210130.0,,20211103,20211103,DIR,FDA-CDER-CTU-2021-81911,,FDA-CTU,,64.0,YR,,M,N,,,20210210.0,N,,US,,2021,Q4,Adult
200163201,20016320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Polyuria,,2021,Q4,1,I,20210130.0,,20211103,20211103,DIR,FDA-CDER-CTU-2021-81911,,FDA-CTU,,64.0,YR,,M,N,,,20210210.0,N,,US,,2021,Q4,Adult
200163201,20016320,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210130.0,,20211103,20211103,DIR,FDA-CDER-CTU-2021-81911,,FDA-CTU,,64.0,YR,,M,N,,,20210210.0,N,,US,,2021,Q4,Adult
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Brain natriuretic peptide abnormal,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,QRS axis abnormal,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Troponin I abnormal,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Acute pulmonary oedema,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,White blood cell disorder,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200204761,20020476,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,,20211019.0,20211101,20211101,EXP,,NVSC2021GR243222,NOVARTIS,,71.0,YR,,M,Y,,,20211101.0,,MD,GR,GR,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Cardiac arrest,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Bradycardia,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Wound,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Acute respiratory failure,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Dizziness,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Electrocardiogram abnormal,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200240611,20024061,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,,,,,,10.0,MG,,,2021,Q4,Fall,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076697,MYLAN,,79.0,YR,,M,Y,,,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Language disorder,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Diarrhoea,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Restlessness,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Fall,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200241891,20024189,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd (10 mg, 1-0-0-0, Tabletten)",,,,,,,,10.0,MG,,QD,2021,Q4,Vomiting,,2021,Q4,1,I,,20211025.0,20211102,20211102,EXP,,DE-MYLANLABS-2021M1076925,MYLAN,,79.0,YR,,M,Y,76.0,KG,20211102.0,,PH,DE,DE,2021,Q4,Elderly
200274341,20027434,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20211023.0,20211103,20211103,EXP,,BR-NOVOPROD-861182,NOVO NORDISK,,70.0,YR,,M,Y,73.5,KG,20211103.0,,MD,BR,BR,2021,Q4,Elderly
200274341,20027434,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg,,,,,Unknown,,,,,,,2021,Q4,Suicide attempt,,2021,Q4,1,I,,20211023.0,20211103,20211103,EXP,,BR-NOVOPROD-861182,NOVO NORDISK,,70.0,YR,,M,Y,73.5,KG,20211103.0,,MD,BR,BR,2021,Q4,Elderly
200294131,20029413,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2021,Q4,Illness,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200294131,20029413,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2021,Q4,Recalled product administered,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200294131,20029413,10,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1x/day",,,,,,,,10.0,MG,,QD,2021,Q4,Myocardial infarction,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200300301,20030030,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood potassium increased,,2021,Q4,1,I,,20211022.0,20211103,20211103,EXP,,NVSC2021GR244446,NOVARTIS,,68.0,YR,,M,Y,,,20211103.0,,MD,GR,GR,2021,Q4,Elderly
200300301,20030030,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Glomerular filtration rate decreased,,2021,Q4,1,I,,20211022.0,20211103,20211103,EXP,,NVSC2021GR244446,NOVARTIS,,68.0,YR,,M,Y,,,20211103.0,,MD,GR,GR,2021,Q4,Elderly
200300301,20030030,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood pressure decreased,,2021,Q4,1,I,,20211022.0,20211103,20211103,EXP,,NVSC2021GR244446,NOVARTIS,,68.0,YR,,M,Y,,,20211103.0,,MD,GR,GR,2021,Q4,Elderly
200300301,20030030,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood creatinine increased,,2021,Q4,1,I,,20211022.0,20211103,20211103,EXP,,NVSC2021GR244446,NOVARTIS,,68.0,YR,,M,Y,,,20211103.0,,MD,GR,GR,2021,Q4,Elderly
200402141,20040214,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Disease progression,,2021,Q4,1,I,20170801.0,20180824.0,20211106,20211106,EXP,,NVSC2018US021080,NOVARTIS,,63.0,YR,,M,Y,,,20211106.0,,MD,US,US,2021,Q4,Adult
200402141,20040214,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hepatic enzyme increased,,2021,Q4,1,I,20170801.0,20180824.0,20211106,20211106,EXP,,NVSC2018US021080,NOVARTIS,,63.0,YR,,M,Y,,,20211106.0,,MD,US,US,2021,Q4,Adult
200402141,20040214,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood bilirubin increased,,2021,Q4,1,I,20170801.0,20180824.0,20211106,20211106,EXP,,NVSC2018US021080,NOVARTIS,,63.0,YR,,M,Y,,,20211106.0,,MD,US,US,2021,Q4,Adult
200402141,20040214,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Mucosal inflammation,,2021,Q4,1,I,20170801.0,20180824.0,20211106,20211106,EXP,,NVSC2018US021080,NOVARTIS,,63.0,YR,,M,Y,,,20211106.0,,MD,US,US,2021,Q4,Adult
200402141,20040214,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Abdominal discomfort,,2021,Q4,1,I,20170801.0,20180824.0,20211106,20211106,EXP,,NVSC2018US021080,NOVARTIS,,63.0,YR,,M,Y,,,20211106.0,,MD,US,US,2021,Q4,Adult
200405041,20040504,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,10.0,MG,,QD,2021,Q4,Angioedema,,2021,Q4,1,I,20211018.0,,20211107,20211107,DIR,FDA-CDER-CTU-2021-83156,,FDA-CTU,,60.0,YR,,F,N,,,20211104.0,N,PH,US,,2021,Q4,Adult
200438081,20043808,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,2 DF,,,U,,,,,,,,,2021,Q4,Diabetic metabolic decompensation,,2021,Q4,1,I,,20211027.0,20211108,20211108,EXP,,NVSC2021SK247838,NOVARTIS,"Kollarova D, Martinka E, Urbanova M. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211108.0,,HP,SK,SK,2021,Q4,Adult
200438081,20043808,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,2 DF,,,U,,,,,,,,,2021,Q4,Weight increased,,2021,Q4,1,I,,20211027.0,20211108,20211108,EXP,,NVSC2021SK247838,NOVARTIS,"Kollarova D, Martinka E, Urbanova M. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211108.0,,HP,SK,SK,2021,Q4,Adult
200438081,20043808,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,2 DF,,,U,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20211027.0,20211108,20211108,EXP,,NVSC2021SK247838,NOVARTIS,"Kollarova D, Martinka E, Urbanova M. Practical experience confirms the results of the RCT and RWE studies with empagliflosin: case reports. FORUM DIABETOLOGICUM. 2021;10(1):53-61",53.0,YR,,M,Y,,,20211108.0,,HP,SK,SK,2021,Q4,Adult
200459111,20045911,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211031.0,,20211108,20211108,DIR,590000,,FDA-CTU,,45.0,YR,,F,N,60.0,KG,20211108.0,N,PH,US,,2021,Q4,Adult
200481291,20048129,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Dizziness,,2021,Q4,1,I,,20211020.0,20211109,20211109,PER,,AE-LUPIN PHARMACEUTICALS INC.-2021-21255,LUPIN,"Gerges F, Komaranchath A, Bakshy FA, Almaghraby A. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. European heart journal-Case reports. 2021;5(2):1-8",74.0,YR,,M,Y,,,20211109.0,,MD,AE,AE,2021,Q4,Elderly
200481291,20048129,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Hypotension,,2021,Q4,1,I,,20211020.0,20211109,20211109,PER,,AE-LUPIN PHARMACEUTICALS INC.-2021-21255,LUPIN,"Gerges F, Komaranchath A, Bakshy FA, Almaghraby A. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. European heart journal-Case reports. 2021;5(2):1-8",74.0,YR,,M,Y,,,20211109.0,,MD,AE,AE,2021,Q4,Elderly
200481291,20048129,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Asthenia,,2021,Q4,1,I,,20211020.0,20211109,20211109,PER,,AE-LUPIN PHARMACEUTICALS INC.-2021-21255,LUPIN,"Gerges F, Komaranchath A, Bakshy FA, Almaghraby A. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. European heart journal-Case reports. 2021;5(2):1-8",74.0,YR,,M,Y,,,20211109.0,,MD,AE,AE,2021,Q4,Elderly
200481291,20048129,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,1,I,,20211020.0,20211109,20211109,PER,,AE-LUPIN PHARMACEUTICALS INC.-2021-21255,LUPIN,"Gerges F, Komaranchath A, Bakshy FA, Almaghraby A. The power of optimal medical therapy using angiotensin receptor-neprilysin inhibitor in acute decompensated heart failure, sparing a critical patient open-heart surgery with a device therapy: a case report. European heart journal-Case reports. 2021;5(2):1-8",74.0,YR,,M,Y,,,20211109.0,,MD,AE,AE,2021,Q4,Elderly
200494921,20049492,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,25/5mg,,,,,Unknown,,,,,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,1,I,20210201.0,20211029.0,20211109,20211109,EXP,,BR-NOVOPROD-862699,NOVO NORDISK,,59.0,YR,,M,Y,,,20211109.0,,MD,BR,BR,2021,Q4,Adult
200494921,20049492,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,25/5mg,,,,,Unknown,,,,,,,2021,Q4,COVID-19,,2021,Q4,1,I,20210201.0,20211029.0,20211109,20211109,EXP,,BR-NOVOPROD-862699,NOVO NORDISK,,59.0,YR,,M,Y,,,20211109.0,,MD,BR,BR,2021,Q4,Adult
200494921,20049492,3,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,25/5mg,,,,,Unknown,,,,,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210201.0,20211029.0,20211109,20211109,EXP,,BR-NOVOPROD-862699,NOVO NORDISK,,59.0,YR,,M,Y,,,20211109.0,,MD,BR,BR,2021,Q4,Adult
200530621,20053062,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,1,,,,,,,,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211021.0,20211101.0,20211110,20211110,EXP,,GB-AstraZeneca-2021A792717,ASTRAZENECA,,47.0,YR,,M,Y,105.0,KG,20211110.0,,MD,GB,,2021,Q4,Adult
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Hepatic steatosis,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Muscle spasms,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Glycosuria,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Proteinuria,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Microalbuminuria,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200535771,20053577,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg mid,,,,,unk,,,,,,,2021,Q4,Gait disturbance,,2021,Q4,1,I,,20211031.0,20211110,20211110,EXP,,BR-NOVOPROD-859990,NOVO NORDISK,,70.0,YR,,M,Y,80.0,KG,20211110.0,,MD,BR,BR,2021,Q4,Elderly
200548782,20054878,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,UNKNOWN,,,,,,,2021,Q4,Off label use,,2021,Q4,2,F,20211005.0,20211110.0,20211110,20211117,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-108745,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20211117.0,,MD,DE,DE,2021,Q4,Adult
200548782,20054878,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,UNKNOWN,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,2,F,20211005.0,20211110.0,20211110,20211117,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-108745,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20211117.0,,MD,DE,DE,2021,Q4,Adult
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Glycosuria,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Vitamin D deficiency,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Acute coronary syndrome,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Proteinuria,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Hypoaesthesia,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200561561,20056156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg (mid),,,,,unknown,,,,,,,2021,Q4,Nausea,,2021,Q4,1,I,,20211102.0,20211111,20211111,EXP,,BR-NOVOPROD-861230,NOVO NORDISK,,70.0,YR,,M,Y,78.4,KG,20211111.0,,MD,BR,BR,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,White blood cell disorder,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Troponin I abnormal,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Brain natriuretic peptide abnormal,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,QRS axis abnormal,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Acute pulmonary oedema,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200586721,20058672,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,,20211103.0,20211111,20211111,EXP,,GR-AstraZeneca-2021A796237,ASTRAZENECA,,71.0,YR,,M,Y,,,20211111.0,,MD,GR,,2021,Q4,Elderly
200594552,20059455,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2021,Q4,COVID-19 pneumonia,,2021,Q4,2,F,20211107.0,20211202.0,20211111,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111003333,ELI LILLY AND CO,,80.0,YR,,M,Y,73.0,KG,20211209.0,,MD,US,US,2021,Q4,Elderly
200594552,20059455,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2021,Q4,Atrioventricular block first degree,,2021,Q4,2,F,20211107.0,20211202.0,20211111,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111003333,ELI LILLY AND CO,,80.0,YR,,M,Y,73.0,KG,20211209.0,,MD,US,US,2021,Q4,Elderly
200594552,20059455,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2021,Q4,Atrioventricular block second degree,,2021,Q4,2,F,20211107.0,20211202.0,20211111,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111003333,ELI LILLY AND CO,,80.0,YR,,M,Y,73.0,KG,20211209.0,,MD,US,US,2021,Q4,Elderly
200594552,20059455,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, daily",,,U,,,,,25.0,MG,,QD,2021,Q4,Ventricular extrasystoles,,2021,Q4,2,F,20211107.0,20211202.0,20211111,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111003333,ELI LILLY AND CO,,80.0,YR,,M,Y,73.0,KG,20211209.0,,MD,US,US,2021,Q4,Elderly
200609834,20060983,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,once a day,,,,,Asked But Unknown,,206073.0,,,Tablet,QD,2021,Q4,Drug ineffective,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200609834,20060983,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,once a day,,,,,Asked But Unknown,,206073.0,,,Tablet,QD,2021,Q4,Diabetic coma,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200609834,20060983,1,PS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,once a day,,,,,Asked But Unknown,,206073.0,,,Tablet,QD,2021,Q4,Blood glucose increased,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200609834,20060983,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,increased twice a day,,,,,Asked But Unknown,,206073.0,,,Tablet,Q12H,2021,Q4,Drug ineffective,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200609834,20060983,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,increased twice a day,,,,,Asked But Unknown,,206073.0,,,Tablet,Q12H,2021,Q4,Diabetic coma,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200609834,20060983,2,SS,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,,increased twice a day,,,,,Asked But Unknown,,206073.0,,,Tablet,Q12H,2021,Q4,Blood glucose increased,,2021,Q4,4,F,,20211207.0,20211112,20211209,EXP,,"MX-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-137588",BOEHRINGER INGELHEIM,,73.0,YR,E,F,Y,,,20211209.0,,MD,MX,MX,2021,Q4,Elderly
200622712,20062271,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg daily,,,Y,,,,,25.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,2,F,,20211110.0,20211112,20211118,EXP,,US-TORRENT-00011316,TORRENT,,66.0,YR,E,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200622712,20062271,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg daily,,,Y,,,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,2,F,,20211110.0,20211112,20211118,EXP,,US-TORRENT-00011316,TORRENT,,66.0,YR,E,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200622712,20062271,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg daily,,,Y,,,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,,20211110.0,20211112,20211118,EXP,,US-TORRENT-00011316,TORRENT,,66.0,YR,E,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Wheezing,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Rhinorrhoea,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Cough,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Malignant mediastinal neoplasm,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Bronchiectasis,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Nasal congestion,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Blood immunoglobulin E increased,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200638991,20063899,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,1 every 1 Days,,,U,,,,,10.0,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211030.0,20211112,20211112,EXP,CA-MHPD-E2B_03478055,CA-Accord-244860,ACCORD,,73.0,YR,,F,Y,101.0,KG,20211112.0,,CN,CA,CA,2021,Q4,Elderly
200666992,20066699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,,20211108.0,20211115,20211210,EXP,,US-BAUSCH-BL-2021-036871,BAUSCH AND LOMB,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384.",66.0,YR,,F,Y,,,20211210.0,,HP,US,US,2021,Q4,Elderly
200666992,20066699,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,2,F,,20211108.0,20211115,20211210,EXP,,US-BAUSCH-BL-2021-036871,BAUSCH AND LOMB,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384.",66.0,YR,,F,Y,,,20211210.0,,HP,US,US,2021,Q4,Elderly
200681401,20068140,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211115,20211115,EXP,,US-drreddys-SPO/USA/21/0143718,DR REDDYS,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32:384-384.",66.0,YR,E,F,Y,,,20211115.0,,HP,US,US,2021,Q4,Elderly
200681401,20068140,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211115,20211115,EXP,,US-drreddys-SPO/USA/21/0143718,DR REDDYS,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32:384-384.",66.0,YR,E,F,Y,,,20211115.0,,HP,US,US,2021,Q4,Elderly
200681401,20068140,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211115,20211115,EXP,,US-drreddys-SPO/USA/21/0143718,DR REDDYS,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32:384-384.",66.0,YR,E,F,Y,,,20211115.0,,HP,US,US,2021,Q4,Elderly
200707411,20070741,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Necrotising fasciitis,,2021,Q4,1,I,20210625.0,,20211115,20211115,DIR,590893,,FDA-CTU,,60.0,YR,,M,N,84.15,KG,20211115.0,N,,US,,2021,Q4,Adult
200707411,20070741,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Sepsis,,2021,Q4,1,I,20210625.0,,20211115,20211115,DIR,590893,,FDA-CTU,,60.0,YR,,M,N,84.15,KG,20211115.0,N,,US,,2021,Q4,Adult
200707411,20070741,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Cellulitis,,2021,Q4,1,I,20210625.0,,20211115,20211115,DIR,590893,,FDA-CTU,,60.0,YR,,M,N,84.15,KG,20211115.0,N,,US,,2021,Q4,Adult
200709211,20070921,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2021,Q4,Pancytopenia,,2021,Q4,1,I,20211005.0,20211105.0,20211115,20211115,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20211115.0,,MD,CH,CH,2021,Q4,Adult
200709211,20070921,18,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2021,Q4,Agranulocytosis,,2021,Q4,1,I,20211005.0,20211105.0,20211115,20211115,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20211115.0,,MD,CH,CH,2021,Q4,Adult
200709211,20070921,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q4,Pancytopenia,,2021,Q4,1,I,20211005.0,20211105.0,20211115,20211115,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20211115.0,,MD,CH,CH,2021,Q4,Adult
200709211,20070921,19,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q4,Agranulocytosis,,2021,Q4,1,I,20211005.0,20211105.0,20211115,20211115,EXP,CH-SM-2021-26833,CH-TEVA-2021-CH-1977053,TEVA,,53.0,YR,A,M,Y,,,20211115.0,,MD,CH,CH,2021,Q4,Adult
200806321,20080632,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211117,20211117,EXP,,US-MYLANLABS-2021M1084758,MYLAN,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. J-Am-Soc-Nephrol 2021;32:381 (plus poster) abstr. PO1164.",43.0,YR,,M,Y,,,20211117.0,,HP,US,US,2021,Q4,Adult
200806321,20080632,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211117,20211117,EXP,,US-MYLANLABS-2021M1084758,MYLAN,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. J-Am-Soc-Nephrol 2021;32:381 (plus poster) abstr. PO1164.",43.0,YR,,M,Y,,,20211117.0,,HP,US,US,2021,Q4,Adult
200826262,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd, 1-0-0-0, Tabletten",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Dyspnoea,,2021,Q4,2,F,,20211111.0,20211117,20211122,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20211122.0,,MD,DE,DE,2021,Q4,Elderly
200826262,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd, 1-0-0-0, Tabletten",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Oedema peripheral,,2021,Q4,2,F,,20211111.0,20211117,20211122,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20211122.0,,MD,DE,DE,2021,Q4,Elderly
200826262,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd, 1-0-0-0, Tabletten",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Angina pectoris,,2021,Q4,2,F,,20211111.0,20211117,20211122,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20211122.0,,MD,DE,DE,2021,Q4,Elderly
200826262,20082626,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"25 milligram, qd, 1-0-0-0, Tabletten",,,,,,,,25.0,MG,Tablet,QD,2021,Q4,Cough,,2021,Q4,2,F,,20211111.0,20211117,20211122,EXP,,DE-MYLANLABS-2021M1083734,MYLAN,,79.0,YR,,F,Y,,,20211122.0,,MD,DE,DE,2021,Q4,Elderly
200827441,20082744,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2021,Q4,Glomerular filtration rate decreased,,2021,Q4,1,I,,20211108.0,20211117,20211117,EXP,,GR-PFIZER INC-202101530237,PFIZER,,68.0,YR,,M,Y,,,20211117.0,,MD,GR,GR,2021,Q4,Elderly
200827441,20082744,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood pressure decreased,,2021,Q4,1,I,,20211108.0,20211117,20211117,EXP,,GR-PFIZER INC-202101530237,PFIZER,,68.0,YR,,M,Y,,,20211117.0,,MD,GR,GR,2021,Q4,Elderly
200827441,20082744,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood creatinine increased,,2021,Q4,1,I,,20211108.0,20211117,20211117,EXP,,GR-PFIZER INC-202101530237,PFIZER,,68.0,YR,,M,Y,,,20211117.0,,MD,GR,GR,2021,Q4,Elderly
200827441,20082744,10,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, 1x/day",,,U,,,,,10.0,MG,,QD,2021,Q4,Blood potassium increased,,2021,Q4,1,I,,20211108.0,20211117,20211117,EXP,,GR-PFIZER INC-202101530237,PFIZER,,68.0,YR,,M,Y,,,20211117.0,,MD,GR,GR,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Tachycardia,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Skin pressure mark,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Loss of consciousness,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Pupils unequal,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Electrocardiogram abnormal,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Nuchal rigidity,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Electrolyte imbalance,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Hypotension,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Anuria,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Decubitus ulcer,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Disorientation,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Hypotonia,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Apnoea,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Cyanosis,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Tachypnoea,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Skin irritation,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Dehydration,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200829321,20082932,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"10 mg, 1-0-0-0",,,U,U,,,,,,,,2021,Q4,Bradypnoea,,2021,Q4,1,I,,20211111.0,20211117,20211117,EXP,,DE-MYLANLABS-2021M1083809,MYLAN,,76.0,YR,,M,Y,,,20211117.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Medication error,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Diabetic nephropathy,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Renal failure,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Labelled drug-drug interaction medication error,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Metabolic acidosis,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200832902,20083290,5,I,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, qd, (10 mg, 0-1-0-0, Tabletten)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,2,F,,20211118.0,20211117,20211129,EXP,,DE-MYLANLABS-2021M1083789,MYLAN,,82.0,YR,,M,Y,82.0,KG,20211129.0,,PH,DE,DE,2021,Q4,Elderly
200846491,20084649,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-APOTEX-2021AP045415,APOTEX,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211118.0,,HP,US,US,2021,Q4,Adult
200846491,20084649,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-APOTEX-2021AP045415,APOTEX,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211118.0,,HP,US,US,2021,Q4,Adult
200865481,20086548,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2021,Q4,Diarrhoea,,2021,Q4,1,I,20211117.0,,20211118,20211118,DIR,591372,,FDA-CTU,,58.0,YR,,M,N,91.6,KG,20211118.0,N,HP,US,,2021,Q4,Adult
200865481,20086548,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211117.0,,20211118,20211118,DIR,591372,,FDA-CTU,,58.0,YR,,M,N,91.6,KG,20211118.0,N,HP,US,,2021,Q4,Adult
200871711,20087171,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1x/day",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-PFIZER INC-202101566669,PFIZER,"Sardarli, K.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology: JASN. 2021;32:384",66.0,YR,,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200871711,20087171,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1x/day",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-PFIZER INC-202101566669,PFIZER,"Sardarli, K.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology: JASN. 2021;32:384",66.0,YR,,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200871711,20087171,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,"25 mg, 1x/day",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-PFIZER INC-202101566669,PFIZER,"Sardarli, K.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology: JASN. 2021;32:384",66.0,YR,,F,Y,,,20211118.0,,HP,US,US,2021,Q4,Elderly
200915021,20091502,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/850mg,,,N,,Unknown,,206111.0,,,Tablet,Q12H,2021,Q4,Hypophagia,,2021,Q4,1,I,20211106.0,20211116.0,20211119,20211119,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138197",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20211119.0,,MD,MY,MY,2021,Q4,Elderly
200915021,20091502,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/850mg,,,N,,Unknown,,206111.0,,,Tablet,Q12H,2021,Q4,Gastroenteritis,,2021,Q4,1,I,20211106.0,20211116.0,20211119,20211119,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138197",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20211119.0,,MD,MY,MY,2021,Q4,Elderly
200915021,20091502,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/850mg,,,N,,Unknown,,206111.0,,,Tablet,Q12H,2021,Q4,Death,,2021,Q4,1,I,20211106.0,20211116.0,20211119,20211119,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138197",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20211119.0,,MD,MY,MY,2021,Q4,Elderly
200915021,20091502,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/850mg,,,N,,Unknown,,206111.0,,,Tablet,Q12H,2021,Q4,Decreased appetite,,2021,Q4,1,I,20211106.0,20211116.0,20211119,20211119,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138197",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20211119.0,,MD,MY,MY,2021,Q4,Elderly
200915021,20091502,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,12.5/850mg,,,N,,Unknown,,206111.0,,,Tablet,Q12H,2021,Q4,Lethargy,,2021,Q4,1,I,20211106.0,20211116.0,20211119,20211119,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138197",BOEHRINGER INGELHEIM,,69.0,YR,E,F,Y,,,20211119.0,,MD,MY,MY,2021,Q4,Elderly
200915671,20091567,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20210812.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-86956,,FDA-CTU,,53.0,YR,,M,N,79.0,KG,20211021.0,N,PH,US,,2021,Q4,Adult
200918781,20091878,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211109.0,20211119,20211119,EXP,,US-EMD Serono-9279433,EMD SERONO INC,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology. 2021 JAN 01;32:384-384.",66.0,YR,E,F,Y,,,20211119.0,,MD,US,,2021,Q4,Elderly
200918781,20091878,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211109.0,20211119,20211119,EXP,,US-EMD Serono-9279433,EMD SERONO INC,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology. 2021 JAN 01;32:384-384.",66.0,YR,E,F,Y,,,20211119.0,,MD,US,,2021,Q4,Elderly
200918781,20091878,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211109.0,20211119,20211119,EXP,,US-EMD Serono-9279433,EMD SERONO INC,"Sardarli K, Leong R, Gill I, Zarouk S. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology. 2021 JAN 01;32:384-384.",66.0,YR,E,F,Y,,,20211119.0,,MD,US,,2021,Q4,Elderly
200919301,20091930,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2021,Q4,Chromaturia,,2021,Q4,1,I,,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87016,,FDA-CTU,,60.0,YR,,M,N,103.0,KG,20210826.0,N,PH,US,,2021,Q4,Adult
200919301,20091930,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2021,Q4,Vomiting,,2021,Q4,1,I,,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87016,,FDA-CTU,,60.0,YR,,M,N,103.0,KG,20210826.0,N,PH,US,,2021,Q4,Adult
200919301,20091930,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2021,Q4,Urine odour abnormal,,2021,Q4,1,I,,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87016,,FDA-CTU,,60.0,YR,,M,N,103.0,KG,20210826.0,N,PH,US,,2021,Q4,Adult
200919301,20091930,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,,,,,12.5,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87016,,FDA-CTU,,60.0,YR,,M,N,103.0,KG,20210826.0,N,PH,US,,2021,Q4,Adult
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Diarrhoea,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Exposure to SARS-CoV-2,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Chills,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Pain,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Pyrexia,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200920291,20092029,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,D,,,,12.5,MG,,QD,2021,Q4,Productive cough,,2021,Q4,1,I,20210729.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87031,,FDA-CTU,,77.0,YR,,M,N,72.0,KG,20210811.0,N,PH,US,,2021,Q4,Elderly
200925701,20092570,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Analgesic drug level increased,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Blood glucose fluctuation,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Atrioventricular block,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Arteriosclerosis,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Atrioventricular block,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Death,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948071,20094807,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,1,I,20210801.0,20211113.0,20211122,20211122,EXP,,BR-NOVOPROD-868142,NOVO NORDISK,,65.0,YR,,M,Y,79.5,KG,20211122.0,,MD,BR,BR,2021,Q4,Elderly
200948202,20094820,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,2,F,20200501.0,20211215.0,20211122,20211223,EXP,,JP-NOVOPROD-867364,NOVO NORDISK,,71.0,YR,,F,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Elderly
200948202,20094820,2,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,UNK,,,,,,,,,,,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,2,F,20200501.0,20211215.0,20211122,20211223,EXP,,JP-NOVOPROD-867364,NOVO NORDISK,,71.0,YR,,F,Y,,,20211223.0,,MD,JP,JP,2021,Q4,Elderly
200953172,20095317,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2021,Q4,Platelet count decreased,,2021,Q4,2,F,20210813.0,20211124.0,20211122,20211206,EXP,,JP-ROCHE-2958279,ROCHE,,81.0,YR,,M,Y,58.0,KG,20211206.0,,MD,JP,JP,2021,Q4,Elderly
200953172,20095317,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2021,Q4,Blood pressure decreased,,2021,Q4,2,F,20210813.0,20211124.0,20211122,20211206,EXP,,JP-ROCHE-2958279,ROCHE,,81.0,YR,,M,Y,58.0,KG,20211206.0,,MD,JP,JP,2021,Q4,Elderly
200953172,20095317,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,,,,,,UNKNOWN,,,,,Tablet,,2021,Q4,Hepatic function abnormal,,2021,Q4,2,F,20210813.0,20211124.0,20211122,20211206,EXP,,JP-ROCHE-2958279,ROCHE,,81.0,YR,,M,Y,58.0,KG,20211206.0,,MD,JP,JP,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Soft tissue haemorrhage,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Peripheral swelling,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Haemoglobin increased,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Haematocrit increased,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957061,20095706,12,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Humerus fracture,,2021,Q4,1,I,20210831.0,,20211119,20211119,DIR,FDA-CDER-CTU-2021-87308,,FDA-CTU,,65.0,YR,,F,N,73.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Condition aggravated,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Psoriasis,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Hepatotoxicity,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,C-reactive protein increased,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200957172,20095717,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,2,F,20200309.0,20211130.0,20211122,20211213,EXP,,NVSC2020CA082760,NOVARTIS,,40.0,YR,,F,Y,,,20211213.0,,MD,CA,CA,2021,Q4,Adult
200961561,20096156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,US-MLMSERVICE-20211104-3206214-1,US-MICRO LABS LIMITED-ML2021-03507,MICRO LABS,,66.0,YR,,F,Y,,,20211122.0,,HP,US,,2021,Q4,Elderly
200961561,20096156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,US-MLMSERVICE-20211104-3206214-1,US-MICRO LABS LIMITED-ML2021-03507,MICRO LABS,,66.0,YR,,F,Y,,,20211122.0,,HP,US,,2021,Q4,Elderly
200961561,20096156,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,UNKNOWN,,,25.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,US-MLMSERVICE-20211104-3206214-1,US-MICRO LABS LIMITED-ML2021-03507,MICRO LABS,,66.0,YR,,F,Y,,,20211122.0,,HP,US,,2021,Q4,Elderly
200975481,20097548,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,,,,,25.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-APOTEX-2021AP045383,APOTEX,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
200975481,20097548,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,,,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-APOTEX-2021AP045383,APOTEX,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
200975481,20097548,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,Y,,,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-APOTEX-2021AP045383,APOTEX,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
200975721,20097572,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200994851,20099485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, od",,,,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211108.0,20211123,20211123,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068860,GLENMARK,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis... Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211123.0,,HP,US,US,2021,Q4,Elderly
200994851,20099485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, od",,,,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211108.0,20211123,20211123,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068860,GLENMARK,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis... Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211123.0,,HP,US,US,2021,Q4,Elderly
200994851,20099485,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, od",,,,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211108.0,20211123,20211123,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068860,GLENMARK,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis... Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211123.0,,HP,US,US,2021,Q4,Elderly
201047272,20104727,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,,20211122.0,20211123,20211202,EXP,,US-AUROBINDO-AUR-APL-2021-047079,AUROBINDO,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology.. 2021;32:384",66.0,YR,,F,Y,,,20211202.0,,HP,US,US,2021,Q4,Elderly
201047272,20104727,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,2,F,,20211122.0,20211123,20211202,EXP,,US-AUROBINDO-AUR-APL-2021-047079,AUROBINDO,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology.. 2021;32:384",66.0,YR,,F,Y,,,20211202.0,,HP,US,US,2021,Q4,Elderly
201047272,20104727,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Once a Day",,,Y,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,2,F,,20211122.0,20211123,20211202,EXP,,US-AUROBINDO-AUR-APL-2021-047079,AUROBINDO,"Sardarli K, Leong R, Gill I, Zarouk SS.. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.. Journal of the American Society of Nephrology.. 2021;32:384",66.0,YR,,F,Y,,,20211202.0,,HP,US,US,2021,Q4,Elderly
201048891,20104889,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201048891,20104889,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hepatotoxicity,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201048891,20104889,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201050451,20105045,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,Y,,,,,25.0,MG,,,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318454,RANBAXY,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32384 (PO1174)",66.0,YR,,F,Y,,,20211124.0,,HP,US,US,2021,Q4,Elderly
201050451,20105045,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,Y,,,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318454,RANBAXY,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32384 (PO1174)",66.0,YR,,F,Y,,,20211124.0,,HP,US,US,2021,Q4,Elderly
201050451,20105045,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, Daily",,,Y,,,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318454,RANBAXY,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J Am Soc Nephrol. 2021;32384 (PO1174)",66.0,YR,,F,Y,,,20211124.0,,HP,US,US,2021,Q4,Elderly
201061511,20106151,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211110.0,20211124,20211124,PER,,US-LUPIN PHARMACEUTICALS INC.-2021-22936,LUPIN,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211124.0,,HP,US,US,2021,Q4,Elderly
201061511,20106151,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 milligram, qd",,,,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,PER,,US-LUPIN PHARMACEUTICALS INC.-2021-22936,LUPIN,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. Journal of the American Society of Nephrology. 2021;32:384",66.0,YR,,F,Y,,,20211124.0,,HP,US,US,2021,Q4,Elderly
201108581,20110858,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"Form strength is 12.5 mg empagliflozin, 1000mg metformin. Unit dose and frequency are not reported.",,,Y,U,Asked But Unknown,,206111.0,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211124.0,20211124,20211124,EXP,,"AU-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140310",BOEHRINGER INGELHEIM,,72.0,YR,E,F,Y,,,20211125.0,,MD,AU,AU,2021,Q4,Elderly
201134813,20113481,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Hepatic steatosis,,2021,Q4,3,F,20211117.0,20211203.0,20211125,20211209,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140084",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,73.0,KG,20211209.0,,MD,JP,JP,2021,Q4,Elderly
201134813,20113481,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Hepatic function abnormal,,2021,Q4,3,F,20211117.0,20211203.0,20211125,20211209,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140084",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,73.0,KG,20211209.0,,MD,JP,JP,2021,Q4,Elderly
201134813,20113481,4,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,D,,Unknown,,204629.0,,,Film-coated tablet,,2021,Q4,Hepatomegaly,,2021,Q4,3,F,20211117.0,20211203.0,20211125,20211209,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140084",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,73.0,KG,20211209.0,,MD,JP,JP,2021,Q4,Elderly
201157602,20115760,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure,,2021,Q4,2,F,,20211206.0,20211126,20211206,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140468",BOEHRINGER INGELHEIM,,78.0,YR,E,M,Y,,,20211206.0,,MD,JP,JP,2021,Q4,Elderly
201157602,20115760,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,,2021,Q4,Ventricular tachycardia,,2021,Q4,2,F,,20211206.0,20211126,20211206,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140468",BOEHRINGER INGELHEIM,,78.0,YR,E,M,Y,,,20211206.0,,MD,JP,JP,2021,Q4,Elderly
201164302,20116430,7,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Oral,"UNK UNK, once daily",,,,,,,,,,Tablet,QD,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,20211106.0,20211205.0,20211126,20211208,EXP,,IR-ASTELLAS-2021US044949,ASTELLAS,,80.0,YR,,F,Y,63.0,KG,20211208.0,,CN,IR,IR,2021,Q4,Elderly
201195271,20119527,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211112.0,20211126,20211126,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2021-23112,LUPIN,"Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clinical Kidney Journal. 2021;14(3):1020-1022",63.0,YR,,F,Y,,,20211126.0,,HP,GB,GB,2021,Q4,Adult
201195271,20119527,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Off label use,,2021,Q4,1,I,,20211112.0,20211126,20211126,EXP,,GB-LUPIN PHARMACEUTICALS INC.-2021-23112,LUPIN,"Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clinical Kidney Journal. 2021;14(3):1020-1022",63.0,YR,,F,Y,,,20211126.0,,HP,GB,GB,2021,Q4,Adult
201236131,20123613,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25mg,,,,,,,,,,,,2021,Q4,Coronary artery occlusion,,2021,Q4,1,I,,20211117.0,20211129,20211129,EXP,,BR-NOVOPROD-869062,NOVO NORDISK,,56.0,YR,,F,Y,,,20211129.0,,MD,BR,BR,2021,Q4,Adult
201246501,20124650,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,12.5,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211108.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89075,,FDA-CTU,,59.0,YR,,M,N,,,20211124.0,N,PH,US,,2021,Q4,Adult
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Penile prosthesis insertion,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Device related infection,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Kidney infection,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Penile prosthesis removal,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201247591,20124759,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,N,,,,12.5,MG,,QD,2021,Q4,Genitourinary tract infection,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89099,,FDA-CTU,,69.0,YR,,M,N,109.0,KG,20211122.0,N,PH,US,,2021,Q4,Elderly
201248091,20124809,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,12.5,MG,,QD,2021,Q4,Dehydration,,2021,Q4,1,I,20210909.0,,20211126,20211126,DIR,FDA-CDER-CTU-2021-89113,,FDA-CTU,,72.0,YR,,M,N,169.0,KG,20211119.0,N,PH,US,,2021,Q4,Elderly
201268252,20126825,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Coated tablet,QD,2021,Q4,Hyponatraemia,,2021,Q4,2,F,20210301.0,20211206.0,20211129,20211213,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-139872",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,60.0,KG,20211213.0,,MD,IT,IT,2021,Q4,Adult
201268252,20126825,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Coated tablet,QD,2021,Q4,Implantable defibrillator insertion,,2021,Q4,2,F,20210301.0,20211206.0,20211129,20211213,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-139872",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,60.0,KG,20211213.0,,MD,IT,IT,2021,Q4,Adult
201268252,20126825,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Coated tablet,QD,2021,Q4,Arrhythmic storm,,2021,Q4,2,F,20210301.0,20211206.0,20211129,20211213,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-139872",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,60.0,KG,20211213.0,,MD,IT,IT,2021,Q4,Adult
201268252,20126825,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,Asked But Unknown,,204629.0,10.0,MG,Coated tablet,QD,2021,Q4,Incarcerated hernia,,2021,Q4,2,F,20210301.0,20211206.0,20211129,20211213,EXP,,"IT-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-139872",BOEHRINGER INGELHEIM,,46.0,YR,A,M,Y,60.0,KG,20211213.0,,MD,IT,IT,2021,Q4,Adult
201275951,20127595,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Splenic vein thrombosis,,2021,Q4,1,I,20211124.0,,20211129,20211129,DIR,592638,,FDA-CTU,,48.0,YR,,M,N,155.5,KG,20211129.0,N,PH,US,,2021,Q4,Adult
201275951,20127595,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Splenic artery aneurysm,,2021,Q4,1,I,20211124.0,,20211129,20211129,DIR,592638,,FDA-CTU,,48.0,YR,,M,N,155.5,KG,20211129.0,N,PH,US,,2021,Q4,Adult
201275951,20127595,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Splenic infarction,,2021,Q4,1,I,20211124.0,,20211129,20211129,DIR,592638,,FDA-CTU,,48.0,YR,,M,N,155.5,KG,20211129.0,N,PH,US,,2021,Q4,Adult
201276071,20127607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2021,Q4,Tooth disorder,,2021,Q4,1,I,20211101.0,20211122.0,20211129,20211129,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140048",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20211129.0,,MD,HU,HU,2021,Q4,Elderly
201276071,20127607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2021,Q4,Carotid artery stenosis,,2021,Q4,1,I,20211101.0,20211122.0,20211129,20211129,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140048",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20211129.0,,MD,HU,HU,2021,Q4,Elderly
201276071,20127607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2021,Q4,Hydrothorax,,2021,Q4,1,I,20211101.0,20211122.0,20211129,20211129,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140048",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20211129.0,,MD,HU,HU,2021,Q4,Elderly
201276071,20127607,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,Unknown,,204629.0,10.0,MG,,QD,2021,Q4,Coronary artery stenosis,,2021,Q4,1,I,20211101.0,20211122.0,20211129,20211129,EXP,,"HU-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140048",BOEHRINGER INGELHEIM,,66.0,YR,E,M,Y,,,20211129.0,,MD,HU,HU,2021,Q4,Elderly
201302191,20130219,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211124.0,20211130,20211130,EXP,,PL-MYLANLABS-2021M1087670,MYLAN,,71.0,YR,,,Y,,,20211130.0,,MD,PL,PL,2021,Q4,Elderly
201302191,20130219,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,1,I,,20211124.0,20211130,20211130,EXP,,PL-MYLANLABS-2021M1087670,MYLAN,,71.0,YR,,,Y,,,20211130.0,,MD,PL,PL,2021,Q4,Elderly
201302191,20130219,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211124.0,20211130,20211130,EXP,,PL-MYLANLABS-2021M1087670,MYLAN,,71.0,YR,,,Y,,,20211130.0,,MD,PL,PL,2021,Q4,Elderly
201302191,20130219,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2021,Q4,Ventricular tachycardia,,2021,Q4,1,I,,20211124.0,20211130,20211130,EXP,,PL-MYLANLABS-2021M1087670,MYLAN,,71.0,YR,,,Y,,,20211130.0,,MD,PL,PL,2021,Q4,Elderly
201302191,20130219,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,U,,,,10.0,MG,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211124.0,20211130,20211130,EXP,,PL-MYLANLABS-2021M1087670,MYLAN,,71.0,YR,,,Y,,,20211130.0,,MD,PL,PL,2021,Q4,Elderly
201337771,20133777,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,ONE tablet to be taken ONCE  a day for diabetes.,,,U,,,,,,,Tablet,QD,2021,Q4,Adverse drug reaction,,2021,Q4,1,I,20211123.0,20211124.0,20211201,20211201,EXP,GB-MHRA-TPP36098686C963037YC1637670841905,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-140360",BOEHRINGER INGELHEIM,,62.0,YR,A,F,Y,94.0,KG,20211201.0,,MD,GB,GB,2021,Q4,Adult
201372162,20137216,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 Milligram Daily;,,,,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,2,F,,20211203.0,20211201,20211213,EXP,,US-TEVA-2021-US-1982251,TEVA,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J-Am-Soc-Nephrol 2021;32:384 (plus poster) abstr. PO1174.",66.0,YR,E,F,Y,,,20211213.0,,HP,US,US,2021,Q4,Elderly
201372162,20137216,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 Milligram Daily;,,,,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,,20211203.0,20211201,20211213,EXP,,US-TEVA-2021-US-1982251,TEVA,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J-Am-Soc-Nephrol 2021;32:384 (plus poster) abstr. PO1174.",66.0,YR,E,F,Y,,,20211213.0,,HP,US,US,2021,Q4,Elderly
201372162,20137216,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 Milligram Daily;,,,,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,2,F,,20211203.0,20211201,20211213,EXP,,US-TEVA-2021-US-1982251,TEVA,"Sardarli K, Leong R, Gill I, Zarouk SS. A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis. J-Am-Soc-Nephrol 2021;32:384 (plus poster) abstr. PO1174.",66.0,YR,E,F,Y,,,20211213.0,,HP,US,US,2021,Q4,Elderly
201374971,20137497,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Asthenia,,2021,Q4,1,I,20211001.0,20211124.0,20211201,20211201,EXP,,AT-ESPERIONTHERAPEUTICS-2021AUT02399,ESPERION THERAPEUTICS,,72.0,YR,,M,Y,,,20211202.0,,MD,AT,AT,2021,Q4,Elderly
201374971,20137497,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, qd",,,,,,,,10.0,MG,,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,20211001.0,20211124.0,20211201,20211201,EXP,,AT-ESPERIONTHERAPEUTICS-2021AUT02399,ESPERION THERAPEUTICS,,72.0,YR,,M,Y,,,20211202.0,,MD,AT,AT,2021,Q4,Elderly
201379961,20137996,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,,,,,,,,2021,Q4,Pain in extremity,,2021,Q4,1,I,20200101.0,20211118.0,20211202,20211202,EXP,,BR-NOVOPROD-869475,NOVO NORDISK,,74.0,YR,,M,Y,99.0,KG,20211202.0,,MD,BR,BR,2021,Q4,Elderly
201379961,20137996,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,,,,,,,,2021,Q4,COVID-19,,2021,Q4,1,I,20200101.0,20211118.0,20211202,20211202,EXP,,BR-NOVOPROD-869475,NOVO NORDISK,,74.0,YR,,M,Y,99.0,KG,20211202.0,,MD,BR,BR,2021,Q4,Elderly
201379961,20137996,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,25 mg,,,,,,,,,,,,2021,Q4,Pyelonephritis,,2021,Q4,1,I,20200101.0,20211118.0,20211202,20211202,EXP,,BR-NOVOPROD-869475,NOVO NORDISK,,74.0,YR,,M,Y,99.0,KG,20211202.0,,MD,BR,BR,2021,Q4,Elderly
201384251,20138425,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,,,UNK,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211124.0,20211202,20211202,EXP,,US-GRANULES-US-2021GRALIT00552,GRANULES INDIA,Hafiz Muhammad Ali Raza.Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.Journal of the American Society of Nephrology.2021;32:381,43.0,YR,A,M,Y,,,20211202.0,,HP,US,US,2021,Q4,Adult
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,N-terminal prohormone brain natriuretic peptide increased,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Wrong technique in product usage process,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Lung disorder,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Congestive cardiomyopathy,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418381,20141838,42,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",,,U,,,,,10.0,MG,,QD,2021,Q4,Glomerular filtration rate abnormal,,2021,Q4,1,I,20210301.0,20211119.0,20211202,20211202,EXP,,NVSC2021PL267813,NOVARTIS,,71.0,YR,,M,Y,,,20211202.0,,MD,PL,PL,2021,Q4,Elderly
201418412,20141841,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,2,F,,20211206.0,20211202,20211216,EXP,,GB-TEVA-2021-GB-1982513,TEVA,"Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin-Kidney-J 2021;14(3):1020-1022.",63.0,YR,A,F,Y,,,20211216.0,,HP,GB,GB,2021,Q4,Adult
201418412,20141841,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q4,Tubulointerstitial nephritis,,2021,Q4,2,F,,20211206.0,20211202,20211216,EXP,,GB-TEVA-2021-GB-1982513,TEVA,"Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin-Kidney-J 2021;14(3):1020-1022.",63.0,YR,A,F,Y,,,20211216.0,,HP,GB,GB,2021,Q4,Adult
201418412,20141841,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,,20211206.0,20211202,20211216,EXP,,GB-TEVA-2021-GB-1982513,TEVA,"Ryan R, Choo S, Willows J, Walker J, Prasad K, Tez D. Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin. Clin-Kidney-J 2021;14(3):1020-1022.",63.0,YR,A,F,Y,,,20211216.0,,HP,GB,GB,2021,Q4,Adult
201420151,20142015,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,UNK,,,,,Tablet,,2021,Q4,Thyroiditis,,2021,Q4,1,I,,20211130.0,20211202,20211202,EXP,,CA-Fresenius Kabi-FK202113299,FRESENIUS KABI,,69.0,YR,,M,Y,,,20211202.0,,PH,CA,,2021,Q4,Elderly
201420151,20142015,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,UNK,,,,,Tablet,,2021,Q4,Cardiac flutter,,2021,Q4,1,I,,20211130.0,20211202,20211202,EXP,,CA-Fresenius Kabi-FK202113299,FRESENIUS KABI,,69.0,YR,,M,Y,,,20211202.0,,PH,CA,,2021,Q4,Elderly
201459771,20145977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20210817.0,,20211203,20211203,DIR,FDA-CDER-CTU-2021-91221,,FDA-CTU,,49.0,YR,,M,N,164.0,KG,20211021.0,N,PH,US,,2021,Q4,Adult
201459771,20145977,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,10.0,MG,,QD,2021,Q4,Endocarditis,,2021,Q4,1,I,20210817.0,,20211203,20211203,DIR,FDA-CDER-CTU-2021-91221,,FDA-CTU,,49.0,YR,,M,N,164.0,KG,20211021.0,N,PH,US,,2021,Q4,Adult
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Aortic thrombosis,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Shock,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Multiple organ dysfunction syndrome,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201468301,20146830,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211124.0,20211203,20211203,EXP,,PT-EMD Serono-9283312,EMD SERONO INC,"Fontes J. Euglycemic diabetic ketoacidosis by iSGLT2 - a potentially fatal entity. Internal Medicine - Journal of the Portuguese Society of Internal Medicine - Book of Abstracts, Vol.28, Special Edition, October 2021. 2021 OCT;VOL.28, SPECIAL EDIT:. doi:https://spmi.pt/27congresso/wpcontent/ uploads/2016/05/livro_de_Resumos_27cnmi_final.pdf#page=482",73.0,YR,E,M,Y,,,20211203.0,,MD,PT,,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Myocardial infarction,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Cardiogenic shock,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Abscess,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Asthenia,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Nausea,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Abdominal pain,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201504622,20150462,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,Unknown,,206111.0,,,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211206.0,20211206,20211207,EXP,,"IL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-141973",BOEHRINGER INGELHEIM,,68.0,YR,E,F,Y,,,20211207.0,,MD,IL,IL,2021,Q4,Elderly
201510211,20151021,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Sepsis,,2021,Q4,1,I,20211021.0,,20211203,20211203,DIR,FDA-CDER-CTU-2021-91547,,FDA-CTU,,59.0,YR,,F,N,,,20211203.0,Y,PH,US,,2021,Q4,Adult
201510211,20151021,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Catheter site infection,,2021,Q4,1,I,20211021.0,,20211203,20211203,DIR,FDA-CDER-CTU-2021-91547,,FDA-CTU,,59.0,YR,,F,N,,,20211203.0,Y,PH,US,,2021,Q4,Adult
201524651,20152465,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Bile duct stone,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Balanoposthitis,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Diabetic neuropathy,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,17,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,,,2021,Q4,Diabetic retinopathy,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 international unit,,,,,,,,60.0,IU,,,2021,Q4,Bile duct stone,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 international unit,,,,,,,,60.0,IU,,,2021,Q4,Balanoposthitis,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 international unit,,,,,,,,60.0,IU,,,2021,Q4,Diabetic neuropathy,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201524651,20152465,18,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,60 international unit,,,,,,,,60.0,IU,,,2021,Q4,Diabetic retinopathy,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,SK-MYLANLABS-2021M1089247,MYLAN,,66.0,YR,,M,Y,93.0,KG,20211206.0,,MD,SK,SK,2021,Q4,Elderly
201586491,20158649,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg daily,,,Y,,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211125.0,20211207,20211207,PER,,US-SCIEGENP-2021SCLIT00972,SCIEGEN,"Sardarli K, Leong R, Gill I, Zarouk SS..A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.Journal of the American Society of Nephrology.2021;32:384",66.0,YR,A,F,Y,,,20211208.0,,HP,US,US,2021,Q4,Elderly
201586491,20158649,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg daily,,,Y,,,,,25.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,20211125.0,20211207,20211207,PER,,US-SCIEGENP-2021SCLIT00972,SCIEGEN,"Sardarli K, Leong R, Gill I, Zarouk SS..A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.Journal of the American Society of Nephrology.2021;32:384",66.0,YR,A,F,Y,,,20211208.0,,HP,US,US,2021,Q4,Elderly
201586491,20158649,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,25 mg daily,,,Y,,,,,25.0,MG,,QD,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211125.0,20211207,20211207,PER,,US-SCIEGENP-2021SCLIT00972,SCIEGEN,"Sardarli K, Leong R, Gill I, Zarouk SS..A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis.Journal of the American Society of Nephrology.2021;32:384",66.0,YR,A,F,Y,,,20211208.0,,HP,US,US,2021,Q4,Elderly
201633011,20163301,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q4,Rash,,2021,Q4,1,I,20211107.0,20211206.0,20211209,20211209,EXP,,SG-EMD Serono-9285301,EMD SERONO INC,,59.0,YR,A,F,Y,,,20211209.0,,HP,SG,,2021,Q4,Adult
201633011,20163301,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,U,,,,,,,,,2021,Q4,Pruritus,,2021,Q4,1,I,20211107.0,20211206.0,20211209,20211209,EXP,,SG-EMD Serono-9285301,EMD SERONO INC,,59.0,YR,A,F,Y,,,20211209.0,,HP,SG,,2021,Q4,Adult
201648211,20164821,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2021,Q4,Urinary tract infection,,2021,Q4,1,I,20210730.0,,20211208,20211208,DIR,FDA-CDER-CTU-2021-92336,,FDA-CTU,,74.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Elderly
201648211,20164821,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2021,Q4,Blood culture positive,,2021,Q4,1,I,20210730.0,,20211208,20211208,DIR,FDA-CDER-CTU-2021-92336,,FDA-CTU,,74.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Elderly
201648211,20164821,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,,,,,,,,,QD,2021,Q4,Candida infection,,2021,Q4,1,I,20210730.0,,20211208,20211208,DIR,FDA-CDER-CTU-2021-92336,,FDA-CTU,,74.0,YR,,M,N,,,20211021.0,N,PH,US,,2021,Q4,Elderly
201720502,20172050,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,U,Unknown,,208658.0,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,20211206.0,20211210.0,20211210,20211213,EXP,,"NZ-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142926",BOEHRINGER INGELHEIM,,43.0,YR,A,M,Y,,,20211213.0,,MD,NZ,NZ,2021,Q4,Adult
201726121,20172612,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,25.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211129.0,20211211,20211211,EXP,,US-EPICPHARMA-US-2021EPCLIT01250,EPIC PHARM,Kamil Sardarli.A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis..Journal of the American Society of Nephrology.32:384,66.0,YR,A,F,Y,,,20211211.0,,HP,US,US,2021,Q4,Elderly
201726121,20172612,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,,,Unknown,,,25.0,MG,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211129.0,20211211,20211211,EXP,,US-EPICPHARMA-US-2021EPCLIT01250,EPIC PHARM,Kamil Sardarli.A patient with combined metformin-induced lactic acidosis and euglycemic diabetic ketoacidosis..Journal of the American Society of Nephrology.32:384,66.0,YR,A,F,Y,,,20211211.0,,HP,US,US,2021,Q4,Elderly
201741311,20174131,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Pancreatitis necrotising,,2021,Q4,1,I,,20211129.0,20211213,20211213,EXP,,US-NOVOPROD-874327,NOVO NORDISK,"Fernandez, Andrea T.;Akhtar, Khawaja H.;Krishan, Satyam;Anwaar, Muhammad Faraz;Allee, Mark. Necrotizing pancreatitis associated with liraglutide and empagliflozin. American Journal of Gastroenterology. 2021;116:S736",48.0,YR,,M,Y,,,20211213.0,,MD,US,US,2021,Q4,Adult
201741311,20174131,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Pancreatic pseudocyst,,2021,Q4,1,I,,20211129.0,20211213,20211213,EXP,,US-NOVOPROD-874327,NOVO NORDISK,"Fernandez, Andrea T.;Akhtar, Khawaja H.;Krishan, Satyam;Anwaar, Muhammad Faraz;Allee, Mark. Necrotizing pancreatitis associated with liraglutide and empagliflozin. American Journal of Gastroenterology. 2021;116:S736",48.0,YR,,M,Y,,,20211213.0,,MD,US,US,2021,Q4,Adult
201771501,20177150,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211207.0,20211213,20211213,EXP,,US-EMD Serono-9285623,EMD SERONO INC,"Hendrickson A, Ye X, Kalra S, Franck A, Urbine D. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes.. Clinical Diabetes. 2021 JAN 01;39(1):121-123. doi:10.2337/cd20-0019",70.0,YR,E,F,Y,,,20211213.0,,MD,US,,2021,Q4,Elderly
201771501,20177150,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q4,Product prescribing error,,2021,Q4,1,I,,20211207.0,20211213,20211213,EXP,,US-EMD Serono-9285623,EMD SERONO INC,"Hendrickson A, Ye X, Kalra S, Franck A, Urbine D. Euglycemic diabetic ketoacidosis in a patient prescribed empagliflozin and a ketogenic diet: A case of misdiagnosed type 1 diabetes.. Clinical Diabetes. 2021 JAN 01;39(1):121-123. doi:10.2337/cd20-0019",70.0,YR,E,F,Y,,,20211213.0,,MD,US,,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Low density lipoprotein increased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Heart rate decreased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Left atrial volume increased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201797191,20179719,15,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,Y,,,,,10.0,MG,,,2021,Q4,Blood creatinine increased,,2021,Q4,1,I,,20211130.0,20211214,20211214,EXP,,NVSC2021TH274966,NOVARTIS,,75.0,YR,,M,Y,,,20211214.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood creatine increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,33,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood creatine increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,34,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood creatine increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,35,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood creatine increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,36,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood glucose increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ventricular internal diameter abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Ejection fraction decreased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hyperkalaemia,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Mitral valve incompetence,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Glycosylated haemoglobin increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Left atrial enlargement,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Blood creatine increased,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Walking distance test abnormal,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201798292,20179829,37,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, UNKNOWN",,,U,,,,,10.0,MG,,,2021,Q4,Cardiac failure chronic,,2021,Q4,2,F,,20211130.0,20211214,20211225,EXP,,NVSC2021TH275038,NOVARTIS,,75.0,YR,,M,Y,,,20211225.0,,MD,TH,TH,2021,Q4,Elderly
201842062,20184206,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/1000mg,,,Y,U,Unknown,,206111.0,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,,20211215.0,20211214,20211218,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142465",BOEHRINGER INGELHEIM,,5.0,DEC,A,M,Y,,,20211218.0,,MD,MY,MY,2021,Q4,Child
201842062,20184206,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/1000mg,,,Y,U,Unknown,,206111.0,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,2,F,,20211215.0,20211214,20211218,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142465",BOEHRINGER INGELHEIM,,5.0,DEC,A,M,Y,,,20211218.0,,MD,MY,MY,2021,Q4,Child
201842062,20184206,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/1000mg,,,Y,U,Unknown,,206111.0,,,,,2021,Q4,Dyspnoea,,2021,Q4,2,F,,20211215.0,20211214,20211218,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142465",BOEHRINGER INGELHEIM,,5.0,DEC,A,M,Y,,,20211218.0,,MD,MY,MY,2021,Q4,Child
201842062,20184206,1,PS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,12.5mg/1000mg,,,Y,U,Unknown,,206111.0,,,,,2021,Q4,Nausea,,2021,Q4,2,F,,20211215.0,20211214,20211218,EXP,,"MY-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-142465",BOEHRINGER INGELHEIM,,5.0,DEC,A,M,Y,,,20211218.0,,MD,MY,MY,2021,Q4,Child
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Pneumonitis,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Cough,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Bronchial hyperreactivity,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Obstructive airways disorder,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Respiratory symptom,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Lung disorder,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Wheezing,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Therapeutic product effect incomplete,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Wrong technique in product usage process,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Left ventricular dysfunction,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Hospitalisation,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Pulmonary function test abnormal,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Productive cough,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Sputum discoloured,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Therapy cessation,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Aspiration,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201856201,20185620,18,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 milligram, qd",,,U,,,,,10.0,MG,,,2021,Q4,Rales,,2021,Q4,1,I,,20211207.0,20211215,20211215,EXP,,CA-APOTEX-2020AP014824,APOTEX,,80.0,YR,,M,Y,,,20211215.0,,HP,CA,CA,2021,Q4,Elderly
201858241,20185824,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Onychoclasis,,2021,Q4,1,I,,20210628.0,20211215,20211215,PER,,US-ALVOGEN-2021-ALVOGEN-117898,ALVOGEN,,71.0,YR,,F,Y,,,20211215.0,,CN,US,US,2021,Q4,Elderly
201858241,20185824,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20210628.0,20211215,20211215,PER,,US-ALVOGEN-2021-ALVOGEN-117898,ALVOGEN,,71.0,YR,,F,Y,,,20211215.0,,CN,US,US,2021,Q4,Elderly
201858241,20185824,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Fatigue,,2021,Q4,1,I,,20210628.0,20211215,20211215,PER,,US-ALVOGEN-2021-ALVOGEN-117898,ALVOGEN,,71.0,YR,,F,Y,,,20211215.0,,CN,US,US,2021,Q4,Elderly
201858241,20185824,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Madarosis,,2021,Q4,1,I,,20210628.0,20211215,20211215,PER,,US-ALVOGEN-2021-ALVOGEN-117898,ALVOGEN,,71.0,YR,,F,Y,,,20211215.0,,CN,US,US,2021,Q4,Elderly
201858241,20185824,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Palpitations,,2021,Q4,1,I,,20210628.0,20211215,20211215,PER,,US-ALVOGEN-2021-ALVOGEN-117898,ALVOGEN,,71.0,YR,,F,Y,,,20211215.0,,CN,US,US,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Arteriosclerosis coronary artery,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Aortic valve stenosis,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Pulmonary hypertension,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Infection,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Lipase increased,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Angina pectoris,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Tricuspid valve incompetence,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Aortic valve sclerosis,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Chronic obstructive pulmonary disease,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201889311,20188931,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Mitral valve incompetence,,2021,Q4,1,I,20200303.0,20211208.0,20211215,20211215,EXP,,DE-MYLANLABS-2021M1091748,MYLAN,,69.0,YR,,M,Y,,,20211215.0,,HP,DE,DE,2021,Q4,Elderly
201897611,20189761,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Death,,2021,Q4,1,I,,20211210.0,20211215,20211215,EXP,,"GB-Breckenridge Pharmaceutical, Inc.-2123049",BRECKENRIDGE,,49.0,YR,,M,Y,176.0,KG,20211215.0,,HP,ES,GB,2021,Q4,Adult
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Thirst,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Polyuria,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Headache,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Somnolence,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Nausea,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201903151,20190315,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211215.0,20211215,20211215,EXP,DE-ADRED-07369-01,DE-BAUSCH-BL-2021-041505,BAUSCH AND LOMB,,71.0,YR,,M,Y,,,20211216.0,,PH,DE,DE,2021,Q4,Elderly
201931321,20193132,8,C,METFORMIN/EMPAGLIFLOZIN,,2,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestasis,,2021,Q4,1,I,20211026.0,20211207.0,20211216,20211216,EXP,,CH-AstraZeneca-2021A875497,ASTRAZENECA,,82.0,YR,,M,Y,,,20211216.0,,MD,CH,,2021,Q4,Elderly
201931321,20193132,9,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestasis,,2021,Q4,1,I,20211026.0,20211207.0,20211216,20211216,EXP,,CH-AstraZeneca-2021A875497,ASTRAZENECA,,82.0,YR,,M,Y,,,20211216.0,,MD,CH,,2021,Q4,Elderly
201931831,20193183,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 dosage form, each morning",,,,,,,,,,Tablet,QD,2021,Q4,Dysuria,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112004950,ELI LILLY AND CO,,77.0,YR,,M,Y,75.0,KG,20211216.0,,CN,DE,DE,2021,Q4,Elderly
201931831,20193183,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 dosage form, each morning",,,,,,,,,,Tablet,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112004950,ELI LILLY AND CO,,77.0,YR,,M,Y,75.0,KG,20211216.0,,CN,DE,DE,2021,Q4,Elderly
201931831,20193183,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 dosage form, each morning",,,,,,,,,,Tablet,QD,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112004950,ELI LILLY AND CO,,77.0,YR,,M,Y,75.0,KG,20211216.0,,CN,DE,DE,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Troponin I abnormal,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,White blood cell disorder,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Brain natriuretic peptide abnormal,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Acute pulmonary oedema,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201939351,20193935,14,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,QRS axis abnormal,,2021,Q4,1,I,,20211209.0,20211216,20211216,EXP,,GR-MYLANLABS-2021M1092002,MYLAN,,71.0,YR,,M,Y,,,20211216.0,,MD,GR,GR,2021,Q4,Elderly
201947411,20194741,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Productive cough,,2021,Q4,1,I,20211201.0,,20211216,20211216,DIR,595241,,FDA-CTU,,62.0,YR,,M,N,162.45,KG,20211216.0,Y,,US,,2021,Q4,Adult
201947411,20194741,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20211201.0,,20211216,20211216,DIR,595241,,FDA-CTU,,62.0,YR,,M,N,162.45,KG,20211216.0,Y,,US,,2021,Q4,Adult
201947411,20194741,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Body temperature increased,,2021,Q4,1,I,20211201.0,,20211216,20211216,DIR,595241,,FDA-CTU,,62.0,YR,,M,N,162.45,KG,20211216.0,Y,,US,,2021,Q4,Adult
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Congestive cardiomyopathy,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Lung disorder,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,N-terminal prohormone brain natriuretic peptide increased,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Wrong technique in product usage process,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201952401,20195240,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, QD",10660.0,MG,U,,,,,10.0,MG,,QD,2021,Q4,Glomerular filtration rate abnormal,,2021,Q4,1,I,20210301.0,20211208.0,20211216,20211216,EXP,,PL-AstraZeneca-2021A859992,ASTRAZENECA,,71.0,YR,,M,Y,,,20211216.0,,MD,PL,,2021,Q4,Elderly
201958791,20195879,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Cardiomegaly,,2021,Q4,1,I,20210410.0,20211210.0,20211216,20211216,EXP,GB-MHRA-EYC 00268653,GB-ELI_LILLY_AND_COMPANY-GB202112006154,ELI LILLY AND CO,,49.0,YR,,M,Y,176.0,KG,20211216.0,,CN,GB,GB,2021,Q4,Adult
201958791,20195879,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Toxicity to various agents,,2021,Q4,1,I,20210410.0,20211210.0,20211216,20211216,EXP,GB-MHRA-EYC 00268653,GB-ELI_LILLY_AND_COMPANY-GB202112006154,ELI LILLY AND CO,,49.0,YR,,M,Y,176.0,KG,20211216.0,,CN,GB,GB,2021,Q4,Adult
201972032,20197203,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Hypoglycaemia,,2021,Q4,2,F,,20211216.0,20211217,20211223,EXP,,BR-NOVOPROD-876255,NOVO NORDISK,,65.0,YR,,M,Y,106.8,KG,20211223.0,,MD,BR,BR,2021,Q4,Elderly
201972032,20197203,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,,20211216.0,20211217,20211223,EXP,,BR-NOVOPROD-876255,NOVO NORDISK,,65.0,YR,,M,Y,106.8,KG,20211223.0,,MD,BR,BR,2021,Q4,Elderly
201972032,20197203,3,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"25 mg, qd",,,,,Unknown,,,25.0,MG,,QD,2021,Q4,Weight increased,,2021,Q4,2,F,,20211216.0,20211217,20211223,EXP,,BR-NOVOPROD-876255,NOVO NORDISK,,65.0,YR,,M,Y,106.8,KG,20211223.0,,MD,BR,BR,2021,Q4,Elderly
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Pain in extremity,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Nausea,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Renal injury,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Vomiting,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202015951,20201595,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 mg,,,U,,,,,10.0,MG,,,2021,Q4,Ketoacidosis,,2021,Q4,1,I,20210527.0,20211213.0,20211217,20211217,EXP,DE-DCGMA-21190704,NVSC2021DE286306,NOVARTIS,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Therapeutic product effect incomplete,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Productive cough,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Asthma,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Wrong technique in product usage process,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Left ventricular dysfunction,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Rales,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Aspiration,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Obstructive airways disorder,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Pneumonitis,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Respiratory symptom,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Bronchial hyperreactivity,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Sputum discoloured,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Lung disorder,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202017141,20201714,4,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,,,,,10.0,MG,,QD,2021,Q4,Wheezing,,2021,Q4,1,I,,20211213.0,20211217,20211217,EXP,,CA-BAUSCH-BL-2021-041443,BAUSCH AND LOMB,,80.0,YR,,M,Y,,,20211217.0,,CN,CA,CA,2021,Q4,Elderly
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Ketoacidosis,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Pain in extremity,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Nausea,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Vomiting,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202019681,20201968,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,10.0,MG,,,2021,Q4,Renal injury,,2021,Q4,1,I,20210527.0,20211215.0,20211217,20211217,EXP,,DE-BAUSCH-BL-2021-041504,BAUSCH AND LOMB,,58.0,YR,,F,Y,90.0,KG,20211217.0,,MD,DE,DE,2021,Q4,Adult
202036911,20203691,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Diabetes mellitus management,,2021,Q4,1,I,,20210920.0,20211219,20211219,EXP,,PT-ALKEM LABORATORIES LIMITED-PT-ALKEM-2021-06083,ALKEM,"Barbosa M, Fernandes V. Rapid-onset clozapine-induced hyperglycaemia: pathways of glycaemic dysregulation. BMJ Case Rep. 2021;14:e243938",45.0,YR,,F,Y,,,20211220.0,,HP,PT,PT,2021,Q4,Adult
202050811,20205081,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,  1.5-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dysuria,,2021,Q4,1,I,,20211209.0,20211220,20211220,EXP,,DE-AUROBINDO-AUR-APL-2021-051928,AUROBINDO,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202050811,20205081,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,  1.5-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211209.0,20211220,20211220,EXP,,DE-AUROBINDO-AUR-APL-2021-051928,AUROBINDO,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202050811,20205081,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram,  1.5-0-0-0, Tabletten",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211209.0,20211220,20211220,EXP,,DE-AUROBINDO-AUR-APL-2021-051928,AUROBINDO,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067791,20206779,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1.5-0-0-0, Tabletten)",,,U,,,,,10.0,MG,,QD,2021,Q4,Dysuria,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE285867,NOVARTIS,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067791,20206779,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1.5-0-0-0, Tabletten)",,,U,,,,,10.0,MG,,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE285867,NOVARTIS,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067791,20206779,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1.5-0-0-0, Tabletten)",,,U,,,,,10.0,MG,,QD,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE285867,NOVARTIS,,77.0,YR,,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067801,20206780,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tabletten",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211215.0,20211220,20211220,EXP,,DE-drreddys-SPO/GER/21/0144916,DR REDDYS,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067801,20206780,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tabletten",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Dysuria,,2021,Q4,1,I,,20211215.0,20211220,20211220,EXP,,DE-drreddys-SPO/GER/21/0144916,DR REDDYS,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202067801,20206780,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tabletten",,,,,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211215.0,20211220,20211220,EXP,,DE-drreddys-SPO/GER/21/0144916,DR REDDYS,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202069411,20206941,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tablet",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211210.0,20211220,20211220,EXP,DE-ADRED-07466-01,DE-TORRENT-00021664,TORRENT,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202069411,20206941,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tablet",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211210.0,20211220,20211220,EXP,DE-ADRED-07466-01,DE-TORRENT-00021664,TORRENT,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202069411,20206941,6,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1.5-0-0-0, Tablet",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dysuria,,2021,Q4,1,I,,20211210.0,20211220,20211220,EXP,DE-ADRED-07466-01,DE-TORRENT-00021664,TORRENT,,77.0,YR,E,M,Y,75.0,KG,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202071402,20207140,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2021,Q4,Lichenoid keratosis,,2021,Q4,2,F,,20211226.0,20211220,20211227,EXP,,US-ASTELLAS-2021US048901,ASTELLAS,,58.0,YR,,M,Y,,,20211227.0,,MD,US,US,2021,Q4,Adult
202071402,20207140,10,C,EMPAGLIFLOZIN\LINAGLIPTIN,EMPAGLIFLOZIN\LINAGLIPTIN,1,Unknown,"UNK UNK, unknown freq.",,,,,,,,,,Formulation unknown,,2021,Q4,Drug eruption,,2021,Q4,2,F,,20211226.0,20211220,20211227,EXP,,US-ASTELLAS-2021US048901,ASTELLAS,,58.0,YR,,M,Y,,,20211227.0,,MD,US,US,2021,Q4,Adult
202072681,20207268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Penile discomfort,,2021,Q4,1,I,20211102.0,,20211219,20211219,DIR,FDA-CDER-CTU-2021-95360,,FDA-CTU,,57.0,YR,,M,N,86.0,KG,20211216.0,N,PH,US,,2021,Q4,Adult
202072681,20207268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Rash,,2021,Q4,1,I,20211102.0,,20211219,20211219,DIR,FDA-CDER-CTU-2021-95360,,FDA-CTU,,57.0,YR,,M,N,86.0,KG,20211216.0,N,PH,US,,2021,Q4,Adult
202072681,20207268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Urticaria,,2021,Q4,1,I,20211102.0,,20211219,20211219,DIR,FDA-CDER-CTU-2021-95360,,FDA-CTU,,57.0,YR,,M,N,86.0,KG,20211216.0,N,PH,US,,2021,Q4,Adult
202072681,20207268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Genital infection fungal,,2021,Q4,1,I,20211102.0,,20211219,20211219,DIR,FDA-CDER-CTU-2021-95360,,FDA-CTU,,57.0,YR,,M,N,86.0,KG,20211216.0,N,PH,US,,2021,Q4,Adult
202072681,20207268,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Pruritus,,2021,Q4,1,I,20211102.0,,20211219,20211219,DIR,FDA-CDER-CTU-2021-95360,,FDA-CTU,,57.0,YR,,M,N,86.0,KG,20211216.0,N,PH,US,,2021,Q4,Adult
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Headache,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Polyuria,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Thirst,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202073551,20207355,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD (1-0-0-0)",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Somnolence,,2021,Q4,1,I,,20211213.0,20211220,20211220,EXP,,NVSC2021DE286257,NOVARTIS,,71.0,YR,,M,Y,,,20211220.0,,PH,DE,DE,2021,Q4,Elderly
202075391,20207539,43,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Depressed level of consciousness,,2021,Q4,1,I,20211101.0,20211210.0,20211220,20211220,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20211220.0,,MD,CH,CH,2021,Q4,Adult
202075391,20207539,43,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Respiratory failure,,2021,Q4,1,I,20211101.0,20211210.0,20211220,20211220,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20211220.0,,MD,CH,CH,2021,Q4,Adult
202075391,20207539,43,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Drug interaction,,2021,Q4,1,I,20211101.0,20211210.0,20211220,20211220,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20211220.0,,MD,CH,CH,2021,Q4,Adult
202075391,20207539,43,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Confusional state,,2021,Q4,1,I,20211101.0,20211210.0,20211220,20211220,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20211220.0,,MD,CH,CH,2021,Q4,Adult
202075391,20207539,43,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,UNK,,,,,,,,,,,,2021,Q4,Trismus,,2021,Q4,1,I,20211101.0,20211210.0,20211220,20211220,EXP,CH-SM-2021-29093,CH-PFIZER INC-202101766837,PFIZER,,63.0,YR,,M,Y,,,20211220.0,,MD,CH,CH,2021,Q4,Adult
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Headache,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Thirst,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Polyuria,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097571,20209757,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, Once a Day",,,U,,,,,10.0,MG,,QD,2021,Q4,Somnolence,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-AUROBINDO-AUR-APL-2021-052434,AUROBINDO,,71.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202102691,20210269,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286549,NOVARTIS,,79.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202102691,20210269,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286549,NOVARTIS,,79.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202102691,20210269,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286549,NOVARTIS,,79.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202102691,20210269,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Anaemia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286549,NOVARTIS,,79.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202102691,20210269,9,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, QD",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286549,NOVARTIS,,79.0,YR,,M,Y,,,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202123861,20212386,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg (10 mg, 0-2-0-0)",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286486,NOVARTIS,,68.0,YR,,F,Y,103.3,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202123861,20212386,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg (10 mg, 0-2-0-0)",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Product prescribing error,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286486,NOVARTIS,,68.0,YR,,F,Y,103.3,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202123861,20212386,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg (10 mg, 0-2-0-0)",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286486,NOVARTIS,,68.0,YR,,F,Y,103.3,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202128001,20212800,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OD",,,U,U,,,,10.0,MG,,,2021,Q4,Hypercalcaemia,,2021,Q4,1,I,,20211207.0,20211221,20211221,EXP,,US-TARO-2021TAR01274,TARO,"Ganesan K, Bradley B, Jones DW, Solomon DS. A Case Report On Type 2 Amiodarone Inducedthyrotoxicosis And Hypercalcemia. Am J Med Sci. 2021;362(3):308-313",64.0,YR,,M,Y,85.0,KG,20211221.0,,MD,US,US,2021,Q4,Adult
202128001,20212800,5,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,"10 mg, OD",,,U,U,,,,10.0,MG,,,2021,Q4,Hyperthyroidism,,2021,Q4,1,I,,20211207.0,20211221,20211221,EXP,,US-TARO-2021TAR01274,TARO,"Ganesan K, Bradley B, Jones DW, Solomon DS. A Case Report On Type 2 Amiodarone Inducedthyrotoxicosis And Hypercalcemia. Am J Med Sci. 2021;362(3):308-313",64.0,YR,,M,Y,85.0,KG,20211221.0,,MD,US,US,2021,Q4,Adult
202128601,20212860,2,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,D,,,,,,,,,2021,Q4,Suspected suicide,,2021,Q4,1,I,,20211214.0,20211221,20211221,EXP,,US-009507513-2112USA006796,MERCK,,15.0,YR,,M,Y,,,20211221.0,,HP,US,US,2021,Q4,Youth
202135611,20213561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Anaemia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112006308,ELI LILLY AND CO,,79.0,YR,,M,Y,,,20211221.0,,CN,DE,DE,2021,Q4,Elderly
202135611,20213561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112006308,ELI LILLY AND CO,,79.0,YR,,M,Y,,,20211221.0,,CN,DE,DE,2021,Q4,Elderly
202135611,20213561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112006308,ELI LILLY AND CO,,79.0,YR,,M,Y,,,20211221.0,,CN,DE,DE,2021,Q4,Elderly
202135611,20213561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112006308,ELI LILLY AND CO,,79.0,YR,,M,Y,,,20211221.0,,CN,DE,DE,2021,Q4,Elderly
202135611,20213561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202112006308,ELI LILLY AND CO,,79.0,YR,,M,Y,,,20211221.0,,CN,DE,DE,2021,Q4,Elderly
202168001,20216800,12,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestatic liver injury,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,CH-SM-2021-29326,NVSC2021CH286595,NOVARTIS,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,CH,2021,Q4,Adult
202168001,20216800,13,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestatic liver injury,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,CH-SM-2021-29326,NVSC2021CH286595,NOVARTIS,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,CH,2021,Q4,Adult
202194071,20219407,11,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestatic liver injury,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,,CH-AstraZeneca-2021A892796,ASTRAZENECA,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,,2021,Q4,Adult
202194071,20219407,11,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hypersensitivity,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,,CH-AstraZeneca-2021A892796,ASTRAZENECA,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,,2021,Q4,Adult
202194071,20219407,12,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cholestatic liver injury,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,,CH-AstraZeneca-2021A892796,ASTRAZENECA,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,,2021,Q4,Adult
202194071,20219407,12,SS,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hypersensitivity,,2021,Q4,1,I,20211125.0,20211214.0,20211222,20211222,EXP,,CH-AstraZeneca-2021A892796,ASTRAZENECA,,50.0,YR,,M,Y,,,20211222.0,,MD,CH,,2021,Q4,Adult
202202101,20220210,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145009,DR REDDYS,,79.0,YR,E,M,Y,,,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202202101,20220210,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145009,DR REDDYS,,79.0,YR,E,M,Y,,,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202202101,20220210,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Anaemia,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145009,DR REDDYS,,79.0,YR,E,M,Y,,,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202202101,20220210,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145009,DR REDDYS,,79.0,YR,E,M,Y,,,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202202101,20220210,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,U,UNKNOWN,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145009,DR REDDYS,,79.0,YR,E,M,Y,,,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202210041,20221004,11,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Liver injury,,2021,Q4,1,I,,20211208.0,20211223,20211223,EXP,,AU-ALKEM LABORATORIES LIMITED-AU-ALKEM-2021-07698,ALKEM,,29.0,YR,,M,Y,,,20211223.0,,HP,AU,AU,2021,Q4,Young Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Vomiting,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Renal injury,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Nausea,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Pain in extremity,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202216101,20221610,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,U,,,,,10.0,MG,,,2021,Q4,Ketoacidosis,,2021,Q4,1,I,20210527.0,20211213.0,20211223,20211223,EXP,,DE-AUROBINDO-AUR-APL-2021-052143,AUROBINDO,,58.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,DE,2021,Q4,Adult
202221361,20222136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,,,,QD,2021,Q4,Perirectal abscess,,2021,Q4,1,I,20211127.0,,20211222,20211222,DIR,FDA-CDER-CTU-2021-96534,,FDA-CTU,,91.0,YR,,M,N,69.4,KG,20211222.0,N,,US,,2021,Q4,Elderly
202221361,20222136,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,D,,,,,,,,QD,2021,Q4,Fournier's gangrene,,2021,Q4,1,I,20211127.0,,20211222,20211222,DIR,FDA-CDER-CTU-2021-96534,,FDA-CTU,,91.0,YR,,M,N,69.4,KG,20211222.0,N,,US,,2021,Q4,Elderly
202242451,20224245,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Pruritus,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-AstraZeneca-2021A875184,ASTRAZENECA,,78.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,,2021,Q4,Elderly
202242451,20224245,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, Tabletten",,,U,,,,,,,Tablet,,2021,Q4,Liver function test abnormal,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-AstraZeneca-2021A875184,ASTRAZENECA,,78.0,YR,,F,Y,90.0,KG,20211223.0,,MD,DE,,2021,Q4,Elderly
202244601,20224460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211220.0,,20211223,20211223,DIR,596260,,FDA-CTU,,59.0,YR,,M,N,108.4,KG,20211223.0,N,PH,US,,2021,Q4,Adult
202244601,20224460,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,Frequency : Daily;?,,,Y,D,,,,25.0,MG,,QD,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,20211220.0,,20211223,20211223,DIR,596260,,FDA-CTU,,59.0,YR,,M,N,108.4,KG,20211223.0,N,PH,US,,2021,Q4,Adult
202244601,20224460,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211220.0,,20211223,20211223,DIR,596260,,FDA-CTU,,59.0,YR,,M,N,108.4,KG,20211223.0,N,PH,US,,2021,Q4,Adult
202244601,20224460,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,20211220.0,,20211223,20211223,DIR,596260,,FDA-CTU,,59.0,YR,,M,N,108.4,KG,20211223.0,N,PH,US,,2021,Q4,Adult
202255611,20225561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Anaemia,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,ID-DE-BFARM-21011734,DE-NOVOPROD-876119,NOVO NORDISK,,79.0,YR,,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202255611,20225561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,ID-DE-BFARM-21011734,DE-NOVOPROD-876119,NOVO NORDISK,,79.0,YR,,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202255611,20225561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,ID-DE-BFARM-21011734,DE-NOVOPROD-876119,NOVO NORDISK,,79.0,YR,,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202255611,20225561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,ID-DE-BFARM-21011734,DE-NOVOPROD-876119,NOVO NORDISK,,79.0,YR,,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202255611,20225561,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, qd (1-0-0-0)",,,U,U,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,ID-DE-BFARM-21011734,DE-NOVOPROD-876119,NOVO NORDISK,,79.0,YR,,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202270781,20227078,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,DE-ADRED-07306-02,DE-TORRENT-00021738,TORRENT,,79.0,YR,E,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202270781,20227078,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,DE-ADRED-07306-02,DE-TORRENT-00021738,TORRENT,,79.0,YR,E,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202270781,20227078,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,DE-ADRED-07306-02,DE-TORRENT-00021738,TORRENT,,79.0,YR,E,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202270781,20227078,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,Anaemia,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,DE-ADRED-07306-02,DE-TORRENT-00021738,TORRENT,,79.0,YR,E,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202270781,20227078,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0",,,U,,,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,DE-ADRED-07306-02,DE-TORRENT-00021738,TORRENT,,79.0,YR,E,M,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Product prescribing error,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Haematemesis,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Abdominal pain,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Cold sweat,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202277011,20227701,8,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 mg,,,,,Unknown,,,,,Tablet,,2021,Q4,Pallor,,2021,Q4,1,I,,20211216.0,20211224,20211224,EXP,,DE-TEVA-2021-DE-1991072,TEVA,,69.0,YR,E,F,Y,,,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202282291,20228229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,UNK,,2021,Q4,Treatment noncompliance,,2021,Q4,1,I,,20211220.0,20211224,20211224,EXP,,SA-TAKEDA-2021TEU010669,TAKEDA,"Alabdaljabar MS, Abdullah KM, Almasood A, Ali SS, Ashmeg A. Euglycemic diabetic ketoacidosis in a sedated patient after coronary artery bypass grafting: a case report. Case Reports in Medicine. 2021",52.0,YR,,M,Y,,,20211224.0,,HP,SA,SA,2021,Q4,Adult
202282291,20228229,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,10 milligram,,,,,,,,10.0,MG,UNK,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,1,I,,20211220.0,20211224,20211224,EXP,,SA-TAKEDA-2021TEU010669,TAKEDA,"Alabdaljabar MS, Abdullah KM, Almasood A, Ali SS, Ashmeg A. Euglycemic diabetic ketoacidosis in a sedated patient after coronary artery bypass grafting: a case report. Case Reports in Medicine. 2021",52.0,YR,,M,Y,,,20211224.0,,HP,SA,SA,2021,Q4,Adult
202293191,20229319,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 Dosage forms Daily; 10 mg, 1.5-0-0-0,",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211216.0,20211225,20211225,EXP,,DE-TEVA-2021-DE-1991018,TEVA,,77.0,YR,E,M,Y,75.0,KG,20211225.0,,PH,DE,DE,2021,Q4,Elderly
202293191,20229319,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 Dosage forms Daily; 10 mg, 1.5-0-0-0,",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Dysuria,,2021,Q4,1,I,,20211216.0,20211225,20211225,EXP,,DE-TEVA-2021-DE-1991018,TEVA,,77.0,YR,E,M,Y,75.0,KG,20211225.0,,PH,DE,DE,2021,Q4,Elderly
202293191,20229319,7,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"1.5 Dosage forms Daily; 10 mg, 1.5-0-0-0,",,,,,Unknown,,,,,Tablet,QD,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,,20211216.0,20211225,20211225,EXP,,DE-TEVA-2021-DE-1991018,TEVA,,77.0,YR,E,M,Y,75.0,KG,20211225.0,,PH,DE,DE,2021,Q4,Elderly
202311021,20231102,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Pruritus,,2021,Q4,1,I,,20211214.0,20211227,20211227,EXP,DE-ADRED-07070-01,DE-PFIZER INC-202101795283,PFIZER,,78.0,YR,,F,Y,90.0,KG,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202311021,20231102,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1x/day",,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Liver function test abnormal,,2021,Q4,1,I,,20211214.0,20211227,20211227,EXP,DE-ADRED-07070-01,DE-PFIZER INC-202101795283,PFIZER,,78.0,YR,,F,Y,90.0,KG,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Frequent bowel movements,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Upper gastrointestinal haemorrhage,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Muscular weakness,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Product monitoring error,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Haematochezia,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Product prescribing error,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,General physical health deterioration,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Faeces discoloured,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202313552,20231355,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 milligram, 1-0-0-0, tablets",,,U,,,,,10.0,MG,Tablet,,2021,Q4,Anaemia,,2021,Q4,2,F,,20211222.0,20211227,20211229,EXP,,DE-009507513-2112DEU007899,MERCK,,79.0,YR,,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Thirst,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Headache,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Polyuria,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Nausea,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202321531,20232153,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,U,,,,,,,Tablet,,2021,Q4,Somnolence,,2021,Q4,1,I,,20211222.0,20211227,20211227,EXP,,DE-009507513-2112DEU007974,MERCK,,71.0,YR,,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202331871,20233187,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211220.0,20211227,20211227,EXP,,DE-TEVA-2021-DE-1992756,TEVA,,79.0,YR,E,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202331871,20233187,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211220.0,20211227,20211227,EXP,,DE-TEVA-2021-DE-1992756,TEVA,,79.0,YR,E,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202331871,20233187,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211220.0,20211227,20211227,EXP,,DE-TEVA-2021-DE-1992756,TEVA,,79.0,YR,E,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202331871,20233187,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Anaemia,,2021,Q4,1,I,,20211220.0,20211227,20211227,EXP,,DE-TEVA-2021-DE-1992756,TEVA,,79.0,YR,E,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202331871,20233187,8,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211220.0,20211227,20211227,EXP,,DE-TEVA-2021-DE-1992756,TEVA,,79.0,YR,E,M,Y,,,20211227.0,,PH,DE,DE,2021,Q4,Elderly
202442101,20244210,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2021,Q4,Respiratory failure,,2021,Q4,1,I,20211101.0,20211220.0,20211229,20211229,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20211229.0,,HP,CH,CH,2021,Q4,Adult
202442101,20244210,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2021,Q4,Depressed level of consciousness,,2021,Q4,1,I,20211101.0,20211220.0,20211229,20211229,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20211229.0,,HP,CH,CH,2021,Q4,Adult
202442101,20244210,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2021,Q4,Trismus,,2021,Q4,1,I,20211101.0,20211220.0,20211229,20211229,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20211229.0,,HP,CH,CH,2021,Q4,Adult
202442101,20244210,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2021,Q4,Drug interaction,,2021,Q4,1,I,20211101.0,20211220.0,20211229,20211229,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20211229.0,,HP,CH,CH,2021,Q4,Adult
202442101,20244210,30,C,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,EMPAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,D,,,,,,,,,2021,Q4,Confusional state,,2021,Q4,1,I,20211101.0,20211220.0,20211229,20211229,EXP,,"CH-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145671",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20211229.0,,HP,CH,CH,2021,Q4,Adult
202454681,20245468,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Frequent bowel movements,,2021,Q4,1,I,,20211219.0,20211229,20211229,EXP,,DE-TEVA-2021-DE-1992341,TEVA,,79.0,YR,E,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202454681,20245468,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Product prescribing error,,2021,Q4,1,I,,20211219.0,20211229,20211229,EXP,,DE-TEVA-2021-DE-1992341,TEVA,,79.0,YR,E,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202454681,20245468,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Faeces discoloured,,2021,Q4,1,I,,20211219.0,20211229,20211229,EXP,,DE-TEVA-2021-DE-1992341,TEVA,,79.0,YR,E,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202454681,20245468,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Upper gastrointestinal haemorrhage,,2021,Q4,1,I,,20211219.0,20211229,20211229,EXP,,DE-TEVA-2021-DE-1992341,TEVA,,79.0,YR,E,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202454681,20245468,6,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Anaemia,,2021,Q4,1,I,,20211219.0,20211229,20211229,EXP,,DE-TEVA-2021-DE-1992341,TEVA,,79.0,YR,E,M,Y,90.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202463721,20246372,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,D,,,,,,,Tablet,,2021,Q4,Anaemia,,2021,Q4,1,I,,20211216.0,20211229,20211229,EXP,,DE-SANOFI US-2021SA423261,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202463721,20246372,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,D,,,,,,,Tablet,,2021,Q4,Muscular weakness,,2021,Q4,1,I,,20211216.0,20211229,20211229,EXP,,DE-SANOFI US-2021SA423261,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202463721,20246372,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,D,,,,,,,Tablet,,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211216.0,20211229,20211229,EXP,,DE-SANOFI US-2021SA423261,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202463721,20246372,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,D,,,,,,,Tablet,,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211216.0,20211229,20211229,EXP,,DE-SANOFI US-2021SA423261,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202463721,20246372,5,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 mg, 1-0-0-0, tablets",,,D,,,,,,,Tablet,,2021,Q4,General physical health deterioration,,2021,Q4,1,I,,20211216.0,20211229,20211229,EXP,,DE-SANOFI US-2021SA423261,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202483701,20248370,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Urosepsis,,2021,Q4,1,I,20211214.0,,20211228,20211228,DIR,FDA-CDER-CTU-2021-97812,,FDA-CTU,,68.0,YR,,M,N,,,20211220.0,N,PH,US,,2021,Q4,Elderly
202487711,20248771,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Fournier's gangrene,,2021,Q4,1,I,20211119.0,,20211228,20211228,DIR,FDA-CDER-CTU-2021-97826,,FDA-CTU,,68.0,YR,,M,N,,,20211219.0,N,PH,US,,2021,Q4,Elderly
202491901,20249190,1,PS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211012.0,,20211228,20211228,DIR,FDA-CDER-CTU-2021-97854,,FDA-CTU,,67.0,YR,,M,N,,,20211216.0,N,PH,US,,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Thirst,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Product monitoring error,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Somnolence,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Headache,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202548451,20254845,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,10 Milligram Daily; 1-0-0-0,,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Polyuria,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992800,TEVA,,71.0,YR,E,M,Y,,,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Pain in extremity,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Ketoacidosis,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Renal injury,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Vomiting,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202551431,20255143,2,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,10Milligram,,,,,,,,10.0,MG,,,2021,Q4,Nausea,,2021,Q4,1,I,20210527.0,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992398,TEVA,,58.0,YR,A,F,Y,90.0,KG,20211230.0,,MD,DE,DE,2021,Q4,Adult
202554771,20255477,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily; 10 mg, 1-0-0-0,",,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Pruritus,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992363,TEVA,,78.0,YR,E,F,Y,90.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202554771,20255477,2,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,"10 Milligram Daily; 10 mg, 1-0-0-0,",,,U,,Unknown,,,10.0,MG,Tablet,QD,2021,Q4,Liver function test abnormal,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992363,TEVA,,78.0,YR,E,F,Y,90.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202577621,20257762,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Hyponatraemia,,2021,Q4,1,I,20211218.0,20211223.0,20211230,20211230,EXP,GB-MHRA-EYC 00269607,GB-PFIZER INC-202101851826,PFIZER,,50.0,YR,,F,Y,,,20211230.0,,PH,GB,GB,2021,Q4,Adult
202577621,20257762,4,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Metastases to liver,,2021,Q4,1,I,20211218.0,20211223.0,20211230,20211230,EXP,GB-MHRA-EYC 00269607,GB-PFIZER INC-202101851826,PFIZER,,50.0,YR,,F,Y,,,20211230.0,,PH,GB,GB,2021,Q4,Adult
202640121,20264012,13,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Rectal haemorrhage,,2021,Q4,1,I,,20211219.0,20211231,20211231,EXP,GB-MHRA-ADR 26338435,GB-GLAXOSMITHKLINE-GBCH2021GSK092328,GLAXOSMITHKLINE,,62.0,YR,,F,Y,,,20211231.0,,PH,GB,GB,2021,Q4,Adult
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Back pain,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Infusion related reaction,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Chest pain,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Abdominal pain,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202642201,20264220,23,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Oral,,,,,,,,,25.0,MG,Tablets,,2021,Q4,Respiratory arrest,,2021,Q4,1,I,20211115.0,20211222.0,20211231,20211231,EXP,,"US-Melinta Therapeutics, LLC-US-MLNT-21-00184",MELINTA THERAPEUTICS,,74.0,YR,,M,Y,122.6,KG,20211231.0,,PH,US,US,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Productive cough,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Pneumonitis,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Aspiration,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Obstructive airways disorder,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Respiratory symptom,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Left ventricular dysfunction,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Bronchial hyperreactivity,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Wrong technique in product usage process,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Rales,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Sputum discoloured,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Asthma,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Wheezing,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Lung disorder,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Therapeutic product effect incomplete,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
202644411,20264441,3,SS,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,,,,U,U,UNKNOWN,,,10.0,MG,,QD,2021,Q4,Pneumonia,,2021,Q4,1,I,,20211222.0,20211231,20211231,EXP,,CA-drreddys-SPO/CAN/21/0145308,DR REDDYS,,80.0,YR,E,M,Y,,,20211231.0,,HP,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure fluctuation,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Influenza,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure diastolic increased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Cough,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pericardial effusion,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pneumonia,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Vital functions abnormal,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Bronchitis,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pulmonary oedema,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Rales,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oedema peripheral,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dizziness,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Fatigue,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Cardiac failure congestive,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Small intestinal obstruction,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Inappropriate schedule of product administration,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Palpitations,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Joint injury,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure systolic increased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Fall,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Limb injury,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Malaise,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure decreased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Heart rate decreased,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
902813621,9028136,25,C,EMPAGLIFLOZIN,EMPAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Orthopnoea,,2021,Q4,21,F,20121201.0,20210812.0,20130123,20211229,EXP,,PHHY2013CA002527,NOVARTIS,,66.0,YR,,F,Y,,,20211229.0,,MD,CA,CA,2021,Q4,Elderly
